text:
ANTIVIRAL COMPOUNDS
COMPOSES ANTIVIRAUX
A61K 31/4184 (2006.01)
A61P 31/14 (2006.01)
BACON, ELIZABETH M. (United States of America)
COTTELL, JEROMY J. (United States of America)
KATANA, ASHLEY ANNE (United States of America)
KATO, DARRYL (United States of America)
KRYGOWSKI, EVAN S. (United States of America)
LINK, JOHN O. (United States of America)
TAYLOR, JAMES (United States of America)
TRAN, CHINH VIET (United States of America)
TREJO MARTIN, TERESA ALEJANDRA (United States of America)
YANG, ZHENG-YU (United States of America)
ZIPFEL, SHEILA (United States of America)
GILEAD PHARMASSET LLC (United States of America)
NORTON ROSE FULBRIGHT CANADA LLP/S.E.N.C.R.L., S.R.L.
61/560,654 United States of America 2011-11-16
The disclosure is related to anti-viral compounds, compositions containing
such compounds,
and therapeutic methods that include the administration of such compounds, as
well as to processes
and intermediates useful for preparing such compounds.
1. A pharmaceutical composition comprising a compound of formula (I):
E1a-V1a¨C(=O)-P1a -W1a -P1b-C(=O)-V1b-E1b (I)
w1a is
and W1a is optionally substituted with one or more groups independently
selected from halo, alkyl,
haloalkyl, or cyano;
Y5 is -O-CH2-, or -CH2-O-; X5 is -CH2-CH2- or -CH=CH-;
E1a is -N(H)(alkoxycarbonyl), -N(H)(cycloalkylcarbonyl) or -
N(H)(cycloalkyloxycarbonyl);
or E1a-V1a taken together are R9a;
E1b is -N(H)(alkoxycarbonyl), -N(H)(cycloalkylcarbonyl) or -
or E1b-V1b taken together are R9b;
V1a and V1b are each independently selected from:
P1b is selected from:
R9a and R9b are each independently:
or a pharmaceutically acceptable salt or prodrug thereof; and
an additional therapeutic agent selected from an NS3 protease inhibitor, an
alpha-glucosidase 1
inhibitor, a hepatoprotectant, a non-nucleoside inhibitor of HCV polymerase,
and a combination
thereof.
2. The pharmaceutical composition of claim 1, wherein said compound has
wherein the imidazole ring shown in formula A1, A2, A3, and A4 is optionally
substituted with one or
more groups independently selected from halo, haloalkyl, cyano, and alkyl;
or a pharmaceutically acceptable salt or prodrug thereof.
wherein the imidazole ring shown in formula A2 and A4 is optionally
substituted with one or more
groups independently selected from halo, haloalkyl, cyano, or alkyl;
4. The pharmaceutical composition of any one of claims 1-3, wherein at least
one of E1a and E1b
is -N(H)(alkoxycarbonyl).
is -N(H)C(=O)OMe.
6. The pharmaceutical composition of any one of claims 1-3, wherein both of
E1a and E1b
are -N(H)C(=O)OMe.
one of E"1 and E1b
is -N(H)(cycloalkylcarbonyl) or -N(H)(cycloalkyloxycarbonyl).
one of E1a and E1b is
cyclopropylcarbonylamino, cyclobutylcarbonylamino, cyclopropyloxycarbonylamino
cyclobutyloxycarbonylamino.
9. The pharmaceutical composition of any one of claims 1-3, wherein E1a and
E1b are each
independently selected from cyclopropylcarbonylamino, cyclobutylcarbonylamino,
cyclopropyloxycarbonylamino or methoxycarbonylamino.
10. The pharmaceutical composition of any one of claims 1-9, wherein at least
one of V1a and V1b is:
11. The pharmaceutical composition of any one of claims 1-10, wherein E1a-V1a
taken together are R9a
or wherein E1b-V1b taken together are R9b.
12. The pharmaceutical composition of any one of claims 1-11, wherein at least
one of P1a and P1b is
selected from:
13. The pharmaceutical composition of any one of claims 1-11, wherein P1a and
P1b are each
independently selected from:
14. The pharmaceutical composition of any one of claims 1-11, wherein one of
P1a and P1b is:
<1MG>
and the other of P1a and P1b is:
one of P1a and P1b is:
one of -V1a ¨C(=O)-
P1a ¨ and -P1b-C(=O)-V1b- is:
one of -V1a -C(=O)-P1a
¨ and -P1b-C(=O)-V1b- is:
20. The pharmaceutical composition of any one of claims 1-3, wherein both of -
V1a ¨C(=O)-P1a ¨ and
-P1b-C(=O)-V1b- are independently selected from:
21. The pharmaceutical composition of any one of claims 1-3, wherein one of -
V1a -C(=O)-P1a - and -
P1b-C(=O)-V1b- is:
and the other of -V1a -C(=O)-P1a - and -P1b-C(=O)-V1b- is:
22. The pharmaceutical composition of claim 1, wherein said compound is a
compound of formula:
<MG>
or a pharmaceutically acceptable salt thereof or prodrug thereof..
27. The pharmaceutical composition of any one of claims 1-26, further
comprising interferon
or pegylated interferon.
28. The pharmaceutical composition of any one of claims 1-27, for treating
hepatitis C in a
patient.
29. The pharmaceutical composition of claim 28, wherein said patient is a
human or an
animal.
comprising a
pharmaceutically acceptable carrier.
31. Use of the pharmaceutical composition of any one of claims 1-30, in the
manufacture of a
medicament for treating hepatitis C.
This application claims the benefit under 35 U.S.C. 119(e) of United States
Application No. 61/560,654 filed on November 16, 2011, which is hereby
incorporated by reference
in its entirety.
Hepatitis C is recognized as a chronic viral disease of the liver which is
characterized by liver
disease. Although drugs targeting the liver are in wide use and have shown
effectiveness, toxicity and
other side effects have limited their usefulness. Inhibitors of hepatitis C
virus (HCV) are useful to
limit the establishment and progression of infection by HCV as well as in
diagnostic assays for HCV.
There is a need for new HCV therapeutic agents. In particular, there is a need
for HCV
therapeutic agents that have broad activity against HCV genotypes (e.g.
genotypes 1 a, lb, 2a, 3a, 4a).
There is also a particular need for agents that are less susceptible to viral
resistance. Resistance
mutations to inhibitors have been described for HCV NS5A for genotypes la and
lb in Antimicrobial
Agents and Chemotherapy, September 2010, Volume 54, p.3641-3650.
In one embodiment the disclosure provides a compound of the disclosure which
compound of formula (I):
Evia C(___0)_pla _wla _plb_c(=0)_vlb_Elb (I)
wherein:
wia is
Y5 N / \ 1-1,\
\ 111
and Wia is optionally substituted with one or more groups independently
Y5 is -0-CH2-, or -CH2-0-; X5 is -CH2-CH2- or -CH=CH-;
or Ela-V1a taken together are R9';
Elb is -N(H)(alkoxycarbonyl), -N(H)(cycloalkylcarbonyl) or -
or Eilw lb taken together are R9b;
V la and Vlb are each independently selected from:
o.or
Pia is selected from:
NN)11FO ,
----CA Or
Pjb is selected from:
N N;71,
N N "11,
or 5Y\
HNy'A H,N1r0
The disclosure also provides isotopically enriched compounds that are
compounds of the
disclosure that comprise an enriched isotope at one or more positions in the
compound.
The present disclosure also provides a pharmaceutical composition comprising a
of the disclosure or a pharmaceutically acceptable salt or prodrug thereof and
The present disclosure also provides a pharmaceutical composition for use in
treating hepatits
C (HCV). In one embodiment the composition comprises at least one additional
therapeutic agent for
treating HCV. In one embodiment, the therapeutic agent is selected from
ribavirin, an NS3 protease
inhibitor, a nucleoside or nucleotide inhibitor of HCV NS5B polymerase, an
or combinations thereof.
In one embodiment, composition further comprises a nucleoside or nucleotide
inhibitor of HCV
NS5B polymerase. In one embodiment, the nucleoside or nucleotide inhibitor of
HCV NS5B
polymerase is selected from ribavirin, viramidine, levovirin, a L-nucleoside,
or isatoribine.
In one embodiment in provided a pharmaceutical composition comprising a
compound as
desribed herein and at least one one nucleoside or nucleotide inhibitor of HCV
NS5B polymerase, and
at least one pharmaceutically acceptable carrier. In one embodiment, the
composition further
comprises an interferon, a pegylated interferon, ribavirin or combinations
thereof. In one
embodiment, the compound is the compound exemplified in Example PY. In one
embodiment the the
nucleoside or nucleotide inhibitor of HCV NS5B polymerase is sofosbuvir.
The present disclosure also provides a pharmaceutical composition further
comprising an
interferon or pegylated interferon.
nucleoside analog.
The present disclosure also provides for a pharmaceutical composition wherein
nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-
nucleoside, and isatoribine
and said interferon is a-interferon or pegylated a-interferon.
The present disclosure also provides for a method of treating hepatitis C,
said method
comprising administering to a human patient a pharmaceutical composition which
comprises a
therapeutically effective amount of a compound of the disclosure.
The present disclosure also provides a method of inhibiting HCV, comprising
administering
to a mammal afflicted with a condition associated with HCV activity, an amount
of a compound of
the disclosure, effective to inhibit HCV.
The present disclosure also provides a compound of the disclosure for use in
(e.g. for use in inhibiting HCV activity or treating a condition associated
with HCV activity), as well
as the use of a compound of the disclosure for the manufacture of a medicament
useful for inhibiting
HCV or the treatment of a condition associated with HCV activity in a mammal.
The present disclosure also provides synthetic processes and novel
intermediates disclosed
herein which are useful for preparing compounds of the disclosure. Some of the
disclosure are useful to prepare other compounds of the disclosure.
In another aspect the disclosure provides a compound of the disclosure, or a
pharmaceutically
acceptable salt or prodrug thereof, for use in the prophylactic or therapeutic
treatment of hepatitis C or
a hepatitis C associated disorder.
In another aspect the disclosure provides a method of inhibiting HCV activity
in a sample
comprising treating the sample with a compound of the disclosure.
Compounds of formula (I) have been found to possess useful activity against
HCV genotypes
1-Additionally certain compounds of formula (I) have significant potency
against resistant variants in
GT1.
Accordingly, certain compounds of formula (I) possess beneficial
pharmacological properties
that make them well suited to fulfill the current need for HCV agents with
such beneficial properties.
In one embodiment the disclosure provides a compound having improved
inhibitory or
pharmacokinetic properties, including enhanced activity against development of
viral resistance,
improved oral bioavailability, greater potency (for example, in inhibiting HCV
activity) or extended
effective half-life in vivo. Certain compounds of the disclosure may have
fewer side effects, less
complicated dosing schedules, or be orally active.
Reference will now be made in detail to certain embodiments of the disclosure,
examples of
which are illustrated in the accompanying structures and formulas. While the
disclosure will be
described in conjunction with the enumerated embodiments, it will be
understood that they are not
intended to limit the disclosure to those embodiments. On the contrary, the
disclosure is intended to
cover all alternatives, modifications, and equivalents, which may be included
within the scope of the
present disclosure as defined by the embodiments.
The compounds of the disclosure exclude compounds heretofore known. However,
within the disclosure to use compounds that previously were not known to have
antiviral properties
for antiviral purposes (e.g. to produce an anti-viral effect in an animal).
With respect to the United
States, the compounds or compositions herein exclude compounds that are
anticipated under 35 USC
102 or that are obvious under 35 USC 103.
Whenever a compound described herein is substituted with more than one of the
designated group, e.g., "R" or "A3", then it will be understood that the
groups may be the same or
different, i.e., each group is independently selected.
"Absent" ¨ Some groups are defined such that they can be absent. When a group
is absent it
becomes a bond connector. The two groups that would otherwise be connected to
that absent group
are connected to each other through a bond.
The "P" groups (e.g. Pla and P11)) defined for formula (I) herein have one
bond to a
of formula (I) and one bond to a W" group. It is to be understood that a
nitrogen of the P group is
connected to the -C(=0)- group of formula (I) and that a carbon of the P group
is connected to the \Via
1\! 4100 411 Nkirk
^,A7L NH,
In the W" group a Y5 group is present. When that Y5group is defined as -0-CH2-
, or
0- group, those Y5 groups have a directionality. The Y5 group is connected to
the W" group in the
same left to right directionality that each is drawn. So for example, when Y5
is -0-C H2-, the directly
following structure is intended:
ThTH
X5\ N
For example, when Y5 is -CH2-0-, the directly following structure is intended:
\ 441 410 N
In the structure I, the Wia group has a left-to-right directionality as
depicted in I and Va as
they drawn.
Eia_via c(_0)-F,Ia _wia
0)-V lb-Elb (I)
For example, the Pia group is connected to the imidazole group of Va, and the
Plb group is
connected to the pentacyclic ring system of Va.
"Alkyl" is C 1-C 18 hydrocarbon containing normal, secondary, tertiary or
cyclic carbon
atoms. Examples are methyl (Me, -CH3), ethyl (Et, -CH2CH3), I -propyl (n-Pr, n-
propyl,
-CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -
CH2CH2CH2CE13),
2-methyl-l-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -
CH(CH3)CH2CH3), 2-
methy1-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -
CH2CH2CH2CH2CH3), 2-pentyl
(-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CF13)2), 2-methyl-2-butyl (-C(CH3)2CH20-
13), 3-
methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-I-butyl (-CH2CH2CH(CH3)2), 2-
methyl-I-butyl
(-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl
(-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl
(-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-
pentyl
(-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl
(-CH(CH2CH3)CH(CH3)2), 2,3-dimethy1-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethy1-2-
(.2.(,CH2)
(-CH(CH3)C(CH3)3, and cyclopropylmethyl
"Alkenyl" is C2-C18 hydrocarbon containing normal, secondary, tertiary or
atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp2 double
bond. Examples include,
but are not limited to, ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2),
cyclopentenyl (-05H7), and
5-hexenyl (-CH2 CH2CH2CH2CH=CH2).
"Alkynyl" is C2-C18 hydrocarbon containing normal, secondary, tertiary or
atoms with at least one site of unsaturation, i.e. a carbon-carbon, sp triple
but are not limited to, acetylenic (-CaCH) and propargyl (-CH2C--CH).
"Alkylene" refers to a saturated, branched or straight chain or cyclic
hydrocarbon radical of 1-18
carbon atoms, and having two monovalent radical centers derived by the removal
of two hydrogen atoms
from the same or two different carbon atoms of a parent alkane. Typical
alkylene radicals include, but are
not limited to, methylene (-CH2-) 1,2-ethyl (-CH2CH2-), 1,3-propyl (-CH2CH2CH2-
), 1,4-butyl
(-CH2CH2CH2CH2-), and the like.
"Alkenylene" refers to an unsaturated, branched or straight chain or cyclic
hydrocarbon radical
of 2-18 carbon atoms, and having two monovalent radical centers derived by the
removal of two
hydrogen atoms from the same or two different carbon atoms of a parent alkene.
Typical alkenylene
radicals include, but are not limited to, 1,2-ethylene (-CH=CH-).
"Alkynylene" refers to an unsaturated, branched or straight chain or cyclic
hydrogen atoms from the same or two different carbon atoms of a parent alkyne.
Typical alkynylene
radicals include, but are not limited to, acetylene (-CC-), propargyl (-CH2C-C-
), and 4-pentynyl
(-CH2CH2CH2CCH).
The term "alkoxy" or "alkyloxy," as used herein, refers to an alkyl group
attached to the
parent molecular moiety through an oxygen atom.
The term "alkoxycarbonyl," as used herein, refers to an alkoxy group attached
to the parent
molecular moiety through a carbonyl group.
The term "cycloalkyl," as used herein, refers to a saturated monocyclic,
hydrocarbon ring
system having three to seven carbon atoms and zero heteroatoms. Representative
cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl,
and cyclohexyl. The
cycloalkyl groups of the present disclosure are optionally substituted with
one, two, three, four, or five
substituents independently selected from alkoxy, alkyl, aryl, cyano, halo,
haloalkoxy, haloalkyl,
heterocyclyl, hydroxy, hydroxyalkyl, nitro, and -NR'RY wherein the aryl and
the heterocyclyl are
further optionally substituted with one, two, or three substituents
independently selected from alkoxy,
alkyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and nitro.
The term -cycloalkylcarbonyl," as used herein, refers to a cycloalkyl group
parent molecular moiety through a carbonyl group.
The term "cycloalkyloxy," as used herein, refers to a cycloalkyl group
attached to the parent
molecular moiety through an oxygen atom.
The term "cycloalkyloxycarbonyl," as used herein, refers to a cycloalkyloxy
group attached to
the parent molecular moiety through a carbonyl group.
"Aryl" means a monovalent aromatic hydrocarbon radical of 6-20 carbon atoms
derived by
the removal of one hydrogen atom from a single carbon atom of a parent
aromatic ring system.
Typical aryl groups include, but are not limited to, radicals derived from
benzene, substituted
benzene, naphthalene, anthracene, biphenyl, and the like.
"Arylalkyl" refers to an acyclic alkyl radical in which one of the hydrogen
atoms bonded to a
carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl
radical. Typical
arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan- 1 -
yl, naphthylmethyl, 2-
naphthylethan-l-yl, naphthobenzyl, 2-naphthophenylethan-l-y1 and the like. The
arylalkyl group
comprises 6 to 20 carbon atoms, e.g., the alkyl moiety, including alkanyl,
alkenyl or alkynyl groups,
of the arylalkyl group is Ito 6 carbon atoms and the aryl moiety is 5 to 14
carbon atoms.
"Substituted alkyl", "substituted aryl", and "substituted arylalkyl" mean
alkyl, aryl, and
arylalkyl respectively, in which one or more hydrogen atoms are each
independently replaced with a
non-hydrogen substituent. Typical substituents include, but are not limited
to: halo (e.g. F, Cl, Br, I),
-R, -OR, -SR, -NR2, -CF3, -CC13, -0CF3, -CN, -NO2, -N(R)C(=0)R, -C(=0)R, -
0C(=0)R, -C(0)0R,
-C(=0)NRR, -S(0)R, -S(=0)20R, -S(=0)2R, -0S(=0)20R, -S(-0)2NRR, and each R is
independently -H, alkyl, aryl, arylalkyl, or heterocycle. Alkylene,
alkenylene, and alkynylene groups
may also be similarly substituted.
The term "optionally substituted" in reference to a particular moiety of the
compound of
formula I, (e.g., an optionally substituted aryl group) refers to a moiety
having 0, 1, 2, or more
substituents.
The symbol " -- " in a ring structure means that a bond is a single or double
bond. In a non-
limiting example, 9 can be D L or D L
"Haloalkyl" as used herein includes an alkyl group substituted with one or
more halogens
(e.g. F, Cl, Br, or I). Representative examples of haloalkyl include
trifluoromethyl, 2,2,2-
trifl uoroethyl, and 2,2,2-trifluoro-1-(trifluoromethyl)ethyl.
"Heterocycle" or "heterocycly1" as used herein includes by way of example and
limitation these heterocycles described in Paquette, Leo A.; Principles of
Modern Heterocyclic
Chemistry (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6,
7, and 9; The
Chemistry of Heterocyclic Compounds, A Series of Monographs" (John Wiley &
Sons, New York,
1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am.
Chem. Soc. (1960)
82:5566. In one specific embodiment, "heterocycle" includes a "carbocycle" as
defined herein,
wherein one or more (e.g. 1, 2, 3, or 4) carbon atoms have been replaced with
a heteroatom (e.g. 0,
N, or S). The term heterocycle also includes "heteroaryl" which is a
heterocycle wherein at least one
heterocyclic rings is aromatic.
Examples of heterocycles include by way of example and not limitation pyridyl,
dihydropyridyl, tetrahydropyridyl (piperidyl), thiazolyl,
tetrahydrothiophenyl, sulfur oxidized
tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl,
imidazolyl, tetrazolyl,
benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl,
benzimidazolyl,
piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl,
tetrahydrofuranyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
octahydroisoquinolinyl, azocinyl,
triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thienyl,
thianthrenyl, pyranyl,
isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, 2H-pyrrolyl,
isothiazolyl, isoxazolyl,
pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazolyl,
purinyl, 4H-quinolizinyl,
phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl,
pteridinyl, 4H-carbazolyl,
carbazolyl, P-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl,
phenanthrolinyl, phenazinyl,
phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl,
imidazolidinyl, imidazolinyl,
pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl,
quinuclidinyl, morpholinyl,
oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl,
isatinoyl, and bis-
tetrahydrofuranyl:
-05/
By way of example and not limitation, carbon bonded heterocycles are bonded at
position 2,
3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position
2, 4, 5, or 6 of a pyrimidine,
position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan,
tetrahydrofuran, thiofuran,
thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole,
imidazole or thiazole,
position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3
of an aziridine, position 2,
3, or 4 of an azetidine, position 2, 3,4, 5, 6,7, or 8 of a quinoline or
position 1, 3, 4, 5, 6, 7, or 8 of an
isoquinoline. Still more typically, carbon bonded heterocycles include 2-
pyridyl, 3-pyridyl, 4-pyridyl,
5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-
pyridazinyl, 2-pyrimidinyl, 4-
pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-
pyrazinyl, 6-pyrazinyl, 2-
thiazolyl, 4-thiazolyl, or 5-thiazolyl.
By way of example and not limitation, nitrogen bonded heterocycles are bonded
at position 1
of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline,
imidazole, imidazolidine, 2-
imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline,
piperidine, piperazine,
indole, indoline, 1H-indazole, position 2 of a isoindole, or isoindoline,
position 4 of a morpholine, and
position 9 of a carbazole, or 13-carboline. Still more typically, nitrogen
bonded heterocycles include 1-
aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-
piperidinyl.
"Carbocycle" refers to a saturated, unsaturated or aromatic ring having up to
about 25 carbon
atoms. Typically, a carbocycle has about 3 to 7 carbon atoms as a monocycle,
about 7 to 12 carbon
atoms as a bicycle, and up to about 25 carbon atoms as a polycycle. Monocyclic
carbocycles typically
have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic
carbocycles typically have 7 to
12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6]
system, or 9 or 10 ring atoms
arranged as a bicyclo [5,6] or [6,6] system. The term carbocycle includes
"cycloalkyl" which is a
saturated or unsaturated carbocycle. Examples of monocyclic carbocycles
include cyclopropyl,
cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-
enyl, cyclohexyl, 1-
cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl, spiryl and
naphthyl.
The term "amino," as used herein, refers to -NH2.
The term "chiral" refers to molecules which have the property of non-
superimposability of the
mirror image partner, while the term "achiral" refers to molecules which are
superimposable on their
mirror image partner.
The term "stereoisomers" refers to compounds which have identical chemical
constitution,
but differ with regard to the arrangement of the atoms or groups in space.
"Diastereomer" refers to a stereoisomer with two or more centers of chirality
and whose
molecules are not mirror images of one another. Diastereomers have different
physical properties,
e.g., melting points, boiling points, spectral properties, and reactivities.
Mixtures of diastereomers
may separate under high resolution analytical procedures such as
electrophoresis and
chromatography.
"Enantiomers" refer to two stereoisomers of a compound which are non-
superimposable
mirror images of one another.
The term "treatment" or "treating," to the extent it relates to a disease or
condition includes
preventing the disease or condition from occurring, inhibiting the disease or
condition, eliminating the
disease or condition, and/or relieving one or more symptoms of the disease or
condition.
Stereochemical definitions and conventions used herein generally follow S. P.
Parker, Ed.,
McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New
York; and
Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994) John
Wiley & Sons, Inc.,
New York. Many organic compounds exist in optically active forms, i.e., they
have the ability to
rotate the plane of plane-polarized light. In describing an optically active
compound, the prefixes (D
and L) or (Rand S) are used to denote the absolute configuration of the
molecule about its chiral
center(s). The prefixes d and 1 or (+) and (-) are employed to designate the
sign of rotation of plane-
polarized light by the compound, with (-) or 1 meaning that the compound is
levorotatory. A
compound prefixed with (+) or d is dextrorotatory. For a given chemical
structure, these
stereoisomers are identical except that they are mirror images of one another.
A specific stereoisomer
may also be referred to as an enantiomer, and a mixture of such isomers is
often called an
enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a
racemic mixture or a
racemate, which may occur where there has been no stereoselection or
stereospecificity in a chemical
reaction or process. The terms "racemic mixture" and "racemate" refer to an
equimolar mixture of
two enantiomeric species, devoid of optical activity. The disclosure includes
all stereoisomers of the
compounds described herein.
Prod rugs
The term "prodrug" as used herein refers to any compound that when
administered to a
biological system generates a compound of the disclosure that inhibits HCV
activity ("the active
inhibitory compound"). The compound may be formed from the prodrug as a result
of: (i)
spontaneous chemical reaction(s), (ii) enzyme catalyzed chemical reaction(s),
(iii) photolysis, and/or
(iv) metabolic chemical reaction(s).
"Prodrug moiety" refers to a labile functional group which separates from the
active inhibitory
compound during metabolism, systemically, inside a cell, by hydrolysis,
enzymatic cleavage, or by some
other process (Bundgaard, Hans, "Design and Application of Prodrugs" in A
Textbook of Drug Design
and Development (1991), P. Krogsgaard-Larsen and H. Bundgaard, Eds. Harwood
Publishers, pp. 113-191). Enzymes which are capable of an enzymatic activation
mechanism with
the prodrug compounds of the disclosure include, but are not limited to,
amidases, esterases, microbial
enzymes, phospholipases, cholinesterases, and phosphases. Prodrug moieties can
serve to enhance
solubility, absorption and lipophilicity to optimize drug delivery,
bioavailability and efficacy. A
prodrug moiety may include an active metabolite or drug itself.
Exemplary prodrug moieties include the hydrolytically sensitive or labile
acyloxymethyl
esters ¨CH20C(----0)R99 and acyloxymethyl carbonates ¨CH2OC(=0)0R99 where R99
is CI¨C6 alkyl,
C1¨C6 substituted alkyl, C6¨C20 aryl or C6¨C20 substituted aryl. The
acyloxyalkyl ester was first used
as a prodrug strategy for carboxylic acids and then applied to phosphates and
phosphonates by
Farquhar et al. (1983)1. Pharm. Sci. 72: 324; also US Patent Nos. 4816570,
and 5792756. Subsequently, the acyloxyalkyl ester was used to deliver
phosphonic acids across cell
membranes and to enhance oral bioavailability. A close variant of the
acyloxyalkyl ester, the
alkoxycarbonyloxyalkyl ester (carbonate), may also enhance oral
bioavailability as a prodrug moiety
in the compounds of the combinations of the disclosure. An exemplary
acyloxymethyl ester is
pivaloyloxymethoxy, (POM) ¨CH20C(-0)C(CH3)3. An exemplary acyloxymethyl
carbonate prodrug
moiety is pivaloyloxymethylcarbonate (POC) ¨CH20C(-0)0C(CF13)3.
Aryl esters of phosphorus groups, especially phenyl esters, are reported to
enhance oral
bioavailability (De Lombaert et al. (1994)1 Med. Chem. 37: 498). Phenyl esters
containing a
carboxylic ester ortho to a phosphate have also been described (Khamnei and
Torrence, (1996)1
Med. Chem. 39:4109-4115). Benzyl esters are reported to generate parent
phosphonic acids. In
some cases, substituents at the ortho- or para- position may accelerate the
hydrolysis. Benzyl analogs
with an acylated phenol or an alkylated phenol may generate the phenolic
compound through the
action of enzymes, e.g., esterases, oxidases, etc., which in turn undergoes
cleavage at the benzylic C¨
O bond to generate phosphoric acid and a quinone methide intermediate.
Examples of this class of
prodrugs are described by Mitchell etal. (1992) 1 Chem. Soc. Perkin Trans.
112345; Glazier WO
91/19721. Still other benzylic prodrugs have been described containing a
carboxylic ester-containing
group attached to the benzylic methylene (Glazier WO 91/19721). Thio-
containing prodrugs are
reported to be useful for the intracellular delivery of phosphonate drugs.
These proesters contain an
ethylthio group in which the thiol group is either esterified with an acyl
group or combined with
another thiol group to form a disulfide. Deesterification or reduction of the
disulfide generates the
free thio intermediate which subsequently breaks down to the phosphoric acid
and episulfide (Puech
et al. (1993) Antiviral Res., 22: 155-174; Benzaria et al. (1996)1 Med. Chem.
39: 4958).
In the context of the present disclosure, protecting groups include prodrug
moieties and
chemical protecting groups.
"Protecting group" refers to a moiety of a compound that masks or alters the
properties of a
functional group or the properties of the compound as a whole. Chemical
protecting groups and
strategies for protection/deprotection are well known in the art. See e.g.,
Protective Groups in
Organic Chemistry, Theodora W. Greene, John Wiley & Sons, Inc., New York,
1991. Protecting
groups are often utilized to mask the reactivity of certain functional groups,
to assist in the efficiency
of desired chemical reactions, e.g., making and breaking chemical bonds in an
ordered and planned
fashion. Protection of functional groups of a compound alters other physical
properties besides the
reactivity of the protected functional group, such as the polarity,
lipophilicity (hydrophobicity), and
other properties which can be measured by common analytical tools. Chemically
intermediates may themselves be biologically active or inactive.
Protected compounds may also exhibit altered, and in some cases, optimized
properties in
vitro and in vivo, such as passage through cellular membranes and resistance
to enzymatic degradation
or sequestration. In this role, protected compounds with intended therapeutic
effects may be referred
to as prodrugs. Another function of a protecting group is to convert the
parental drug into a prodrug,
whereby the parental drug is released upon conversion of the prodrug in vivo.
Because active
prodrugs may be absorbed more effectively than the parental drug, prodrugs may
possess greater
potency in vivo than the parental drug. Protecting groups are removed either
in vitro, in the instance
of chemical intermediates, or in vivo, in the case of prodrugs. With chemical
intermediates, it is not
particularly important that the resulting products after deprotection, e.g.,
alcohols, be physiologically
acceptable, although in general it is more desirable if the products are
pharmacologically innocuous.
Protecting groups are available, commonly known and used, and are optionally
prevent side reactions with the protected group during synthetic procedures,
i.e. routes or methods to
prepare the compounds of the disclosure. For the most part the decision as to
which groups to protect,
when to do so, and the nature of the chemical protecting group "PG" will be
dependent upon the
chemistry of the reaction to be protected against (e.g., acidic, basic,
oxidative, reductive or other
conditions) and the intended direction of the synthesis. PGs do not need to
be, and generally are not,
the same if the compound is substituted with multiple PG. In general, PG will
be used to protect
functional groups such as carboxyl, hydroxyl, thio, or amino groups and to
thus prevent side reactions
or to otherwise facilitate the synthetic efficiency. The order of deprotection
to yield free deprotected
groups is dependent upon the intended direction of the synthesis and the
reaction conditions to be
encountered, and may occur in any order as determined by the artisan.
Various functional groups of the compounds of the disclosure may be protected.
example, protecting groups for ¨OH groups (whether hydroxyl, carboxylic acid,
phosphonic acid, or
other functions) include "ether- or ester-forming groups". Ether- or ester-
forming groups are capable
of functioning as chemical protecting groups in the synthetic schemes set
forth herein. However,
some hydroxyl and thio protecting groups are neither ether- nor ester-forming
groups, as will be
understood by those skilled in the art, and are included with amides,
discussed below.
A very large number of hydroxyl protecting groups and amide-forming groups and
corresponding chemical cleavage reactions are described in Protective Groups
in Organic Synthesis,
Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991, ISBN 0-471-62301-
6) ("Greene").
See also Kocienski, Philip J.; Protecting Groups (Georg Thieme Verlag
Stuttgart, New York, 1994),
which is incorporated by reference in its entirety herein. In particular
Chapter 1, Protecting Groups:
An Overview, pages 1-20, Chapter 2, Hydroxyl Protecting Groups, pages 21-94,
Chapter 3, Diol
Protecting Groups, pages 95-117, Chapter 4, Carboxyl Protecting Groups, pages
118-154, Chapter 5,
Carbonyl Protecting Groups, pages 155-184. For protecting groups for
carboxylic acid, phosphonic
acid, phosphonate, sulfonic acid and other protecting groups for acids see
Greene as set forth below.
By way of example and not limitation, variables described herein may recursive
substituents
in certain embodiments. Typically, each of these may independently occur 20,
19, 18, 17, 16, 15, 14,
13, 12, 11, 10,9, 8, 7,6, 5,4, 3,2, 1, or 0, times in a given embodiment. More
typically, each of
these may independently occur 12 or fewer times in a given embodiment.
Whenever a compound
described herein is substituted with more than one of the same designated
group, e.g., "RI" or
then it will be understood that the groups may be the same or different, i.e.,
each group is
independently selected. Wavy lines indicate the site of covalent bond
attachments to the adjoining
groups, moieties, or atoms.
In one embodiment of the disclosure, the compound is in an isolated and
purified form.
Generally, the term "isolated and purified" means that the compound is
substantially free from
biological materials (e.g. blood, tissue, cells, etc.). In one specific
embodiment of the disclosure, the
term means that the compound or conjugate of the disclosure is at least about
50 wt.% free from
biological materials; in another specific embodiment, the term means that the
compound or conjugate
of the disclosure is at least about 75 wt.% free from biological materials; in
another specific
embodiment, the term means that the compound or conjugate of the disclosure is
at least about 90
wt.% free from biological materials; in another specific embodiment, the term
means that the
compound or conjugate of the disclosure is at least about 98 wt.% free from
biological materials; and
in another embodiment, the term means that the compound or conjugate of the
disclosure is at least
about 99 wt.% free from biological materials. In another specific embodiment,
the disclosure
provides a compound or conjugate of the disclosure that has been synthetically
prepared (e.g., ex
vivo).
Stereoisomers
The compounds of the disclosure may have chiral centers, e.g., chiral carbon
or phosphorus
atoms. The compounds of the disclosure thus include racemic mixtures of all
stereoisomers,
including enantiomers, diastereomers, and atropisomers. In addition, the
compounds of the disclosure
include enriched or resolved optical isomers at any or all asymmetric, chiral
atoms. In other words,
the chiral centers apparent from the depictions are provided as the chiral
isomers or racemic mixtures.
Both racemic and diastereomeric mixtures, as well as the individual optical
isomers isolated or
synthesized, substantially free of their enantiomeric or diastereomeric
partners, are all within the
scope of the disclosure. The racemic mixtures are separated into their
individual, substantially
optically pure isomers through well-known techniques such as, for example, the
separation of
diastereomeric salts formed with optically active adjuncts, e.g., acids or
bases followed by conversion
back to the optically active substances. In most instances, the desired
optical isomer is synthesized by
means of stereospecific reactions, beginning with the appropriate stereoisomer
of the desired starting
The compounds of the disclosure can also exist as tautomeric isomers in
certain cases.
Although only one tautomer may be depicted, all such forms are contemplated
disclosure. For example, ene-amine tautomers can exist for purine, pyrimidine,
imidazole, guanidine,
amidine, and tetrazole systems and all their possible tautomeric forms are
disclosure.
Salts and Hydrates
Examples of physiologically or pharmaceutically acceptable salts of the
disclosure include salts derived from an appropriate base, such as an alkali
metal (for example,
sodium), an alkaline earth metal (for example, magnesium), ammonium and NX4+
(wherein X is C1-
C4 alkyl). Physiologically acceptable salts of a hydrogen atom or an amino
group include salts of
organic carboxylic acids such as acetic, benzoic, lactic, fumaric, tartaric,
maleic, malonic, malic,
isethionic, lactobionic and succinic acids; organic sulfonic acids, such as
methanesulfonic,
ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and inorganic
acids, such as
hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically
acceptable salts of a compound
of a hydroxy group include the anion of said compound in combination with a
suitable cation such as
Na+ and NX4+ (wherein X is independently selected from H or a C1¨C4 alkyl
group).
For therapeutic use, salts of active ingredients of the compounds of the
disclosure will
typically be physiologically acceptable, i.e. they will be salts derived from
a physiologically
acceptable acid or base. However, salts of acids or bases which are not
physiologically acceptable
may also find use, for example, in the preparation or purification of a
compound. All salts, whether or not derived form a physiologically acceptable
acid or base, are
within the scope of the present disclosure.
Metal salts typically are prepared by reacting the metal hydroxide with a
compound of this
disclosure. Examples of metal salts which are prepared in this way are salts
containing Li+, Na+, and
K+. A less soluble metal salt can be precipitated from the solution of a more
soluble salt by addition
of the suitable metal compound.
In addition, salts may be formed from acid addition of certain organic and
inorganic acids,
e.g., HC1, HBr, H2SO4,1-13PO4 or organic sulfonic acids, to basic centers,
typically amines, or to
acidic groups. Finally, it is to be understood that the compositions herein
comprise compounds of the
disclosure in their un-ionized, as well as zwitterionic form, and combinations
with stoichiometric
amounts of water as in hydrates.
Also included within the scope of this disclosure are the salts of the
parental compounds with
one or more amino acids. Any of the natural or unnatural amino acids are
suitable, especially the
naturally-occurring amino acids found as protein components, although the
amino acid typically is
one bearing a side chain with a basic or acidic group, e.g., lysine, arginine
or glutamic acid, or a
neutral group such as glycine, serine, threonine, alanine, isoleucine, or
leucine.
Methods of Inhibition of HCV
Another aspect of the disclosure relates to methods of inhibiting the activity
of HCV
comprising the step of treating a sample suspected of containing HCV with a
compound or
composition of the disclosure.
Compounds of the disclosure may act as inhibitors of HCV, as intermediates for
inhibitors or have other utilities as described below. The inhibitors will
generally bind to locations on
the surface or in a cavity of the liver. Compounds binding in the liver may
bind with varying degrees
of reversibility. Those compounds binding substantially irreversibly are ideal
candidates for use in
this method of the disclosure. Once labeled, the substantially irreversibly
binding compounds are
useful as probes for the detection of HCV. Accordingly, the disclosure relates
to methods of detecting
NS3 in a sample suspected of containing HCV comprising the steps of: treating
a sample suspected of
containing HCV with a composition comprising a compound of the disclosure
bound to a label; and
observing the effect of the sample on the activity of the label. Suitable
labels are well known in the
diagnostics field and include stable free radicals, fluorophores,
radioisotopes, enzymes,
chemiluminescent groups and chromogens. The compounds herein are labeled in
fashion using functional groups such as hydroxyl or amino. In one embodiment
provides a compound of any one of formulae (I) and (A1)-(A4) that comprises or
that is bound or
linked to one or more detectable labels. Within the context of the disclosure
samples suspected of
containing HCV include natural or man-made materials such as living organisms;
tissue or cell
cultures; biological samples such as biological material samples (blood,
serum, urine, cerebrospinal
fluid, tears, sputum, saliva, tissue samples, and the like); laboratory
samples; food, water, or air
samples; bioproduct samples such as extracts of cells, particularly
recombinant cells synthesizing a
desired glycoprotein; and the like. Typically the sample will be suspected of
containing HCV.
Samples can be contained in any medium including water and organic
solvent/water mixtures.
Samples include living organisms such as humans, and man made materials such
as cell cultures.
The treating step of the disclosure comprises adding the compound of the
disclosure to the
sample or it comprises adding a precursor of the composition to the sample.
The addition step
comprises any method of administration as described above.
If desired, the activity of HCV after application of the compound can be
observed by any
method including direct and indirect methods of detecting HCV activity.
Quantitative, qualitative,
and semiquantitative methods of determining HCV activity are all contemplated.
Typically one of the
screening methods described above are applied, however, any other method such
as observation of the
physiological properties of a living organism are also applicable.
Many organisms contain HCV. The compounds of this disclosure are useful in the
or prophylaxis of conditions associated with HCV activation in animals or in
However, in screening compounds capable of inhibiting HCV activity it should
be kept in
mind that the results of enzyme assays may not always correlate with cell
culture assays. Thus, a cell
based assay should typically be the primary screening tool.
Pharmaceutical Formulations
The compounds of this disclosure are formulated with conventional carriers and
excipients,
which will be selected in accord with ordinary practice. Tablets will contain
excipients, glidants,
fillers, binders and the like. Aqueous formulations are prepared in sterile
form, and when intended for
delivery by other than oral administration generally will be isotonic. All
formulations will optionally
contain excipients such as those set forth in the Handbook of Pharmaceutical
Excipients (1986).
Excipients include ascorbic acid and other antioxidants, chelating agents such
as EDTA,
carbohydrates such as dextrin, hydroxyalkylcellulose,
hydroxyalkylmethylcellulose, stearic acid and
the like. The pH of the formulations ranges from about 3 to about 11, but is
ordinarily about 7 to 10.
Typically, the compound will be administered in a dose from 0.01 milligrams to
2 grams. In one
embodiment, the dose will be from about 10 milligrams to 450 milligrams. In
another embodiment,
the dosage will be from about 25 to about 250 milligrams. In another
embodiment, the dosage will be
about 50 or 100 milligrams. In one embodiment, the dosage will be about 100
milligrams. It is
contemplated that the compound may be administered once, twice or three times
a day.
While it is possible for the active ingredients to be administered alone it
may be preferable to
present them as pharmaceutical formulations. The formulations, both for
veterinary and for human
use, of the disclosure comprise at least one active ingredient, as above
defined, together with one or
more acceptable carriers therefor and optionally other therapeutic
ingredients. The carrier(s) must be
"acceptable" in the sense of being compatible with the other ingredients of
the formulation and
physiologically innocuous to the recipient thereof.
The formulations include those suitable for the foregoing administration
routes. The
formulations may conveniently be presented in unit dosage form and may be
prepared by any of the
methods well known in the art of pharmacy. Techniques and formulations
generally are found in
Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such
methods include the
step of bringing into association the active ingredient with the carrier which
constitutes one or more
accessory ingredients. In general the formulations are prepared by uniformly
and intimately bringing
into association the active ingredient with liquid carriers or finely divided
solid carriers or both, and
then, if necessary, shaping the product.
Formulations of the present disclosure suitable for oral administration may be
presented as
discrete units such as capsules, cachets or tablets each containing a
predetermined amount of the
active ingredient; as a powder or granules; as a solution or a suspension in
an aqueous or non-aqueous
liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid
emulsion. The active ingredient
may also be administered as a bolus, electuary or paste.
A tablet is made by compression or molding, optionally with one or more
ingredients. Compressed tablets may be prepared by compressing in a suitable
machine the active
ingredient in a free-flowing form such as a powder or granules, optionally
mixed with a binder,
lubricant, inert diluent, preservative, surface active or dispersing agent.
Molded tablets may be made
by molding in a suitable machine a mixture of the powdered active ingredient
moistened with an inert
liquid diluent. The tablets may optionally be coated or scored and optionally
are formulated so as to
provide slow or controlled release of the active ingredient therefrom.
For administration to the eye or other external tissues e.g., mouth and skin,
the formulations
are preferably applied as a topical ointment or cream containing the active
ingredient(s) in an amount
of, for example, 0.075 to 20% w/w (including active ingredient(s) in a range
between 0.1% and 20%
in increments of 0.1% w/w such as 0.6% w/w, 0.7% w/w, etc.), preferably 0.2 to
15% w/w and most
preferably 0.5 to 10% w/w. When formulated in an ointment, the active
ingredients may be employed
with either a paraffinic or a water-miscible ointment base. Alternatively, the
active ingredients may
be formulated in a cream with an oil-in-water cream base.
If desired, the aqueous phase of the cream base may include, for example, at
least 30% w/w of
a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such
as propylene glycol,
butane 1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol
(including PEG 400) and
mixtures thereof. The topical formulations may desirably include a compound
which enhances
absorption or penetration of the active ingredient through the skin or other
affected areas. Examples
of such dermal penetration enhancers include dimethyl sulphoxide and related
analogs.
The oily phase of the emulsions of this disclosure may be constituted from
known ingredients
in a known manner. While the phase may comprise merely an emulsifier
(otherwise known as an
emulgent), it desirably comprises a mixture of at least one emulsifier with a
fat or an oil or with both a
fat and an oil. Preferably, a hydrophilic emulsifier is included together with
a lipophilic emulsifier
which acts as a stabilizer. It is also preferred to include both an oil and a
fat. Together, the
emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying
wax, and the wax
together with the oil and fat make up the so-called emulsifying ointment base
which forms the oily
dispersed phase of the cream formulations.
Emulgents and emulsion stabilizers suitable for use in the formulation of the
include Tween 60, Span 80, cetostearyl alcohol, benzyl alcohol, myristyl
alcohol, glyceryl mono-
stearate and sodium lauryl sulfate.
The choice of suitable oils or fats for the formulation is based on achieving
the desired
cosmetic properties. The cream should preferably be a non-greasy, non-staining
and washable
product with suitable consistency to avoid leakage from tubes or other
containers. Straight or
branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl
stearate, propylene glycol
diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl
palmitate, butyl stearate, 2-
ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP
may be used, the
last three being preferred esters. These may be used alone or in combination
depending on the
properties required. Alternatively, high melting point lipids such as white
soft paraffin and/or liquid
paraffin or other mineral oils are used.
Pharmaceutical formulations according to the present disclosure comprise one
compounds of the disclosure together with one or more pharmaceutically
acceptable carriers or
excipients and optionally other therapeutic agents. Pharmaceutical
formulations containing the active
ingredient may be in any form suitable for the intended method of
administration. When used for oral
use for example, tablets, troches, lozenges, aqueous or oil suspensions,
dispersible powders or
granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared.
Compositions intended
for oral use may be prepared according to any method known to the art for the
manufacture of
pharmaceutical compositions and such compositions may contain one or more
agents including
sweetening agents, flavoring agents, coloring agents and preserving agents, in
order to provide a
palatable preparation. Tablets containing the active ingredient in admixture
with non-toxic
pharmaceutically acceptable excipient which are suitable for manufacture of
tablets are acceptable.
These excipients may be, for example, inert diluents, such as calcium or
sodium carbonate, lactose,
lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium
phosphate; granulating
and disintegrating agents, such as maize starch, or alginic acid; binding
agents, such as cellulose,
microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents,
such as magnesium
stearate, stearic acid or talc. Tablets may be uncoated or may be coated by
known techniques
including microencapsulation to delay disintegration and adsorption in the
gastrointestinal tract and
thereby provide a sustained action over a longer period. For example, a time
delay material such as
glyceryl monostearate or glyceryl distearate alone or with a wax may be
employed.
Formulations for oral use may be also presented as hard gelatin capsules where
the active
ingredient is mixed with an inert solid diluent, for example calcium phosphate
or kaolin, or as soft
gelatin capsules wherein the active ingredient is mixed with water or an oil
medium, such as peanut
oil, liquid paraffin or olive oil.
Aqueous suspensions of the disclosure contain the active materials in
admixture with
excipients suitable for the manufacture of aqueous suspensions. Such
excipients include a suspending
agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl
methylcelluose,
sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and
dispersing or wetting
agents such as a naturally occurring phosphatide (e.g., lecithin), a
condensation product of an alkylene
oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation
product of ethylene oxide with
a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a
condensation product of ethylene
oxide with a partial ester derived from a fatty acid and a hexitol anhydride
(e.g., polyoxyethylene
sorbitan monooleate). The aqueous suspension may also contain one or more
preservatives such as
ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more
flavoring agents and
one or more sweetening agents, such as sucrose or saccharin.
Oil suspensions may be formulated by suspending the active ingredient in a
vegetable oil,
such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil
such as liquid paraffin. The
oral suspensions may contain a thickening agent, such as beeswax, hard
paraffin or cetyl alcohol.
Sweetening agents, such as those set forth above, and flavoring agents may be
added to provide a
palatable oral preparation. These compositions may be preserved by the
addition of an antioxidant
such as ascorbic acid.
Dispersible powders and granules of the disclosure suitable for preparation of
an aqueous
suspension by the addition of water provide the active ingredient in admixture
with a dispersing or
wetting agent, a suspending agent, and one or more preservatives. Suitable
agents and suspending agents are exemplified by those disclosed above.
Additional excipients, for
example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the disclosure may also be in the form of
oil-in-water
emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis
oil, a mineral oil, such
as liquid paraffin, or a mixture of these. Suitable emulsifying agents include
naturally-occurring
gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides,
such as soybean
lecithin, esters or partial esters derived from fatty acids and hexitol
anhydrides, such as sorbitan
monooleate, and condensation products of these partial esters with ethylene
oxide, such as
polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening
and flavoring
agents. Syrups and elixirs may be formulated with sweetening agents, such as
glycerol, sorbitol or
sucrose. Such formulations may also contain a demulcent, a preservative, a
flavoring or a coloring
agent.
The pharmaceutical compositions of the disclosure may be in the form of a
sterile injectable
preparation, such as a sterile injectable aqueous or oleaginous suspension.
This suspension may be
formulated according to the known art using those suitable dispersing or
wetting agents and
suspending agents which have been mentioned above. The sterile injectable
preparation may also be
a sterile injectable solution or suspension in a non-toxic parenterally
acceptable diluent or solvent,
such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
Among the acceptable
vehicles and solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride
solution. In addition, sterile fixed oils may conventionally be employed as a
solvent or suspending
medium. For this purpose any bland fixed oil may be employed including
synthetic mono- or
diglycerides. In addition, fatty acids such as oleic acid may likewise be used
in the preparation of
injectables.
The amount of active ingredient that may be combined with the carrier material
to produce a
single dosage form will vary depending upon the host treated and the
particular mode of
administration. For example, a time-release formulation intended for oral
administration to humans
may contain approximately 1 to 1000 mg of active material compounded with an
appropriate and
convenient amount of carrier material which may vary from about 5 to about 95%
of the total
compositions (weight:weight). The pharmaceutical composition can be prepared
to provide easily
measurable amounts for administration. For example, an aqueous solution
intended for intravenous
infusion may contain from about 3 to 500 pg of the active ingredient per
milliliter of solution in order
that infusion of a suitable volume at a rate of about 30 mL/hr can occur.
Formulations suitable for administration to the eye include eye drops wherein
ingredient is dissolved or suspended in a suitable carrier, especially an
aqueous solvent for the active
ingredient. The active ingredient is preferably present in such formulations
in a concentration of 0.5
to 20%, advantageously 0.5 to 10% particularly about 1.5% w/w.
Formulations suitable for topical administration in the mouth include lozenges
comprising the
active ingredient in a flavored basis, usually sucrose and acacia or
tragacanth; pastilles comprising the
active ingredient in an inert basis such as gelatin and glycerin, or sucrose
and acacia; and
mouthwashes comprising the active ingredient in a suitable liquid carrier.
Formulations for rectal administration may be presented as a suppository with
a suitable base
comprising for example cocoa butter or a salicylate.
Formulations suitable for intrapulmonary or nasal administration have a
particle size for
example in the range of 0.1 to 500 microns (including particle sizes in a
range between 0.1 and 500
microns in increments microns such as 0.5, 1, 30 microns, 35 microns, etc.),
which is administered by
rapid inhalation through the nasal passage or by inhalation through the mouth
so as to reach the
alveolar sacs. Suitable formulations include aqueous or oily solutions of the
active ingredient.
Formulations suitable for aerosol or dry powder administration may be prepared
conventional methods and may be delivered with other therapeutic agents such
as compounds
heretofore used in the treatment or prophylaxis of conditions associated with
HCV activity.
Formulations suitable for vaginal administration may be presented as
pessaries, tampons,
creams, gels, pastes, foams or spray formulations containing in addition to
the active ingredient such
carriers as are known in the art to be appropriate.
Formulations suitable for parenteral administration include aqueous and non-
aqueous sterile
injection solutions which may contain anti-oxidants, buffers, bacteriostats
and solutes which render
the formulation isotonic with the blood of the intended recipient; and aqueous
and non-aqueous sterile
suspensions which may include suspending agents and thickening agents.
The formulations are presented in unit-dose or multi-dose containers, for
example sealed
ampoules and vials, and may be stored in a freeze-dried (lyophilized)
condition requiring only the
addition of the sterile liquid carrier, for example water for injection,
immediately prior to use.
Extemporaneous injection solutions and suspensions are prepared from sterile
powders, granules and
tablets of the kind previously described. Preferred unit dosage formulations
are those containing a
daily dose or unit daily sub-dose, as herein above recited, or an appropriate
fraction thereof, of the
It should be understood that in addition to the ingredients particularly
mentioned above the
formulations of this disclosure may include other agents conventional in the
art having regard to the
type of formulation in question, for example those suitable for oral
administration may include
flavoring agents.
The disclosure further provides veterinary compositions comprising at least
one active
ingredient as above defined together with a veterinary carrier therefor.
Veterinary carriers are materials useful for the purpose of administering the
composition and
may be solid, liquid or gaseous materials which are otherwise inert or
acceptable in the veterinary art
and are compatible with the active ingredient. These veterinary compositions
may be administered
orally, parenterally or by any other desired route.
Compounds of the disclosure can also be formulated to provide controlled
release of the
active ingredient to allow less frequent dosing or to improve the
pharmacokinetic or toxicity profile of
the active ingredient. Accordingly, the disclosure also provides compositions
comprising one or more
compounds of the disclosure formulated for sustained or controlled release.
Effective dose of active ingredient depends at least on the nature of the
condition being
treated, toxicity, whether the compound is being used prophylactically (lower
doses), the method of
delivery, and the pharmaceutical formulation, and will be determined by the
clinician using
conventional dose escalation studies.
Routes of Administration
One or more compounds of the disclosure (herein referred to as the active
ingredients) are
administered by any route appropriate to the condition to be treated. Suitable
routes include oral,
rectal, nasal, topical (including buccal and sublingual), vaginal and
parenteral (including
subcutaneous, intramuscular, intravenous, intradermal, intrathecal and
epidural), and the like. It will
be appreciated that the preferred route may vary with for example the
condition of the recipient. An
advantage of the compounds of this disclosure is that they are orally
bioavailable and can be dosed
orally.
HCV Combination Therapy
In another embodiment, non-limiting examples of suitable combinations include
combinations of one or more compounds of formula (I) and (Al-A4) with one or
more interferons,
ribavirin or its analogs, HCV N53 protease inhibitors, alpha-glucosidase 1
inhibitors,
hepatoprotectants, nucleoside or nucleotide inhibitors of HCV NS5B polymerase,
non-nucleoside
inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, TLR-7 agonists,
cyclophillin inhibitors,
HCV IRES inhibitors, pharmacokinetic enhancers, and other drugs or therapeutic
agents for treating
HCV.
More specifically, one or more compounds as described herein may be combined
with one or
more compounds selected from the group consisting of:
1) interferons, e.g., pegylated rIEN-alpha 2b (PEG-Intron), pegylated rIEN-
alpha 2a
(Pegasys), rIEN-alpha 2b (Intron A), rIEN-alpha 2a (Roferon-A), interferon
alpha (MOR-22, OPC-18,
Alfaferone, Alfanative, Multiferon, subalin), interferon alfacon-1 (Infergen),
(Wellferon), interferon alpha-n3 (Alferon), interferon-beta (Avonex, DL-8234),
interferon-omega
(omega DUROS, Biomed 510), albinterferon alpha-2b (Albuferon), IFN alpha-2b
XL, BLX-883
(Locteron), DA-3021, glycosylated interferon alpha-2b (AVI-005), PEG-Infergen,
PEGylated
interferon lambda-1 (PEGylated IL-29), and belerofon;
2) ribavirin and its analogs, e.g., ribavirin (Rebetol, Copegus), and
taribavirin (Viramidine);
3) HCV N53 protease inhibitors, e.g., boceprevir (SCH-503034, SCH-7),
telaprevir (VX-
950), TMC435350, BI-1335, BI-1230, MK-7009, VBY-376, VX-500, GS-9256, GS-9451,
BMS-
605339, PHX-1766, AS-101, YH-5258, YH5530, YH5531, ABT-450, ACH-1625, ITMN-
MK5172, MK6325, and MK2748;
4) alpha-glucosidase 1 inhibitors, e.g., celgosivir (MX-3253), Miglitol, and
UT-231B;
5) hepatoprotectants, e.g., emericasan (IDN-6556), ME-3738, GS-9450 (LB-
84451), silibilin,
and MitoQ;
6) nucleoside or nucleotide inhibitors of HCV NS5B polymerase, e.g., R1626,
(R4048), IDX184, IDX-102, BCX-4678, valopicitabine (NM-283), MK-0608,
sofosbuvir (GS-7977
(formerly PSI-7977)), and INX-189 (now BMS986094);
7) non-nucleoside inhibitors of HCV NS5B polymerase, e.g., PF-868554, VCH-759,
VCH-
916, JTK-652, MK-3281, GS-9190, VBY-708, VCH-222, A848837, ANA-598, GL60667,
GL59728,
A-63890, A-48773, A-48547, BC-2329, VCH-796 (nesbuvir), GSK625433, BILN-1941,
XTL-2125,
ABT-072, ABT-333, GS-9669. PSI-7792, and GS-9190;
8) HCV NS5A inhibitors, e.g., AZD-2836 (A-831), BMS-790052, ACH-3102, ACH-
MK8325, MK4882, MK8742, PSI-461, IDX719, and A-689;
9) TLR-7 agonists, e.g., imiquimod, 852A, GS-9524, ANA-773, ANA-975, AZD-8848
(DSP-
3025), and SM-360320;
10) cyclophillin inhibitors, e.g., DEB10-025, SCY-635, and NIM811;
11) HCV IRES inhibitors, e.g., MCI-067;
12) pharmacokinetic enhancers, e.g., BAS-100, SP1-452, PF-4194477, TMC-41629,
GS-
9350, GS-9585, and roxythromycin; and
13) other drugs for treating HCV, e.g., thymosin alpha 1 (Zadaxin),
nitazoxanide (Alinea,
NTZ), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101),
GS-9525, KRN-
7000, civacir, GI-5005, XTL-6865, BIT225, PTX-111, ITX2865, TT-033i, ANA 971,
NOV-205,
tarvacin, EHC-18, VGX-410C, EMZ-702, AVI 4065, BMS-650032, BMS-791325,
Bavituximab,
MDX-1106 (ONO-4538), Oglufanide, and VX-497 (merimepodib).
more compounds selected from the group consisting of non-nucleoside inhibitors
of HCV NS5B
polymerase (ABT-072 and ABT-333), HCV NS5A inhibitors (ACH-3102 and ACH-2928)
and HCV
NS3 protease inhibitors(ABT-450 and ACH-1625).
In yet another embodiment, the present application discloses pharmaceutical
comprising a compound as described herein, or a pharmaceutically acceptable
salt, solvate, and/or
ester thereof, in combination with at least one additional therapeutic agent,
and a pharmaceutically
acceptable carrier or excipient.
According to one embodiment, the therapeutic agent used in combination with
the compound
as described herein can be any agent having a therapeutic effect when used in
combination with the
compound as described herein. For example, the therapeutic agent used in
compound as described herein can be interferons, ribavirin analogs, NS3
protease inhibitors, NS5b
polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-
nucleoside inhibitors of
HCV, and other drugs for treating HCV.
In another embodiment, the present application provides pharmaceutical
comprising a compound of formula (I), or a pharmaceutically acceptable salt,
solvate, and/or ester
thereof, in combination with at least one additional therapeutic agent
selected from the group
consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b,
IFN alpha-2b XL,
rIFN-alpha 2a, consensus IFN alpha, infergen, rebif, locteron, AVI-005, PEG-
infergen, pegylated
IFN-beta, oral interferon alpha, feron, reaferon, intermax alpha, r-IFN-beta,
infergen + actimmune,
IFN-omega with DUROS, albuferon, rebetol, copegus, levovirin, VX-497,
viramidine (taribavirin), A-
831, A-689, NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB
1941, MK-0608,
NM-107, R7128, VCH-759, PF-868554, GSK625433, XTL-2125, SCH-503034 (SCH-7), VX-
(Telaprevir), ITMN-191, and BILN-2065, MX-3253 (celgosivir), UT-231B, IDN-
6556, ME 3738,
MitoQ, and LB-84451, benzimidazole derivatives, benzo-1,2,4-thiadiazine
derivatives, and
phenylalanine derivatives, zadaxin, nitazoxanide (alinea), BIVN-401
(virostat), DEB10-025, VGX-
410C, EMZ-702, AVI 4065, bavituximab, oglufanide, PYN-17, KPE02003002, actilon
(CPG-10101),
KRN-7000, civacir, GI-5005, ANA-975 (isatoribine), XTL-6865, ANA 971, NOV-205,
tarvacin,
EHC-18, and NIM811 and a pharmaceutically acceptable carrier or excipient.
In yet another embodiment, the present application provides a combination
agent comprising:
a) a first pharmaceutical composition comprising a compound of
formula (I), or a
pharmaceutically acceptable salt, solvate, or ester thereof; and
b) a second pharmaceutical composition comprising at least one additional
agent selected from the group consisting of HIV protease inhibiting compounds,
HIV non-nucleoside
inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse
transcriptase, HIV nucleotide
inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41
inhibitors, CXCR4 inhibitors, gp120
inhibitors, CCR5 inhibitors, interferons, ribavirin analogs, NS3 protease
inhibitors, alpha-glucosidase
1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other
drugs for treating HCV,
and combinations thereof.
In another embodiment is provided a pharmaceutical composition comprising a
formula (I) as described herein and a nucleoside or nucleotide inhibitors of
HCV NS5B polymerase
and optionally an interferon or ribavirin. In one embodiment, the compound is
methyl {(2S)-1-
[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyll -
(methoxymethyppyrrolidin-2-y1]-1H-imidazol-5-yll -1,11-
dihydroisochromeno[4',3':6,7]naphtho [1,2-
d]imidazol-2-y1)-5-methylpyrrolidin-l-y1]-3-methyl-l-oxobutan-2-yll carbamate
having the formula:
OA N.H
I N N 4 10. Ni
-N 0
and the inhibitor is sofosbuvir.
Combinations of the compounds of formula I and additional active therapeutic
agents may be
selected to treat patients infected with HCV and other conditions such as HIV
infections.
Accordingly, the compounds of formula I may be combined with one or more
compounds useful in
treating HIV, for example HIV protease inhibiting compounds, non-nucleoside
inhibitors of HIV
reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV
nucleotide inhibitors of
reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4
inhibitors, gpl 20 inhibitors,
CCR5 inhibitors, interferons, ribavirin analogs, NS3 protease inhibitors, NS5b
polymerase inhibitors,
alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors
of HCV, and other drugs
for treating HCV.
More specifically, one or more compounds of formula (I) or (A1)-(A4) may be
with one or more compounds selected from the group consisting of 1) HIV
protease inhibitors, e.g.,
amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir,
lopinavir + ritonavir, nelfinavir,
saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir
(DMP-450), JE-2147
(AG1776), AG1859, DG35, L-756423, R00334649, KNI-272, DPC-681, DPC-684, and
GW640385X, DG17, PPL-100, 2) a HIV non-nucleoside inhibitor of reverse
transcriptase, e.g.,
capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+) calanolide A,
etravirine, GW5634,
DPC-083, DPC-961, DPC-963, MIV-150, and TMC-120, TMC-278 (rilpivirine),
efavirenz, BILR 355
BS, VRX 840773, UK-453,061, RDEA806, 3) a HIV nucleoside inhibitor of reverse
transcriptase,
e.g., zidovudine, emtricitabine, didanosine, stavudine, zalcitabine,
lamivudine, abacavir, amdoxovir,
elvucitabine, alovudine, MIV-210, racivir ( -FTC), D-d4FC, emtricitabine,
phosphazide, fozivudine
tidoxil, fosalvudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461,
abacavir + lamivudine,
abacavir + lamivudine + zidovudine, zidovudine + lamivudine, 4) a HIV
nucleotide inhibitor of
reverse transcriptase, e.g., tenofovir, tenofovir disoproxil fumarate +
emtricitabine, tenofovir
disoproxil fumarate + emtricitabine + efavirenz, and adefovir, 5) a HIV
integrase inhibitor, e.g.,
curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric
acid, 3,5-dicaffeoylquinic
acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid,
derivatives of aurintricarboxylic
acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl
ester, tyrphostin, derivatives of
tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-
870812, and L-870810,
MK-0518 (raltegravir), BMS-707035, MK-2048, BA-011, BMS-538158, GSK364735C, 6)
a gp41
inhibitor, e.g., enfuvirtide, sifuvirtide, FB006M, TRI-1144, SPC3, DES6, Locus
gp41, CovX, and
REP 9, 7) a CXCR4 inhibitor, e.g., AMD-070, 8) an entry inhibitor, e.g.,
SPO1A, TNX-355, 9) a
gp120 inhibitor, e.g., BMS-488043 and BlockAide/CR, 10) a G6PD and NADH-
oxidase inhibitor,
e.g., immunitin, 10) a CCR5 inhibitor, e.g., aplaviroc, vicriviroc, INCB9471,
PRO-140, INCB15050,
PF-232798, CCR5mAb004, and maraviroc, 11) an interferon, e.g., pegylated rIFN-
alpha 2b,
pegylated rIFN-alpha 2a, rIFN-alpha 2b, IFN alpha-2b XL, rIFN-alpha 2a,
consensus IFN alpha,
infergen, rebif, locteron, AVI-005, PEG-infergen, pegylated IFN-beta, oral
interferon alpha, feron,
reaferon, intermax alpha, r-IFN-beta, infergen + actimmune, IFN-omega with
DUROS, and albuferon,
12) ribavirin analogs, e.g., rebetol, copegus, levovirin, VX-497, and
viramidine (taribavirin) 13) NS5a
inhibitors, e.g., A-831, A-689, and BMS-790052, 14) NS5b polymerase
inhibitors, e.g., NM-283,
valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, MK-0608, NM-107,
R7128, VCH-
759, PF-868554, GSK625433, and XTL-2125, 15) NS3 protease inhibitors, e.g.,
SCH-503034 (SCH-
7), VX-950 (Telaprevir), ITMN-191, and BILN-2065, 16) alpha-glucosidase 1
inhibitors, e.g., MX-
3253 (celgosivir) and UT-231B, 17) hepatoprotectants, e.g., IDN-6556, ME 3738,
MitoQ, and LB-
84451, 18) non-nucleoside inhibitors of HCV, e.g., benzimidazole derivatives,
benzo-1,2,4-
thiadiazine derivatives, and phenylalanine derivatives, 19) other drugs for
treating Hepatitis C, e.g.,
zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), DEB10-025, VGX-410C, EMZ-
702, AVI 4065,
bavituximab, oglufanide, PYN-17, KPE02003002, actilon (CPG-10101), KRN-7000,
civacir, Gl-
5005, ANA-975 (isatoribine), XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, and
NIM811, 19)
pharmacokinetic enhancers, e.g., BAS-100 and SPI452, 20) RNAse H inhibitors,
e.g., ODN-93 and
ODN-112, 21) other anti-HIV agents, e.g., VGV-1, PA-457 (bevirimat), ampligen,
HRG214, cytolin,
polymun, VGX-410, KD247, AMZ 0026, CYT 99007, A-221 HIV, BAY 50-4798, MDX010
(iplimumab), PBS119, ALG889, and PA-1050040.
It is contemplated that the second therapeutic agent will be administered in a
manner that is
known in the art and the dosage may be selected by someone of skill in the
art. For example, the
second agent may be administered in a dose from about 0.01 milligrams to about
2 grams per day.
Metabolites of the Compounds
Also falling within the scope of this disclosure are the in vivo metabolic
products of the
compounds described herein. Such products may result for example from the
oxidation, reduction,
hydrolysis, amidation, esterification and the like of the administered
compound, primarily due to
enzymatic processes. Accordingly, the disclosure includes compounds produced
by a process
comprising contacting a compound of this disclosure with a mammal for a period
of time sufficient to
yield a metabolic product thereof. Such products typically are identified by
preparing a radiolabelled
(e.g., CH or H3) compound of the disclosure, administering it parenterally in
a detectable dose (e.g.,
greater than about 0.5 mg/kg) to an animal such as rat, mouse, guinea pig,
monkey, or to man,
allowing sufficient time for metabolism to occur (typically about 30 seconds
to 30 hours) and
isolating its conversion products from the urine, blood or other biological
samples. These products
are easily isolated since they are labeled (others are isolated by the use of
antibodies capable of
binding epitopes surviving in the metabolite). The metabolite structures are
determined in
conventional fashion, e.g., by MS or NMR analysis. In general, analysis of
metabolites is done in the
same way as conventional drug metabolism studies well-known to those skilled
in the art. The
conversion products, so long as they are not otherwise found in vivo, are
useful in diagnostic assays
for therapeutic dosing of the compounds of the disclosure even if they possess
no HCV ¨inhibitory
activity of their own.
Methods for determining stability of compounds in surrogate gastrointestinal
secretions are
Exemplary Methods of Making the Compounds
The disclosure also relates to methods of making the compositions of the
disclosure. The
compositions are prepared by any of the applicable techniques of organic
synthesis. Many such
techniques are well known in the art. However, many of the known techniques
are elaborated in
Compendium of Organic Synthetic Methods (John Wiley & Sons, New York), Vol. 1,
Harrison and Shuyen Harrison, 1971; Vol. 2, Ian T. Harrison and Shuyen
Harrison, 1974; Vol. 3,
Louis S. Hegedus and Leroy Wade, 1977; Vol. 4, Leroy G. Wade, Jr., 1980; Vol.
5, Leroy G.
Wade, Jr., 1984; and Vol. 6, Michael B. Smith; as well as March, J., Advanced
Organic Chemistry,
Third Edition, (John Wiley & Sons, New York, 1985), Comprehensive Organic
Synthesis.
Selectivity, Strategy & Efficiency in Modem Organic Chemistry. In 9 Volumes,
Barry M. Trost,
Editor-in-Chief (Pergamon Press, New York, 1993 printing). Other methods
suitable for preparing
compounds of the disclosure are described in International Patent Application
WO 2006/020276.
A number of exemplary methods for the preparation of the compositions of the
disclosure are
provided in the schemes and examples below. These methods are intended to
illustrate the nature of
such preparations and are not intended to limit the scope of applicable
Generally, the reaction conditions such as temperature, reaction time,
solvents, work-up
procedures, and the like, will be those common in the art for the particular
reaction to be performed.
The cited reference material, together with material cited therein, contains
detailed descriptions of
such conditions. Typically the temperatures will be -100 C to 200 C, solvents
will be aprotic or
protic, and reaction times will be 10 seconds to 10 days. Work-up typically
consists of quenching any
unreacted reagents followed by partition between a water/organic layer system
(extraction) and
separating the layer containing the product.
Oxidation and reduction reactions are typically carried out at temperatures
near room
temperature (about 20 C), although for metal hydride reductions frequently the
temperature is reduced
to 0 C to -100 C, solvents are typically aprotic for reductions and may be
either protic or aprotic for
oxidations. Reaction times are adjusted to achieve desired conversions.
Condensation reactions are typically carried out at temperatures near room
although for non-equilibrating, kinetically controlled condensations reduced
temperatures (0 C to -
100 C) are also common. Solvents can be either protic (common in equilibrating
reactions) or aprotic
(common in kinetically controlled reactions).
Standard synthetic techniques such as azeotropic removal of reaction by-
products and use of
anhydrous reaction conditions (e.g., inert gas environments) are common in the
art and will be applied
when applicable.
The terms "treated", "treating", "treatment", and the like, when used in
connection with a
chemical synthetic operation, mean contacting, mixing, reacting, allowing to
react, bringing into
contact, and other terms common in the art for indicating that one or more
chemical entities is treated
in such a manner as to convert it to one or more other chemical entities. This
means that "treating
compound one with compound two" is synonymous with "allowing compound one to
react with
compound two", "contacting compound one with compound two", "reacting compound
one with
compound two", and other expressions common in the art of organic synthesis
for reasonably
indicating that compound one was "treated", "reacted", "allowed to react",
etc., with compound two.
For example, treating indicates the reasonable and usual manner in which
organic chemicals are
allowed to react. Normal concentrations (0.01M to 10M, typically 0.1M to 1M),
temperatures (-
100 C to 250 C, typically -78 C to 150 C, more typically -78 C to 100 C, still
more typically 0 C to
100 C), reaction vessels (typically glass, plastic, metal), solvents,
pressures, atmospheres (typically
air for oxygen and water insensitive reactions or nitrogen or argon for oxygen
or water sensitive), etc.,
are intended unless otherwise indicated. The knowledge of similar reactions
known in the art of
organic synthesis is used in selecting the conditions and apparatus for
"treating" in a given process.
In particular, one of ordinary skill in the art of organic synthesis selects
conditions and apparatus
reasonably expected to successfully carry out the chemical reactions of the
described processes based
on the knowledge in the art.
Modifications of each of the exemplary schemes and in the Examples (hereafter
"exemplary
schemes") leads to various analogs of the specific exemplary materials
produce. The above-cited
citations describing suitable methods of organic synthesis are applicable to
such modifications.
In each of the exemplary schemes it may be advantageous to separate reaction
one another and/or from starting materials. The desired products of each step
or series of steps is
separated and/or purified (hereinafter separated) to the desired degree of
homogeneity by the
techniques common in the art. Typically such separations involve multiphase
crystallization from a solvent or solvent mixture, distillation, sublimation,
or chromatography.
Chromatography can involve any number of methods including, for example:
reverse-phase and
normal phase; size exclusion; ion exchange; high, medium, and low pressure
methods and apparatus; small scale analytical; simulated moving bed (SMB) and
preparative thin or
thick layer chromatography, as well as techniques of small scale thin layer
and flash chromatography.
Another class of separation methods involves treatment of a mixture with a
reagent selected to
bind to or render otherwise separable a desired product, unreacted starting
material, reaction by
product, or the like. Such reagents include adsorbents or absorbents such as
molecular sieves, ion exchange media, or the like. Alternatively, the reagents
can be acids in the case
of a basic material, bases in the case of an acidic material, binding reagents
such as antibodies,
binding proteins, selective chelators such as crown ethers, liquid/liquid ion
extraction reagents (LIX),
or the like.
Selection of appropriate methods of separation depends on the nature of the
involved. For example, boiling point, and molecular weight in distillation and
sublimation, presence
or absence of polar functional groups in chromatography, stability of
materials in acidic and basic
media in multiphase extraction, and the like. One skilled in the art will
apply techniques most likely
to achieve the desired separation.
A single stereoisomer, e.g., an enantiomer, substantially free of its
stereoisomer may be
obtained by resolution of the racemic mixture using a method such as formation
of diastereomers
using optically active resolving agents (Stereochemistry of Carbon Compounds,
(1962) by E. L.
Eliel, McGraw Hill; Lochmuller, C. H., (1975)1 Chromatogr., 113,3) 283-302).
Racemic mixtures
of chiral compounds of the disclosure can be separated and isolated by any
suitable method,
including: (1) formation of ionic, diastereomeric salts with chiral compounds
and separation by
fractional crystallization or other methods, (2) formation of diastereomeric
compounds with chiral
derivatizing reagents, separation of the diastereomers, and conversion to the
pure stereoisomers, and
(3) separation of the substantially pure or enriched stereoisomers directly
under chiral conditions.
Under method (1), diastereomeric salts can be formed by reaction of
enantiomerically pure
chiral bases such as brucine, quinine, ephedrine, strychnine, a-methyl-13-
phenylethylamine
(amphetamine), and the like with asymmetric compounds bearing acidic
functionality, such as
carboxylic acid and sulfonic acid. The diastereomeric salts may be induced to
separate by fractional
crystallization or ionic chromatography. For separation of the optical isomers
of amino compounds,
addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid,
tartaric acid, mandelic
acid, or lactic acid can result in formation of the diastereomeric salts.
Alternatively, by method (2), the substrate to be resolved is reacted with one
enantiomer of a
chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994)
Stereochemistry of
Organic Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric compounds
can be formed
by reacting asymmetric compounds with enantiomerically pure chiral
derivatizing reagents, such as
menthyl derivatives, followed by separation of the diastereomers and
hydrolysis to yield the free,
enantiomerically enriched substrate. A method of determining optical purity
involves making chiral
esters, such as a menthyl ester, e.g., (-) menthyl chloroformate in the
presence of base, or Mosher
ester, oc-methoxy-cc-(trifluoromethyl)phenyl acetate (Jacob III. (1982)J. Org.
Chem. 47:4165), of
the racemic mixture, and analyzing the NMR spectrum for the presence of the
two atropisomeric
diastereomers. Stable diastereomers of atropisomeric compounds can be
separated and isolated by
normal- and reverse-phase chromatography following methods for separation of
atropisomeric
naphthyl-isoquinolines (Hoye, T., WO 96/15111). By method (3), a racemic
mixture of two
enantiomers can be separated by chromatography using a chiral stationary phase
(Chiral Liquid
Chromatography (1989) W. J. Lough, Ed. Chapman and Hall, New York; Okamoto,
(1990)1 of
Chromatogr. 513:375-378). Enriched or purified enantiomers can be
distinguished by methods used
to distinguish other chiral molecules with asymmetric carbon atoms, such as
optical rotation and
I 0 circular dichroism.
Schemes and Examples
General aspects of these exemplary methods are described below and in the
Examples. Each
of the products of the following processes is optionally separated, isolated,
and/or purified prior to its
use in subsequent processes.
A number of exemplary methods for the preparation of compounds of the
provided herein, for example, in the Examples below. These methods are
intended to illustrate the
nature of such preparations and are not intended to limit the scope of
applicable methods. Certain
compounds of the disclosure can be used as intermediates for the preparation
of other compounds of
the disclosure. In the exemplary methods described herein, the fragment E-V-
can also be written as
R9-. PG represents a protecting group common for the given functional group
that it is attached. The
installation and removal of the protecting group can be accomplished using
standard techniques, such
as those described in Wuts, P. G. M., Greene, T. Protective Groups in Organic
Synthesis, 4th ed.;
John Wiley & Sons, Inc.: Hoboken, New Jersey, 2007.
Scheme I. Representative synthesis of E-V-C(=0)-P-W-P-C(=0)-V-E
0 a c:\
H2N¨V-C(=0)-P-W-P-C(=0)-V-E ________________________________________ >\---NH-
V-C(=0)-P-W-P-C(=0)-V-E
la lb
2 OACI0 0
H2N¨V-C(=0)-P-W-P-C(=0)-V¨NH2 ________________ > NH-V-C(=0)-P-W-P-C(=0)-V-
NH--
1c Id
Scheme 1 shows a general synthesis of an E-V-C(=0)-P-W-P-C(=0)-V-E molecule of
disclosure wherein, for illustrative purposes, E is methoxycarbonylamino. The
treatment of either la
or lc with one or two equivalents respectively of methyl chloroformate under
basic conditions (e.g.
sodium hydroxide) provides the molecule lb or Id.
Scheme 2. Representative synthesis of E-V-C(=0)-P-W-P-C(=0)-V-E
E-V-C(=0)-P-W¨C + HO V-E E-V-C(=0)-P-W¨C¨
N' 0
2a H 2b 2c 0\
V-E
E-V
---N HO --N
J¨w + 2
2d 2b 2e OV-E
Scheme 2 shows a general synthesis of an E-V-C(:=0)-P-W-P-C(=0)-V-E molecule
disclosure wherein, for illustrative purposes, P is pyrrolidine. Coupling of
amine 2a with acid 2b is
accomplished using a peptide coupling reagent (e.g. HATU) to afford 2c.
Alternatively, amine 2d is
coupled with two equivalents of 2b under similar conditions to provide 2e.
Scheme 6. Representative synthesis of R'-V-C(=0)-P-R2
E-V-C(=0)-P-W¨C-- + HO E-V-C(=0)-P-W¨C--
6a H 6b 6c ox
V-NH-PG
PG-HN-V-C(=0)-P-W¨C-- + HO ¨V-E --..- PG-HN-V-C(=0)-P-W¨C--
6d H 6e 6f 0.\
PG-HN-V-C(=0)-P-W¨C-- + HO PG-HN-V-C(=0)-P-W¨C.¨
N--- 0 N---
6d H 6b 6g
_____________________________________________ ,
PG-HN-P-W¨C--<' + --V-E PG-HN-P-W¨C-
6h H 6e 6i cyx
PG-HN-P-W¨C-- + HO ______________ i PG-HN-P-W¨C-
6h H 6b 6j 0.\
PG-HN-W¨C¨ + HO ----V-E PG-HN-W¨C--
6k H 6e 61 c).\
PG-HN-W¨C-- + HO PG-HN-W¨C--
6k H 6b 6m 0.\
Scheme 6 shows a general synthesis of an Rj-V-C(=0)-P-R2 intermediate wherein,
illustrative purposes, P is pyrrolidine, RI is a generic group that is
depicted as either -E or a amino
protecting group, and R2 is a generic group that is depicted as -W-P-C(=0)-V-
E, -W-P-C(=0)-V-
NH-PG, -W-P-NH-PG, or -W-NH-PG. Coupling of amine 6a (or 6d, 6h, 6k) with acid
6b or 6e is
accomplished using a peptide coupling reagent (e.g. HATU) to afford 6c (or 6f,
6g, 61, 6j, 61, 6m)
Scheme 7. Representative synthesis of E-V-C(=0)-R'
0 CI 0
H2N¨V-C(=0)-P-W-P-C(=0)-V-NH-PG--NH-V-C(=0)-P-W-P-C(=0)-V-NH-PG
_________________________________________ _
7a \ 7b
0 CI 0,
H2N¨V-C(=0)-P-W-P-PG ____________________ . NH-V-C(=0)-P-W-P-PG
7c \ 7d
H2N¨V-C(=0)-P-W-PG , >\¨NH-V-C(=0)-P-W-PG
7e 0 \ 7f
H2N¨V-C(=0)-P-PG NH-V-C(=0)-P-PG
_________________________________________ ,
0\ 7h
H2N¨V-C(=0)-0-PG YNH-V-C(=0)-0-PG
71 0\ 7j
Scheme 7 shows a general synthesis of an E-V-C(=0)-R1 intermediate wherein,
illustrative purposes, E is methoxycarbonylamino and R' is a generic group
that is depicted as either -
P-W-P-C(--0)-V-NH-PG, -P-W-P-PG, -P-W-PG, -P-PG, or -0-PG. Treatment of 7a (or
7c, 7e, 7g,
71) with methyl chloroformate under basic conditions (e.g. sodium hydroxide)
provides the molecule
7b (or 7d, 7f, 7h, 7j).
Scheme 9. Representative synthesis of RI-P-R2
NH2 HO
--P-C(=0)-V-E NH2
Br II NH2 0
Br 111 NH
9b P-C(=0)-V-E
9a 9c o
N_..,õ. P-C(=0)-V-E
Br 411 N
--P-PG NH2
Br 11 NH2 0 .
Br 0 NH
9e P-PG
9a gf 0
P-PG
Br se N
Scheme 9 shows a general synthesis of an Rt-P-R2 intermediate wherein, for
purposes, R' is -C(==0)-V-E or a protecting group and fe is a substituted
benzimidazole. The
formation of the benzimidazole is accomplished by coupling the acid 9b or 9e
with an arylamine 9a,
using a peptide coupling reagent such as HATU, to afford 9c or 9d. Cyclization
of the amide in the
presence an acid (such as acetic acid) affords the benzimidazole containing
molecule 9d or 9g.
The formation of multiple benzimidazoles is performed in the same manner,
bis-diamine to provide the corresponding bis-benzimidazole.
Scheme 20. Representative synthesis of W-P-W-P-R2
Br 0
Cl Br
+ , Br iikh 1401110
11 1.0 _______________
20a 20b Cl 20c
O== __________________________________________________ 0110 Br
.- .
CI Si 20d CI el 20e
0 140 OP-PG
0 __________________________________________________________ .
______________ 1
CI 20f
P-PG HN-----
HN----µ 0 N
0 Os, N ______________________________________________ ISO
ISI 0,..B 1401
CI 20g/h ---6
I __
0 s) Br H 20i/j
N N \ 411,N yP-PG
_______________________ = )1_,N
. N
20k PG-P H
Scheme 20 shows a general synthesis of an R1-P-W-P-R2 intermediate of the
wherein, for illustrative purposes, R' and R2 are independent protecting
groups and W is a two
aromatic ring unit constructed via a transition metal mediated cyclization.
Alkylation of phenol 20b
with an alkyl bromide, such as 20a, provides the ether 20c. Cyclization of the
aromatic rings in the
presence of a palladium catalyst provides the compound 20d. Treatment of 20d
with CuBr2 provides
the a-haloketone 20e, which provides 20f upon addition of an acid under basic
conditions (e.g. Et3N).
Reaction of 20f with an amine or amine salt (e.g. ammonium acetate) affords
the imidazole containing
molecule 20g. Oxidation of 20g, 20i, or 201 can be accomplished by heating in
the presence of Mn02
to provide 20h, 20j, or 20m, respectively. Conversion of 20g or 20h with a
palladium catalyst, such
as Pd2dba3 and X-Phos, and a boron source such as bis(pinacolato)diboron
provides the boronic ester
201 or 20j. The boronic ester is coupled with an appropriate coupling partner
(e.g. 20k) using a
palladium catalyst, such as Pd(PPh3)4 or PdC12(dP130, to afford 201 or 20m.
For each transition metal
mediated cross-coupling reaction, the roles of the nucleophile and
electrophile can be reversed to
provide the same coupling product. Other transition metal mediated cross
couplings that enable the
construction of W, but employ alternative coupling partners and reagents,
include, but are not limited
to, the Negishi, Kumada, Stille, and Ullman couplings. For the preparation of
alternate two aromatic
ring containing W groups, this general scheme can be applied through the
appropriate choice of the
starting reagents.
so s"
01111 __
011O 21a
CI 20d
= oe
_________________________________________ PG-P 0
21 b 0
= 40$ Br
______________________ PG-P)Z0
0 21d
PG-P10Se
FG-P
21fig
Scheme 21 shows a general synthesis of an R'P-W-P-R2 intermediate of the
Treatment of 20d with an
activated vinyl reagent (e.g. potassium vinyltrifluoroborate) in the presence
of a palladium catalyst
(e.g. palladium acetate and S-Phos) provides the vinyl compound 21a.
Conversion to the
corresponding a-halo ketone can be accomplished by bromination with N-
bromosuccinimide,
followed by oxidation with Mn02. Displacement of the a-halo ketone proceeds by
the addition of an
acid under basic conditions (e.g. Et3N). Bromination of 21d proceeds upon
treatment with pyridinium
tribromide, and is followed by the addition of a second acid under basic
conditions to provide the
diester 21e. Reaction of 21e with an amine or amine salt (e.g. ammonium
acetate) affords the
imidazole containing molecule 21f. Oxidation of 21f can be accomplished in the
presence of Mn02 to
provide 21g.
Scheme 22. Representative synthesis of E-V-C(=0)-P-W-P-R
0 0* 0
Br ' E-V-C(=0)-PAO
0 21b 0
0 Oil Br
E-V-C(=0)-PO
0 22b
E-V-C(=0)-P10 0 OP-PG
\ 11N
E-V-C(=0)-P7 1
L-HN
22d/e
Scheme 22 shows a general synthesis of an E-V-C(=0)-P-W-P-R intermediate of
disclosure wherein, for illustrative purposes, R is a protecting group and W
is a two aromatic ring
unit. Displacement of the a-halo ketone 21b proceeds by the addition of an
acid under basic
conditions (e.g. Et3N). Bromination of 22b proceeds upon treatment with
pyridinium tribromide, and
is followed by the addition of a second acid under basic conditions to provide
the diester 22c.
Reaction of 22c with an amine or amine salt (e.g. ammonium acetate) affords
the imidazole
containing molecule 22d. Oxidation of 22d can be accomplished in the presence
of Mn02 to provide
22e.
Scheme 23. Representative synthesis of R-P-W-P-C(=0)-V-E
PG 0 Br-PAO 410
0 osi OyP-(0=)C-V-E
PG-PAO 0
N AL N,r,P-(0=)C-V-E
23b/c
unit. Displacement of the a-halo ketone 21d proceeds by the addition of an
conditions (e.g. Et,N). Reaction of 23a with an amine or amine salt (e.g.
ammonium acetate) affords
the imidazole containing molecule 23b. Oxidation of 23b can be accomplished in
the presence of
Mn02 to provide 23c.
Scheme 25. Representative synthesis of E-V-C(=0)-P-W-P-C(=0)-V-E
H2N-V-C(=0)-P-W-P-C(=0)-V-E __________________ NH-V-C(=0)-P-W-P-C(=0)-V-E
25a 25b
2CI 0 0
H2N-V-C(=0)-P-W-P-C(=0)-V-NH2 ___________
25c 25d
Scheme 25 shows a general synthesis of an E-V-C(=0)-P-W-P-C(=0)-V-E molecule
disclosure wherein, for illustrative purposes, E is ethylcarbonylamino. The
treatment of either 25a or
25c with one or two equivalents respectively of propionyl chloride under basic
conditions (e.g.
sodium hydroxide) provides the molecule 25b or 25d.
Scheme 26. Representative syntheses of E-V-C(=0)-P-R and RI-P-R
PG-PN__N
ii El
PG-P
E-V-C(=0)-PNH
)-1-N i/ Br
26c 26e
N,/ I
26d 26f
Scheme 26 shows a general synthesis of an E-V-C(=-0)-P-R and an R1-P-R
molecule of the
disclosure wherein, for illustrative purposes R is a haloimidazole. Treatment
of the aldehyde 26a with
glyoxal, in the presence of ammonium hydroxide provides the imidazole 26b.
Treatment with either
N-bromosuccinamide or iodine provides the corresponding haloimidazole 26c and
26d respectively.
Separation from the corresponding bis-halogenated compound can be accomplished
by preparative
HPLC chromatography. The conversion of the bis-haloimidazole to the mono-
haloimidazole can also
be accomplished upon heating in the presence of sodium sulfite. Further
functionalization of the P
group can be accomplished upon removal of the protecting group and coupling
with an appropriate
acid (E-V-C(=0)-0H).
0 so Br
Br el
21b 0 27a
0 o 0
______________________ PG-PAO Ili
0 2il Br1d
PG-PAO SO 0
N \ AL N
yPPG
PG-PY -N
21f/g
Scheme 27 shows an alternate general synthesis of an RI-P-W-P-R2 intermediate
invention wherein, for illustrative purposes, R1 and R2 are independent
protecting groups and W is a
two aromatic ring unit constructed via a transition metal mediated
cyclization. Bromination of 21b
with a brominating agent (i.e. pyridinium tribromide) provides the dibromide
27a. Displacement of
the primary bromide then proceeds by the addition of an acid under basic
conditions (e.g. K2CO3) to
provide 21d. Conversion to 21f or 21g can be accomplished following methods
described in Scheme
Br so Br
0 ipe
_____________________________________ .- Br .
0 27a
' E-V-C(=0)-PAO II
0 0 P-PG
-..õ--
0 ____________________________________________________________ .
E-V-C(=0)-PAO 04111
:LI_ \ 400 AL
E-V-C(=0)-P [1 W-11 N
Scheme 28 shows an alternate general synthesis of an E-V-C(=0)-P-W-P-R
intermediate of
the invention wherein, for illustrative purposes, R is a protecting group and
W is a two aromatic ring
unit. Bromination of 21b with a brominating agent (i.e. pyridinium tribromide)
provides the
dibromide 27a. Displacement of the primary bromide then proceeds by the
addition of an acid under
basic conditions (e.g. K2CO3) to provide 22d. Conversion to 22d or 22e can be
following methods described in Scheme 22.
Specific Embodiments
In one embodiment the disclosure provides a compound which has formula:
plb_c(=0)/1b_Elb
Eia_via_c(=0).pia 1.11 N
(Al)
0 pib-C(=0)-Vlb-Eib
Eia_via_c(=0)_p i evn H N
(A2)
Plb-C(=0)-Vlb-Eib
4 N N
Eia_via_c(=0)_p H
H, 11 pib_C(=0)-Vlb-Eib
/1\I \=
Ela_v1 a_c(=m_p H N
wherein the imidazole ring shown in formula Al, A2, A3, and A4 is optionally
more groups independently selected from halo, haloalkyl, cyano, or alkyl;
171N.õ(Fob_c(0)-vb-Eib
71\1\ I
Ela_v1 a_q=0)_ pla H
(A2) or
Aik 1-1,1\1_,./ b_q,D)_vib_Eib
ElaV a_q=0)-F, H
In one embodiment at least one of Eta and Ell' is -N(H)(alkoxycarbony1).
In one embodiment at least one of Ela and En' is -N(H)C(=0)0Me.
In one embodiment both of Ela and Elb are -N(H)C(=0)0Me.
In one embodiment at least one of Ela and EH' is -N(H)(cycloalkylcarbonyl) or
-N(H)(cycloalkyloxycarbony1).
In one embodiment at least one of Ela and Eth is cyclopropylcarbonylamino,
cyclobutylcarbonylamino, cyclopropyloxycarbonylamino or
In one embodiment Eia and En' are each independently selected from
methoxycarbonylamino.
In one embodiment at least one of Via and Vlb is:
¨=
In one embodiment Ela-Vla taken together are R9a or wherein Elb-V lb taken
together are R9b.
In one embodiment at least one of Pia and 131b is selected from:
N3.,,\
N NA. or
In one embodiment Pia and Plb are each independently selected from:
N )1=4
?.? or 51
>22,
.713,
In one embodiment one of pa and Plb is:
and the other of PI' and 131b is:
51y22,
In one embodiment one of P1' and Plb is:
and the other of PI' and P1b is:
In one embodiment at least one of Pla and 1311) is:
1 NN)11.,
õo Fy0
In one embodiment at least one of Pla and P11) is:
In one embodiment at least one of -VI' ¨ and -131b-C(=0)-0- is:
In one embodiment at least one of -Via -C(-0)-Pla - and -131b-C(-0)-0- is:
-tXr0 11,0 417
NN.)41.7
NNA NN7%/z,
p ____f7 ,....(N??1,
5____:3
,-0
\-/
X.,..7e
.1,1õ...--:--0 ==.,CMe
NN)11.7
'ttiXr 0 117
NN)t,
NNA or rc....._:.:
,C31
In one embodiment both of -V" -C(---0)-P" - and -111b-C(=0)-0- are
independently selected
X.--n
-t,..,Xr0 'tXr0
NIN-`2z, NNA
=i
X,.....4\4e
NN27,
:f .1.170 N)
N../z, )
........c. N_Iy'ti,
5_ J
In one embodiment one of-Via -C(-0)-Pla- and -131b-C(=0)-0- is:
'1/4? 0
Y\
7.\ /z,
NNA `11,r.0 '11,9r 4-49r
.........(.
NN222,
õr0Me
r,OMe
t, or NN.7`11,
and the other of -Via -C(-0)-Pla -and -1311)-C(=0)-Vb- is:
\./
\,-
\..-'
µ217r 0
.1.1.0
5..j NN,itz,
NN/izz,
xlMe
.7.1,7.0 7(C:Me µ,,70Me
N 11, µ1.1(\r0
shr N,
70 or
_Ny,
5 In one embodiment the disclosure provides a compound of formula:
N...H
'1\\µµrON
1 \ W
ilk AL\ N--TrNN2 0
) .. N
Iiii. . _
\NN - 11
H -N0.
\ CA N. H
0 H\
0 N \ I 411 "If N
H ,N 0
H y----
/0 0
-0 H H
0____)--__ N\ = Ai N-7(---N
WO N ------ 0
N--Z ---N 0
/0 c,,, \H
H0_..._
.-.
--- 0
0\\ H
)L-N
- 0 ' 0 H N 7-_------
\ -
N \______
-- \\ 40 N \
O. U- i_i\I___.f0 - H
.0-J=LH
0 H -
,,.,õ\\
0 N \ N--(NN 0-
-- a NN
4I II. N
hr N
/.(:) 0 µ\\\
1-1\1 H 7 .
_.s.....f0 " = AIL
-----\ ,7-- N W.
N1 N -----.;'-
U H 0 =
FIFI,ir0
-- 0
0 N 0 H
N -n 0
.--
--y ==-y.0 m \ . 00 õyõ--NN ....
ç NJL Nti
-I-- /H
N 0 = 11 n--;
0 NI, \ 0. AA N-.87--N\___
1111 1\1_____,Z---"I\ W. N
Fl 0-
c----C
W H
/-N, 0 Fl 20'
Nil -m-k- N--. I. N IP
/ --µ :N,AN\ . Will N 0 0,
0 = " \____ J. H
,:-
-0 H 0
----1\1 0
0 H N \ = AL N---r 'N 0
vv. N
----- N----/L-N\I 0
\,,='U H ,N----f
\0I N.
0 N-Ir N
* NNI \
N7-N = liik N0.µss\
\ _________ j \
H. N
/0----/
,--- 0
0 :---)
0 N H 0 N --r- N =
Hy \ = 4,40 N
-----\ N /--- N 0 0
1-1\1---f
0----
---- 0
--o .._.....e NI \ .
* N HN---e
-----\UN"---7L-N\IH
/\--rN
I * 11W. N - N
cN ___________ Y - N 0 *
H )( N
No =:-.-. \
= H
0 NH \
0 Nil \ = = N
0 N ---).--- N __ N 0
U \H I-N
....--- 0
H 0 =
--- 0 _Th\L=fOLI \ = 40.
N N 0
In one embodiment the disclosure provides a compound of formula:
H _______________________________________
\hi N
HN 0
or a pharmaceutically acceptable salt or prothug thereof.
¨0
¨0 0
0HN \
0 HN¨f0
-0 H
0 H .0\
0 \ -a¨k
Mr. N 0
0.)NN-H
\ 41. I
\ AL\ N N
0¨
--O
'1=1 0 H
0).LN.H
A NN;-N NoN
The disclosure will now be illustrated by the following non-limiting Examples.
following abbreviations are used throughout the specification, including the
(aq) Aqueous
(g) Gas
(s) Solid
C Degree Celsius
Ac Acetate
ACN Acetonitrile
apprx Approximate
Bis-pinB/(Bpin)2/(pinB)2 Bis(pinacolato)diboron
BOC/Boc tert-Butoxycarbonyl
calc'd Calculated
CC50 50% Cytotoxicity concentration
COMU I -[( I -(Cyano-2-ethoxy-2-
oxoethylideneaminooxy)dimethylaminomorpholino)]
uronium hexafluorophosphate
dba dibenzalacetone
DCM Dichloromethane
dd Doublet of doublets
ddd Doublet of doublet of doublets
DIPEA/DIEA N,N-Diisopropylethylamine
DMA N,N-Dimethylacetamide
DMAP 4-Dimethylaminopyridine
DME Dimethoxyethane
DMEM Eagle's minimal essential medium
DMF Dimethylformamide
DMSO/dmso Dimethylsulfoxide
dppf 1,1'-bis( diphenylphosphanyl) ferrocene
dt Doublet of triplets
EC50 Half maximal effective concentration
ESI Electrospray ionization
Et Ethyl
ext. External
FBS Fetal bovine serum
HATU 2-( 1 H-7-Azabenzotriazol-1 -y1)-1,1 ,3,3-tetramethyl
uronium hexafluorophosphate Methanaminium
HPLC High performance liquid chromatography
hr/h Hour
Hz Hertz
Coupling constant
LCMS Liquid chromatography mass spectrometry
Multiplet
m/z Mass to charge
M+ Mass peak
Me Methyl
mg Milligram
MHz Megahertz
min Minute
mL Milliliter
mmol Millimole
Moc Methoxycarbonyl
MS Mass spectrometry
MTBE Methyl tert-butyl ether
NADPH Nicotinamide adenine dinucleotide phosphate
NBS N-Bromosuccinimide
NMM N-Methylmorpholine
NMR Nuclear magnetic resonance
o/n Over night
Papp Apparent permeability
PBS Phosphate buffer system
Pd/C Palladium on carbon
Ph Phenyl
Phg/PhGly Phenyl glycine
Piv Pivalate
Pro Proline
pyr Pyridine
qd Quartet of doublets
quant Quantitative
quint Quintet
rt/RT Room temperature
SPhos 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl
t-Bu tert-Butyl
TEMPO (2,2,6,6-Tetramethyl-piperidin- 1 -yl)oxyl
Tf Trifluoromethanesulfonate
TFA Trifluoroacetic acid
THF Tetrahydrofuran
Thr Threonine
TLC Thin layer chromatography
tol. Toluene
UV Ultraviolet
Val Valine
w/v Weight to volume
w/w Weight to weight
X-Phos/XPOS/Xphos 2-Dicyclohexylphosphino-2',4',6'-
triisopropylbiphenyl
6 Chemical shift
1-tg Microgram
Microliter
Example LQ
Br 0 0
HO 0
K2003, DMF 110*
Cl 41 Br it, 18 hr. Br el
7-hydroxy-1-tetralone 89% CI
1-bromo-2-(bromomethyl)-
4-chlorobenzene 7-(2-bromo-5-chlorobenzyloxy)-
3,4-dihydronaphthalen-1(2H)-one
Pd(OPiv)2, P(4-F-Ph)3, t-BuCO2H, 0 00 CuBr2,
CHCI3, Et0Ac
K2CO3, DMA, 60 C, 24 hr.
= 80 C, 2 hr.
67 - 85% CI
3-chloro-10,11-dihydro-5H-
dibenzo[c,g]chromen-8(9H)-one
1. HO
0 0 Bloc 0 H
CI = 411 Nõ
______________________________________ ' 410
= Br 2. NH4CI, Toluene, DIPEA, CH3CN,
50 C N Boc
2-methoxyethanol,
110 C tert-butyl 2-(9-chloro-
1,4,5,11-
9-bromo-3-chloro-10,11-dihydro-5H-
tetrahydroisochromeno[4',3':6,7]naph
dibenzo[c,g]chromen-8(9H)-one tho[1,2-d]imidazol-2-
yl)pyrrolidine-1-
carboxylate
\ 0 0
0 B-B
mn02, CH2Cl2, it CI * N b
N Boo
Pd2dba3, KOAc, XPOS,
tert-butyl 2-(9-chloro-1,11- dioxane, 90 C
dihydroisochromeno[4',3':6,7jnaphtho[1,2-
d]imidazol-2-y1)pyrrolidine-1-carboxylate
¨0 K
1N-y_
II H Br
O -W1 N Boo _______________________
Pd(PPh3)4, PdC12(dppf),
K2CO3, DME/ DMF, 85 C
tert-butyl 249-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-
djimidazol-2-yl]pyrrolidine-1-carboxylate
1. HCI, Et0H, 60 C
,H
õ H
N N 2.
\N1,)N Wit N Boo o
H_0
tert-butyl 249-(2-{1-[N-(methoxycarbonyl)valyl]pyrrolidin-2-
y11-1H-imidazol-5-y1)-1,11- COMU, DIPEA, DMF, RT
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-
yllpyrrolidine-1-carboxylate
\ Ala NN
NYN
11-91 N
N,õ0
[1-(2-{542-(1-
{Rmethoxycarbonyl)aminoRphenypacetyl}pyrrolidin
-2-yI)-1,11-
d]imidazol-9-y1]-1H-imidazol-2-yl}pyrrolidin-1-y1)-3-
methy1-1-oxobutan-2-yl]carbamic acid
7-(2-bromo-5-ehlorobenzyloxy)-3,4-dihydronaphthalen-1(2H)-one
To a stirred solution of 7-hydroxy-l-tetralone (13.9 g, 85.7 mmol) and 1-bromo-
(bromomethyl)-4-chlorobenzene (25.6 g, 90.0 mmol) in dimethylformamide (850
mL) was added
potassium carbonate (24 g, 172 mmol). The reaction was stirred under argon for
18 hours then diluted
with ethyl acetate (1 L). The organics were washed three times with water and
once with brine. The
organic layer was then dried with magnesium sulfate, filtered and
concentrated. To the resulting oil
was added methanol (500 mL) and the suspension was agitated for thirty
minutes. 7-(2-bromo-5-
chlorobenzyloxy)-3,4-dihydronaphthalen-1(2H)-one (27.8 g, 89% yield) was
isolated by filtration.
3-ehloro-10,11-dihydro-5H-dibenzolc,gichromen-8(9H)-one
To a 1 L flask containing palladium(II) pivalate (1.18 g, 3.8 mmol), tri(4-
fluorophenyl)phosphine (1.20 g, 3.8 mmol), pivalic acid (2.33 g, 22.8 mmol)
and potassium carbonate
(31.8 g, 228 mmol) was added a solution of 7-(2-bromo-5-chlorobenzyloxy)-3,4-
dihydronaphthalen-
1(2H)-one (27.8 g, 76.2 mmol) in dimethyacetamide (380 mL). The flask was
evacuated and
backfilled with argon 5 times and then stirred under argon at 60 C for 24
hours. The reaction was
cooled to room temperature and diluted with MTBE and water. The resulting
biphasic mixture was
stirred for 3 hours and filtered through Celite, rinsing with MTBE. The
organic layer of the filtrate
was separated and then washed twice with water and once with brine. The
organics were then dried
with magnesium sulfate, filtered, concentrated and purified by flash column
(Hexanes/DCM) to yield 3-chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one
(14.4 g, 67%
yield) as an off-white solid.
9-bromo-3-ehloro-10,11-dihydro-5H-dibenzole,dchromen-8(914)-one
To a mixture of 3-chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (14.8
g, 52
mmol) in chloroform (50 mL) and ethyl acetate (50 mL) was added copper(II)
bromide (24.3 g, 104
mmol). The reaction was heated to 80 C for 2 hours and then cooled to room
temperature. The
mixture was diluted with dichloromethane and washed twice with a 5:1 solution
of saturated aqueous
ammonium chloride and aqueous ammonium hydroxide (-38%), and washed once with
water. The
organic layer was dried with magnesium sulfate, filtered and concentrated to
yield 9-bromo-3-chloro-
10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (18.5 g, >95% yield) with >95%
purity.
Note: This reaction is not always this clean. Sometimes there is over-
bromination and
sometimes there is significant starting material. These impurities can be
removed by flash column
tert-Butyl 2-(9-ehloro-1,4,5,11-tetrahydroisochromeno[4',3':6,71naphtholl,2-
dlimidazol-2-
yl)pyrrolidine-1-earboxylate
To a solution of (1R)-2-(tert-butoxycarbonyl)cyclopentanecarboxylic acid
(10.17 g, 47.25
mmol) and 9-bromo-3-chloro-10,11-dihydro-6H-naphtho[2,3-cichromen-8(9H)-one
(5.7 mg, 15.7
mmol) in acetonitrile (50 mL) was added diisopropylethylamine (11.11 mL, 64
mmol). The reaction
was stirred at 50 C for 4 hours and was then diluted with ethyl acetate. The
organics were washed
with water and brine, dried (MgSO4) and concentrated. The resulting crude
residue was purified by
flash chromatography to yield (2S)-1-tert-butyl 2-(3-chloro-8-oxo-8,9,10,11-
tetrahydro-5H-
naphtho[c,gichromen-9-y1) pyrrolidine-1,2-dicarboxylate (4.52 g, 58%). To a
solution of (2S)-1-tert-
butyl 2-(3-chloro-8-oxo-8,9,10,11-tetrahydro-6H-naphtho[2,3-c]chromen-9-y1)
pyrrolidine-1,2-
dicarboxylate (3.27 mg, 6.56 mmol) in a mixture of toluene (11 mL) and 2-
methoxyethanol (0.7 mL)
was added ammonium acetate (5.06 g, 65.6 mmol). The reaction mixture was
heated to 110 C for 3
hours, cooled to room temperature and diluted with ethyl acetate. The organics
were washed with
water and brine, dried (Na2SO4), and concentrated. The crude residue was
purified by flash
chromatography to yield tert-butyl 2-(9-chloro-1,4,5,11-
tetrahydroisochromeno[41,31:6,7]naphtho[1,2-
dlimidazol-2-yl)pyrrolidine-1-carboxylate (1.95 g, 61%). LCMS-ESr: calculated
C27H28C1N3034 2: 477.98; observed [M+1]+: 478.47
tert-Butyl 2-(9-chloro-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
yOpyrrolidine-1-carboxylate
To a solution of tert-butyl 2-(9-chloro-1,4,5,11-
d]imidazol-2-yOpyrrolidine- 1 -carboxylate (1.9 g, 3.96 mmol) in
dichloromethane (35 mL) was added
manganese(IV) oxide (17 g, 198 mmol). The reaction mixture was stirred at room
temperature for 18
hours, diluted with ethyl acetate. The organics were washed with water and
brine, dried (Na2SO4),
and concentrated. The crude residue was purified by flash chromatography to
yield tert-butyl 2-(9-
chloro-1,11-dihydroisochromeno[41,3':6,71naphtho[1,2-d]imidazol-2-
yl)pyrrolidine-1-carboxylate
(1.52 g, 81%). LCMS-ESI+: calculated for C27H26C1N303 42: 475.9; observed
[M+1]': 476.45.
tert-Butyl 2-19-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1,11-
dihydroisochromeno[4',3':6,71naphtholl,2-dlimidazol-2-yl]pyrrolidine-1-
A degassed mixture of tert-butyl 2-(9-chloro-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-
d]imidazol-2-yl)pyrrolidine-l-carboxylate (1.52 g, 3.17 mmol),
bis(pinacolato)diboron (1.21 g, 4.75
mmol), potassium acetate (934 mg, 9.52 mmol),
tris(dibenzylideneacetone)palladium (116 mg, 0.13
mmol) and 2-dicyclohexylphosphino-2', 4', 6'-tri-i-propy1-1, l'-biphenyl (121
mg, 0.08 mmol) in
1,4-dioxane (16 mL) was heated to 90 C for 1.5 hours, cooled to room
temperature and diluted with
ethyl acetate. The organics were washed with water and brine, dried (Na2SO4),
and concentrated. The
crude residue was purified by flash chromatography to yield tert-butyl 2-[9-
(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-
ylipyrrolidine-1-
carboxylate (1.7 g, 94%)
tert-Butyl 2-19-(2-{1-IN-(methoxycarbonyl)valyllpyrrolidin-2-y111-1H-imidazol-
5-y1)-1,11-
dihydroisochromeno[4',3':6,7]naphtholl,2-dlimidazol-2-yllpyrrolidine-1-
To a solution of methyl (S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-l-
y1)-3-methyl-l-
oxobutan-2-ylcarbamate (1.48 g, 3.97 mmol), tert-butyl 249-(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-
2-y1)-1,11-dihydroisoehromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-
ylipyrrolidine-1-carboxylate (1.88
g, 1.48 mmol), tetrakis(triphenyl phosphine)palladium(0) (191 mg, 0.16 mmol)
and dichloro[1,11-
bis(diphenylphosphino) ferrocene]palladium(I1) (242 mg, 0.33 mmol) in a
mixture of 1,2-
dimethoxyethane (37.0 mL) and dimethylformamide (6 mL) was added a solution of
carbonate (2M in water, 5 mL, 9.93 mmol). The resulting mixture was degassed
and then heated to
85 C under argon for 18 hours. After cooling to room temperature, the
reaction was diluted with
and concentrated.
The crude residue was purified by flash chromatography to yield tert-butyl 249-
(2-114N-
(methoxycarbonyl)valyl]pyrrolidin-2-y1 1-1H-imidazol-5-y1)-1,11-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidine- 1 -
carboxylate (1.45 mg, 59%).
LCMS-ESI+: calculated for C41H47N706 73 733.86; observed [M+1]+: 734.87.
11-(245-12-(1-ll(Methoxycarbonyl)aminoffphenypacetyl}pyrrolidin-2-y1)-1,11-
dihydroisochromenopte,3':6,7]naphtholl,2-d]imidazol-9-y11-1H-imidazol-2-
y1}pyrrolidin-1-y1)-3-
methyl-1-oxobutan-2-yl]carbamic acid
A solution of tert-butyl 219-(2-114N-(methoxycarbonyl)valyl]pyrrolidin-2-y11-
1H-imidazol-
1 5 5-y1)-1,11-dihydroisochromeno[4',3`:6,7]naphtho[1,2-d]imidazol-2-
yl]pyrrolidine-1-carboxylate (462
mg, 0.63 mmol), ethanol (6 mL) and concentrated HC1 (2 mL) was heated to 60 C
for 1 hour. The
reaction was concentrated and the crude material dissolved in DCM (6 mL). This
solution was
concentrated and to this material was added a solution of (R)-2-
(methoxycarbonylamino)-2-
phenylacetic acid (172 mg, 0.82 mmol) and COMU (311 mg, 073 mmol) in DMF (6
mL). To the
resulting solution was added diisopropylethylamine (330 u.L, 1.89 mmol). After
stirring for 18 hours
at room temperature, the reaction was diluted with ethyl acetate, washed with
water and brine, dried
(Na2SO4), concentrated and purified by preparative reverse phase HPLC (Gemini,
15 to 45%
ACN/H20 + 0.1% TFA). The product fractions were lyophilized to give [1-(2-1542-
(1 -
{Rmethoxycarbonypaminoliphenyl)acetyl pyrrol id in-2-y1)-1,11-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-y1]-1H-imidazol-2-yll
pyrrolidin-l-y1)-3-
methyl-1 -oxobutan-2-ylicarbamic acid (231 mg, 45%). LCMS-ESr: calculated for
C46H48N8078:
824.92; observed [M+1]+: 826.00
Example LR
pN 1) HCI, Me0H CO2 Me
2) Boc20, NaHCO3
Me02Cy¨N ___________________________________________ H>n
Boc Me02C
(2S,4S)-1-tert-butyl 2-methyl 4-cyanopyrrolidine-
1 ,2-d icarboxylate (2S,4S)-1-tert-butyl 2,4-
dimethyl pyrrolidine-1,2,4-
tricarboxylate
CO2H HO
1) EtO2CCI Mel
(t-Bu)2PYr
z- 2) NaBH4 H>MeO2CN N
Boc Me02C Ag0Tf
(3S,5S)-1-(tert-butoxycarbony1)-5- (2S,4S)-1-tert-butyl 2-methyl 4-
(methoxycarbonyl)pyrrolidine-3-carboxylic acid (hydroxymethyl)pyrrolidine-
1,2-
dicarboxylate
¨0 ¨0
LiOH
Me02C HO2C>
7¨BNoc Boc
(2S,4S)-1-tert-butyl 2-methyl (2S,4S)-1-(tert-
butoxycarbony1)-4-
4-(methoxymethyl)pyrrolidine-
(methoxymethyl)pyrrolidine-2-
1,2-dicarboxylate carboxylic acid
(2S,4S)-1-tert-butyl 2,4-dimethyl pyrrolidine-1,2,4-tricarboxylate
To a solution of (2S,4S)-1-tert-butyl 2-methyl 4-cyanopyrrolidine-1,2-
dicarboxylate (9.0 g,
35.4 mmol) in Me0H (196 mL) was added HC1 (4M in 1,4-dioxane, 100 mL, 403
mmol). The
solution was stirred at room temperature for 16h and concentrated in vacuo.
The crude intermediate
was dissolved in Et0Ac (180 mL) and basified with aqueous bicarbonate (sat.).
Di-tert-butyl
dicarbonate (8.5 g, 38.9 mmol) was added and the biphasic solution was stirred
for 12h. The layers were then separated and the aqueous layer was
backextracted with Et0Ac. The
combined organic layers were washed with brine, dried over Na2SO4, and
concentrated. The crude oil
was purified by silica gel chromatography (15% to 40% to 100% Et0Ac/Hexanes)
to provide (2S,4S)-
1-tert-butyl 2,4-dimethyl pyrrolidine-1,2,4-tricarboxylate (9.56 g, 94%).
(3S,5S)-1-(tert-butoxycarbony1)-5-(methoxycarbonyl)pyrrolidine-3-carboxylic
To a solution of (2S,4S)-1-tert-butyl 2,4-dimethyl pyrrolidine-1,2,4-
tricarboxylate (9.56 g,
33.3 mmol) in THF (70 mL) at 0 C (external temperature, ice bath) was added
NaOH (1N aqueous,
33 mL, 33.3 mmol) dropwise over 15 min. The solution was stirred at 0 C for
5h before acidification
with HC1 (1N). The solution was extracted with Et0Ac (3x). The combined
organic layers were
dried over Na2SO4 and concentrated. The crude oil was purified by silica gel
chromatography (2% to
5% to 10% Me0H/CH2C12) to provide (3S,5S)-1-(tert-butoxycarbony1)-5-
(methoxycarbonyl)pyrrolidine-3-carboxylic acid (6.38g, 70%).
(2S,4S)-1-tert-butyl 2-methyl 4-(hydroxymethyl)pyrrolidine-1,2-dicarboxylate
To a solution of (3S,5S)-1-(tert-butoxycarbonyI)-5-
(methoxycarbonyl)pyrrolidine-3-
carboxylic acid (6.38 g, 23.3 mmol) in THF (116 mL) at 0 C (external
temperature, ice bath) was
added Et3N (4.9 mL, 35.0 mmol) and ethyl chloroformate (2.7 mL, 28.0 mmol).
The resulting
solution was stirred at 0 C for 45 min, during which time a white precipitate
forms. The reaction
mixture was filtered through celite and concentrated.
The crude intermediate was dissolved in THF (59 mL) and cooled to 0 C
(external
temperature, ice bath). NaBH4 (4.41 g, 116.7 mmol) in H20 (59 mL) was slowly
added and the
resulting solution was stirred at 0 C for 2 h. The reaction mixture was
diluted with Et0Ac and
washed with H20. The aqueous layer was backextracted with Et0Ac. The combined
organic layers
were dried over Na2SO4 and concentrated. The crude oil was purified by silica
gel chromatography
(42% to 69% to 100% Et0Ac/Hexanes) to provide (2S,4S)-1-tert-butyl 2-methyl 4-
(hydroxymethyl)pyrrolidine-1,2-dicarboxylate (3.63 g, 60%).
(2S,4S)-1-tert-butyl 2-methyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate
To a solution of (2S,4S)-1-tert-butyl 2-methyl 4-(hydroxymethyl)pyrrolidine-
dicarboxylate (2.57 g, 9.9 mmol) in CH2C12 (50 mL) was added Ag0Tf (4.07 g,
15.8 mmol) and 2,6-
di-tert-butylpyridine (4.4 mL, 19.8 mmol). The reaction mixture was cooled to
0 C (external
temperature, ice bath) and Mel (0.98 mL, 15.8 mmol) was slowly added. The
resulting slurry was
stirred at 0 C for 1.5 h and at room temperature for 1.5 h. The slurry was
diluted with CH2C12 and
filtered through celite. The filtrate was concentrated to dryness, dissolved
in Et20, and washed with
HC1 (IN) and brine. The aqueous layers were backextracted with Et20 and the
combined organic
layers were dried over Na2SO4 and concentrated. The crude oil was purified by
chromatography (10% to 75% to 100% Et0Ac/Hexanes) to provide (2S,4S)-1-tert-
butyl 2-methyl 4-
(methoxymethyl)pyrrolidine-1,2-dicarboxylate (2.11 g, 78%). 'H-NMR: 400 MHz,
(CDC13) 6:
(mixture of rotomers, major reported) 4.20 (t, 1H), 3.71 (s, 3H), 3.67 (m,
1H), 3.34 (m, 2H), 3.30 (s,
3H), 3.16 (t, 1H), 2.43 (m, 2H), 1.74 (m, 1H), 1.38 (s, 9H).
(2S,4S)-1-(tert-butoxycarbony1)-4-(methoxymethyl)pyrrolidine-2-carboxylic acid
To a solution of (2S,4S)-1-tert-butyl 2-methyl 4-(methoxymethyl)pyrrolidine-
dicarboxylate (2.11 g, 7.7 mmol) in a mixture of THF (38 mL) and Me0H (15 mL)
was added LiOH
(2.5 M aqueous, 15 mL, 38.6 mmol). The resulting solution was stirred at room
temperature for 2h,
and acidified with aqueous HO (1N). The desired product was extracted with
CH2C12 (4x). The
combined organic layers were dried over Na2SO4 and concentrated to provide
(2S,4S)-1-(tert-
butoxyearbony1)-4-(methoxymethyl)pyrrolidine-2-carboxylic acid (2.0 g, 99%).
1H-NMR: 400 MHz,
(CDC13) 6: (mixture of rotomers, major reported) 4.33 (t, 1H), 3.65 (m, 1H),
3.35 (m, 2H), 3.32 (s,
Example LR-1
N Boc
1. cc (2S,4R)-tert-butyl 2-(9-chloro-4,5-dihydro-
5H-naphtho
HO)
0 r-NN) (methoxymethyl)
pyrrolidine-1-carboxylate
c AL Boo
W o/
DIPEA, CH3CN, 50:0 O -F
2. NH4CI, Toluene,
9-bromo-3-chloro-10,11-dihydro- 110 C
5H-dibenzo[c,g]chromen-8(9H)-
CI 11
one N Boc
(2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-
[c,g]chromeno[8,9-d]imidazol-2-y1)-4-
(methoxymethyl)
B-B
Mn02, CH20I2, rt CI= N,
(2S,4S)-tert-butyl 2-(9-chloro-5H-naphtho[ Pd2dba3, KOAc, XPOS,
c,g]chromeno[8,9-d]imidazol-2-y1)-4- dioxane, 90 C
(methoxymethyl)pyrrolidine-1-carboxylate
0 ¨0 s.\__4ii
(2S,4S)-tert-butyl 4-(methoxymethyl)-2-(9-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-y1)-5H-naphtho
[c,g]chromeno[8,9-d]imidazol-211)pyrrolidine-
1-carboxylate
N N Boc
(2S,4S)-tert-butyl 2-(9-(2-((S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidin-2-y1)-1H-imidazol-5-y1)-5H-naphtho
[c,g]chromeno[8,9-d]imidazol-2-y1)-4-(methoxymethyl)pyrrolidine-1-
1 HCI, Et0H, 60 C
2. lib
N 0 methyl {2-[2-{9-[2-(1-{2-Rmethoxycarbonyl)amino]-3-
H methylbutanoyl}pyrrolidin-2-y1)-1H-imidazol-5-
y1]-1,11-
0 H dihydroisochromeno[4',3':6,7Thaphtho[1,2-d]imidazol-2-y1}-
COMU, DIPEA, DMF, RT 4-(methoxymethyl)pyrrolidin-1-yI]-2-oxo-1-
phenylethylIcarbamate
(2S,4S)-tert-butyl-2-(9-chloro-4,5-dihydro-5H-naphtho[2,3-cichromenol8,9-
djimidazol-2-y1)-4-
(methoxymethyl)pyrrolidine-l-carboxylate:
To a solution of ((S)-1-(tert-butoxycarbony1)-4-(methoxymethyl)pyrrolidine-2-
acid (5.9 g, 23.1 mmol) and 9-bromo-3-chloro-10,11-dihydro-5H-
naphtho[c,g]chromen-8(9H)-one
(5.6 mg, 15.4 mmol) in acetonitrile (60 mL) was added diisopropylethylamine
(5.35 mL, 30.8 mmol).
The reaction was stirred at 50 C for 18 hours and was then diluted with ethyl
acetate. The organics
were washed with water and brine, dried (MgSO4) and concentrated. The
resulting crude residue was
purified by flash chromatography to yield (2S)-1-tert-buty1-2-(3-chloro-8-oxo-
8,9,10,11-tetrahydro-
6H-naphtho[2,3-c]chromen-9-y1)-4(methoxymethyl) pyrrolidine-1,2-dicarboxylate
(5.12 g, 61 A). To
a solution of (2S)-1-tert-buty1-2-(3-chloro-8-oxo-8,9,10,11-tetrahydro-6H-
naphtho[2,3-clehromen-9-
y1)-4(methoxymethyppyrrolidine-1,2-dicarboxylate (5.11 mg, 9.42 mmol) in a
mixture of toluene (94
mL) and 2-methoxyethanol (0.1 mL) was added ammonium acetate (23.5 g, 304
reaction mixture was heated to 110 C for 18 hours, cooled to room temperature
and diluted with
crude residue was purified by flash chromatography to yield (2S,4R)-tert-butyl
2-(9-chloro-4,5-
dihydro-5H-naphtho[c,g]chromeno[8,9-d]imidazol-2-y1)-4-
(methoxymethyppyrrolidine-l-carboxylate
(1.05g, 21%) and (2S,4S)-tert-buty1-2-(9-chloro-4,5-dihydro-6H-naphtho[2,3-
c]chromeno[8,9-
d]imidazol-2-y1)-4-(methoxymethyppyrrolidine-1-carboxylate (2.0 g, 41%). LCMS-
ESI': calculated
for C29H32C1N304 2: 522.0; observed [M+1]+: 522.2.
(2S,4S)-tert-buty1-2-(9-chloro-5H-naphtho[c,g]chromeno18,9-dlimidazol-2-y1)-4-
(methoxymethyl)pyrrolidine-1-carboxylate.
To a solution of (2S,4S)-tert-buty1-2-(9-chloro-4,5-dihydro-5H-
naphtho[c,g]chromeno[8,9-
d]imidazol-2-y1)-4-(methoxymethyppyrrolidine-l-carboxylate (1.99 g, 3.82 mmol)
dichloromethane (30 mL) was added manganese(IV) oxide (10 g, 115 mmol). The
reaction mixture
was stirred at room temperature for 18 hours, diluted with ethyl acetate. The
with water and brine, dried (Na2SO4), and concentrated. The crude residue was
chromatography to yield(2S,4S)-tert-buty1-2-(9-chloro-6H-naphtho[2,3-
c]chromeno[8,9-d]imidazol-2-
y1)-4-methoxymethyl)pyrrolidine-l-carboxylate (1.05g, 21%) and (2S,4S)-tert-
buty1-2-(9-chloro-4,5-
dihydro-6H-naphtho[2,3-c]chromeno18,9-d]imidazol-2-y1)-4-
(methoxymethyppyrrolidine-1-
carboxylate (1.64 g, 82%). LCMS-ESI+: calculated for C29H30CIN3042: 520.02;
observed [M+1]+:
520.97.
(2S,4S)-tert-buty1-4-(methoxymethyl)-2-(9-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y1)-5H-
naphthoic,Ochromeno18,9-dlimidazol-2-yl)pyrrolidine-l-carboxylate:
A degassed mixture of - (2S,4S)-tert-buty1-2-(9-chloro-5H-
naphthok,glchromeno[8,9-
d]imidazol-2-y1)-4-(methoxymethyl) pyrrolidine-1 -carboxylate (649 mg1.25
mmol),
bis(pinacolato)diboron (635 mg, 2.5 mmol), potassium acetate (368 mg, 3.7
tris(dibenzylideneacetone)palladium (46 mg, 0.05 mmol) and 2-
dicyclohexylphosphino-2', 4', 6'-tri-i-
propy1-1, l'-biphenyl (60 mg, 0.12 mmol) in 1,4-dioxane (7 mL) was heated to
90 C for 3 hours,
cooled to room temperature and diluted with ethyl acetate. The organics were
washed with water and
brine, dried (Na2SO4), and concentrated. The crude residue was purified by
flash chromatography to
yield (2S,4S)-tert-butyl 4-(methoxymethyl)-2-(9-(4,4,5,5-tetramethyl-1,3,2-
naphtho[c,g]chromeno[8,9-d]imidazol-2-yppyrrolidine-1-carboxylate (467 mg,
61%) LCMS-ESI+:
calculated for C35H42BN306: 611.54; observed [M+1]+: 612.96.
(2S,4S)-tert-butyl 2-(9-(24(S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidin-2-
y1)-1H-imidazol-5-y1)-5H-naphthole,glehromenol8,9-djimidazol-2-y1)-
4(methoxymethyl)pyrrolidine-1-earboxylate
To a solution of (2S,4S)-tert-butyl 4-(methoxymethyl)-2-(9-(4,4,5,5-
tetramethyl-1,3,2-
dioxaborolan-2-y1)-5H-naphtho [c,g]chromeno [8,9-d] imidazol-2-yppyrrolidine-1-
carboxylate (467
mg, 0.76 mmol), methyl (S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-l-y1)-
3-methyl-l-
oxobutan-2-ylcarbamate (342 mg, 0.92 mmol), tetrakis(triphenylphosphine)
palladium(0) (44 mg,
0.04 mmol) and dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) (56
a mixture of 1,2-dimethoxyethane (11.0 mL) and dimethylformamide (1.9 mL) was
added a solution
of potassium carbonate (2M in water, 1.15 mL, 2.29 mmol). The resulting
mixture was degassed and
then heated to 85 C under argon for 18 hours. After cooling to room
temperature, the reaction was
diluted with ethyl acetate. The organics were washed with water and brine,
dried (Na2SO4), and
concentrated. The crude residue was purified by flash chromatography to yield
(2S,4S)-tert-butyl 2-
(9-(2-((S)-14(S)-2-(methoxycarbonylamino)-3-methylbutanoyppyn-olidin-2-y1)-1 H-
imidazol-5-y1)-
5H-naphtho[c,g] chromeno [8,9-d] imidazol-2-y1)-4-(methoxymethyl)pyrrolidine-l-
mg, 67%). LCMS-ESI calculated for C43H511\17073 777.91; observed [M+1]+:
methyl 12-12-{9-12-(1-{2-1(methoxycarbonyl)aminol-3-methylbutanoyl} pyrrolidin-
2-y1)-1H-
imidazol-5-y1]-1,11-dihydroisochromenol4',3%6,7lnaphtho 11,2-cflimidazol-2-y11-
(methoxymethy 1)pyrrolidin-1 -y1]-2-oxo-1-phenylethylIcarbamate
A solution of (2S,4S)-tert-butyl 2-(9-(2-((S)-1-((S)-2-(methoxycarbonylamino)-
methylbutanoyl)pyrrolidin-2-y1)-1H-imidazol-5-y1)-5H-naphtho[c,g]chromeno[8,9-
d]imidazol-2-y1)-
4-(methoxymethyl)pyrrolidine-1-carboxylate (196 mg, 0.25 mmol), ethanol (3 mL)
and concentrated
HC1 (1 mL) was heated to 60 C for 1 hour. The reaction was concentrated and
the crude material
dissolved in DCM (6 mL). This solution was concentrated and to this material
was added a solution
of (R)-2-(methoxycarbonylamino)-2-phenylacetic acid (69 mg, 0.33 mmol) and
COMU (124 mg, 029
mmol) in DMF (4 mL). To the resulting solution was added diisopropylethylamine
(1301AL, 0.76
mmol). After stirring for 2 hours at room temperature, the reaction was
diluted with ethyl acetate,
washed with water and brine, dried (Na2SO4), concentrated and purified by
preparative reverse phase
HPLC (Gemini, 15 to 45% ACN/H20 + 0.1% TFA). The product fractions were
lyophilized to give
methyl {2-[2-1942-(1-{2-[(methoxycarbonypamino]-3-methylbutanoyll pyrrolidin-2-
y1)-1H-
imidazol-5-y1]-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-y1}-
(methoxymethyl)pyrrolidin-1-y1]-2-oxo-1-phenylethylIcarbamate (84 mg, 39%).
LCMS-ESr:
calculated for C48H52N808: 868.98; observed [M+1]+: 870.11
Example LS
n 1. HC
Et0H, 60 C
AL N
N--71-"N N Boo 2. 0
0 N)L07
(2S,4S)-tert-butyl 2-(9-(2-((S)-1-((S)-2-
(methoxycarbonylamino)-3- 0 111
methylbutanoyl)pyrrolidin-2-y1)-1H-imidazol-5-y1)-5H-naphtho HATU,
fogjohromeno[8,9-c]imidazol-2-y1)-4- DIPEA,
(methoxymethyl)pyrrolidine-1- DMF, RT
0= H
H N0
methyl {142-{942-(1-{2-[(methoxycarbonyl)amino]-3-
methylbutanoyllpyrrolidin-2-y1)-1H-imidazol-5-y11-
1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-
d]imidazol-2-y1}-4-(methoxymethyl)pyrrolidin-1-y1]-3-
methy1-1-oxobutan-2-yl}carbamate
methyl fl-[2-{942-(l-{2-KmethoxyearbonyHaminol-3-methylbutanoyljpyrrolidin-2-
y1)-1 H-
imidazol-5-y11-1,11-dihydroisochromeno14',3':6,71naphthol 1,2-di imidazol-2-
y11-4-
(methoxymethyl)pyrrolidin-l-y11-3-methyl-l-oxobutan-2-yl}carbamate
4-(methoxymethyl)pyrrolidine- 1 -carboxylate (116 mg, 0.15 mmol), ethanol (5
mL) and concentrated
dissolved in DCM (10 mL). This solution was concentrated and to this material
of 2-methoxycarbonylamino-3-methylbutyric acid (38 mg, 0.22 mmol) and HATU (79
mg, 0.21
mmol) in DMF (1.4 mL). To the resulting solution was added
diisopropylethylamine (270 uL, 1.5
mmol). After stirring for 18 hours at room temperature, the reaction was
HALC (Gemini, 15 to 45% ACN/H20 + 0.1% TFA). The product fractions were
methyl {142-1942-0 -{2-[(methoxycarbonypamino]-3-methylbutanoyll pyrrolidin-2-
imidazol-5 -y1]- 1,11 -dihydroisochromeno [4',3':6,7]naphtho [ 1 ,2-d]imidazol-
2-y11-4-
(methoxymethyppyrrolidin-l-y1]-3-methyl-l-oxobutan-2-ylIcarbamate (58 mg,
13%). LCMS-ESI+:
calculated for C45H54-1\1808: 834.96; observed [11/1+11+: 835.70.
Example LT
0 ¨0
N -N
n. H
Boc Pd(PPh3)4, PdC12(dppf),
(2 S,4 S)-tert-butyl 4-(methoxymethyl)-2-(9-(4,4,5,5-
[c,g]chromeno[8,9-djimidazol-2-y1)pyrrolidine-
A .H 0 =
u N
411mat N
N,7N N l3oc
(2S,4S)-tert-butyl 2-(9-(24(S)-14(S)-2-
methylbutanoyl)azabicyclo[3.1.0]hexan-3-y1)-1H-
imidazol-5-y1)-5H-naphtho[c,g]chromeno[8,9-cflimidazol-
2-y1)-4-(methoxymethyl)pyrrolidine-1-carboxylate
1. HC1, Et0H, 60 C
--0 N 4.
2. nik
H,0
0 H methyl {2-[2-{9-12-(2-{2-
[(methoxycarbonypamino]-3-
COMU, DIPEA, DMF, RT methylbutanoy1}-2-azabicyclo[3.1.0]hex-3-y1)-
1H-imidazol-5-
y1]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-djimidazol-
2-y1}-4-(methoxymethyppyrrolidin-1-y11-2-oxo-1-
phenylethyl}carbamate
(2S,4S)-tert-butyl-2-(9-(24(S)-14(S)-2-(methoxycarbonylamino)
methylbutanoyl)azabicyclo[3.1.01hexan-3-y1)-1H-imidazol-5-y1)-51-1-
naphtho[c,glchromeno18,9-
dlimidazol-2-y1)-4-(methoxymethyl)pyrrolidine-1-carboxylate
dioxaborolan-2-y1)-5H-naphtho[c,g]chromeno[8,9-d]imidazol-2-yl)pyrrolidine-1-
mg, 0.91 mmol), methyl (S)-1-((lS,3S,5S)-3-(5-bromo-1H-imidazol-2-y1)-2-
azabicyclo[3.1.0]hexan-
2-y1)-3-methyl-1-oxobutan-2-ylcarbamate (350 mg, 0.91 mmol)
tetrakis(triphenylphosphine)
palladium(0) (53 mg, 0.04 mmol) and dichloro[1,1'-
bis(diphenylphosphino)ferrocene]palladium(II)
(67 mg, 0.07 mmol) in a mixture of 1,2-dimethoxyethane (11.0 mL) and
dimethylformamide (1.9
mL) was added a solution of potassium carbonate (2M in water, 1.37 mL, 2.7
mmol). The resulting
mixture was degassed and then heated to 85 C under argon for 18 hours. After
cooling to room
temperature, the reaction was diluted with ethyl acetate. The organics were
yield (2S,4S)-tert-butyl 2-(9-(2-((S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)azabicycloP .1.0Thexan-3-y1)-1H-imidazol-5-y1)-5H-
d]imidazol-2-y1)-4-(methoxymethyppyrrolidine- 1 -carboxylate (271 mg, 38%).
LCMS-ESI+:
calculated for C441-151N707. 789.92; observed [M+1]+: 790.76.
methyl 12-12-{942-(2-{2-1(methoxycarbonypamino1-3-methylbutanoy1}-2-
azabicyclo[3.1.01hex-3-
y1)-1H-imidazol-5-y11-1,1 1-dihydroisochromeno[4',3':6,71naphtho11,2-
dlimidazol-2-y1}-4-
(methoxymethyl)pyrrolidin-1-y11-2-oxo-1-phenylethyl}carbamate:
methylbutanoyl)azabicyclo [3.1.0] hexan-3-y1)-1H-imidazol-5-y1)-5 H-
d]imidazol-2-y1)-4-(methoxymethyppyrro lidine- 1 -carboxylate (196 mg, 0.25
mmol), ethanol (3 mL)
and concentrated HC1 (1 mL) was heated to 60 C for 1 hour. The reaction was
concentrated and the
crude material dissolved in DCM (6 mL). This solution was concentrated and to
this material was
added a solution of (R)-2-(methoxycarbonylamino)-2-phenylacetic acid (69 mg,
0.33 mmol) and
COMU (124 mg, 029 mmol) in DMF (4 mL). To the resulting solution was added
diisopropylethylamine (1301AL, 0.76 mmol). After stirring for 2 hours at room
temperature, the
reaction was diluted with ethyl acetate, washed with water and brine, dried
(Na2SO4), concentrated
and purified by preparative reverse phase HPLC (Gemini, 15 to 45% ACN/H20 +
0.1% TFA). The
product fractions were lyophilized to give methyl {2-12-{912-(2-{2-
[(methoxycarbonyl)amino]-3-
methylbutanoyll-2-azabicyclo[3.1.0]hex-3-y1)-1H-imidazol-5-y11-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y11-4-
(methoxymethyppyrrolidin-1-y1]-2-
oxo-l-phenylethylIcarbamate (84 mg, 39%). LCMS-ES1+: calculated for
C49H52N808: 880.99;
observed [M+1]+: 882.09
Example LZ
Br HO AK K2CO3, DMF Br 0
41 _________________
Pd(OPiv)2, P(4-F-Ph)3, t-BuCO2H,
Cl 0 Br 4- 441W _______ o . .0 IN
0 K2003, DMA, 60 C
1-bromo-2- 5-hydroxy-1- 5-(2-bromo-5-chlorobenzyloxy)-
(bromomethyl)-4- tetralone 3,4-dihydronaphthalen-
1(2H)-one
. 411 CuBr2, Et0Ac,
0 CHCI3, 85 C =
Br Boc-Pro-OH, DIPEA,
CI 111 o.
Cl 44I 4) >
0 MeCN, 50
8-chloro-2,3,4,6-tetrahydro- 2-bromo-8-chloro-2,3,4,6-tetrahydro-
1H-dibenzo[c,h]chromen-1-one 1H-dibenzo[c,h]chromen-
1-one
0 õ---_
CI W . . IP NH40Ac, toluene, 0
CI NH
41/ O 02F
Mn02, CH2Cl2
0 0 N" reflux 11---.1.3 __ li
------/C tert-butyl (2S)-2-(9-chloro-3,4,5,7-
(2S)-1-tert-butyl 2-(8-chloro-1- tetrahydroisochromeno[3',4':5,6]napht
oxo-2,3,4,6-tetrahydro-1 H- ho[1,2-d]imidazol-2-yl)pyrrolidine-1-
dibenzo[c,h]chromen-2-y1) carboxylate
pyrrolidine-1,2-dicarboxylate
NH (Bpi ----..4
n)2, Pd2(dba)3, X-Phos, \ 0
-0 * NH
CI 11 ell
/ IT-
N KOAc, dioxane, 90 C 1\1"<iNil
tert-butyl (2S)-2-(9-chloro-3,7- tert-
butyl (25)-2-19-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-
dihydroisochromeno[3',4':5,6]naphtho[1,2- 2-yI)-3,7-
d]imidazol-2-yl)pyrrolidine-1-carboxylate
dlimiclazol-2-yllpyrrolidine-1-carboxylate
1) HCI, Et0H, 60 C 0
--_V
ijiz
___________________ ). 0,13 ii HN
41 NH ----1.___ o N \
0---- :----Br
N--t\il 1- N--Z-N
2) Moc-Val-OH, HATU, 0'
DIPEA, DMF u H
methyl R2S)-3-methyl-1-oxo-1-{(2S)-249-(4,4,5,5-
tetra methyl-1,3,2-dioxaborolan-2-y0-3,7-
d]imidazol-2-yl]pyrrolidin-1-yl}butan-2-
yllcarbamate
HN--µ0 1) HCI, Et0H, 60
---- \/0 ....e NH \ ill C:OWAIL r_iNH ,1-.)_-0¨
Pd(PPh3)4, PcIC12(dppf),
K2O03, DME, DMF, 85 C U H DIPEA,
2) Moc-Val-OH, HATU,
tert-butyl (2R)-245-(2-{(28)-14N-(methoxycarbony1)-L-valyl]pyrrolidin-
2-y1}-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazol-9-y1)-
1H-imidazol-2-yllpyrrolidine-1-carboxylate
N H 0 HN
N 4111. NH
methyl {(2S)-1-R2R)-2-(5-{2-R2S)-1-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-y1]-
3,7-dihydroisochromeno[3',4':5,6]naphtho[1 ,2-cl]imidazol-9-
yI}-1 H-imidazol-2-yl)pyrrolidin-1-y1]-
3-methyl-l-oxobutan-2-y1}carbamate
5-(2-bromo-5-chlorobenzyloxy)-3,4-dihydronaphthalen-1(21/)-one
To a stirred solution of 5-hydroxy-I -tetralone (2.0 g, 12.3 mmol) and 1-bromo-
(bromomethyl)-4-chlorobenzene (3.6 g, 12.7 mmol) in dimethylformamide (125 mL)
was added
potassium carbonate (3.5 g, 25.1 mmol). The reaction was stirred under argon
for 1 hour then diluted
chlorobenzyloxy)-3,4-dihydronaphthalen-1(2H)-one (4.25 g, 94% yield) was
8-chloro-2,3,4,6-tetra hydro-/H-dibenzolc,hichromen-1 -one
To a flask containing palladium(II) pivalate (68 mg, 0.22 mmol), tri(4-
fluorophenyl)phosphine (70 mg, 0.22 mmol), pivalic acid (135 mg, 1.3 mmol) and
carbonate (1.83 g, 13.1 mmol) was added a solution of 5-(2-bromo-5-
chlorobenzyloxy)-3,4-
dihydronaphthalen-1(21/)-one (1.61 g, 4.4 mmol) in dimethyacetamide (23 mL).
The flask was
evacuated and backfilled with argon 5 times and then stirred under argon at 60
C for 24 hours. The
reaction was poured directly onto a silica gel column and purified by flash
column chromatography
(hexanes/DCM) to yield 8-chloro-2,3,4,6-tetrahydro-
/H-dibenzo[c,h]chromen-1 -one (1.22 g, 97% yield) as an off-white solid.
2-bromo-8-chloro-2,3,4,6-tetrahydro-1 ibenzo le,h]ch rom en-1 -one
To a mixture of 8-chloro-2,3,4,6-tetrahydro-/H-dibenzo[c,h]chromen-1-one (2.58
g, 9.1
mmol) in chloroform (9.1 mL) and ethyl acetate (9.1 mL) was added copper(II)
bromide (4.65 g, 19.9
organic layer was dried with magnesium sulfate, filtered and concentrated. The
crude material was
purified by flash column chromatography (hexanes/DCM) to yield 2-bromo-8-
chloro-2,3,4,6-
tetrahydro-/H-dibenzo[c,h]chromen-l-one (2.45 g, 75% yield).
(2S)-1-tert-butyl 2-(8-chloro-1-oxo-2,3,4,6-tetrahydro-1H-dibenzolc,h1chromen-
2-y1)
To a solution of 2-bromo-8-chloro-2,3,4,6-tetrahydro-/H-dibenzo[c,h]chromen-1-
one (1.05 g,
2.9 mmol) and Boc-Pro-OH (1.75 g, 8.1 mmol) in acetonitrile (9.0 mL) was added
diisopropylethylamine (1.5 mL, 8.7 mmol). The solution was stirred under argon
at 50 C for two
hours. Extra Boc-Pro-OH (620 mg, 2.9 mmol) and diisopropylethylamine (0.5 mL,
2.9 mmol) were
added and the reaction was stirred at 50 C for 16 hours. The reaction was
cooled to room
temperature and diluted with ethyl acetate. The organics were washed with
with magnesium sulfate and concentrated. The crude material was purified by
flash column
chromatography and the product (2S)-1-tert-butyl 2-(8-chloro-l-oxo-2,3,4,6-
tetrahydro-/H-
dibenzo[c,h]chromen-2-y1) pyrrolidine-1,2-dicarboxylate was isolated as a
mixture of diastereomers
(0.99 g, 69% yield).
tert-butyl (2S)-2-(9-chloro-3,4,5,7-
tetrahydroisochromeno13',4':5,61naphtho[1,2-d]imidazol-2-
To a solution of (2S)-I-tert-butyl 2-(8-chloro-1-oxo-2,3,4,6-tetrahydro-/H-
dibenzo[c,h]chromen-2-y1) pyrrolidine-1,2-dicarboxylate (2.2 g, 4.4 mmol) in
toluene (40 mL) was
added ammonium acetate (7 g, 91 mmol). The reaction mixture was vigorously
refluxed for 3 hours,
then cooled to room temperature and diluted with ethyl acetate. The organics
were washed with water
and brine, dried with magnesium sulfate and concentrated. The crude material
was purified by flash
column chromatography to yield tert-butyl (2S)-2-(9-chloro-3,4,5,7-
tetrahydroisochromeno[31,41:5,6]naphtho[1,2-d]imidazol-2-yl)pyrrolidine- I -
carboxylate (1.13 g, 54%
yield) as well as recovered (2S)-1-tert-butyl 2-(8-chloro-l-oxo-2,3,4,6-
dibenzo[c,h]chromen-2-y1) pyrrolidine-1,2-dicarboxylate (0.8 g, 36%). ). LCMS-
ESI+: calculated for
C27H28N303: 477.98; observed [M+1]+: 478.54.
tert-butyl (2S)-2-(9-chloro-3,7-dihydroisochromeno13',4':5,61naphtho11,2-
To a solution of Intermediate tert-butyl (2S)-2-(9-chloro-3,4,5,7-
tetrahydroisochromeno[31,41:5,6]naphtho[1,2-d]imidazol-2-yppyrrolidine-1-
carboxylate (1.43 g, 3.0
mmol) in dichloromethane (30 mL) was added manganese(IV) oxide (15 g, 198
mmol). The mixture
was stirred for four hours at room temperature then filtered through Celite.
The Mn02 was
thoroughly rinsed with dichloromethane and the total filtrate was concentrated
to yield tert-butyl (2S)-
2-(9-chloro-3,7-dihydroisochromeno[3',4':5,6]naphtho[1,2-d] imidazol-2-
(1.37 g, 96% yield). This material was used without further purification.
tert-butyl (2S)-2-19-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-3,7-
3 5 dihydroisochromeno13',4%5,61naphtho[1,2-d]imidazol-2-Apyrrolidine-1-
To a solution of tert-butyl (2S)-2-(9-chloro-3,7-
dihydroisochromeno[31,41:5,6]naphtho[1,2-
d]imidazol-2-Apyrrolidine-l-carboxylate (1.4 g, 2.9 mmol) in dioxane (20 mL)
bis(pinacolato)diboron (1.5 g, 5.9 mmol),
tris(dibenzylideneacetone)dipalladium(0) (110 mg, 0.12
mmol), X-Phos (145 mg, 0.30 mmol) and potassium acetate (870 mg, 8.9 mmol).
The mixture was
degassed with a stream of argon for ten minutes. The degassed reaction was
heated under argon to 90
C for 2.5 hours then cooled to room temperature and diluted with ethyl
acetate. The organics were
washed with water and brine, dried with magnesium sulfate and concentrated.
The crude material was
purified by flash column chromatography (DCM/Et0Ac) to yield tert-butyl (2S)-
249-(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-y1)-3,7-
dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazol-2-
yl]pyrrolidine-l-carboxylate (1.5 g, 90% yield).
methyl [(25)-3-methyl-l-oxo-1-{(2S)-2-19-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y1)-3,7-
I 0 dihydroisochromenop',4%5,6jnaphtholl,2-djimidazol-2-yljpyrrolidin-l-
yl}butan-2-
ylicarbamate
A solution of tert-butyl (2S)-249-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-
y1)-3,7-
dihydroisochromeno[31,41:5,6]naphtho[1,2-d]imidazol-2-yl]pyrrolidine-1-
mmol), concentrated HC1 (2 mL) and ethanol (20 mL) was heated to 60 C for 2
hours. The reaction
was concentrated and redissolved in a minimal amount of methanol. An equal
volume of
dichloromethane was added and the solution was again concentrated.
Dichloromethane was added to
the resulting residue and concentrated off two more times. The resulting crude
material was dissolved
in dimethylformamide (17 mL). To this solution was added (S)-2-
methylbutanoic acid (455 mg, 2.6 mmol), HATU (955 mg, 2.5 mmol) and
diisopropylethylamine (3
mL, 17 mmol). The reaction was stirred at room temperature for one hour then
diluted with ethyl
acetate. The organics were washed with water (x2) and brine, dried with
magnesium sulfate and
concentrated. The resulting residue was purified by flash column
chromatography to yield
Intermediate methyl R2S)-3-methy1-1-oxo-1-{(2S)-249-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-
y1)-3 ,7-dihydroisochromeno[31,4':5,61naphtho[1,2-d] imidazol-2-yl]pyrrolidin-
l-y1 Ibutan-2-
yl]carbamate (780 mg, 72% yield over 2 steps).
tert-butyl (2R)-2-15-(2-{(2S)-1-1N-(methoxycarbony1)-L-va1yllpyrrolidin-2-y1}-
dihydroisochromeno[3',4':5,61naphtho11,24]imidazol-9-y1)-1H-imidazo1-2-
y1ipyrrolidine-l-
A mixture of Pentacyclic Intermediate methyl [(2S)-3-methyl- -oxo-1-{(2S)-249-
(4,4,5,5-
yl]pyrrolidin-1 -yllbutan-2-yl]carbamate (780 mg, 1.3 mmol), (S)-tert-butyl 2-
(5-bromo-1H-imidazol-
2-yl)pyrrolidine-1 -carboxylate (450 mg, 1.4 mmol),
tetrakis(triphenylphosphine)palladium(0) (30 mg,
0.03 mmol), PdC12(dppf) (60 mg, 0.08 mmol), 2M aqueous potassium carbonate
(1.9 mL, 3.9 mmol),
dimethoxyethane (10 mL) and dimethylformamide (2 mL) was degassed with argon
for 15 minutes.
The reaction was then heated to 85 C for 3 hours. Upon completion, the
reaction was cooled to room
temperature, diluted with ethyl acetate and filtered through Celite. The
filtrate was washed with water
and brine, dried (MgSO4) and concentrated. The resulting crude material was
column chromatography (Et0Ac/Me0H) to yield Intermediate tert-butyl (2R)-245-
(2-{(2S)-14N-
(methoxycarbony1)-L-valyl]pyrrolidin-2-y11-3,7-
dihydroisochromeno[31,4':5,61naphtho[1,2-
dlimidazol-9-y1)-1H-imidazol-2-ylipyrrolidine- 1 -carboxylate (390 mg, 43%
yield).
methyl {(2S)-1-1(2R)-2-(5-12-1(2S)-1-{(2S)-2-1(methoxyca rbonyl)am ino1-3-
methylbutanoyl) pyrrolidin-2-y11-3,7-dihydroisochromenol3 ',4':5,61 naphtha
1,2-d I im idazol-9-
y11-1 H-im idazol-2-yl)pyrrolid in- 1-y11-3-methyl-1-oxobuta n-2-ylIca rbamate
A mixture of Intermediate tert-butyl (2R)-245-(2-1(2S)-14N-(methoxycarbony1)-L-
valylipyrrolidin-2-y1}-3,7-dihydroisochromeno[31,41:5,6]naphtho[1,2-d]imidazol-
9-y1)-1H-imidazol-
2-yllpyrrolidine-1-carboxylate (390 mg, 0.53 mmol), concentrated HC1 (2 mL)
and ethanol (10 mL)
was heated to 60 C for 2 hours. The reaction was concentrated and redissolved
in a minimal amount
of methanol. An equal volume of dichloromethane was added and the solution was
concentrated. Dichloromethane was added to the resulting residue and
concentrated off two more
times. One half of the crude material (-0.27 mmol) was dissolved in
dimethylformamide (2.5 mL).
To this solution was added (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid
(66 mg, 0.38
mmol), HATU (140 mg, 0.37 mmol) and diisopropylethylamine (0.48 mL, 2.7 mmol).
The reaction
was stirred at room temperature for 2 hours, and then diluted with
acetonitrile (2 mL) and methanol (2
mL). To this solution was added ten drops of 5M aqueous NaOH solution and
stirring was continued
for 30 minutes. The reaction was diluted with ethyl acetate and the organic
layer was washed with
water and brine. The combined aqueous washings were extracted three times with
ethyl acetate, and
the combined organic layers were dried (MgSO4) and concentrated. The crude
material was purified
by reverse phase HPLC (Gemini, 15 to 45% ACN/H20 + 0.1% TFA) to yield methyl
{(2S)-1-[(2R)-2-
(5-{2-[(2S)-1-{(2S)-2-Rmethoxycarbonypamino]-3-methylbutanoyllpyrrolidin-2-y1]-
dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-
yl)pyrrolidin-1-y1]-3-
methyl-l-oxobutan-2-ylIcarbamate (140 mg, 67% yield over 2 steps). LCMS-ESI':
Example MA
0 NH NJN
methyl {(1R)-2-R2R)-2-(5-2-R2S)-1-{(2S)-21(methoxycarbonyDamino]-3-
methylbutanoyl}pyrrolidin-2-y11-3,7-
dihydroisochromeno[3',4':5,6]naphtho[1 ,2-d]imidazol-9-y1}-1 H-imidazol-2-
yl)pyrrolidin-1-y1]-
2-oxo-1 -phenylethyllcarbamate
This compound was made in an analogous manner to methyl {(2S)-1-[(2R)-2-(5-12-
[(2S)-1-
{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin-2-y1]-3,7-
dihydroisochromeno[3',4':5,6]naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-2-
methyl-l-oxobutan-2-yll carbamate, substituting (R)-2-(methoxycarbonylamino)-2-
for (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid and substituting COMU
for HATU in the
final amide coupling step. LCMS-ES1+: calculated for C46H48N807: 824.92;
observed [M+1]+: 825.72.
Example MB
0 Aat
OqOj_Brr\\ Pd(PPh3)4,
PdC12(dP0),
+ :B =
K2CO3, DME, DMF,
methyl (S)-14(S)-2-(5-bromo-11-1- tert-butyl (2S)-249-(4,4,5,5-tetramethy1-
1,3,2-dioxaborolan-
imidazol-2-yl)pyrrolidin-1-y1)-3- 2-y1)-3,7-
methy1-1-oxobutan-2-ylcarbamate d]imidazol-2-yl]pyrrolidine-1-carboxylate
0 \F
H HN
1) HCI, Et0H, 60 C
0 \ = = N 4. J--""0 _______________ =
HO /0
H DIPEA, DMF
tert-butyl (25)-2-[9-(2-{(2R)-14N-(methoxycarbony1)-L- (R)-2-
(methoxycarbonylamino)-
valyl]pyrrolidin-2-y11-1H-imidazol-5-y1)-3,7- 2-phenylacetic acid
dihydroisochromeno[3',4':5,6]naphtho[1,2-dJimidazol-2-
yl]pyrrolidine-1-carboxylate
)¨NH 0
N so. NH 40
N N''--Ly!)1
methyl {(25)-1-[(2R)-2-(5-{2-[(2S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-
phenylacetyl}pyrrolidin-2-y1]-3,7-
y1)pyrrolidin-1-y1]-3-
methyl-1-oxobutan-2-ylIcarbam ate
tert-butyl (2S)-2-19-(2-{(2R)-1-IN-(methoxycarbony1)-L-valyllpyrrolidin-2-y1}-
y1)-3,7-dihydroisochromenol3',4%5,6lnaphtholl,2-dlimidazol-2-yllpyrrolidine-1-
A mixture of tert-butyl (2S)-249-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-
dihydroisochromeno[3',41:5,6]naphtho[1,2-d]imidazol-2-yl]pyrrolidine-1 -
carboxylate (450 mg, 0.79
mmol), methyl (S)-1-4S)-2-(5-bromo-1H-imidazol-2-yppyrrolidin-1-y1)-3-methyl-1-
oxobutan-2-
ylcarbamate (325 mg, 0.87 mmol), tetrakis(triphenylphosphine)palladium(0) (30
mg, 0.02 mmol),
PdC12(dppf) (35 mg, 0.05 mmol), 2M aqueous potassium carbonate (1.2 mL, 2.4
dimethoxyethane (6.8 mL) and dimethylformamide (1.2 mL) was degassed with
argon for 15 minutes.
The reaction was then heated to 85 C for 2.5 hours. Upon completion, the
reaction was cooled to
room temperature, diluted with ethyl acetate and filtered through Celite. The
filtrate was washed with
water and brine, dried (MgSO4) and concentrated. The resulting crude material
column chromatography (Et0Ac/Me0H) to yield tert-butyl (2S)-249-(2-{(2R)-14N-
(methoxycarbony1)-L-valyllpyrrolidin-2-y11-1H-imidazol-5-y1)-3,7-
dihydroisochromeno[31,4':5,6]naphtho[1,2-d]imidazol-2-yllpyrrolidine- 1 -
carboxylate (270 mg, 46%
methyl {(2S)-1-1(2R)-2-(5-12-1(2S)-1-{(2R)-2-1(methoxyearbonyl)amino1-2-
phenylacetyl}pyrrolidin-2-y1]-3,7-dihydroisochromeno13',4':5,61naphthol1,2-
dlimidazol-9-y1}-
1H-imidazol-2-yl)pyrrolidin-l-y11-3-methyl-1-oxobutan-2-y1}carbamate:
A mixture of tert-butyl (2S)-249-(2-{(2R)-14N-(methoxycarbony1)-L-
valylipyrrolidin-2-y11-
1H-imidazol-5-y1)-3,7-dihydroisochromenoP ',4':5,61naphtho[1,2-d]imidazol-2-
carboxylate (270 mg, 0.37 mmol), concentrated HCI (1.5 mL) and ethanol (8 mL)
was heated to 60 C
for 1 hour. The reaction was concentrated and redissolved in a minimal amount
of methanol. An
equal volume of dichloromethane was added and the solution was again
concentrated.
Dichloromethane was added to the resulting residue and concentrated off two
more times. The crude
material was dissolved in 5:1 dichloromethane/dimethylformamide (3.8 mL). To
this solution was
added (R)-2-(methoxycarbonylamino)-2-phenylacetic acid (96 mg, 0.46 mmol),
COMU (190 mg, 0.44
mmol) and diisopropylethylamine (0.20 mL, 1.1 mmol). The reaction was stirred
at 0 C for 30
minutes then warmed to room temperature. Upon completion, the reaction was
diluted with
acetonitrile (2 mL) and methanol (2 mL). To this solution was added ten drops
of 5M aqueous NaOH
solution and stirring was continued for 30 minutes. The reaction was diluted
with ethyl acetate and
the organic layer was washed with water and brine. The combined aqueous
washings were extracted
three times with ethyl acetate, and the combined organic layers were dried
(MgSO4) and concentrated.
The crude material was purified by reverse phase HPLC (Gemini, 15 to 45%
ACN/H20 + 0.1% TFA)
to yield methyl {(2S)-1-[(2R)-2-(5-{2-[(2S)-1-1(2R)-2-[(methoxycarbonypamino]-
phenylacetyllpyrrolidin-2-y1]-3,7-dihydroisochromeno[31,4':5,6]naphtho[1,2-
d]imidazol-9-y11-1H-
imidazol-2-yppyrrolidin-1-y11-3-methyl-1-oxobutan-2-y1 carbamate (155 mg, 5 I%
yield over 2
steps). LCMS-ESI+: calculated for C46H48N807: 824.92; observed [M+1 I':
Example MC
W- 1) HCI, Et0H, 60 C
11 N 1\3oc
D1PEA, DMF
tert-butyl 2-[9-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-
2-y1)-1,11-dihydroisochromeno[4',3:6,7]naphtho[1,2-
d]imidazol-2-yl]pyrrolidine-1-carboxylate
\ it 0¨e pd(PPh ) PdCI (cloof)
NH ow
- 10' N H K2CO3, DME, DMF, 85 C
methyl R2S)-3-methy1-1-oxo-1-{(2S)-249-(4,4,5 (S)-tert-butyl 2-(5-bromo-
,5-
tetramethyl-1,3,2-dioxaborolan-2-y1)-3,11- 1H-imidazol-2-yl)pyrrolidine-
dihydroisochromeno[4',3.:6,7]naphtho[1,2-d]imidazol- 1-carboxylate
2-yl]pyrrolidin-1-yllbutan-2-yl)carbamate
0 HN-0
Id 1) HCI, Et0H, 60 C
a NF)1
r 2) Moc-Val-OH, HATU,
H 0 DIPEA, DMF
tert-butyl (2R)-2-15-(2-{(2S)-14N-(methoxycarbony1)-L-
valyl]pyrrolidin-2-y11-3,11-
dihydroisochromeno[4',3.:6,7]naphtho[1,2-d]imidazol-
-0 9-y1)-1H-imidazol-2-yl]pyrrolidine-1-carboxylate
N 40/
\N JN
dimethyl (25,2'S)-1,1-((25,2'S)-2,21-pyrrolidin-2-y1)-
5H-naphtholc,gichromeno[8,9-d]imidazol-9-y1)-1H-imidazol-2-y1)
pyrrolidin-1-y1))bis(3-methy1-1-oxobutane-2,1-diAdicarbamate
dimethyl (2S,2'S)-1,1'4(2S,2'S)-2,21-pyrrolidin-2-y1)-5H-
naphthole,gichromeno18,9-dlimidazol-
9-y1)-lH-imidazol-2-yOpyrrolidin-l-y1))bis(3-methyl-1-oxobutane-2,l-
diy1)dicarbamate
This compound was made in an analogous manner to methyl {(2S)-14(2R)-2-(5-{2-
{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyllpyrrolidin-2-y11-3,7-
dihydroisochromeno[31,41:5,6]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-
yppyrrolidin-1-y11-3-
methyl-1-oxobutan-2-ylIcarbamate, substituting 7-hydroxy-1-tetralone for 5-
hydroxy-l-tetralone in
the first step of the sequence. All reactions in the synthesis gave similar
product yields as in the
synthesis of methyl {(2S)-1-R2R)-2-(5-{2-[(2S)-1-1(2S)-2-
methylbutanoyllpyrrolidin-2-y11-3,7-dihydroisochromeno3,4':5,6]naphtho[1,2-
imidazol-2-y1)pyrrolidin-1-y1]-
3-methyl-1-oxobutan-2-yllcarbamate. LCMS-ESI+: calculated for C43H501\1807:
790.91; observed
[M+1]+: 791.6.
Example MD
HN 0 0
N N\ 4/01/N_VY
methyl [1-(2-{5-[2-(1-{Rmethoxycarbonyl)amino]-3-methyl-1-
oxobutan-2-yllpyrrolidin-2-y1)-1,11-
dihydroisochromeno[43':6,7]naphtho[1,2-d]imidazol-9-y1]-1H-
imidazol-2-yllpyrrolidin-1-y1)-phenyl-1-oxoacet-2-ylicarbamate
This compound was made in an analogous manner to dimethyl (2S,2'S)-1,1'-
((2S,2'S)-2,2'1-
pyrrolidin-2-y1)-5H-naphtho[c,g]chromeno[8,9-d]imidazol-9-y1)-1 H-imidazol-2-
yppyrrolidin-1 -
y1))bis(3-methyl-l-oxobutane-2,1-diy1)dicarbamate, substituting (R)-2-
phenylacetic acid for (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid and
substituting COMU
for HATU in the final amide coupling step. LCMS-ESI : calculated for
C46f148N807: 824.92;
observed [M+1] : 825.67.
Example ME
(Bpin)2, Pd2(dba)3, X-Phos,
Cl.
N Boc KOAc, dioxane, 90 C
tert-butyl 2-(9-chloro-1,4,5,11-
tetrahydroisochromeno[4',3':6,7]naphtho[1,2-
0 1) HCI, EtOH, 6000
0NH
'13 4.0 MP 2) Moc-Val-OH, HATU,
0' DIPEA, DMF
tert-butyl (26)-249-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)-3,4,5,11-
tetrahydroisochromeno[4',3.:6,7]naphtho[1,2-
pd(PPh3)4, PdC12(cIPPf),
11. NH
K2003, DME, DMF, 8500
0 (S)-tert-butyl 2-(5-
bromo-1H-
imidazol-2-yl)pyrrolidine-1-
methyl [(2S)-3-methy1-1-oxo-14(2S)-249-(4,4,5,5- carboxylate
tetramethy1-1,3,2-dioxaborolan-2-y1)-3,4,5,11-
d]imidazol-2-yl]pyrrolidin-1-yl}butan-2-yl]carbamate
\NH 1) HCI, Et0H, 6000
0 DIPEA, DMF
tert-butyl (2R)-245-(2-{(28)-1-EN-
(methoxycarbony1)-L-valyl]pyrrolidin-2-y1}-3,4,5,11-
d]imidazol-9-y1)-1H-imidazol-2-yl]pyrrolidine-1-
0 fp11--).___
1\1.-}"N
dimethyl (2S,2'S)-1,1-((25,2'S)-2,21-pyrrolidin-2-y1)-
7H-clihydro-naphtho[c,g]chromeno[8,9-d]imidazol-9-y1)-1H-imidazol-2-y1)
pyrrolidin-1-y1))bis(3-methy1-1-oxobutane-2,1-thyhdicarbamate
dimethyl (2S,2'S)-1,1'4(2S,2'S)-2,21-pyrrolidin-2-y1)-7H-dihydro-
naphthok,Ochromeno[8,9-
diimidazol-9-31)-1H-imidazol-2-yDpyrrolidin-l-ylDbis(3-methyl-1-oxobutane-2,1-
This compound was made in an analogous manner to dimethyl (2S,TS)-1,1'-
((2S,2'S)-2,21-
yppyrrolidin-1-
yMbis(3-methyl-1-oxobutane-2,1-diypdicarbamate, omitting the Mn02 oxidation of
tert-butyl 2-(9-
chloro-1,4,5,1 1-tetrahydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-
yl)pyrrolidine-1 -
carboxylate. LCMS-ESI+: calculated for C43H52N807: 792.40; observed [M+1]+:
Example MF
Cr-
ip H
methyl [1-(2-{5-[2-(1-{Rmethoxycarbonyl)amino]-3-methyl-l-oxobutan-2-
yl}pyrrolidin-2-y1)-
1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-djimidazol-9-yI]-1H-
imidazol-2-
yl}pyrrolidin-1-0-phenyl-l-oxoacet-2-yl]carbamate
methyl 11-(2-15-12-(1-11(methoxycarbonyl)amino1-3-methyl-l-oxobutan-2-
yllpyrrolidin-2-y1)-
1,4,5,1l-tetrahydroisochromeno14',3%6,71naphtholl,2-dlimidazol-9-y11-1H-
yllpyrrolidin-1-y1)-phenyl-1-oxoacet-2-ylicarbamate
This compound was made in an analogous manner to dimethyl (2S,21S)-
1,11((2S,2S)-2,21-
1 0 pyrrolidin-2-y1)-7H-dihydro-naphtho[c,g]chromeno[8,9-d]imidazol-9-y1)-
1 H-imidazol-2-
yl)pyrrolidin-l-y1))bis(3-methyl-1 -oxobutane-2,1 -diy1)dicarbamate,
substituting (R)-2-
(methoxycarbonylamino)-2-phenylacetic acid for (S)-2-(methoxycarbonylamino)-3-
methylbutanoic
acid and substituting COMU for HATU in the final amide coupling step. LCMS-
Example MG
N / NH
,B = 0K2CO3, DME, DMF, 85 C
methyl (S)-1-((S)-2-(5-bromo-1H- tert-butyl 2-(9-chloro-1,4,5,11-
imidazol-2-yl)pyrrolidin-1-y1)-3- tetrahydroisochromeno[4',3':6,7lnaphtho[
methyl-1-oxobutan-2-ylcarbamate 1,2-djimidazol-2-yppyrrolidine-1-
¨00'
0 (\)7--- 1) HCI, Et0H, 60 C
0 N = NH
N/jN HO DIPEA, DMF
tert-butyl (2S)-249-(2-{(2R)-14N-(methoxycarbony1)-L- (R)-2-
valyl]pyrrolidin-2-y11-1H-imidazol-5-y1)-3,4,5,11- 2-phenylacetic acid
tetrahydroisochromeno[4',3':6,7Inaphtho[1,2-d)imidazol-
2-yl]pyrrolidine-1-carboxylate
0='
N NH
N,)N ith
[1-(2-{5-(2-(1-{[(methoxycarbonypamino](phenyl)acetyllpyrrolidin-2-y1)-
tetrahydroisochromeno[4',3':6,7]naphtho[1,2-dlimidazol-9-y1]-1H-imidazol-2-
yl}pyrrolidin-1-y1)-3-methyl-1-oxobutan-2-ylIcarbamic acid
This compound was made in an analogous manner to methyl {(2S)-1-R2R)-2-(5-{2-
{(2R)-2-[(methoxycarbonypamino]-2-phenylacetyll pyrrolidin-2-y1]-3,7-
dihydroisochromeno[31,4':5,6]naphtho[l ,2-d]imidazol-9-y11-1 H-imidazol-2-
yl)pyrrolidin-1
methyl-1 -oxobutan-2-yl}carbamate, substituting tert-butyl (2S)-219-(2-1(2R)-1
41\1-
(methoxycarbony1)-L-valylipyrrolidin-2-y1}-1H-imidazol-5-y1)-3,4,5,1 1 -
tetrahydroisochromeno[41,3':6,7]naphtho[ 1 ,2-d] imidazol-2-ylipyrrol id ine-
1 -carboxylate for tert-butyl
(2S)-2-[9-(2-{(2R)- 1 [N-(methoxycarbony1)-L-valyl] pyrrol id in-2-y! 1- 1 H-
imidazol-5-y1)-3,7-
dihydroisochromeno[3',4.:5,6]naphtho[1,2-d]imidazol-2-ylipyrrolidine-1 -
carboxylate. LCMS-ESI+:
calculated for C46H501\1807: 826.94; observed [M+1]+: 827.64.
Example MM
0 1. HCI, Et0H, 60 C
=--1:-----)' 2.
/ ---0/ 4111 11 NBoc0v
HC)''.1r0 III
tetramethy1-1,3,2-dioxaborolan-2-y1)-1,11- HATU, DIPEA, DMF, RT
dihydroisochromeno[4',3':6,71naphtho[1,2-d]imidazol-2-yl)pyrrolidine-
"B 40 kli,,rõ..-N
, % 11 Br
N -.../¨N
41 ii c)ji
N..........(1-----
0 __________________________________________________________________ 1.-
0 Pd(PPh3)4, PdC12(dPPO,
1-1'N--f K2003,
DME/ DMF, 85 C
(2S,4S)-methyll {4-(methoxymethyl)-2-[(9-(4,4,5,5- o,
tetramethy1-1,3,2-dioxaborolan-2-y))-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-
2-yl)pyrrolidin-1y1]-3-methy1-1-oxobutan-2-yl}carbamate
Ei\oc = 40.
FI/1\1-f
0 N 0
tert-butyl (2S)-2-[5-(2-{(2S,4S)-1-[N-(methoxycarbonyI)-
L-valy11-4-methylpyrrolidin-2-y1}-1,11-dihydroisochromeno 0 H
[43':6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y1 COMU, DIPEA, DMF, RT
Ipyrrolidine-1-carboxylate
0 (¨)
= <Li N\H N
methyl {(1R)-2-[(2S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-[(methoxycarbonyl)
amino]-3-methylbutanoy1}-4-(methoxymethyppyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3.:6,7]naphtho[1,2-djimidazol-9-y11-1H-imidazol-
2-yppyrrolidin-1-y1]-2-oxo-1-phenylethyl}carbamate
(2S,4S)-methyl (4-(methoxymethyI)-2-[(9-(4,4,5,5-tetramethy1-1,3,2-dioxa
borolan-2-yI)- 1,11-
dihydroisochromeno141,3%6,7]naphtho[1,2-dlimidazol-2-y1) pyrrolidin-ly11-3-
methyl-1-
oxobutan-2-yl}earbamate
A solution of (2S,4S)-tert-butyl 4-(methoxymethyl)-2-(9-(4,4,5,5-tetramethyl-
1,3,2-
dioxaborolan-2-y1)- 1,11-dihydroisochromeno[41,3':6,7]naphtho[1,2-d]-imidazol-
2-yppyrrolidine-l-
carboxylate (424 mg, 0.69 mmol), ethanol (6 mL) and concentrated HCI (2 mL)
for 1 hour. The reaction was concentrated and the crude material dissolved in
DCM (10 mL). This
solution was concentrated and to this material was added a solution of 2-
methoxycarbonylamino-3-
1 0 methylbutyric acid (152 mg, 0.86 mmol) and HATU (303 mg, 0.79 mmol) in
DMF (6 mL). To the
resulting solution was added diisopropylethylamine (360 uL, 2.08 mmol). After
stirring for 2 hours at
room temperature, the reaction was diluted with ethyl acetate, washed with 5%
NaHCO3 solution,
water and brine, dried (Na2SO4), concentrated and dried under vacuum to give
(2S,4S)-methyl {4-
(methoxymethyl)-2-[(9-(4,4,5,5-tetramethyl-1,3,2-dioxaboro 1,11lan-2-y1)-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-yl)pyrrolidin-l-y11-3-
methyl-l-oxobutan-2-
yllcarbamate.
tert-buty1(2S)-245-(2-{(2S,4S)-1-1N-(methoxycarbony1)-L-valy11-4-methylpyrroli
din-2-y1}-1,11-
dihydroisochromeno14',3':6,71naphtho11,2-dlimidazol-9-y1)-11-1-imidazol-2-
yllpyrrolidine-1-
To a solution of (2S, 4S)-methy114-(methoxymethyl)-2-[(9-(4,4,5,5-tetramethyl-
dioxaborolan-2-y1)-1,11-dihydroiso chromeno[41,3':6,7]naphtho[1,2-dlimidazol-2-
yl)pyrrolidin-ly1]-
3-methyl-l-oxobutan-2-ylIcarbamate (0.69 mmol), (S)-tert-butyl 2-(5-bromo-1H-
yl)pyrrolidine-1-carboxylate (220 mg, 0.69 mmol), tetrakis(triphenylphosphine)
0.02 mmol) and dichloro[1,1'-bis(diphenylphosphino) ferrocene]palladium(II)
(31 mg, 0.04 mmol) in
a mixture of 1,2-dimethoxyethane (6.0 mL) and dimethylformamide (1.0 mL) was
added a solution of
potassium carbonate (2M in water, 1.04 mL, 2.0 mmol). The resulting mixture
was degassed and
(tert-butyl (2S)-2-[5-
(2-{(2S,4S)- I 4N-(methoxycarbony1)-L-valy1]-4-methylpyrrolidin-2-y11-1,11-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-
yl]pyrrolidine-l-
carboxylate (145 mg, 27%).
methylf(1R)-2-1(2S)-2-(5-{2-1(2S,4S)-1-{(2S)-2-1(methoxycarbonypaminol-3-
methylbutanoy1}-4-
(methoxymethyl)pyrrolidin-2-y1I-1,11-dihydroiso chromeno14',3':6,71naphtho[1,2-
y11-1H-imidazol-2-Apyrrolidin-I-y11-2-oxo-1-phenylethyl}carbamate
A solution of tert-butyl (2S)-245-(2-1(2S,4S)-14N-(methoxycarbony1)-L-valy1]-4-
methylpyrrolidin-2-yll -1,11-dihydroisochromeno [41,3':6,7]naphtho[1,2-
dJimidazol-9-y1)-1H-
imidazol-2-yl]pyrrolidine- 1 -carboxylate (145 mg, 0.18 mmol), ethanol (3 mL)
and concentrated HC1
(1 mL) was heated to 60 C for I hour. The reaction was concentrated and the
crude material
COMU (92 mg, 021
(100 [iL, 0.56
methyl {(1R)-2-[(2S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-Rmethoxycarbonyl)amino]-3-
methylbutanoy11-4-
(methoxymethyppyrrolidin-2-y1]-1,11-dihydroisochromeno [4',31:6,7]naphtho[1,2-
d]imidazol-9-y1}-
1H-imidazol-2-y1)pyrrolidin-1-y1]-2-oxo-l-phenylethylIcarbamate (68 mg, 39%).
MS (ESI) m/z 870
[M + E1] . 1H NMR (400 MHz, dmso) 6 8.71 (s, 1H), 8.22 (d, 1H, J = 8 Hz), 8.09
(m, 1H), 7.88 ¨
7.63 (m, 6H), 7.36 -7.29 (m, 611), 5.41 (d, 1H, J= 8.4 Hz), 5.30 ¨ 5.24 (m,
2H), 5.14 ¨ 5.10 (m, 1H),
4.13 -3.09 (m, 15H), 2,47 - 1.80 (m, 8H), 0.80 (dd, 6H, J= 6.4 Hz, J= 23 Hz).
Example MN
0 1...1
¨0)LN=,J,t_." 0 N
, ¨s_
1-1\-11j)
C(DI:13 4141# "60c
tetramethy1-1,3,2-dioxaborolan-2-y1)-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-dlimidazol
-2-yl)pyrrolidine-1-carboxylate
)1-N 0 H 1. HCI, Et0H, 60 C
--0 Ne,N
W-11 N I3oc 2.
H.0 )1.
o H
tert-butyl (2S,4S)-2-[9-(2-{(2S4S)-14N-(methoxycarbony1)- COMU, DIPEA, DM
F, RT
L-valy1]-4-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-3,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y11-
4-(methoxymethyl)pyrrolidine-1-carboxylate
----0 N =
u=0
.N-t
methyl {(2S)-1-[(2S,4S)-2-(5-{2-[(2S,4S)-1-{(2R)-21(methoxycarbonyl)amino]-2-
phenylacety11-4-(methoxymethyppyrrolidin-2-y11-1,11-
dihydroisochromeno[4',3':6,7]
naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-2-y1)-4-methylpyrrolidin-1-y1]-3-
methy1-1-
oxobutan-2-ylIcarbamate
tert-buty1(2S,4S)-2-19-(2-{(2S4S)-1-1N-(methoxyearbony1)-L-valy11-4-methyl
pyrrolidin-2-yl}-
1H-imidazol-5-y1)-3,11-dihydroisochromenol41,3':6,71naphtho
[1 ,2-d imidazol-2-ylJ-4-
(methoxymethyl)pyrrolidine-l-carboxylate
dioxaborolan-2-y1)-1,11-dihydroisochromeno[4',3':6,7] naphtho [1,2-d]imidazol -
2-yl)pyrrolidine-1 -
carboxylate (438 mg, 0.72 mmol), methyl (S)-1-((2S,4S)-2-(5-bromo-1H-imidazol-
2-y1)-4-
methylpyrrolidin-1-y1)-3-methy1-1 -oxobutan-2-ylcarbamate (276 mg, 0.72 mmol),
tetrakis(triphenylphosphine) palladium(0) (41 mg, 0.04 mmol) and dichloro[1,1'-
bis(diphenylphosphino) ferrocenelpalladium(11) (52 mg, 0.07 mmol) in a mixture
of 1,2-
dimethoxyethane (8.6 mL) and dimethylformamide (1.5 mL) was added a solution
of potassium
carbonate (2M in water, 1.07 mL, 2.15 mmol). The resulting mixture was
degassed and then heated
to 85 C under argon for 18 hours. After cooling to room temperature, the
The crude residue was purified by flash chromatography to yield tert-butyl
(2S,4S)-2-[9-(2-{(2S4S)-
14N-(methoxycarbony1)-L-valy1]-4-methylpyrrolidin-2-y1 -1H-imidazol-5-y1)-3,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1]-
4-(methoxymethyppyrrolidine-1-carboxylate (182 mg, 32%).
methyl {(2S)-1-1(2S,4S)-2-(5-{2-1(2S,4S)-1-{(2R)-2-[(methoxyearbonyl)aminol-2-
phenylacetyll-4-
(methoxymethyl)pyrrolidin-2-yll-1,11-dihydroisochromeno
14',3':6,71naphthol1,24imidazol-9-
y11-1H-imidazol-2-y1)-4-methylpyrrolidin-1-y11-3-methyl-1-oxobutan-2-
y1}earbamate
A solution of tert-butyl (2S,4S)-2-[9-(2-{(2S4S)-11N-(methoxycarbony1)-L-
valy1]-4-
methylpyrrolidin-2-y11-1H-imidazol-5-y1)-3,11-
d]imidazol-2-y1]-4-(methoxy methyppyrrolidine-l-carboxylate (182 mg, 0.18
and concentrated HC1 (I mL) was heated to 60 C for 1 hour. The reaction was
COMU (85 mg, 0.2 mmol) in DMF (3 mL). To the resulting solution was added
diisopropylethylamine (90 uL, 0.52 mmol). After stirring for 2 hours at room
product fractions were lyophilized to give methyl{(2S)-1-[(2S,4S)-2-(5-{2-
[(2S,4S)-1-{(2R)-2-
Rmethoxycarbonypamino1-2-phenylacetyll-4-(methoxymethyppyrrolidin-2-y1]-1,11-
dihydroisochromeno [41,31:6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-
methylpyrrolidin-1-
y1]-3-methyl-l-oxobutan-2-ylIcarbamate (32 mg, 39%). MS (ESI) m/z 884 [M + Hr.
1H NMR (400 MHz, dmso) 6 8.70 (s, 1H), 8.21 (d, 1H, J= 8 Hz), 8.08 (s, 1H),
7.90¨ 7.64
(m, 6H), 7.34 ¨ 7.31 (m, 3H), 7.64 (d, 1H, J= 8.4 Hz), 5.47 (d, 1H, J= 7.6
Hz), 5.28 ¨ 5.25 (m, 3H),
5.05 ¨ 5.01 (m, 1H), 4.19 ¨ 4.04 (m, 3H), 3.67 ¨ 3.15 (m, 15H), 2.51 -2.46 (m,
4H), 1.95¨ 1.92 (m,
2H), 1.82¨ 1.76(m, 1H), 1.10 (d, 3H, J= 6 Hz), 0.75 (dd, 6H, J= 6.8 Hz, J= 14
Hz).
Example MO
0 = .11
\ -N N H
HATU, DIPEA, DMF, RT
methyl {(2S)-1-[(2S,4S)-2-(5-{2-[(2S,4S)-4-(methoxy
methyppyrrolidin-2-y1]-1,11-dihydroisochromeno
[4',3':6,7]naphtho[1,2-djimidazol-9-y1}-1H-imidazol-2-
y1)-4-(methyl)pyrrolidin-1-y11-3-methyl-1-oxobutan-2-y1)
carbamate
\ 4411. AL\
methyl {(2S)-1-[(2S,4S)-2-(5-{2-1(2S,4S)-1-{(2S)-2-
(methoxycarbonyl)amino]-3-methylbutanoy11-4-methoxy
methylpyrrolidin-2-yI]-1,11-dihydroisochromeno[4',3':6,7]
naphtho[1,2-dlimidazol-9-y11-1H-imidazol-2-y1)-
4-methylpyrrolidin-1-y1]-3-methyl-1-oxobutan-2-yl}carbamate
methyl {(2S)-1-1(2S,4S)-2-(5-{2-1(2S,4S)-1-{(2S)-2-1(methoxycarbonyl)amino1-3-
methylbutanoyll-4-methoxymethylpyrrolidin-2-y11-1,11-
dihydroisochromeno14',3':6,7inaphtholl,2-dlimidazol-9-y1}-1H-imidazol-2-y1)-4-
methylpyrrolidin-l-y11-3-methyl-1-oxobutan-2-yl}carbamate
To a solution of methyl {(2S)-1-[(2S,4S)-2-(5-{2-[(2S,4S)-4-
(methoxymethyppyrrolidin-2-
y1]-1,11-dihydroisochromeno[41,3':6,7] naphtho[1,2-d]imidazol-9-y11-1H-
imidazol-2-y1)-4-
(methyppyrrolidin-1-y1]-3-methy1-1-oxobutan-2-ylIcarbamate (57 mg, 0.08 mmol),
methoxycarbonylamino-3-methylbutyric acid (19 mg, 0.1 mmol), HATU (303 mg,
0.79 mmol) in
DMF (1 mL) was added diisopropylethylamine (43 uL, 0.24 mmol). After stirring
for 2 hours at
water and brine, dried (Na2SO4), concentrated and purified by preparative
reverse phase HPLC
(Gemini, 15 to 43% ACN/H20 + 0.1% TFA). The product fractions were lyophilized
to give methyl
{(2S)-1-[(2S,4S)-2-(5- {2-[(2S,4S)-1-{ (2S)-2-[(methoxycarbonyl)amino]-3 -
methyl butanoy11-4-
methoxymethylpyrrolidin-2-y1]-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-
d]imidazol-9-y1 -1H-
imidazol-2-y1)-4-methylpyrrolidin-1-y1]-3-methyl- 1-
oxobutan-2-yllearbamate. (13 mg, 19%). MS
(ESI) m/z 850 [M + H].
1H NMR (400 MHz, dmso) 6 8.66 (s, 1H), 8.28 ¨ 8.13 (m, 1H), 8.12 ¨ 7.99 (m,
1H), 7.90 ¨
7.75 (m, 3H), 7.73 ¨7.65 (m, I H), 7.63 ¨ 7.57 (m, 1H), 7.34 ¨ 7.19 (m, 2H),
5.30 ¨ 5.24 (m, 2H),
5.21 ¨4.95 (m, 2H), 4.33 ¨3.93 (m, 6H), 3.23 -3.58 (m, 12H), 2.76 ¨2.59 (m,
6H), 1.12¨ 1.07 (m, 3H), 0.86 ¨ 0.68 (m, 12H).
Example MP
)1--N
N=NyE¨Br
)-o/B L
Pd(PPh3)4, PdClz(dPPf),
(2S,45)-tert-butyl 4-(methoxymethyl)-2-(9-(4,4,5,5-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol
)\--N"H r,
H 1. HCI, Et0H, 60 C
u N N N
= 2. 0
N Boc II
tert-butyl (2S,4S)-249-(2-{(2S,5S)-1-[N-(methoxycarbony1)-
L-valy1]-5-methylpyrrolidin-2-y11-1H-imidazol-5-y1)-3,11- HATU, DIPEA, DMF,
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yli-
-o>\---N"H 0
= \ r\j,ir
N os%L.
methyl {(2S)-1-[(2S,5S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoy11-4-methoxy
naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-
tert-buty1(2S,4S)-2-19-(2-{(2S,5S)-1-IN-(methoxyearbony1)-L-valy11-5-m ethyl
pyrrolidin-2-y1}-
1H-imidazol-5-y1)-3,11-dihydroisochromeno[4',3%6,71naphtho 11,2-dlimidazol-2-
(methoxymethyppyrrolidine-l-earboxylate
dioxaborolan-2-y1)-1,11-dihydroisochromeno[4',3':6,7] naphtho[l ,2-d]imidazol -
2-yl)pyrrolidine-1-
1 0 carboxylate (217 mg, 0.35 mmol), methyl (S)-14(2S,5S)-2-(5-bromo-1H-
methylpyrrolidin- 1 -y1)-3-methyl- 1 -oxobutan-2-ylearbamate (170 mg, 0.39
tetrakis(triphenylphosphine) palladium(0) (21 mg, 0.02 mmol) and dichloro[1,11-
bis(diphenylphosphino) ferrocene]palladium(11) (26 mg, 0.04 mmol) in a mixture
dimethoxyethane (4.3 mL) and dimethylformamide (0.75 mL) was added a solution
(2S,4S)-249-(2-1(2S,5S)-
14N-(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y11-1H-imidazol-5-y1)-3,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-y1]-4-(methoxy
methyl)pyrrolidine-1-
methyl{(2S)-1-1(2S,5S)-2-(5-12-1(2S,4S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyll-
4-methoxymethylpyrrolidin-2-y11-1,11-dihydroisochromeno 14',3%6,7)naphtholl,2-
y1}-1H-imidazol-2-y1)-5-methylpyrrolidin-l-y11-3-methy1-1-oxobutan-2-
y1}carbamate
A solution of tert-butyl (2S,4S)-249-(2-1(2S,5S)-14N-(methoxycarbony1)-L-
dihydroisochromeno[41,31:6,7]naphtho [1,2-
d]imidazol-2-y1]-4-(methoxy methyl)pyrrolidine-1 -carboxylate (108 mg, 0.14
and concentrated HC1 (0.7 mL) was heated to 60 C for 1 hour. The reaction was
concentrated and
the crude material dissolved in DCM (10 mL). This solution was concentrated
and to this material
was added a solution of 2-methoxycarbonylamino-3-methylbutyric acid (31 mg,
HATU (60 mg, 0.16 mmol) in DMF (2 mL). To the resulting solution was added
reaction was diluted with ethyl acetate, washed with 5% NaHCO3 solution, water
and brine, dried
(Na2SO4), After stirring for 2 hours at room temperature, the reaction was
washed with 5% NaHCO3 solution, water and brine, dried (Na2SO4), concentrated
and purified by
preparative reverse phase HPLC (Gemini, 15 to 43% ACN/H20 + 0.1% TFA). The
product fractions
were lyophilized to give methyl {(2S)-1-[(2S,5S)-2-(5-12-[(2S,4S)-1-{(2S)-2-
Rmethoxycarbonyl)amino]-3-methylbutanoy11-4-methoxy methylpyrrolidin-2-y1]-
1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-5-
y1]-3-methyl-1-oxobutan-2-yllcarbamate (52 mg, 45%). MS (ES!) m/z 850 [M +
1H NMR (400 MHz, dmso) 6 8.69 (s, 1H), 8.18 (d, 1H, J= 7.6 Hz), 7.99 ¨ 7.86
(m, 4H), 7.72
(s, 1H), 7.64 (d, 1H, J = 8.8 Hz), 7.51 (d, 1H, J= 8 Hz), 7.23 (d, 1H, J= 8.4
Hz), 5.29 (s, 2H), 5.22 ¨
5.18 (m, 1H), 5.01 ¨4.70 (m, 1H), 4.64¨ 4.61 (m, 1H), 4.21-4.17 (m, 1H), 4.09-
4.05 (m, 1H), 3.92 ¨
3.88 (m, 1H), 3.59 ¨ 3.08 (m, 14H), 2.67¨ 1.83 (m, 7H), 1.43 (d, 3H, J= 6.4
Hz), 0..91-0.71 (m,
12H).
Example MQ
/ I /
0 __H-- 0, ,O.-
B¨B
----0/ \O's
INII-- ________________ ir.
CI . . If I\\J Pd2dba3, KOAc, XPOS,
0 N Boc dioxane, 90 C
(23,4R)-tert-butyl 2-(9-chloro-1,11-dihydroiso
chromeno[4',3':6,7]naphtho[1,2-d]imidazol
-2-yI)-4-(methoxymethyl)pyrrolidine-1-carboxylate 0 H
.,õ LN r)
; Lf
0 -- it p-Br
\ N -.."-N1
o;13 ilisoNNµl --- Pd(PPh3)4, PdC12(dP100,
(2S,4R)-tert-butyl 4-(methoxymethyl)-2-(9-(4,4,5,5-
dihydroisochromeno[4',3':6,7]riaphtho[1,2-d]imidazol
HC1, Et0H, 60 C
0_õJ . 2.
___________________________________________________________ ).-
ci k 0
)L V
H-0 N 0
(2S,4R)-tert-butyl 2-(9-(2-((S)-1-((S)-2-(methoxycarbonyl i
amino)-3-methylbutanoyl)pyrrolidin-2-y1)-1H-imidazol-5-y1)- 0 H
1,11-dihydroisochromeno[4',3':6,7jnaphtho[1,2-d]imidazol COMU, DIPEA,
DMF, RI
-2-yI)-4-(methoxymethyl)pyrrolidine-1-carboxylate
--0 \___ i;-,
__.,-= --7 NI \ . /AL N 7r,...-...N 0
\ N-õõ71-Thl W410 N
,N...e
methyl {(1R)-2-[(2S,4R)-2-(9-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)
amino]-3-methylbutanoyl}pyrrolidin-2-y1)-1H-imidazol-5-y1]-1,11-
dihydroisochromeno[4',3':6,7)-
naphtho[1,2-d]imidazol-2-y1}-4-(methoxymethyl)pyrrolidin-1-y1]-2-oxo-
(2S,4R)-tert-buty1-4-(methoxymethyl)-2-(9-(4,4,5,5-tetramethyl-1,3,2-dioxa
borolan-2-y1)-1,11-
dihydroisochromeno14',31:6,7Jnaphtho[1,2-dlimidazol-2-y1) pyrrolidine-l-
A degassed mixture of - (2S,4R)-tert-buty1-2-(9-chloro-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1)-4-(methoxymethyl)
pyrrolidine-1-
carboxylate (335 mg, 0.64 mmol), bis(pinacolato)diboron (246 mg, 0.96 mmol),
potassium acetate
(190 mg, 1.9 mmol), tris(dibenzylideneacetone) palladium (24 mg, 0.02 mmol)
and 2-
dicyclohexylphosphino-2', 4', 6'-tri-i-propy1-1, 1 '-biphenyl (31 mg, 0.06
mmol) in 1,4-dioxane (3.3
mL) was heated to 90 C for 3 hours, cooled to room temperature and diluted
with ethyl acetate. The
organics were washed with water and brine, dried (Na2SO4), and concentrated.
The crude residue was
purified by flash chromatography to yield (2S,4R)-tert-butyl 4-(methoxymethyl)-
2-(9-(4,4,5,5-
dihydroisochromeno[41,31:6,7]naphtho[1,2-djimidazol -2-
yl)pyrrolidine-l-carboxylate (379 mg, 96%).
(2S,4R)-tert-buty12-(9-(24(S)-1-((S)-2-(methoxycarbonylamino)-3-methyl
butanoyl)pyrrolidin-
2-y1)-1H-imidazol-5-y1)-1,11-dihydroisochromeno14',3%6,7] naphthol1,2-
dlimidazol -2-y1)-
4(methoxymethyl) pyrrolidine-l-carboxylate.
To a solution of (2S,4R)-tert-butyl 4-(methoxymethyl)-2-(9-(4,4,5,5-
dioxaborolan-2-y1)- 1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-djimidazol-2-
y1) pyrrolidine-l-
carboxylate (299 mg, 0.49 mmol), methyl (S)-1-((S)-2-(5-bromo-1H-imidazol-2-
yl)pyrrolidin-1 -y1)-3-
methyl-l-oxobutan-2-ylcarbamate (217 mg, 0.58 mmol),
tetrakis(triphenylphosphine) palladium(0)
(28 mg, 0.02 mmol) and dichloro[1,1'-
bis(diphenylphosphino)ferrocene]palladium(II) (35 mg, 0.04
mmol) in a mixture of 1,2-dimethoxyethane (4.3 mL) and dimethylformamide (0.75
mL) was added a
solution of potassium carbonate (2M in water, 0.73 mL, 1.46 mmol). The
resulting mixture was
degassed and then heated to 85 C under argon for 18 hours. After cooling to
room temperature, the
reaction was diluted with ethyl acetate. The organics were washed with water
(Na2SO4), and concentrated. The crude residue was purified by flash
(2S,4R)-tert-butyl 2-(9-(2-((S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidin-2-y1)-
1H-imidazol-5-y1)-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-dlimidazol-2-
y1)-4-
(methoxymethyppyrrolidine-1-carboxylate (170 mg, 45%).
m ethyl{(1 R)-2-1(2S,4R)-2-(9-{2-1(2S)-1-{(2S)-2-I(methoxyca rbonyl)a m ino1-3-
methylbutanoyl}pyrrolidin-2-y1)-1H-imidazol-5-y11-1,11-dihydroisochromeno
[4',3':6,71naphthoil,2-dlimidazol-2-y1}-4-(methoxymethyl)pyrrolidin-1-y11-2-
oxo-
methylbutanoyl)pyrrolidin-2-y1)-1H-imidazol-5-y1)-1,11-
dihydroisochromeno[41,3':6,7]naphtho [1,2-
d]imidazol-2-y1)-4-(methoxymethyppyrrolidine-1-carboxy late (170 mg, 0.22
and concentrated HCI (1 mL) was heated to 60 C for 1 hour. The reaction was
diisopropylethylamine (110 t, 0.66 mmol). After stirring for 2 hours at room
product fractions were lyophilized to give methyl 1(1R)-2-[(2S,4R)-2-(9-12-
[(2S)-1-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyll pyrrolidin-2-y1)-1H-imidazol-5-y1]-
dihydroisochromeno[4',31:6,7]-naphtho[1,2-djimidazol-2-y11-(methoxymethyl)
pyrrolidin-l-y1]-2-
oxo-phenylethylIcarbamate (67 mg, 35%). MS (ESI) m/z 870 [M + Hr. 1H NMR (400
MHz, dmso)
6 8.71 (s, 1H), 8.20 (d, 1H, J = 8.4 Hz), 8.01 (m, 1H), 7.91 ¨7.64 (m, 6H),
7.38 -7.28 (m, 6H), 6.85
(s, 1H), 5.51 (d, 1H, J = 7.2 Hz), 5.39 ¨ 5.29 (m, 3H), 5.13 ¨ 5.09 (m, 1H),
4.11 -3.04 (m, 15H), 2.77 -
1.98 (m, 8H), 0.79 (dd, 6H, J = 6.8 Hz, J = 12.8 Hz).
Example MR
0 \-0\ ,0--;/
,. B¨B\
----'0' 0-----
o r\il-r)
ci 41 . ii 1`µi Pd2dba3, KOAc, XPOS,
111 N Boc dioxane, 90 C
(2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-1,11-
/ _ H
r-N
o ¨0
N---/¨N
_\.....0µ it.
____________________________________________________ ).
B =r\\I
N Boc Pd(PPh3)4, PdC12(dppf),
tetramethy1-1,3,2-dioxaborolan-2-y1)-4,5-dihydro-1,11-
)\-- '1\I n = 0
II,_ .-----)
--so <,..y.......( NI \ AL\
Tr N )0.
----\ N---../LN WO N I3oc 2. ilo __
U k 0
H,0 N)L0
(2S,4S)-tert-butyl 2-(9-(2-((S)-1-((S)-2-(methoxycarbonyl
amino)-3-methylbutanoyl)pyrrolidin-2-yI)-1H-imidazol- %
5-y1-4,5-dihydro-1,11-dihydroisochromeno[4',3':6,7Thaphtho
[1,2-d]imidazol-2-y1)-4-(methoxymethyppyrrolidine-1- COMU, DI PEA, DM F, RT
0 H :
"r)
N....f
0.,
methyl {(1R)-2-[(2S,4S)-2-(9-{2-[(2S)-1-{(2S)-2-[(methoxy
carbonypamino]-3-methylbutanoyl}pyrrolidin-2-y1)-1H-imidazol-
5-y1]-1,11-dihydroisochromeno[4',3':6,7]-4,5-dihydro-naphtho[1,2-d]
imidazol-2-y1}-4-(methoxymethyppyrrolidin-1-y1]-2-oxo-1-
phenylethyllcarbamate
(2S,4S)-tert-buty14-(methoxymethyl)-2-(9-(4,4,5,5-tetramethy1-1,3,2-dioxaboro
lan-2-y1)-4,5-
dihydro-1,11-dihydroisochromeno14',31:6,71naphtholl,2-djimidazol -2-
A degassed mixture of (2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol -2-y1)-4-
carboxylate (322 mg, 0.61 mmol), bis(pinacolato) diboron (235 mg, 0.92 mmol),
(182 mg, 1.9 mmol), tris(dibenzylideneacetone)palladium (23 mg, 0.02 mmol) and
dicyclohexylphosphino-2', 4', 6'-tri-i-propy1-1, l'-biphenyl (29 mg, 0.06
mmol) in I ,4-dioxane (3.3
1 0 organics were washed with water and brine, dried (Na2SO4), and
concentrated. The crude residue was
purified by flash chromatography to yield (2S,4S)-tert-butyl 4-(methoxymethyl)-
tetramethyl-1,3,2-dioxaborolan-2-y1)-4,5-dihydro-1,11-
dihydroisochromeno[41,3':6,7]naphtho[ I ,2-
d]imidazol-2-yppyrrolidine-1-carboxylate (267 mg, 70%).
(2S,4S)-tert-buty12-(9-(24(S)-14(S)-2-(methoxycarbonylamino)-3-methylbutano
yl)pyrrolidin-2-
1 5 y1)-1H-imidazol-5-y1-4,5-dihydro-1,11-dihydroisochromeno
[4',3%6,71naphtho11,2-dlimidazol-2-
y1)-4-(methoxymethyl)pyrrolidine-l-carboxylate
dioxaborolan-2-y1)-4,5-dihydro-1,11-dihydroisochrome no[41,3':6,71naphthop ,2-
d]imidazol-2-
yppyrrolidine-1-carboxylate (267 mg, 0.52 mmol), methyl (S)-1-((S)-2-(5-bromo-
20 yl)pyrrolidin-l-y1)-3-methyl- 1 -oxobutan-2-ylcarbamate (195 mg, 0.52
mmol), tetrakis
(triphenylphosphine) palladium(0) (25 mg, 0.02 mmol) and dichloro[1,1'-
bis(diphenylphosphino)ferrocene] palladium(II) (32 mg, 0.04 mmol) in a mixture
carbonate (2M in water, 0.65 mL, 1.3 mmol). The resulting mixture was degassed
25 85 C under argon for 18 hours. After cooling to room temperature, the
The crude residue was purified by flash chromatography to yield (2S,4S)-tert-
butyl 2-(9-(2-((S)-1-
((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidin-2-y1)-1H-imidazo1-5-
y1-4,5-dihydro-
1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1)-4-
30 carboxy late (75 mg, 22%).
methyl{(1R)-2-1(2S,4S)-2-(9-12-1(2S)-1-{(2S)-2-1(methoxycarbonyl)aminol-3-
methylbutanoyl}pyrrolidin-2-y1)-111-imidazol-5-y11-1,11-dihydroisochromeno
14%3%6,71-4,5-
dihydro-naphtho[1,2-djimidazol-2-y11-(methoxymethyl)pyrrolidin-l-y11-2-oxo-1-
35 A solution of (2S,4S)-tert-butyl 2-(9-(2-((S)-1-((S)-2-(methoxy
carbonylamino)-3-
methylbutanoyl)pyrrolidin-2-y1)-1H-imidazol-5-y1-4,5-dihydro-1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1)-4-(methoxymethyl)
pyrrolidine-l-
carboxylate (75 mg, 0.09 mmol), ethanol (2 mL) and concentrated HC1 (0.6 mL)
DCM (6 mL). This
solution was concentrated and to this material was added a solution of (R)-2-
(methoxycarbonylamino)-2-phenylacetic acid (26 mg, 0.13 mmol) and COMU (47 mg,
DMF (2 mL). To the resulting solution was added diisopropylethylamine (50 uL,
0.29 mmol). After
stirring for 2 hours at room temperature, the reaction was diluted with ethyl
acetate, washed with
(1R)-2-[(2S,4S)-2-(9-12-[(2S)-1-{ (2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyl } pyrrolidin-2-
y1)-1 H-imidazol-5-y1]-1,11-dihydroisochromeno[41,31:6,7]-4,5-dihydro-naphtho
[1,2-d] imidazol-2-yll -
4-(methoxymethyl)pyrrolidin-l-y1]-2-oxo-l-phenylethyl } carbamate (15 mg,
18%).
MS (ESI) m/z 872 [M + H]+.
1H NMR (400 MHz, dmso) 6 7.95 ¨ 7.63 (m, 6H), 7.35 - 7.25 (m, 7H), 6.97 (s,
1H), 5.42 (d,
1H, J= 6.8 Hz), 5.18 (s, 2H), 5.09 (s, 2H), 4.28 -2.63 (m, 19H), 2.47 - 1.80
(m, 8H), 0.77 (dd, 6H, J =
4.8 Hz, = 12.4 Hz).
Example MS
)1"-N 0
NVBr
---"X
0 \ N
7"-cl W-41 N Boo K2CO3, DME/ DMF, 85 C
dihydroisochromeno[4',3':6,7]naphtho[1,2-djimidazol
,H . 41 0 r
Or \11 2. *
N Boc NN 41
c---F Fr N v
(2S,4S)-tert-butyl 2-(9-(2-((S)-1-((S)-2-(methoxycarbonyl H
amino)-3-methylbutanoyl)pyrrolidin-2-yI)-1H-benzo[d]imidazol- COMU, DIPEA,
DMF, RT
6-yI)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol
-2-y1)-4-(methoxymethyl)pyrrolidine-1-carboxylate
)L-N1'1-1 r
N 0,40 )140
H'N***-f
methyl {(2S)-2-[[(2S,4S)-2-{9-[2-((2S)-1-{(2S)-2-[(methoxycarbonyl)
amino]-3-methylbutanoyl}pyrrolidin-2-y1)-1H-benzo[djimidazol-6-y]-1,11-
oxo-1-phenylethyl}carbamate
(2S,4S)-tert-buty12-(9-(24(S)-14(S)-2-(methoxycarbonylamino)-3-
y1)-1H-benzoldlimidazol-6-y1)- 1,11-dihydroisochromeno14',3`:6,71naphtholl,2-
djimidazol-2-y1)-
4-(methoxymethyl) pyrrolidine-l-earboxylate
dioxaborolan-2-y1)- 1,11 -dihydroisochromeno [4,3:6,7] naphtho[1,2-d]imidazol -
2-yl)pyrrolidine- 1 -
carboxylate (400 mg, 0.85 mmol), methyl (S)-14(S)-2-(6-bromo-1H-
benzo[d]imidazol-2-
yl)pyrrolidin-l-y1)-3-methyl-1-oxobutan-2-ylcarbamate (360 mg, 0.85 mmol),
The crude residue was purified by flash chromatography to (2S,4S)-tert-butyl 2-
(9-(24(S)-14(S)-2-
(methoxycarbonylamino)-3-methylbutanoyppyrrolidin-2-y1)-1H-benzo[d]imidazol-6-
y1)-1,11-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-y1)-4-
methyl{(2S)-2-11(2S,4S)-2-19-12-42S)-1-{(2S)-2-1(methoxycarbonyl)aminol-3-
methylbutanoyl}pyrrolidin-2-y1)-11-1-benzoldJimidazol-6-y]-1,11-dihydroiso
chromenopl',3':6,71naphtho11,2-d]imidazol-2-y1}-4-(methoxymethyppyrrolidin-1-
yli-2-oxo-1 -
phenylethyl} carbamate
methylbutanoyl)pyrrolidin-2-y1)-1H-benzo[d] imidazol-6-y1)-1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1)-4-
carboxylate (156 mg, 0.18 mmol), ethanol (3 mL) and concentrated HC1 (1 mL)
solution was concentrated and to (90 mg, 0.12 mmol) of this material was added
a solution of (R)-2-
014 mmol) in
DMF (2 mL). To the resulting solution was added diisopropylethylamine (60 1AL,
(Gemini, 15 to 49% ACN/1-120 + 0.1% TFA). The product fractions were
lyophilized to give methyl
{(2S)-2-[[(2S,4S)-2-{9-[2-((2S)-1-{ (2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyllpyrrolidin-
2-y1)-1H-benzo[d]imidazol-6-y]-1,11-dihydroisochrome no[4',31:6,7]naphtho[1,2-
d]imidazol-2-y11-4-
(methoxymethyl)pyrrolidin- 1 -y1]-2-oxo- 1 -phenylethyl carbamate (62 mg,
56%). MS (ESI) rn/z 920
[M + H].
I H NMR (400 MHz, dmso)S 8.73 (s, 1H), 8.17 (d, 2H, J = 8.4 Hz), 7.94 (d, 3H,
J = 8.8 Hz),
7.84 ¨7.67 (m, 6H), 7.37 - 7.29 (m, 6H), 5.48 (d, 1H, J= 7.6 Hz), 5.35 ¨ 5.20
(m, 5H), 4.14 -3.12 (m,
15H), 2.52 - 1.92 (m, 8H), 0.80 (dd, 6H, J = 6.8 Hz, Jr6.4 Hz).
Example MT
Or N
,H 0
¨"
=-5 1. HCI, Et0H, 60 C
W-41 N Boc 2.
`-'
amino)-3-methylbutanoyl)pyrrolidin-2-yI)-1H-benzo[d]
imidazol-6-y1)-1,11-dihydroisochromeno[4',3':6,7]naphtho
[1,2-cl]imidazol-2-y1)-4-(methoxymethyppyrrolidine-1-
N 7XN N ojs,
methyl {(2S)-2-R2S,4S)-2-{942-((2S)-1-{(2S)-2-[(methoxycarbonyl)
amino]-3-methylbutanoyl}pyrrolidin-2-y1)-1H-benzo[d]imidazol-6-y]-1,11-
dihydroisochromeno[4',3.:6,7]naphtho[1,2-d]imidazol-2-y1}-4-(methoxy
methyl)pyrrolidin-1-y1]-3-methyl-1-oxobutan-2-ylIcarbamate
methyl{(2S)-2-K2S,4S)-2-19-12-42S)-1-1(2S)-2-1(methoxyearbonyl)aminol-3-
methylbutanoyl}pyrrolidin-2-y1)-1H-benzoldlimidazol-6-y1-1,11-dihydroiso
ehromeno14',3':6,7lnaphtholl,241-limidazol-2-y1}-4-(methoxymethyl)pyrrolidin-1-
yll-3-methyl-
1-oxobutan-2-yllearbamate
A solution of (2S,4S)-tert-buty1-2-(9-(2-((S)-1-((S)-2-(methoxycarbonylamino)-
methylbutanoyl)pyrrolidin-2-y1)-1H-benzo [d]imidazol-6-y1)-1,11-
dihydroisochromeno[4',3':6,7]naphthop ,2-djimidazol-2-y1)-4-
01 mmol) in
DMF (1 mL). To the resulting solution was added diisopropylethylamine (50 piL,
{(2S)-2-[(2S,4S)-2-{9-[2-((2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyllpyrrolidin-2-
y1)-1H-benzo[d]imidazol-6-y1-1,11-dihydroisochrome no[4',37:6,7]naphtho[1,2-
40%). MS (ESI) miz
886 [M + Hr.
1H NMR (400 MHz, dmso) 6 8.71 (s, 1H), 8.15 (d, 1H, J = 8 Hz), 7.95 ¨ 7.64 (m,
8H), 7.28
(dd, 2H, J = 8.8 Hz, J = 14.4 Hz), 5.31 (s, 2H), 5.23 ¨5.19 (m, 2H), 4.09 ¨
3.85 (m, 5H), 3.58 -3.28
(m, 14H), 2.47 ¨ 1.89 (m, 9H), 0.83 ¨ 0.72 (m, 12H).
Example MU
yoc N
0 ... N ,...4.
NI 1¨) C_
E3 * \ /0¨`
sr...N
,Nõ..{ Pd(PPh3)4, PdC12(dPPO,
H K2CO3, DME/ DMF, 85 C
0õ
(2S)-methyll {-2-[(9-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)-1,11-dihydroisochromeno[4',3':6,7]
naphtho[1,2-d]imidazol-2-yl)pyrrolidin-1y1]-3-methyl-1-
oxobutan-2-yl}carbamate
0 IF\II r) 1
Boc Nit \ * 41. 'p----N 1. HCI, Et0H, 60 C
µN-...2---N N ....õ.,,\L---, __________ ).
ci k 0 2.
:.= H 0
N)L07
tert-butyl (2S,4S)-2-[5-(2-{(2S,4S)-1-[N-(methoxycarbonyI)- 0 H
L-valy1]-pyrrolidin-2-y11-1,11-dihydroisochromeno COMU, DI PEA DMF, RT
[4',31:6,7)naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y1]-4-
jiN \ 41
AI N (),,,=µ
methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)
amino]-3-methylbutanoy1}-pyrrolidin-2-y1]-1,11-dihydroisochromeno
[4',31:6,71naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y1)-
4-(methoxymethyppyrrolidin-1-y11-2-oxo-1-phenylethyl}carbamate
tert-butyl (2S,4S)-2-l5-(2-{(2S,4S)-1-11\1-(methoxyearbony1)-L-valyll-
pyrrolidin-2-yl}-1,11-
dihydroisochromeno[4',3':6,71naphtho[1,2-dlimidazol-9-y1)-1H-imidazol-2-y1]-4-
(methoxymethyl)pyrrolidine-1-earboxylate
To a solution of (2 S)-methyl { -24(9-(4,4,5,5-tetramethyl- 1,3 ,2-
dioxaborolan-2-y1)- 1,11 -
dihydroisochromeno [4',3':6,7]naphtho[1 ,2-dlimidazol-2-yl)pyrrolidin- 1y1]-3 -
methyl-1 -oxobutan-2-
yll carbamate (460 mg, 0.74 mmol), (2S,4S)-tert-butyl 2-(5-bromo-1H-imidazol-2-
(methoxymethyl)pyrrolidine-l-carboxylate (250 mg, 0.61 mmol), tetrakis
(triphenylphosphine)
palladium(0) (35 mg, 0.03 mmol) and dichloro[1,1'-bis (diphenylphosphino)
ferrocenejpalladium(II)
(45 mg, 0.06 mmol) in a mixture of 1,2-dimethoxyethane (9.0 mL) and
dimethylformamide (1.5 mL)
was added a solution of potassium carbonate (2M in water, 0.92 mL, 1.84 mmol).
tert-butyl (2S,4S)-2-[5-(2-{(2S,4S)-14N-(methoxycarbony1)-L-valy11-pyrrolidin-
2-y1 -1,11-
1 0 dihydroisochromeno[41,3':6,7] naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-
2-y1J-4-
(methoxymethyppyrrolidine-1-carboxylate (123 mg)
methyl{(1 R)-2-1(2S,4S)-2-(5-{2- K2S)-1-{(2S)-2-Kmethoxyca rbonyl)amino]-3-
methylbuta noy1}-
pyrrolid in-2-y1]-1,11-dihydroisoch romeno 14',3%6,71naphtho 11,2-d] im idazol-
9-y1}-1 H-imidazol-
2-y1)-4-(m ethoxym ethyppyrrolidin-1 -y1J-2-oxo-1-phenylethyl}earbamate
A solution tert-butyl (2S,4S)-2-[5-(2-1(2S,4S)-14N-(methoxy carbony1)-L-valy1]-
pyrrolidin-
2-y11-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d] imidazol-9-y1)-1H-
imidazol-2-y1]-4-
(methoxymethyl)pyrrolidine-carboxylate (122 mg, 0.16 mmol), ethanol (3 mL) and
concentrated HC1
of (R)-2-(methoxycarbonylamino)-2-phenylacetic acid (43 mg, 0.2 mmol) and COMU
(77 mg, 018
(80 4, 0.37
methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S)-1-1(2S)-2-[(methoxycarbonyl)amino]-3-
pyrrolidin-2-y1]-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-
y11-1H-imidazol-2-y1)-
4-(methoxymethyppyrrolidin-1-y1]-2-oxo- 1 -phenylethyl} carbamate (60 mg,
44%). MS (ESI) m/z 870
[M + Hr.
1H NMR (400 MHz, dmso) 6 8.71 (s, 1H), 8.22 (d, 1H, J = 8 Hz), 8.09 (m, 1H),
7.88 ¨7.63
(m, 6H), 7.36 -7.29 (m, 6H), 5.41 (d, 1H, J = 8.4 Hz), 5.30 ¨ 5.24 (m, 2H),
5.14 ¨ 5.10 (m, 1H), 4.13
-3,09 (m, 15H), 2.47- 1.80 (m, 8H), 0.80 (dd, 61-1, J = 6.4 Hz, J = 23 Hz).
Example MV
A H
µ%sc0
N Br µB NIrTh\\I
___________________________________________________________________ >-
(1R,3S,5R)-tert-butyl -3-(9-(4,4,5,5-tetramethyl- K2CO3,
Dioxane/ DMSO,
1,3,2-dioxaborolan-2-yI)-1,11-dihydroisochromeno 95 C
[4',3':6,7Thaphtho[1,2-d]imidazol-2-y1)-2-azabicyclo
[3.1.0]hexane-2-carboxylate
"r
0 7r
-- 0 \ 400 /AL\ N
1. HCI, EtOH, 60 C
W-11 N Boc
2. *
0 -JL
(1R,3S,5R)-tert-butyl 3-(9-(2-((S)-1-((S)-2-(methoxy H' N0
carbonylamino)-3-methylbutanoyI)-4-methoxymethyl
pyrrolidin-2-y1)-1H-imidazol-5-y1)-1,11-
COMU, DIPEA, DMF, RT
-2-y1)-2-azabicyclo[3.1.0Thexane-2-carboxylate
/7, N
W-11 N
methyl {(1R)-2-[(1R,3S,5R)-2-(9-{2-[(2S,5S)-1-{(2S)-2-[(methoxy
carbonyl)amino]-3-methylbutanoy11-4-methoxymethylpyrrolidin-2-y11-
1H-imidazol-5-y11-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]
imidazol-2-y1)-2-azabicyclo[3.1.0Thex-3-y1]-2-oxo-1-phenylethyl}carbamate
(1R,3S,5R)-tert-buty13-(9-(2-((S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyI)-4-
methoxymethylpyrrolidin-2-y1)-1R-imidazol-5-y1)- 1,11-
dihydroisochromeno[4',3%6,71naphtholl,2-dlimidazol-2-y1)-2-azabicyclo13.1.01
hexane-2-
To a solution of (IR,3S,5R)-tert-butyl -3-(9-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)-
1,11-dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-y1)-2-azabicyclo
[3.1.0Thexane-2-
(methoxymethyl)pyrrolidin-l-y1)-3-methyl-1-oxobutan-2-ylcarbamate (142 mg,
0.31 mmol), tetrakis
(triphenylphosphine) palladium(0) (35 mg, 0.03 mmol) and dichloro[1,1'-bis
(diphenylphosphino)
ferrocene]palladium(10 (22 mg, 0.03 mmol) in a mixture of 1,4-dioxane (3.0 mL)
dimethylsulfoxide (3.0 mL) was added a solution of potassium carbonate (2M in
water, 0.46 mL, 0.9
mmol). The resulting mixture was degassed and then heated to 95 C under argon
for 7 hours. After
cooling to room temperature, the reaction was diluted with ethyl acetate. The
chromatography to (1R,3S,5R)-tert-butyl 3-(9-(2-((S)-1-((S)-2-(methoxycarbonyl
amino)-3-
methylbutanoy1)-4-methoxymethylpyrrolidin-2-y1)-1H-imidazol-5-y1)-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-4imidazol-2-y1)-2-azabicyclo[3.1.0]
hexane-2-carboxylate
(101 mg, 42%).
methyl{(1R)-2-1(1R,3S,5R)-2-(9-{2-1(2S,5S)-1-{(2S)-2-1(methoxyca rbonyl)am
inoI-3-
methylbutanoy11-4-methoxymethylpyrrolidin-2-y1F1H-imidazol-5-y1}-1,11-
dihydroisochromeno14',3%6,71naphtho[1,2-dlimidazol-2-y1)-azabieyelo13.1.01hex-
3-y11-2-oxo-1-
phenylethyl)carbamate
A solution (1R,3S,5R)-tert-butyl 3-(9-(24(S)-14(S)-2-(methoxycarbonylamino)-3-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1)-2-aza
bicyclo[3.1.0]hexane-2-carboxylate
(101 mg, 0.16 mmol), ethanol (3 mL) and concentrated HC1 (1 mL) was heated to
60 C for 1 hour.
The reaction was concentrated and the crude material dissolved in DCM (3 mL).
phenylacetic acid (35 mg, 0.17 mmol) and COMU (63 mg, 015 mmol) in DMF (3 mL).
resulting solution was added diisopropylethylamine (70 [.tL, 0.38 mmol). After
room temperature, the reaction was diluted with ethyl acetate, washed with
ACN/H20 + 0.1% TFA). The product fractions were lyophilized to give methyl
{(1R)-2-
[(1R,3 S,5R)-2-(9-{2-[(2 S,5S)-1-{(2 S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyl -4-
methoxymethylpyrrolidin-2-y1]-1H-imidazol-5 y11-1,11-
cl]imidazol-2-y1)-2-azabicyclo [3.1.0]hex-3-y1]-2-oxo-1 -phenylethyllearbamate
(71 mg, 63).
MS (ESI) m/z 882 [M + H].
1H NMR (400 MHz, dmso) 6 8.66 (s, 1H), 8.17 (d, 1H, J = 8.8 Hz), 8.04 (s, 1H),
(m, 6H), 7.39 -7.22 (m, 6H), 5.72 (d, 1H, J= 7.6 Hz), 5.68 (s, 1H), 5.25 (s,
1H), 5 .13 ¨ 5.01 (m,
2H), 4.12 -4.00 (m, 2H), 3.81 ¨3.00 (m, 13H), 2.60 (m, 1H), 2.43 ¨2.37 (m,
3H), 1.92-1.82 (m, 3H),
0.83 ¨0.58 (m, 7H), 0.59 (s, 1H), 0.00 (s, 1H).
Example MW
\ .41 411:1
L) 0
methyl {(1R)-2-R2S,4S)-2-(9-{2-R1R,3S,5R)-1-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoy1}-5-azabicyclo
[3.1.0]hex-3-y1]-1H-imidazol-5-y11-1,11-dihydroisochromeno
14',31:6,7]naphtho[1,2-djimidazol-2-y1)-4-(difluoromethoxy)
methylpyrrolidin-1-yI]-2-oxo-1-phenylethyllcarbamate
This compound was synthesized using the same conditions as example 00
substituting with
the respective (1R,3S,5R)-2-((S)-2-(methoxycarbonylamino)-3-methylbutanoy1)-2-
azabicyclo[3.1.0Thexane-3-carboxylic acid and (2S,4S)-1-(tert-butoxycarbony1)-
((difluoromethoxy)methyl)pyrrolidine-2-carboxylic acid as appropriate.
MS (ES!) m/z 918 [M + H].
Example MX
)\-1\1' 0
¨0 //0
111 õ N
methyl {(1R)-2-R2S,4S)-2-(9-{2-[(1R,3S,5R)-1-{(23,3S)-
3-methoxy-2-[(methoxycarbonyl)amino]butanoy1}-5-azabicyclo
[41,31:6,71naphtho[1,2-dlimidazol-2-y1)-4-(difluoromethoxy)
methylpyrrolidin-1-yI]-2-oxo-1-phenylethyl}carbamate
the respective (1R,3S,5R)-2-((2S,3S)-3-methoxy-2 (methoxycarbonylamino)
butanoy1)-2-
azabicyclo[3.1.0]hexane-3-carboxylic acid and (2S,3R)-3-methoxy-2-
(methoxycarbonylamino)butanoic acid as appropriate.
MS (ESI) m/z 898 [M + FI]+.
Example MY
* Br 0 N
/ MeCN
+ Et 3N . K
9-bromo-3-chloro-10,11-dihydro-5H- (2S,4S)-1-(tert- 0 N
butoxycarbonyI)-4- /
methylpyrrolidine-2-
carboxylic acid (2S,4S)-1-tert-butyl 2-(3-chloro-8-
8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-
9-y1) 4-methylpyrrolidine-1,2-dicarboxylate
NH40Ac ll, 70' Mn02
xylenes 41) Ci 14 '',i cH2a2
_______________________________________ = ci
' N Boc \ N Boc
ref lux
(2S,4S)-tert-butyl 2-(9-chloro-4,5- (2S,4S)-tert-butyl 2-(9-chloro-5H-
naphtho[
dihydro-5H-naphtho[c,g]chromeno[8,9-
c,g]chromeno[8,9-d]imidazol-2-y1)-4-
dlimidazol-2-y1)-4-(methyl) methylpyrrolidine-1-carboxylate
-,0ANH 0 ..
bis(pinacolato)diboron )-3-_ + kil -:----)r,
X-Phos, Pd2dba3, KOAc )õ,.0 µ13 411
41IAL ,i
Dioxane
100 C cNN Br 11
(2S,4S)-tert-buty1-2-(9-(2-((S)-1-((S)-2-
methyl (S)-1-((S)-2-(5-bromo-1H-
(methoxycarbonylamino)methylbutanoyl)azabicyclo
imidazol-2-yl)pyrrolidin-1-y1)-3-methyl- [3.1.0]hexan-
3-y1)-1H-imidazol-5-y1)-5H-
1-oxobutan-2-ylcarbamate naphtho[c,g]chromeno[8,9-d]imidazol-
methylpyrrolidine-1-carboxylate
OANH
Pd(PPh3)4,
1. µ,..r0 0 HCI
Pd(dIDIDO2C12, K2CO3 N H
DME T---) _______________ s
___________ ' I NNA \ 411 41 \ N N 2. COMU,
DIPEA, DMF
85 C C Hi =. N Boc
. _
(2S,4S)-tert-butyl 2-(9-(2-((S)-1-((S)-2- A
(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidin- 0 ii
2-y1)-1H-imidazol-5-y1)-5H-naphtho[c,g]chromeno[8,9-
d]imidazol-2-y1)-4-methylpyrrolidine-1-carboxylate (R)-2-
(methoxycarbonylamin
o)-2-phenylacetic acid
10 N 0 1 i T - - )
c .
NNA \ 11 a \ YN lp
HN,,a-,.
methyl {242-{9-[2-(1-{2-[(methoxycarbonyl)amino]-3- 0
methylbutanoyllpyrrolidin-2-y1)-1H-imidazol-5-y1]-1,11-
(2S,4S)-1-tert-butyl 2-(3-chloro-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,gichromen-9-y1) 4-
methylpyrrolidine-1,2-dicarboxylate
To a solution of 9-bromo-3-chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-
one (1.32
g, 3.63 mmol) in MeCN (40 mL) was added (2S,4S)-1-(tert-butoxycarbony1)-4-
carboxylic acid (1.0 g, 4.36 mmol) and DIPEA (0.7 mL, 3.99 mmol). After
stirring for 18 h, the
solution was diluted with Et0Ac and washed successively with saturated aqueous
NaHCO3 and brine.
The organics were dried over MgSO4, filtered and concentrated under reduced
pressure. The crude
residue was purified by silica column chromatography (10% to 40%
Et0Ac/hexanes) to afford
(2S,4S)-1 -tert-butyl 2-(3-chloro-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,g]chromen-9-y1) 4-
methylpyrrolidine-1,2-dicarboxylate (1.31 g, 70%).
(2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H-naphtholc,gichromeno[8,9-
d1imidazol-2-y1)-4-
(2 S,4S)-1-tert-butyl 2-(3-chloro-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,g]chromen-9-y1)
4-methylpyrrolidine-1,2-dicarboxylate (1.31 g, 2.56 mmol) was added xylenes
(25 mL) and
ammonium acetate (3.95 g, 51.2 'mop and the solution was heated to 136 C and
stirred overnight.
The following morning, the solution was cooled to rt and was diluted with
Et0Ac and washed
successively with water, saturated aqueous NaHCO3 and brine. The organics were
dried over MgSO4,
filtered and concentrated under reduced pressure. The crude residue was
purified by silica column
chromatography (60% to 100 % Et0Ac/hexanes) to afford (2S,4S)-tert-butyl 2-(9-
chloro-4,5-dihydro-
5H-naphtho[c,g]chromeno[8,9-dJimidazol-2-y1)-4-methylpyrrolidine-l-carboxylate
(2S,4S)-tert-butyl 2-(9-chloro-5H-naphtholc,g1chromeno18,9-d1imidazol-2-y1)-4-
To a solution of (2S,4S)-tert-butyl 2-(9-chloro-4,5-dihydro-5H-
d]imidazol-2-y1)-4-(methyppyrrolidine-1-carboxylate (935 mg, 1.9 mmol) in
CH2C12 (20 mL) was
added Mn02 (8.25 g, 95 mmol). The reaction mixture was stirred for 3 h, and
then filtered over celite.
The filter cake was washed with copious CH2C12 and Me0H, and the filtrate was
concentrated under
reduced pressure. The crude residue was purified by silica column
chromatography (0% to 10 %
Me0H/Et0Ac) to afford (2S,4S)-tert-butyl 2-(9-chloro-5H-
naphtho[c,g]chromeno[8,9-d]imidazol-2-
y1)-4-methylpyrrolidine-1-carboxylate (692 mg, 74%).
(2S,4S)-tert-buty1-2-(942-((S)-1-((S)-2-
(methoxycarbonylamino)methylbutanoyl)azabicyclo13.1.01hexan-3-y1)-11-1-
imidazol-5-y1)-511-
naphtholc,gichromeno18,9-dlimidazol-2-y1)-4-methylpyrrolidine-1-carboxy1ate
(2S,4S)-tert-butyl 2-(9-chloro-5H-naphtho[c,g]chromeno[8,9-d]imidazol-2-y1)-4-
methylpyrrolidine-1 -carboxylate (692 mg, 1.41 mmol) in dioxane (15 mL) was
bis(pinacolato)diboron (1.07 g, 4.23 mmol), KOAc (415 mg, 4.23 mmol), X-Phos
mmol), and Pd2dba3 (26 mg, 0.03 mmol). The solution was degassed with N2 for
10 min, then heated
to 100 C for 16 h. The solution was cooled to rt, diluted with Et0Ac, washed
with saturated aqueous
NaHCO3, brine, dried with MgSO4, and concentrated. Purified by silica gel
30 % Me0H/Et0Ac) to afford (2S,4S)-tert-buty1-2-(9-(24(S)-14(S)-2-
[3.1.0]hexan-3-y1)-1H-imidazol-5-y1)-5H-naphtho[c,dchromeno[8,9-d]imidazol-2-
methylpyrrolidine-l-carboxylate (821 mg, quant).
(2S,4S)-tert-butyl 2-(9-(24(S)-14(S)-2-(methoxyca rbonylam ino)-3-
methylbutanoyl)pyrrolid in-2-
yl)-1H-imidazol-5-y1)-5H-naphthole,giehromeno18,9-dlim idazol-2-y1)-
4(methyl)pyrrolidine- I -
To a solution of (2S,4S)-tert-buty1-2-(9-(2-((S)-1-((S)-2-
(methoxycarbonylamino)methylbutanoyl)azabicyclo[3.1.0]hexan-3-y1)-1H-imidazol-
naphtho[c,g]chromeno[8,9-d]imidazol-2-y1)-4-methylpyrrolidine- 1 -carboxylate
(821 mg, 1.41 mmol),
methyl (S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-l-y1)-3-methyl-l-
oxobutan-2-ylcarbamate
(1.05 g, 2.82 mmol), tetrakis(triphenylphosphine) palladium(0) 162 mg, 0.14
mmol) and
dichloro[1,11-bis(diphenylphosphino)ferrocene]palladium(11) (102 mg, 0.14
mmol) in DME (15 mL)
mixture was degassed and then heated to 85 C for 18 hours. After cooling to
reaction was diluted with ethyl acetate. The organics were washed with
saturated sodium bicarbonate
and brine, dried over MgSO4 and concentrated. The crude residue was purified
by flash
chromatography to yield (2S,4S)-tert-butyl 2-(9-(2-((S)-1-((S)-2-
methylbutanoyppyrrolidin-2-y1)-1H-imidazol-5-y1)-5H-naphtho[e,gichromeno[8,9-
4methylpyrrolidine-1-carboxylate (386 mg, 37%).
Methyl {2- 12-t9-12-(1 rbonyl)am inol-3-methylbutanoyl}pyrrolidin-2-
yI)-1 H-
im idazol-5-y11-1,11-dihydroisochromeno[4',3':6,7]naphtho II ,2-d] imidazol-2-
y1}-4-
(methyppyrrolidin-l-y1]-2-oxo-l-phenylethyl}carbamate
A solution of (2S,4S)-tert-butyl 2-(9-(2-((S)-I -((S)-2-(methoxycarbonylamino)-
methylbutanoyl)pyrrolidin-2-y1)-1H-imidazol-5-y1)-5H-naphtho[o,gichromeno[8,9-
4methylpyrrolidine-l-carboxylate (386 mg, 0.52 mmol), CH2C12 (8 mL), Me0H (2
mL) and HC1 (4M
in Dioxane, 2 mL) and was stirred overnight. The reaction was concentrated and
dissolved in DMF (8 mL). This solution was concentrated and to this material
of (R)-2-(methoxycarbonylamino)-2-phenylacetic acid (108 mg, 0.52 mmol) and
COMU (248 mg,
0.52 mmol). To the resulting solution was added diisopropylethylamine (0.45
mL, 2.6 mmol). After
stirring for 2 hours at room temperature, the reaction was diluted with 10%
Me0H/Et0Ac, washed
with saturated NaHCO3 water and brine, dried (Na2SO4), concentrated and
purified by HPLC to give
methyl {2-[2-{9-[2-( I -12-[(methoxycarbonypamino]-3 -methylbutanoyl
pyrrolidin-2-y1)-1H-
imidazol-5-y1]-1,11-dihydroisochromeno[41,31:6,7]naphtho{1,2-dlimidazol-2-y11-
4-methylpyrrolidin-
l-y1]-2-oxo-1-phenylethylIcarbamate (27 mg, 6%). LCMS-ESE : calculated for
Example NB
0 H .F----) 1. HCI
\,0\ N D.
/13 lit IP. rNiBoc 2. HATU, DIPEA, DMF
7-0 o
(2S,4S)-tert-buty1-2-(9-(2-((S)-1-((S)-2- ()A OH
(methoxycarbonylamino)methylbutanoyl)azabicyclo H o
[3.1.0]hexan-3-y1)-1H-imidazol-5-y1)-5H-
naphtho[c,g]chromeno[8,9-d]imidazol-2-y1)-4- (S)-2-(methoxycarbonylamino)-
(methyl)pyrrolidine-1-carboxylate 3-methylbutanoic acid
o H n
N . Pd(dIDIDO2C12,
)(dB II 41/4 DME
Boc N
methyl [(2S)-3-methy1-1-{(2S,4S)-4-methy1-2-[9- 0 IV Br
c -. N
(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1,11-
dihydroisochromeno[4',3':6,71naphtho[1,2-djimidazol-2- (S)-tert-butyl 2-(5-
yl]pyrrolidin-1-y11-1-oxobutan-2-yl]carbamate imidazol-2-yl)pyrrolidine-1-
.,:
1. HCI
( N H .--7-1 ___________________________ )1.
\ = . N 2. COMU, DIPEA, DMF
\ __ I-1 = N ..,`
HN0, 0 ,
tert-butyl (2S)-245-(2-{(2S,4S)-14N- kl
00=-,,,.-:,.,-
(methoxycarbonyI)-L-valy1]-4-methylpyrrolidin-2-y1}-
N H OH
1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- o
djimidazol-9-y1)-1H-imidazol-2-yllpyrrolidine-1- (R)-2-
carboxylate phenylacetic acid
0,J-NH
N H n
O NN7 \ II AI NN
c Hi M. N
HN,_,0
methyl {(1R)-2-[(2S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-Rmethoxycarbonyl)aminoj-3-
methylbutanoy1}-4-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-djimidazol-9-y11-1H-imidazol-2-
yppyrrolidin-1-y1]-2-oxo-1-phenylethyllcarbamate
Methyl K2S)-3-methyl-1-1(2S,4S)-4-methyl-2-19-(4,4,5,5-tetramethyl-1,3,2-
1,11-dihydroisochromeno141,3':6,71naphtho[1,2-dlimidazol-2-yllpyrrolidin-1-y1}-
1-oxobutan-2-
(2S,4 S)-tert-buty1-2-(9-(2-((S)-1-((S)-2-
(methoxycarbonylamino)methylbutanoyDazabicyclo[3.1.0]hexan-3-y1)-1H-imidazol-5-
naphtho[c,gichromeno[8,9-d]imidazol-2-y1)-4-(methyppyrrolidine-1-carboxylate
(950 mg, 1.63
mmol) was dissolved in DCM (12 mL), Me0H (3 mL) and HC1 (4 M in dioxane, 3 mL)
was added.
The reaction mixture was stirred for 4 h and then concentrated under reduced
residue was treated with (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid
HATU (620 mg, 1.63 mmol) and DMF (15 mL), then DIPEA (1.42 mL, 8.15 mmol) was
dropwise. After 1 h, the mixture was diluted with Et0Ac and washed
successively with saturated
aqueous NaHCO3 and brine. The organics were dried over MgSO4, filtered and
chromatography (0% to 30%
Me0H/Et0Ac) to afford methyl [(2S)-3-methy1-1-{(2S,4S)-4-methyl-249-(4,4,5,5-
tetramethy1-1,3,2-
dioxaborolan-2-y1)-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-
yl]pyrrolidin-1-y11-
1-oxobutan-2-ylicarbamate (596 mg, 57%).
Tert-butyl (2S)-245-(2-1(2S,4S)-1-1N-(methoxycarbony1)-L-valy1]-4-
methylpyrrolidin-2-y11-1,11-
dihydroisochromeno14',31:6,7]naphtholl,2-diimidazol-9-y1)-1H-imidazol-2-
Methyl R2S)-3-methy1-1-{(2S,4S)-4-methyl-2-[9-(4,4,5,5-tetramethyl-1,3,2-
y1)-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-l-
y1}-1-oxobutan-2-
yl]carbamate (298 mg, 0.47 mmol), (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-
yppyrrolidine-1 -
carboxylate (443 mg, 1.4 mmol), Pd(PPh3)4 (54 mg, 0.05 mmol), PdC12(dppf)2 (36
and K2CO3(2M in H20, 0.78 mL, 1.55 mmol) were combined in DME (5 mL). The
mixture was
degassed with bubbling N2 for 10 min the heated to 85 C for 16 h. After
cooling, the reaction mixture
was diluted with Et0Ac, and washed successively with saturated aqueous NaHCO3
and brine. The
organics were dried over MgSO4, filtered and concentrated under reduced
pressure. The crude residue
was purified by silica column chromatography (0% to 30% Me0H/Et0Ac) to afford
tert-butyl (2S)-2-
[5-(2-1(2S,4S)-14N-(methoxycarbony1)-L-valy11-4-methylpyrrolidin-2-y11-1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-
yl]pyrrolidine-1-
carboxylate (84 mg, 24%).
Methyl 1(1R)-2-1(2S)-2-(5-12-1(2S,4S)-1-1(2S)-2-1(methoxyearbonyl)amino1-3-
methylbutanoy1}-
4-methylpyrrolidin-2-y1]-1,11-dihydroisochromeno14',3':6,7inaphtholl,2-
dlimidazol-9-y1}-1H-
imidazol-2-y1)pyrrolidin-l-y11-2-oxo-1-phenylethyl1carbamate
Tert-butyl (2S)-245-(2-{(2S,4S)-14N-(methoxycarbony1)-L-valy11-4-
methylpyrrolidin-2-yll-
1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-
yl]pyrrolidine- 1 -
carboxylate (84 mg, 0.11 mmol) was dissolved in DCM (2.5 mL), Me0H (0.5 mL)
and HC1 (4 M in
dioxane, 0.5 mL) was added. The reaction mixture was stirred for 18 hand then
reduced pressure. The crude residue was treated with (R)-2-
(methoxycarbonylamino)-2-phenylacetic
acid (23 mg, 0.11 mmol), COMU (53 mg, 0.11 mmol) and DMF (3 mL), then DIPEA
(0.10 mL, 0.56
mmol) was added dropwise. After 30 min, the mixture was diluted with 10%
Me0H/Et0Ac and
washed successively with saturated aqueous NaHCO3 and brine. The organics were
dried over
MgSO4, filtered and concentrated under reduced pressure. The crude residue was
purified by HPLC to
afford methyl {(1R)-2-[(2S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-
methylbutanoy11-4-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',31:6,7]naphtho[1,2-
djimidazol-9-y11-1H-imidazol-2-yl)pyrrolidin-l-y1]-2-oxo-l-
phenylethylIcarbamate (41 mg, 45%).
LCMS-ESI4: calculated for C47H50N807: 838.38; observed [M+1]+: 839.39
Example NC
N r\11 2. HATU, DIPEA, DMF
NNA \
________________ H N Bac 0
tert-butyl (2S,4S)-249-(2-{(2S,4S)-111\1-(methoxycarbony1)-
L-valy1]-5-methylpyrrolidin-2-y11-1H-imidazol-5-y1)-1,11- (S)-2- 0
dihydroisochromeno[4',3':6,7Thaphtho[1,2-d]imidazol-2-y1J-
4-methylpyrrolidine-1-carboxylate 3-methylbutanoic acid
0 tE\L70
NN N
methyl {(2S)-1-[(2S,5S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoy11-4- 0
methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-djimidazol-9-y1}-
1H-imidazol-2-y1)-5-methylpyrrolidin-1-y1]-3-methy1-1-
oxobutan-2-yllcarbamate
Methyl {(2S)-1-R2S,5S)-2-(5-{2-1(2S,4S)-1-((2S)-2-1(methoxycarbonyl)aminol-3-
methylbutanoy1}-4-methylpyrrolidin-2-y1J-1,11-
dihydroisochromeno14',3%6,71naphthol1,2-
d]imidazol-9-y1}-1H-imidazol-2-y1)-5-methy1pyrrolidin-1-y11-3-methyl-1-
Tert-butyl (2S,4S)-249-(2-{(2S,4S)-14N-(methoxycarbony1)-L-valy1]-5-
y1 } - I H-imidazol-5-y1)-1,11-dihydroisochromeno[41,3':6,7]naphtho[ I ,2-
cliimidazol-2-y1]-4-
methylpyrrolidine-l-carboxylate (164 mg, 0.23 mmol) was dissolved in DCM (2.57
mL), Me0H (0.7
mL) and HC1 (4 M in dioxane, 0.7 mL) was added. The reaction mixture was
stirred for 16 h and then
concentrated under reduced pressure. The crude residue was treated with (S)-2-
(methoxycarbonylamino)-3-methylbutanoic acid (30 mg, 0.17 mmol), HATU (65 mg,
DMF (3 mL), then DIPEA (0.15 mL, 0.85 mmol) was added dropwise. After 45 min,
diluted with 10% Me0H/Et0Ac and washed successively with saturated aqueous
residue was purified by HPLC to afford methyl {(2S)-1-[(2S,5S)-2-(5-{2-
[(2S,4S)-1-{(2S)-2-
Rmethoxycarbonyl)amino1-3-methylbutanoy11-4-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',31:6,71naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-5-
methylpyrrolidin-1 -
y1]-3-methyl-l-oxobutan-2-ylIcarbamate (23 mg, 16%).
LCMS-ESI4: calculated for C45H54N807: 818.41; observed [M+I]+: 820.70.
Example ND
BOG N 0
PC(PPh3)4,
NNA H
N 1 + N
Fd(dPPf)2C12, K2C0i.
2-0B 41. 6oc DME
(2S,4S)-tert-butyl 2-(5- (2S,4S)-tert-butyl-2-(9-(2-((S)-14(S)-2-
iodo-1H-imidazol-2-y1)-4- (methoxycarbonylamino)methylbutanoyl)azabicyclo
methylpyrrolidine-1- [3.1.01hexan-3-y1)-1H-imidazol-5-y1)-5H-
carboxylate naphtho[c,g]chromeno[8,9-d]imidazol-2-y1)-4-
Boc N H 2. HATU, DIPEA, DMF
4/1 AL\
rFNi
tert-butyl (2S,4S)-2-(5-{2-[(2S,4S)-1-(tert-
butoxycarbony1)-4-methylpyrrolidin-2-y11-1,11- (S)-2-
dihydroisochromeno[4',3.:6,71naphtho[1,2-dlimidazol-9- 3-methylbutanoic
y1}-1H-imidazol-2-y1)-4-methylpyrrolidine-1-carboxylate
I\1N Ny'N
_______________________________________________ rF1 N
methyl {(2S)-1-[(2S,5S)-2-(5-{2-[(28,4S)-1-{(2S)-2- 0
[(methoxycarbonyl)amino]-3-methylbutanoy1}-4-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-2-y1)-
4-methylpyrrolidin-1-y1]-3-methy1-1-oxobutan-2-ylIcarbamate
Tert-butyl (2S,4S)-2-(512-1(2S,4S)-1-(tert-butoxyearbony1)-4-methylpyrrolidin-
2-y11-1,11-
dihydroisochromenol4',3':6,7lnaphtholl,2-dlimidazol-9-y1)-1H-imidazol-2-y1)-4-
methylpyrrolidine-1-earboxylate
(2S,4S)-tert-buty1-2-(9-(24(S)-14(S)-2-
(methoxycarbonylamino)methylbutanoyl)azabicycloP .1.0Thexan-3-y1)-1H-imidazol-
naphtho[c,dchromeno[8,9-d]imidazol-2-y1)-4-methylpyrrolidine-1-carboxylate
(293 mg, 0Ø78
mmol), (2S,4S)-tert-butyl 2-(5-iodo-1H-imidazol-2-y1)-4-methylpyrrolidine-1-
carboxylate (300 mg,
0.52 mmol), Pd(PPh3)4 (60 mg, 0.052 mmol), PdC12OPPO2 (38 mg, 0.052 mmol), and
K2CO3(2M in
H20, 0.86 mL, 1.72 mmol) were combined in DME (6 mL). The mixture was degassed
with bubbling
N2 for 10 min the heated to 85 C for 16 h. After cooling, the reaction
mixture was diluted with
Et0Ac, and washed successively with saturated aqueous NaHCO3 and brine. The
organics were dried
over MgSO4, filtered and concentrated under reduced pressure. The crude
silica column chromatography (100% Et0Ac) to afford tert-butyl (2S,4S)-2-(5-12-
[(2S,4S)-1-(tert-
butoxycarbony1)-4-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4`,3':6,7]naphtho [1,2-
d]imidazol-9-y11-1H-imidazol-2-y1)-4-methylpyrrolidine-1-carboxylate (183 mg,
Methyl {(2S)-1-1(2S,5S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-1(methoxyearbonyl)aminol-3-
dihydroisochromeno14',3':6,7inaphthol1,2-
cllimidazol-9-y1}-1H-imidazol-2-y1)-4-methylpyrrolidin-1-y11-3-methyl-1-
Tert-butyl (2S,4S)-2-(5-12-[(2S,4S)-1-(tert-butoxycarbony1)-4-methylpyrrolidin-
2-y1]-1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-4-
methylpyrrolidine-
1-carboxylate (183 mg, 0.26 mmol) was dissolved in DCM (4 mL), Me0H (1 mL) and
HC1 (4 M in
dioxane, 1 mL) was added. The reaction mixture was stirred for 2 h and then
reduced pressure. The crude residue was treated with (S)-2-
methylbutanoic acid (91 mg, 0.52 mmol), HATU (198 mg, 0.52 mmol) and DMF (5
mL), then
DIPEA (0.45 mL, 2.6 mmol) was added dropwise. After 1 h, the mixture was
diluted with 10%
Me0H/Et0Ac and washed successively with saturated aqueous NaHCO3 and brine.
The organics
were dried over MgSO4, filtered and concentrated under reduced pressure. The
crude residue was
purified by HPLC to afford methyl {(2S)-1-[(2S,5S)-2-(5-12-[(2S,4S)-1-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyll -4-methylpyrrol idin-2-y1]-1,11-
dihydroisochromeno [4',3':6,7]naphtho[1,2-dlimidazol-9-y1 -1H-imidazol-2-y1)-4-
methylpyrrolidin-l-
y11-3-methy1-1-oxobutan-2-y1} carbamate (6 mg, 3%). LCMS-ESr: calculated for
C45H54N807:
818.41; observed [M+1] : 819.41.
Example NF
NH 0 H
__________________________________ 0
+ NN Pd(dP1002C12, K2CO3,
I 0 N Boc DMSO,
methyl (S)-1-((2S,4S)-2-(5-iodo-1H- [3.1.0]hexan-3-y1)-1H-imidazol-5-y1)-5H-
imidazol-2-y1)-4-methylpyrrolidin-1-y1)- naphtho[c,g]chromeno[8,9-
d]imidazol-2-y1)-4-
3-methyl-1-oxobutan-2-ylcarbamate methylpyrrolidine-1-carboxylate
)t..NH 1. HCI
2. COMU, DIPEA, DMF
= 0 IR11 n
I 1\1N c 40
N Bo 0
tert-butyl (2S,4S)-2-[9-(2-{(2S,4S)-1[N-(methoxycarbony1)- 0
L-yaly1]-4-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-1,11- (R)-2-
dihydroisochromeno[4',3':6,7Thaphtho[1,2-d]imidazol-2-y1]-4- 2-phenylacetic
,JLNH
1\1N
methyl {(2S)-1-1(2S,4S)-2-(5-{2-1(2S,4S)-1-{(2R)-2-
Rmethoxycarbonyl)amino]-2-phenylacety11-4-methylpyrrolidin-2-
y1]-1,11-dihydroisochromeno[43':6,71naphtho[1,2-d]imidazol-9-
y11-1H-imidazol-2-y1)-4-methylpyrrolidin-1-y1]-3-methyl-l-
Tert-butyl (2S,4S)-2-19-(2-{(2S,4S)-1-IN-(methoxycarbony1)-L-valyII-4-
1H-imidazol-5-y1)-1,11-dihydroisochromeno14',3':6,71naphthol1,2-dlimidazol-2-
(2S,4S)-tert-buty1-2-(9-(2-((S)-14(S)-2-
(methoxycarbonylamino)methylbutanoyDazabicyclop.1.0Thexan-3-y1)-1H-imidazol-5-
naphtho[c,g]chromeno[8,9-cliimidazol-2-y1)-4-methylpyrrolidine-1-earboxylate
methyl (S)-1-((2S,4S)-2-(5-iodo-1H-imidazol-2-y1)-4-methylpyrrolidin-l-y1)-3-
ylcarbamate (501 mg, 1.15 mmol), Pd(PPh3)4 (111 mg, 0.096 mmol), PdC12(dPPO2
(70 mg, 0.096
mmol), and K2CO3(2M in H20, 1.6 mL, 3.17 mmoL) were combined in DMSO (6 mL)
and dioxane
(6 mL). The mixture was degassed with bubbling N2 for 10 min the heated to 95
C for 14 h. After
cooling, the reaction mixture was diluted with Et0Ac, and washed successively
with saturated
chromatography (0 %- 30%
Me0H/Et0Ac) to afford tert-butyl (2S,4S)-249-(2-{(2S,4S)-14N-(methoxycarbony1)-
L-valy1]-4-
methylpyrrolidin-2-ylf -1H-imidazol-5-y1)-1,11-dihydroisochromeno[4',3
':6,7]naphtho [1,2-
d]imidazol-2-y1]-4-methylpyrrolidine-l-carboxylate (257 mg, 35%).
Methyl {(2S)-1-1(2S,4S)-2-(5-12-1(2S,4S)-1-{(2R)-2-1(methoxyearbony1)aminoi-2-
pheny1acetyl}-4-
methylpyrrolidin-2-y11-1,11-dihydroisochromem44',3':6,7lnaphtholl,2-dlimidazol-
9-y1}-1H-
imidazol-2-y1)-4-methylpyrrolidin-1-y11-3-methyl-1-oxobutan-2-yllearbamate
Tert-butyl (2S,4S)-249-(2-{(2S,4S)-14N-(methoxycarbony1)-L-valy11-4-
y11-1H-imidazol-5-y1)-1,11-dihydroisochromeno[41,31:6,71naphtho[1,2-d]
methylpyrrolidine- 1 -carboxylate (257 mg, 0.34 mmol) was dissolved in DCM (4
mL), Me0H (1 mL)
and HC1 (4 M in dioxane, 1 mL) was added. The reaction mixture was stirred for
3 h and then
concentrated under reduced pressure. The crude residue was treated with (R)-2-
(methoxycarbonylamino)-2-phenylacetic acid (71 mg, 0.34 mmol), COMU (161 mg,
DMF (6 mL), then DIPEA (0.3 mL, 1.67 mmol) was added dropwise. After 15 h, the
[(2S,4S)-1-1(2R)-2-
[(methoxycarbonyl)amino]-2-phenylacety11-4-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-dlimidazol-9-y11-1H-imidazol-2-y1)-4-
y1]-3-methy1-1-oxobutan-2-yllcarbamate (152 mg, 53%). LCMS-ESI+: calculated
for C48H52N807:
852.40; observed [M+11+: 854.26. 'H NMR (CD30D): 8.677 (s, 1H), 8.232-7.837
(m, 5H), 7.695-
7.673 (m, 2H), 7.496-7.426 (m, 5H), 5.499 (s, 1H), 5.445-5.401 (m, 1H), 5.337
(s, 1H), 5.253-5.208
(q, 1H, J= 7.2 Hz), 4.870 (m, 1H), 4.230 (d, 1H, J= 7.2 Hz), 3.781 (m, 1H),
3.671 (s, 3H), 3.607 (s,
3H), 3.425 (m, 3H), 2.750-2.689 (m, 2H), 2.683 (m, 2H), 2.384 (m, 1H), 1.894
(quint, 2H, J-12 Hz),
1.249-1.151 (m, 6H), 0.974-0.890 (m, 6H).
Example NG
ID 41 0 Et3N
Boc 0 0
IV)&
= 44I 441 0
111 MeCN 0
Boc 0
(2S,5S)-1-tert-butyl 2-(2-oxo-2-(8-
3-(2-bromoacety1)-10,11-dihydro-5H-õ,.c r`l N7IL oxo-
8,9,10,11-tetrahydro-5H-
dibenzo[c,g]chromen-8(9H)-one : OH
dibenzo[c,g]chromen-3-ypethyl) 5-
pyridiunium 0
tribromide yos:)0( 0 = AL 0 cs2003
_________________ Ø N acetone __ -)...-
0H2C12/Me0H .: 0 Will Br 40 C
..7-
7----)
(25,5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-
HO,ir N
5H-dibenzo[c,dchromen-3-y1)-2-oxoethyl) 1-tert- 0 Boc
butyl 5-methylpyrrolidine-1,2-dicarboxylate (2S, 5S)-1-(tert-
butoxycarbonyI)-5-
0 carboxylic acid
Boc /?' 0 sk
N AL 0
NH40Ac
' = 0 W. ON
PhMe, Me0Et01-1 Ill
0 Boo reflux
(25,5S)-2-(2-(94(2S,5S)-1-(tert-butoxycarbony1)-5-
nnethylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,g]chromen-3-y1)-2-oxoethyl) 1 -tert-butyl 5-
Boc N H .n,õ0
riN=A \ = II N..õ_õ-----N MnO ç\
= // µ \
41 410 N,
"÷. _____ H' N Boc CH2C12 C i [`.11
= N Boc
tert-butyl (25,5S)-2-(9-(2-[(2S,5S)-1-(tert-butoxycarbony1)- tert-
butyl (2S,4S)-2-(5-{2-[(2S,4S)-1-(tert-
5-methylpyrrolidin-2-y1]-1H-imidazol-5-y11-1,4,5,11-
tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-
dihydroisochromeno[4',3':6,71naphtho[1,2-dlimidazol-9-
y1)-5-methylpyrrolidine-1-carboxylate y11-1H-imidazol-2-y1)-5-
1. HC1 0ANH
__________________ 0.-
2. HATU, D1PEA, DMF )õ,.0
N o H
C\ ti 1,7, \ 411
'' =
(S)-2- methyl {(2S)-1-
R2S,5S)-2-(5-{2-1(25,4S)-1-{(2S)-2- 0
(methoxycarbonylamino) (methoxycarbonyl)amino]-3-methylbutanoy1}-5-
methylpyrrolidin-
-3-methylbutanoic acid 2-y1]-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-djimidazol-
9-y1}-1H-imidazol-2-y1)-5-methylpyrrolidin-1-y1]-3-methy1-1-
oxobutan-2-y1}carbamate
(2S,5S)-1-tert-butyl 2-(2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-
dibenzoic,gichromen-3-yl)ethyl)
5-methylpyrrolidine-1,2-dicarboxylate
To a solution of 3-(2-bromoacety1)-10,11-dihydro-5H-dibenzok,gjchromen-8(9H)-
one in
MeCN (30 mL) was added (2S,5S)-1-(tert-butoxycarbony1)-5-methylpyrrolidine-2-
(1.2 g, 3.23 mmol) and triethyl amine (0.48 mL, 3.55 mmol) and the solution
was heated to 50 C.
After stirring for 15 h, the solution was cooled to rt, and diluted with Et0Ac
and washed successively
with saturated aqueous NaHCO3 and brine. The organics were dried over MgSO4,
filtered and
concentrated under reduced pressure. The crude residue was purified by silica
chromatography (20% to 50% Et0Ac/hexanes) to afford (2S,5S)-1 -tert-butyl 2-(2-
oxo-2-(8-oxo-
1 0 8,9,10,11 -tetrahydro-5H-dibenzo[c,dchromen-3 -yl)ethyl) 5 -
(1.09 g, 65%).
(2S,5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzok,gichromen-3-y1)-2-
oxoethyl) 1-
tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate
(2 S,5 S)-1-tert-butyl 2-(2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,g]chromen-3-
yl)ethyl) 5-methylpyrrolidine-1,2-dicarboxylate (1.29 g, 2.48 mmol) was
dissolved in a solution of
DCM (17.5 mL) and Me0H (7 mL), then treated with pyridinium tribromide (873
mg, 2.73 mmol).
After stirring at RT for 1 h, the reaction mixture was diluted with DCM and
10% HC1, and extracted
with DCM. The organic phase was dried over MgSO4, filtered and concentrated
under reduced
pressure and the crude material was carried on without further purification.
(2S,5S)-2-(2-(9-42S,5S)-1-(tert-butoxycarbony1)-5-methylpyrrolidine-2-
carbonyloxy)-8-oxo-
8,9,10,11-tetrahydro-5H-dibenzoic,gichromen-3-y1)-2-oxoethyl) 1-tert-butyl 5-
(2S,5 S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3 -
oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate (700 mg, 1.17
mmol) was treated with a
solution of (2S,5S)-1-(tert-butoxycarbony1)-5-methylpyrrolidine-2-carboxylic
acid (375 mg, 1.64
mmol) in acetone (6 mL) and Cs2CO3 (267 mg, 0.82 mmol). The stirred reaction
mixture was heated
to 40 C for 16 h, then cooled to RT and diluted with CH2C12 and extracted 3X.
The organic phase was
washed with brine, then dried over MgSO4, filtered and concentrated under
reduced pressure. The
crude residue was purified by silica column chromatography (40% to 100%
(2S,5S)-2-(2-(9-((2S,5S)-1-(tert-butoxyearbony1)-5-methylpyrrolidine-2-
8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-y1)-2-oxoethyl) 1-tert-butyl 5-
methylpyrrolidine-1,2-
dicarboxylate (464 mg, 53%).
Tert-butyl (2S,5S)-2-(9-12-1(2S,5S)-1-(tert-butoxycarbony1)-5-methylpyrrolidin-
2-y11-1H-
imidazol-5-y11-1,4,5,11-tetrahydroisochromeno14',3%6,71naphtholl,2-di im idazo
1-2-yI)-5-
methylpyrrolidine-l-carboxylate
(2S,5 S)-2-(2-(9-((2S,5 S)-1 -(tert-butoxycarbony1)-5-methylpyrroli dine-2-
carbonyloxy)-8-
oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-y1)-2-oxoethyl) 1-tert-butyl
methylpyrrolidine-I,2-dicarboxylate (464 mg, 0.62 mmol) and NH40Ac (8.48 g,
110.0 mmol) were
suspended in a solution of 10:1 PhMe/2-methoxyethanol (22 mL). The stirred
reaction mixture was
heated to 110 C for 20 h, then cooled to RT and diluted with Et0Ac. The
organic phase was washed
with water, saturated aqueous NaHCO3, and brine, then dried over MgSO4,
filtered and concentrated
under reduced pressure. The crude residue was purified by silica column
Me0H/Et0Ac) to afford tert-butyl (2S,5S)-2-(9-12-[(2S,5S)-1-(tert-
methylpyrrolidin-2-yli- I H-imidazol-5-y1 -1,4,5,11-tetrahydroisochromeno
[4',3':6,7]naphtho [1,2-
d]imidazol-2-y1)-5-methylpyrrolidine-1 -carboxylate (393 mg, 90%).
Tert-butyl (2S,4S)-2-(5-{2-1(2S,4S)-1-(tert-butoxyea rbony1)-5-
dihydroisochromeno14',3':6,71naphtho[1,2-dlimidazol-9-y11-1H-imidazol-2-y1)-5-
Tert-butyl (2S,5S)-2-(9-{2-[(2S,5S)-1-(tert-butoxycarbony1)-5-methylpyrrolidin-
2-y1]-1H-
imidazol-5-y11-1,4,5,11-tetrahydroisochromeno[41,3':6,7]naphtho[1,2-dlimidazol-
methylpyrrolidine-l-carboxylate (393 mg, 0.55 mmol) was suspended in DCM (7
mL) and activated
Mn02 (1.45 g, 16.7 mmol) was added in a single portion. The reaction mixture
After stirring for 2.5 h, the mixture was cooled to rt and the slurry was
filtered over celite. The filter
cake was washed with copious CH2Cl2 and Me0H and the filtrate was concentrated
pressure. The crude material was taken on to the next step without further
purification to afford tert-
butyl (2S,4S)-2-(5-{2-[(2S,4 S)-1-(tert-butoxycarbony1)-5-methylpyrrolidin-2-
dihydroisochromeno[4',3':6,71naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-5-
1 -carboxylate (328 g, 85%).
Methyl {(2S)-1-1(2S,5S)-2-(5-12-1(2S,4S)-1-{(2S)-2-1(methoxycarbonyl)am ino1-3-
methylbuta noy1}-5-methylpyrrolidin-2-y1]-1,11-dihydroisoch rom eno
14',3':6,71 na phtho 1,2-
di im idazol-9-y1}-1 H-imidazol-2-y1)-5-methylpy rrolidin-1-y11-3-rn ethyl-1-
yl}earbamate
dihydroisochromeno [41,3 ':6,7]naphtho[1,2-d]imidazol-9-y1 -1H-im idazol-2-y1)-
5-methylpyrrolidine-
1-carboxylate (164 mg, 0.23 mmol) was dissolved in DCM (7 mL), Me0H (1.5 mL)
dioxane, 1.5 mL) was added. The reaction mixture was stirred for 16 h and then
DIPEA (0.4 mL, 2.34 mmol) was added dropwise. After 35 min, the mixture was
purified by HPLC to afford methyl {(2S)-1-[(2S,5S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyl -5-methylpyrrolidin-2-y1]-1,11-
y1]-3-methyl-1-oxobutan-2-ylIcarbamate (132 mg, 69%). LCMS-ESI+: calculated
818.41; observed [M+1]+: 820.19. 'H NMR (CD30D): 8.492 (m, 1H), 8.179-7.538
5.201 (m, 3H), 5.125-5.082 (m, 1H), 4.070 (m, 1H), 3.383-3.592 (m, 4 H), 3.225
(m, 5H), 1.992-1.892 (m, 3H), 1.568 (d, 3H, J=6.4 Hz), 1.490 (d, 3H, J=6.8
Hz), 1.266 (m, 2H),
1.020-0.806 (m, 14H).
Example NI
Boc N N = 1 H 1. HCI
2. HATU, DIPEA, DMF
OH 9
tert-butyl (2S,4S)-2-(5-{2-[(2S,45)-1-(tert- o -
butoxycarbony1)-4-methylpyrrolidin-2-y1]-1,11- HRL,zo-,
dihydroisochromeno[4',3':6,7Thaphtho[1,2-dlimidazol-9-
(2S,3R)-3-methoxy-2-
o)butanoic acid
411 YN 9
N ()
methyl R2S,3R)-3-methoxy-1-{(25,5S)-2-[9-(2-{(25,5S)-1-[N-
(methoxycarbony1)-0-methyl-L-threony11-5-methylpyrrolidin-2-y1}-1H-
imidazol-5-y1)-1,11-dihydroisochromeno[4,3':6,7]naphtho[1,2-dlimidazol-2-
y1]-5-methylpyrrolidin-1-y11-1-oxobutan-2-ylicarbamate
Methyl [(2S,3R)-3-methoxy-1-{(2S,5S)-2-19-(2-{(2S,5S)-1-1N-(methoxyearbony1)-0-
methyl-L-
threony11-5-methylpyrrolidin-2-y11-1H-imidazol-5-y1)-1,1 I-
dihydroisoehromeno14',3':6,71naphtho [1,2-d I imidazol-2-y11-5-
methylpyrrolidin-1-y11-1-
dihydroisochromeno[4',31:6,7]naphtho[l ,2-d]imidazol-9-y11-1H-imidazol-2-y1)-4-
1 -carboxylate (164 mg, 0.23 mmol) was dissolved in DCM (7 mL), Me0H (1.5 mL)
reduced pressure. The crude residue was treated with (2S,3R)-3-methoxy-2-
(methoxycarbonylamino)butanoic acid (90 mg, 0.46 mmol), HATU (175 mg, 0.46
mmol) and DMF
(6 mL), then DIPEA (0.4 mL, 2.34 mmol) was added dropwise. After 30 min, the
mixture was diluted
with 10% Me0H/Et0Ac and washed successively with saturated aqueous NaHCO3 and
brine. The
was purified by HPLC to afford methyl [(2S,3R)-3-methoxy-1-{(2S,5S)-249-(2-
{(2S,5S)-14N-
(methoxycarbony1)-0-methyl-L-threonyl]-5-methylpyrrolidin-2-y11-1H-imidazol-5-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1]-5-methylpyrrolidin-l-
y11-1-oxobutan-2-
ylicarbamate (97 mg, 50%). LCMS-ESI : calculated for C45H54N809: 850.40;
observed [M-1-1]:
851.58. 'H NMR (CD30D): 8.631 (s, 1H), 8.191-7.938 (m, 7 H), 6.100 (m, 1 H),
5.925 (m, 1H),
5.303 (m, 3H), 5.179 (t, 1H, J=6.8 Hz), 4.406-4.358 (m, 2H), 3.754- 3.598 (m,
8H), 3.376 (s, 3H),
3.263 (s, 3H), 2.625-2.256 (m, 6H), 2.038-1.955 (m, 2H), 1.598 (d, 3H, J=6.4
Hz), 1.530 (d, 3H,
J=6.8 Hz), 1.302-1.099 (m, 6H).
Example NJ
Boc )(/) 0= am 0 cs2co3
N=-2., 0 illkBr acetone
(2S,5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-
tetrahydro-5H-dibenzo[c,dchromen-3-y1)-2- HO N
oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2- 0 Boc
(2S,4S)-1-(tert-butoxycarbony1)-
4-(methoxymethyl)pyrrolidine-2-
õ--0/
Boc i? 0 it 0
O NH40Ao
y-N
PhMe, Me0Et0H
(2S,5S)-2-(2-(9-((2S,4S)-1-(tert-butoxycarbony1)-4-
(methoxymethyl)pyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-
tetrahydro-51-1-dibenzo[o,dchromen-3-y1)-2-oxoethyl) 1-tert-
butyl 5-methylpyrrolidine-1,2-dicarboxylate
Boc N H
\ 41=YThj Mn02
= N
= N Boc CH2Cl2
tert-butyl (2S,5S)-2-(9-{24(2S,5S)-1-(tert-butoxycarbony1)-4-
(methoxymethyl)pyrrolidin-2-y1]-1H-imidazol-5-y1}-1,4,5,11-
tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1)-5-
0 1. HCI
Boc N IR1
'.( N yoo 2. HATU, DIPEA, DMF
NNA= N
H N B0,J.INH
tert-butyl (2S,4S)-2-(542-1(2S,4S)-1-(tert- = o
butoxycarbony1)-4-(methoxymethyppyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3':6,71naphtho[1,2-dlimidazol-9- OH
y1}-1H-imidazol-2-y1)-5-methylpyrrolidine-1-carboxylate (2S,3S)-2-
3-methylpentanoic acid
.--0/
H )
\ =
methyl {(2S,3S)-1-[(2S,5S)-2-(5-(2-[(2S,4S)-1-{(2S,3S)-2- 0
((methoxycarbonyl)amino]-3-methylpentanoy1)-4-(methoxymethyl)pyrrolidin-
2-y1]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-dlimidazol-9-y11-1H
-imidazol-2-y1)-5-methylpyrrolidin-1-y11-3-methyl-1-oxopentan-2-y1}carbamate
(2S,5S)-2-(2-(942S,4S)-1-((ert-butoxycarbony1)-4-(methoxymethyl)pyrrolidine-2-
carbonyloxy)-
8-oxo-8,9,10,11-tetrahydro-5H-dibenzoic,gIchromen-3-y1)-2-oxoethyl) 1-tert-
butyl 5-
(2S,5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-y1)-
oxoethyl) 1 -tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate (800 mg, 1.34
solution of (2S,4S)-1-(tert-butoxycarbony1)-4-(methoxymethyl)pyrrolidine-2-
carboxylic acid (485
mg, 1.87 mmol) in acetone (6 mL) and Cs2CO3 (306 mg, 0.94 mmol). The stirred
was heated to 40 C for 16 h, then cooled to RT and diluted with CH2C12 and
extracted 3X. The
organic phase was washed with brine, then dried over MgSO4, filtered and
chromatography (40% to 100%
Et0Ac/hexanes) to afford (2S,5S)-2-(2-(9-((2S,5S)-1-(tert-butoxycarbony1)-5-
carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-y1)-2-
oxoethyl) 1-tert-butyl 5-
methylpyrrolidine-1,2-dicarboxylate (680 mg, 65%).
Tert-butyl (2S,5S)-2-(9-12-R2S,5S)-1-(tert-butoxycarbony1)-4-
(methoxymethyl)pyrrolidin-2-yI--
1H-imidazol-5-y11-1,4,5,11-tetrahydroisochromeno[4',3':6,71naphtho[1,2-
duirnidazol-2-y1)-5-
(2 S,5S)-2-(2-(9-((2S,5 S)-1-(tert-butoxycarbony1)-5-methylpyrrolidine-2-
methylpyrrolidine-1,2-dicarboxylate (680 mg, 0.87 mmol) and NH40Ac (10.0 g,
Me0H/Et0Ac) to afford tert-butyl (2S,5S)-2-(9-{2-[(2S,5S)-1-(tert-
(methoxymethyl)pyrrolidin-2-y1]-1H-imidazol-5-y1 1-1,4,5,11-
Tert-butyl (2S,4S)-2-(5-12-1(2S,4S)-1-(tert-butoxycarbony1)-4-
(methoxymethyl)pyrrolidin-2-y11-
1,11-dihydroisochromeno[4',3%6,7Inaphtholl,2-d]imidazol-9-y1}-1H-imidazol-2-
Tert-butyl (2S,5S)-2-(9-{2-[(2S,5S)-1-(tert-butoxycarbony1)-4-
y1]-1H-imidazol-5-y11-1,4,5,11-tetrahydroisochromeno[41,3':6,7]naphtho[1,2-
Mn02 (1.6 g, 18.8 mmol) was added in a single portion. The reaction mixture
cake was washed with copious CH2C12 and Me0H and the filtrate was concentrated
butyl (2S,4S)-2-(5- {2-[(2S,4S)-1-(tert-butoxycarbony1)-4-
(methoxymethyppyrrolidin-2-y1]-1,11-
1-carboxylate (414 g, 90%).
Methyl {(2S,3S)-1-1(2S,5S)-2-(5-12-1(2S,4S)-1-1(2S,3S)-2-
1(methoxycarbonyl)aminoi-3-
methylpentanoy11-4-(methoxymethyl)pyrrolidin-2-y11-1,11-
dihydroisochromeno[4',3':6,7]naphthol1,2-djimidazol-9-y1}-1H-imidazol-2-y1)-5-
methylpyrrolidin-1-y1]-3-methyl-1-oxopentan-2-yl}earbamate
Tert-butyl (2S,4S)-2-(5-12-[(2S,4S)-1-(tert-butoxycarbony1)-4-
y11-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-dlimidazol-9-y11-1H-imidazol-
methylpyrrolidine-1-carboxylate (207 mg, 0.28 mmol) was dissolved in DCM (4
1.5 h and then
concentrated under reduced pressure. The crude residue was treated with
(2S,3S)-2-
(methoxycarbonylamino)-3-methylpentanoic acid (106 mg, 0.56 mmol), HATU (214
mg, 0.56 mmol)
and DMF (5 mL), then DIPEA (0.49 mL, 2.8 mmol) was added dropwise. After 30
min, the mixture
was diluted with 10% Me0H/Et0Ac and washed successively with saturated aqueous
NaHCO3 and
brine. The organics were dried over MgSO4, filtered and concentrated under
crude residue was purified by HPLC to afford methyl {(2S,3S)-1-[(2S,5S)-2-(5-
{2-[(2S,4S)-1-
{(2S,3S)-2-[(methoxycarbonypamino]-3-methylpentanoy11-4-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-5-
y11-3-methyl-1-oxopentan-2-ylIcarbamate (132 mg, 69%). LCMS-ESI': calculated
Example NK
Boc 0 0 0
Et3N riN)(0 = 46
= MeCN c
3-(2-bromoacety1)-10,11-dihydro- Bloc 0 (2S,4S)-1-tert-butyl 2-(2-oxo-2-
(8-oxo-8,9,10,11-
5H-dibenzo[c,g]chromen-8(9H)-one tetrahydro-5H-dibenzo[c,g]chromen-3-
yl)ethyl) 4-
(2S,4S)-1-(tert-butoxycarbony1)-4-
methylpyrrolidine-2-carboxylic acid
Cs2CO3
pyridiunium Boc /5) 0 ja 0
tribromide
CH2C12/Me0H Yjsc-2, Wilt Br MeTHF
(2S',4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-
HOy-N/
5H-dibenzo[c,g]chromen-3-yI)-2-oxoethyl) 1-tert-
0 Boc
0 (methoxymethyl)pyrroli
/0 0 0
-0 dine-2-
=0 NH40Ac
1.17N/
(methoxymethyppyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-
tetrahydro-5H-dibenzo[c,g]chromen-3-y1)-2-oxoethyl) 1-tert-butyl
BOC N Ifr\11 MnO
tert-butyl (2S,5S)-2-(9-{2-[(2S,5S)-1-(tert-butoxycarbony1)-
4-(methoxymethyl)pyrrolidin-2-y1]-1H-imidazol-5-y1}-
1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-
djimidazol-2-y1)-4-methylpyrrolidine-1-carboxylate
Boc N n'1. HCI
*AKYN2 HATU, DIPEA, DMF
OH CY
tert-butyl (2S,4S)-2-[5-(2-{(2S,4S)-1-[N-(methoxycarbony1)-L- 0
valy1]-4-(methoxymethyl)pyrrolidin-2-y1}-1,11 FIN
dihydroisochromeno[4',3.:6,7]naphtho[1,2-d]imidazol-9-y1)-
1H-imidazol-2-y1]-4-methylpyrrolidine-1-carboxylate 0
(methoxycarbonylamino)
butanoic acid
)-(NH
NN 441 N
= N V;\
methyl {(2S,3R)-3-methoxy-1-[(2S,4S)-2-[9-(2-{(2S,4S)-1-[N- o
(methoxycarbony1)-0-methyl-L-threonyll-4-methylpyrrolidin-2-y1}-1H-
imidazol-5-y1)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-
2-y1J-4-(methoxymethyl)pyrrolidin-1-y1]-1-oxobutan-2-ylIcarbamate
dibenzolc,gichromen-3-3/1)ethyl)
To a solution of 3-(2-bromoacety1)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-
one (647
mg, 1.74 mmol) in MeCN (20 mL) was added ((2S,4S)-1-(tert-butoxycarbony1)-4-
2-carboxylic acid (559 mg, 2.44 mmol) and DIPEA (0.36 mL, 2.09 mmol) and the
heated to 60 C. After stirring for 3 h, the solution was cooled to rt, and
purified by silica
column chromatography (20% to 50% Et0Ac/hexanes) to afford (2S,4S)-1-tert-
butyl 2-(2-oxo-2-(8-
oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,dchromen-3-ypethyl) 4-methylpyrrolidine-
1,2-dicarboxylate
(2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo1c,g1chromen-3-y1)-
2-oxoethyl) 1-
yl)ethyl) 4-methylpyrrolidine-1,2-dicarboxylate (621 mg, 1.19 mmol) was
DCM (10 mL) and Me0H (4 mL), then treated with pyridinium tribromide (421 mg,
1.3 mmol). After
stirring at RT for 1.5 h, the reaction mixture was diluted with DCM and 10%
HC1, and extracted with
DCM. The organic phase was dried over MgSO4, filtered and concentrated under
reduced pressure
and the crude material was carried on without further purification.
(2S,4S)-2-(2-(9-42S,4S)-1-(tert-butoxycarbony1)-4-(methoxymethyl)pyrrolidine-2-
8-oxo-8,9,10,11-tetrahydro-5H-dibenzolc,Ochromen-3-y1)-2-oxoethyl) 1-tert-
(2 S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzok,g]chromen-3-y1)-
mg, 2.36 mmol) in Me-THF (12 mL) and Cs2CO3 (384 mg, 1.18 mmol). The stirred
(methoxymethyl)pyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo1c,g]chromen-3 -
y1)-2-oxoethyl) 1-tert-butyl 4-methylpyrrolidine-1,2-dicarboxylate (651 mg,
1H-imidazol-5-y11-1,4,5,11-tetrahydroisochromeno14',3%6,71naphtho[1,2-
dlimidazol-2-y1)-4-
(2S,4S)-2-(2-(94(2S,4S)-1-(tert-butoxycarbony1)-4-(methoxymethyppyrrolidine-2-
(methoxymethyl)pyrrolidin-2-y1]-1H-imidazol-5-y11-1,4,5,11-
tetrahydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-y1)-4-
Tert-butyl (2S,4S)-2-15-(2-1(2S,4S)-1-IN-(methoxyearbony1)-L-valy1J-4-
(methoxymethyl)pyrrolidin-2-y1}-1,11-dihydroisochromeno[4',3':6,7]naphtholl,2-
y1)-1H-imidazol-2-y11-4-methylpyrrolidine-1-earboxylate
y1]-1H-imidazol-5-y11-1,4,5,11-tetrahydroisochromeno[4',3.:6,7]naphtho[1,2-
methylpyrrolidine-1-carboxylate (382 mg, 0.52 mmol) was suspended in DCM (8
After stirring for 15 h, the mixture was cooled to 11 and the slurry was
purification to afford ten-
butyl (2S,4S)-2-[5-(2-{(2S,4S)-14N-(methoxycarbony1)-L-valy1]-4-
(methoxymethyppyrrolidin-2-y11-
1,11-dihydroisochromeno[4',3%6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-
methylpyrrolidine-1-carboxylate (347 g, 91%).
Methyl {(2S,3R)-3-methoxy-1-1(2S,4S)-249-(2-{(2 S,4S)-1-IN-(methoxyearbony1)-0-
threonyli-4-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-1,11-
dihydroisochromeno[4',3%6,71naphtholl.,2-d]imidazol-2-y11-4-
(methoxymethyl)pyrrolidin-l-y11-
1-oxobutan-2-yl}earbamate
Tert-butyl (2S,4S)-245-(2-{(2S,4S)-14N-(methoxycarbony1)-L-valyl]-4-
(methoxymethyl)pyrrolidin-2-y11-1,11-dihydroisochromeno[4',3':6,7]naphtho [1,2-
d] imidazol-9-y1)-
1H-imidazol-2-y1]-4-methylpyrrolidine-l-carboxylate (174 mg, 0.24 mmol) was
dissolved in DCM (4
mL), Me0H (1 mL) and HC1 (4 M in dioxane, 1 mL) was added. The reaction
mixture was stirred for
5 h and then concentrated under reduced pressure. The crude residue was
treated with ((2S,3R)-3-
methoxy-2-(methoxycarbonylamino)butanoic acid (92 mg, 0.48 mmol), HATU (182
crude residue was purified by HPLC to afford methyl {(2S,3R)-3-methoxy-1-
[(2S,4S)-249-(2-
{ (2 S,4S)-14N-(methoxycarbony1)-0-methyl-L-threony1]-4-methylpyrrolidin-2-y1}-
y1)-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1]-4-
(methoxymethyl)pyrrolidin-1-
y11-1-oxobutan-2-yllcarbamate (72 mg, 34%). LCMS-ESI+: calculated for
C46H56N8010: 880.41;
observed [M+1]+: 882.39. 'H NMR (CD30D): 8.558 (s, 1H), 8.123-7.572 (m, 7H),
5.436-5.391 (dd,
1H, J=7.2, 3.6 Hz), 5.252 (s, 2H), 5.220 (m, 1H), 4.493-4.444 (m, 2H), 4.287-
4.206 (m, 2H), 3.756-
3.256 (m, 21H), 2.834 (m, 1H), 2.717-2.621 (m, 2H), 2.500 (m, 1H), 2.150 (m,
1H), 1.882 (m, 1H),
1.208 (d, 3H, J=6.4 Hz), 1.159-1.099 (m, 6H).
Example NL
0 ilk 0 DIPEA , -,0,i-NH
* MeCN o
9 -,õ=0
3-(2-bromoacetyI)-10,11-dihydro- ''0). NH
one o ,,,..cN,A = *all
5H-dibenzo[c,g]chromen-8(9H)- .,õ1,,.(,ro mow
I - = L, OH
(2S,5S)-2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-
5H-dibenzo[c,gjchromen-3-yl)ethyl 1-((S)-2-
(2S,5S)-1-((S)-2- (methoxycarbonylamino)-3-
0 methylpyrrolidine-2-
'ID,J.LNH carboxylic acid
pyridiunium o Cs2CO3
0 o MeTHF ____ I.
________ )1.
N )-i(
CH2C12/Me0H "'"C 0 = W AL . Br -----\
HOli,---,N,'"
(2S,5S)-2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H- a 60c
dibenzo[c,g]chromen-3-yI)-2-oxoethyl 1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoy1)-5- (2S,4S)-1-(tert-
methylpyrrolidine-2-carboxylate butoxycarbony1)-4-
0.J NH carboxylic acid
0 NA NH40Ac
,,,.. N . AL
.3.---\ PhMe, Me0Et0H ).
c o WID ON/ ref lux
0 Boo
(2S,4S)-1-tert-butyl 2-(3-(2-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoy1)-5-methylpyrrolidine-2-carbonyloxy)acety1)-8-oxo-8,9,10,11-
tetrahydro-5H-dibenzo[c,g]chromen-9-y1) 4-methylpyrrolidine-1,2-dicarboxylate
0 nY30 Mn02
_______________________________________________________________ =
N 11A1 411 N CH2Cl2
N c
tert-butyl (2S,4S)-249-(2-{(2S,5S)-1411-(methoxycarbony1)-L-valy1]-5-
methylpyrrolidin-2-y11-
1H-imidazol-5-y1)-1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-
dlimidazol-2-y1]-4-
= \õ=Lr0 0 1. HCI
____________________________________________________________________ =
NN = 441 YNN 2. HATU, DIPEA, DMF N Boc
tert-butyl (2S,4S)-2-[9-(2-{(2S,4S)-1-[N-(methoxycarbony1)-L-
valy1]-4-methylpyrrolidin-2-y11-1H-imidazol-5-y1)-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1]-4-
methylpyrrolidine-1-carboxylate (2S,3R)-3-methoxy-2-
0 (methoxycarbonylami
OA NH no)butanoic acid
[P\11
N = AL YN 9
"". cN mr -ft N
methyl {(2S)-1-[(2S,5S)-2-(5-{2-[(2S,4S)-1-{(2S,3R)-3-methoxy-2-
[(methoxycarbonypamino]butanoy1}-4-
methylpyrrolidin-2-y1]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-9-y1}-1H-imidazol-2-
y1)-5-methylpyrrolidin-1-y1]-3-methy1-1-oxobutan-2-ylIcarbamate
(2S,5S)-2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-51-1-dibenzo[c,g1chromen-3-yOethyl
1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoy1)-5-methylpyrrolidine-2-carboxylate
To a solution of 3-(2-bromoacety1)-10,11-dihydro-5H-dibenzo[c,gichromen-8(9H)-
mg, 2.02 mmol) in MeCN (20 mL) was added (2S,5S)-1-((S)-2-
methylbutanoy1)-5-methylpyrrolidine-2-carboxylic acid (600 mg, 2.09 mmol) and
DIPEA (0.35 mL,
2.02 mmol) and the solution was heated to 60 C. After stirring for 4 h, the
solution was cooled to rt,
and diluted with Et0Ac and washed successively with saturated aqueous NaHCO3
was purified by silica column chromatography (40% to 80% Et0Ac/hexanes) to
afford (2S,5S)-2-oxo-
2-(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,gichromen-3-ypethyl 1-((S)-2-
3-methylbutanoy1)-5-methylpyrrolidine-2-carboxylate (1.16 g, quant.).
(2S,5S)-2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzoic,glchromen-3-y1)-2-
oxoethyl 1-((S)-
2-(methoxycarbonylamino)-3-methylbutanoy1)-5-methylpyrrolidine-2-carboxYlate
(2S,5 S)-2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-d ibenzo[c,g]chromen-3-
yl)ethyl 1-((S)-2-
(400 mg, 0.61 mmol)
was dissolved in a solution of DCM (15 mL) and Me0H (6 mL), then treated with
pyridinium
tribromide (409 mg, 1.28 mmol). At 2 h, an additional portion of pyridinium
tribromide (40 mg) was
added. After stirring at RT for another 20 min, the reaction mixture was
diluted with DCM and 10%
HC1, and extracted with DCM. The organic phase was dried over MgSO4, filtered
under reduced pressure and the crude material was carried on without further
purification.
(2S,4S)-1-tert-butyl 2-(3-(2-42S,5S)-14(S)-2-(methoxycarbonylamino)-3-
methylbutanoy1)-5-
methylpyrrolidine-2-carbonyloxy)acetyI)-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,gf chromen-
(2S,5S)-2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-y1)-2-
oxoethyl
1-((S)-2-(methoxycarbonylam ino)-3-methylbutanoy1)-5-methylpyrrolidine-2-
carboxylate ) was
treated with a solution of (2S,4S)-1-(tert-butoxycarbony1)-4-methylpyrrolidine-
2-carboxylic acid (280
mg, 1.22 mmol) in Me-THF (6 mL) and Cs2CO3 (199 mg, 0.61 mmol). The stirred
was heated to 50 C for 2.5 h, then cooled to RT and diluted with CH2C12and
Et0Ac/hexanes) to afford (2S,4S)-1-tert-butyl 2-(3-(2-((2S,5S)-1-((S)-2-
dibenzo[c,g]chromen-9-y1) 4-methylpyrrolidine-1,2-dicarboxylate (441 mg, 90%).
Tert-butyl (2S,4S)-2-19-(2-{(2S,5S)-1-1N-(methoxycarbony1)-L-valy11-5-
methylpyrrolidin-2-y1}-
1H-imidazol-5-y1)-1,4,5,11-tetrahydroisochromenof4',3%6,71naphthol1,2-
dlimidazol-2-y11-4-
(2 S,4 S)-1 -tert-butyl 2-(3-(2-((2S,5S)-14(S)-2-(methoxycarbonylamino)-3-
methylbutanoy1)-
5-methylpyrrolidine-2-carbonyloxy)acety1)-8-oxo-8,9,10,11-tetrahydro-5H-
y1) 4-methylpyrrolidine-1,2-dicarboxylate (441 mg, 0.55 mmol) and NH40Ac (5 g,
65.0 mmol) were
heated to 110 C for 7 h, then cooled to RT and diluted with Et0Ac. The
methylpyrrol idin-2-y1 -11-1-imidazol-5-y1)-1,4,5,11-
d]imidazol-2-y1]-4-methylpyrrolidine- 1 -carboxylate (266 mg, 63%).
Tert-butyl (2S,4S)-249-(2-{(2S,4S)-1-IN-(methoxycarbony1)-L-valy11-4-
1H-imidazol-5-y1)-1,11-dihydroisochromenol4',3%6,71naphtholl,2-dlimidazol-2-
Tert-butyl (2S,4S)-249-(2-1(2S,5S)-14N-(methoxycarbony1)-L-valy1]-5-
y1}-1H-imidazol-5-y1)-1,4,5,11 tetrahydroisochromeno[4',31:6,7]naphtho[1,2-
d]imidazol-2-y1]-4-
Mn02 (908 mg, 10.45 mmol) was added in a single portion. The reaction mixture
was stirred
overnight. After stirring for 15 h, additional activated Mn02 (500 mg, 5.75
mmol) was added in a
single portion.
After stirring 2 h at 35 C, the mixture was cooled to rt and the slurry was
filtered over celite.
The filter cake was washed with copious CH2Cl2 and Me0H and the filtrate was
reduced pressure. The crude material was taken on to the next step without
further purification to
afford tert-butyl (2S,4S)-249-(2-1(2S,4S)-14N-(methoxycarbony1)-L-valy1]-4-
y1}-1H-imidazol-5-y1)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-
2-y1]-4-
methylpyrrolidine-1-carboxylate (266 mg, quant).
Methyl {(2S)-1-1(2S,5S)-2-(5-{2-1(2 S,4S)-1-{(2S,3R)-3-m ethoxy-2-
1 0 [(methoxyearbonyl)am int)] butanoy1}-4-methylpyrrolidin-2-y11-1,1 1-
dihydroisochromeno 14',3 ':6,7] naphthol ,2411 im idazol-9-y1}-1 H-imidazol-2-
methylpyrrolidin- -y11-3-methyl-l-oxobutan-2-ylIcarbamate
y11-1H-imidazol-5-y1)-1,11-dihydroisochromeno[41,31:6,71naphtho [1,2-
methylpyrrolidine-1 -carboxylate (266 mg, 0.23 mmol) was dissolved in DCM (4
mL), Me0H (1mL)
and HCI (4 M in dioxane, 1 mL) was added. The reaction mixture was stirred for
(methoxycarbonylamino)butanoic acid (44 mg, 0.23 mmol), HATU (87 mg, 0.23
mmol) and DMF (5
mL), then DIPEA (0.3 mL, 1.75 mmol) was added dropwise. After 30 min, the
was purified by HPLC to afford methyl {(2S)-1-[(2S,5S)-2-(5-12-[(2S,4S)-1-
{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyll -5-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno [41,31:6,7]naphtho [I ,2-d]imidazol-9-y11-1H-imidazol-2-y1)-
5-methylpyrrolidin-1-
y1]-3-methyl-1-oxobutan-2-ylIcarbamate (59 mg, 31%). LCMS-ESI+: calculated for
834.41; observed [M+1]': 836.89. 'H NMR (CD30D): 8.186 (s, 1H), 7.800-7.291
5.213 (dd, 1H, J=7.2, 3.6 Hz), 5.027-4.918 (m, 4H), 4.620 (t, 1H, J=6.8 Hz),
4.246 (m, 1H), 4.116 (m,
1H), 3.972 (d, 1H, J=8.8 Hz), 3.701-3.675 (m, 1H), 3.503 (s, 3H), 3.479 (s,
3H), 3.177 (s, 3H), 2.554-
2.191 (m, 3H), 1.906-1.821 (m, 6H), 1.392 (d, 2H, J=6.4 Hz), 1.113-0.728 (m,
Example NM
Boc N 0
tj s Pd(dppf)2C12,
K2CO3
I + , N
0' 11\/ DMSO, Dioxane
(2S,4S)-tert-butyl 2-(5- methyl [(2S)-3-methyl-1-{(2S,4S)-4-methy1-2-[9- 0
iodo-1H-imidazol-2-y1)-4- (4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-
(methoxymethyl)pyrrolidin dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-
e-1-carboxylate 2-ylipyrrolidin-1-y11-1-oxobutan-2-yl]carbamate
0 2. COMU,
W. 1\1 00
ir OH
0 (R)-2-
tert-butyl (2S,4S)-2-15-(2-{(2S,4S)-14N-(methoxycarbony1)-L-
valy1]-4-methylpyrrolidin-2-y11-1,11- o)-2-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1)-
1H-imidazol-2-y1]-4-(methoxymethyl)pyrrolidine-1-
Ny'N
methyl ((1R)-2-[(2S,4S)-2-(5-{24(2S,4S)-1-{(2S)-2-[(methoxycarbonyl)amino]-
3-methylbutanoy1}-4-methylpyrrolidin-2-y1)-1,11-
dihydroisochromeno[4',3':6,71naphtho[1,2-dlimidazol-9-01-1H-imidazol-2-y1)-
4-(methoxymethyl)pyrrolidin-1-y1)-2-oxo-1-phenylethyl}carbamate
Tert-butyl (2S,4S)-2-15-(2-{(2S,4S)-1-1N-(methoxyearbony1)-L-valy11-4-
1,11-dihydroisochromeno[4',3%6,71naphtholl,2-dlimidazol-9-y1)-1H-imidazol-2-
yll-4-
(methoxymethyl)pyrrolidine-l-earboxylate
Methyl R2S)-3-methy1-1-1(2S,4S)-4-methyl-249-(4,4,5,5-tetramethyl-1,3,2-
y1)-1,11-dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-ylipyrrolidin-l-
yll-1-oxobutan-2-
yl]carbamate (312 mg, 0.49 mmol), methyl (S)-1-((2S,4S)-2-(5-iodo-1H-imidazol-
methylpyrrolidin-l-y1)-3-methyl-1-oxobutan-2-ylcarbamate (219 mg, 0.54 mmol),
Pd(PPh3)4 (58 mg,
0.05 mmol), PdC12(dpp02 (36 mg, 0.05 mmol), and K2CO3(2M in H20, 0.8 mL, 1.6
mmoL) were
combined in DMSO (5 mL) and dioxane (5 mL). The mixture was degassed with
bubbling N2 for 10
min the heated to 95 C for 5 h. After cooling, the reaction mixture was
diluted with Et0Ac, and
column chromatography (0%- 30% Me0H/Et0Ac) to afford tert-butyl (2S,4S)-245-(2-
{(2S,4S)-1-
[N-(methoxycarbony1)-L-valy1]-4-methylpyrrolidin-2-y1 -1,11-
dihydroisochromeno[4',31:6,71naphtho[1,2-d]imidazol-9-y1)- I H-imidazol-2-y1]-
(methoxymethyppyrrolidine- 1 -carboxylate (166 mg, 43%).
Methyl {(1R)-2-1(2S,4S)-2-(5-{2-1(2S,4S)-1-{(2S)-2-1(methoxycarbonyl)a mino1-3-
methylbuta noy1}-4-methylpyrrolidin-2-y11-1,1 1-dihydroisochrom eno14',3
':6,71na phtho[1,2-
dl imidazol-9-y1}-1 H-im idazol-2-y1)-4-(methoxymethyl)pyrrolidin-l-y11-2-oxo-
phenylethylIcarba mate
Tert-butyl (2S,4S)-2-[5-(2-{(2S,4S)-14N-(methoxycarbony1)-L-valy1]-4-
y11-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-
(methoxymethyppyrrolidine-1-carboxylate (166 mg, 0.21 mmol) was dissolved in
DCM (4 mL),
Me0H (1 mL) and HC1 (4 M in dioxane, 1 mL) was added. The reaction mixture was
stirred for 2 h
and then concentrated under reduced pressure. The crude residue was treated
with (R)-2-
DMF (5 mL), then DIPEA (0.18 mL, 1.05 mmol) was added dropwise. After 1 h, the
residue was purified by HPLC to afford methyl {(1R)-2-[(2S,4S)-2-(5-{2-
Rmethoxycarbonyl)amino]-3 -methylbutanoyl} -4-methylpyrrolidin-2-y1]-1,11-
(methoxymethyppyrrolidin-1-y1]-2-oxo-1-phenylethylIcarbamate (71 mg, 38%).
calculated for C49H54N808: 882.41; observed [M+1]+: 884.34. 'H NMR (CD30D):
8.462 (s, 1H),
8.029-7.471 (m, 7H), 7.394-7.343 (m, 5H), 5.410 (d, 2H, J=6.8 Hz), 5.300 (m,
4.341 (m, 1H), 4.236 (d, 1H, J=7.2 Hz), 3.603 (s, 3H), 3.551 (s, 3H), 3.522-
1H), 2.550 (m, 2H), 1.977-1.926 (m, 4H), 1.221 (d, 3H, J=3.2 Hz), 0.897-0.779
(dd, 6H, J=19.2, 6.8
Example NO
,)1
Boc TF CH3
Et0 µ,.--------
-----0 CH3-MgBr A
EtO, ,..L-.N ____________ . -,,NH r
, µ B' oc THF, -40 - 0 C DCM 0
Et00 (S)-ethyl 5-methyl-
(S)-1-tert-butyl 2-ethyl 5- 3,4-dihydro-2H-
oxopyrrolidine-1,2- (S)-ethyl 2-(tert-
dicarboxylate butoxycarbonylamino)-5- pyrrole-2-
oxohexanoate carboxylate
H2 (g)-----)."CH3 (Boc)20
Et0 ,s.:), .'ICH3 LION
___________ , Et0 õ---_,,, ' If Boc )1 Pi
Pd/C 0 DIEA, DMAP 0 Et0H, H20
(2S,5S)-1-tert-butyl 2-ethyl
(2S,5S)-ethyl 5- 5-
methylpyrrolidine dicarboxylate
-2-carboxylate
TEMPO, NaBr
---)='ICH3 Borane NaCIO, NaHCO3
----=.ICH3
----).',CH3 H =-=-
,0 N
TIss ' _____________ 1 HO ,õ.---N ' ) '
0 Boc Dimethysulfide Boo DCM, 0 C 0 BOO
(2S,5S)-1-(tert- (2S,5S)-tert-butyl 2- (2S,5S)-tert-butyl 2-
formyl-
butoxycarbony1)-5- (hydroxymethyl)-5- 5-methylpyrrolidine-1-
methylpyrrolidine-2- methylpyrrolidine-1- carboxylate
carboxylic acid carboxylate
0=/ ------
N, ICH3 12, Na2003 )..,CH3 Na2S03
1\1. 0.----N
_______ . õ_,,.---N r---- _________ .
Ammonia (aq)....._\ NH Boo Dioxane / H20
' 11¨NH 60c Dioxane, H20
Me0H, 10 C 1
(2S,5S)-tert-butyl 2-(1 H- (2S,5S)-tert-
butyl 2-(4,5-diiodo-
imidazol-2-y1)-5- 1H-imidazol-2-y1)-5-
methylpyrrolidine-1-carboxylate methylpyrrolidine-
----).,,0H3 1. HCI / Dioxane N.,,,,y,-----N
\...,,..
Nõ.õ1õ------N
--NH ------\µ's
$--NH 6 c 0 HN.---e
2. L-Valine MOO I
I HATU, DIEA 0--
(2S,5S)-tert-butyl 2-(5-iodo-1H- (2S)-1-[(2S,5S)-2-(5-iodo-1H-imidazol-
2-y1)-
imidazol-2-y1)-5-methylpyrrolidine- 5-
methylpyrrolidin-1-yI]-2-[(1-
1-carboxylate methoxyethenyl)amino)-3-methylbutan-1-one
(S)-ethyl 2-(tert-butoxycarbonylamino)-5-oxohexanoate
A solution of ethyl N-Boc (S)-pyroglutamate (20.0 g, 77.7 mmol) was in
anhydrous THF (150
mL) in a two neck round bottom under argon was cooled to -40 C. Methyl-
magnesium bromide
solution (3.0 M in Ether, 28.5 mL, 85.5 mmol) was added to the reaction
mixture dropwise over 30
minutes. The reaction was stirred for 4 hrs at -40 C then for 1 hr at 0 C.
The reaction was
partitioned between ethyl acetate and saturated ammonium chloride solution and
acidified with 1 N
HC1. The aqueous layer was extracted two more times with ethylacetate. The
combined and dried with sodium sulfate. The crude material was purified by
(20% - 40% Et0Ac/hexanes) to yield (S)-ethyl 2-(tert-butoxycarbonylamino)-5-
oxohexanoate as a
viscous oil and was used directly in the following step.
(S)-ethyl 5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylate
(S)-ethyl 2-(tert-butoxycarbonylamino)-5-oxohexanoate in a 1 L flask was
treated with a
trifluoro acetic acid / dichloromethane solution (1:1 mixture, 100 mL).
Effervescence was observed
and the mixture was allowed to stir for 4 hours at room temperature. After
which time the volatiles
were removed in vacuo to yield (S)-ethyl 5-methyl-3,4-dihydro-2H-pyrrole-2-
carboxylate as an oil,
and used directly in the following step.
(2S,5S)-ethyl 5-methylpyrrolidine-2-carboxylate
The crude imine 3 in a 1L flask was dissolved with ethanol (400 mL) was
charged with argon three times (3x). Palladium on carbon (apprx. 750 mg, 10%
w/w, dry) was added
and the reaction was evacuated of gas and charged with hydrogen gas (3x). The
reaction was allowed
to stir under atmospheric hydrogen for 16 hours. The mixture was filtered
through a plug of celite and
the filtrate was concentrated in vacuo. Diethyl ether was added to the oil and
a precipitate formed.
The mixture was filtered to yield (2S,5S)-ethyl 5-methylpyrrolidine-2-
carboxylate, as a white solid
(10.6 g, 67.4 mmol, 86.7% over three steps). 'H NMR (400 MHz, cdc13) ö 4.48
(dd, 1H), 4.27 (q, 2H),
3.92 - 3.80 (m, IH), 2.52 - 2.36 (m, 1H), 2.32 -2.13 (m, 2H), 1.75 - 1.60 (m,
1H), 1.51 (d, 3H), 1.30
(t, 3H).
(2S,5S)-1-tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-dicarboxylate
To a solution of (2S,5S)-ethyl 5-methylpyrrolidine-2-carboxylate (7.0 g, 44.5
mmol) in
dichloromethane (250 mL), ditertbutylanhydride (10.7 g, 49.0 mmol),
diisopropylethylamine (17.1
mL, 98.0 mmol) dropwise over 10 minutes, and dimethyl amino pyridine (0.27 g,
2.23 mmol) were
added successively. Effervescence was observed and the mixture was allowed to
stir for 16 hours at
room temperature. The reaction was washed with HCI (250 mL, of 1N). The
organic layer was then
dried with sodium sulfate. The crude material was purified by column
chromatography (5% - 25%
Et0Ac/hexanes) to yield (2S,5S)-1-tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-
dicarboxylate as an oil
(6.46 g, 25.1 mmol, 56%). LCMS-ESI': calc'd for CI3H23N04: 257.16 (M4); Found:
258.70 (M+H+).
(2S,5S)-1-(tert-butoxycarbonyI)-5-methylpyrrolidine-2-carboxylic acid
To a solution of (2S,5S)-1-tert-butyl 2-ethyl 5-methylpyrrolidine-1,2-
dicarboxylate (6.46 g,
25.1 mmol) in ethanol (20 mL) was added lithium hydroxide mono hydrate (2.11
g, 50.2 mmol) and
deionized water (12mL). The mixture was allowed to stir for 16 hours then
partitioned between
ethylacetate and a 1:1 mixture of saturated brine and IN HC1. The aqueous
layer was extracted an
additional time with ethyl acetate. The organic layers were combined, dried
with sodium sulfate and
the solvent was removed in vacuo to yield (2S,5S)-1-(tert-butoxycarbony1)-5-
carboxylic acid as a white solid (quant.) and was used directly in the
following step.
(2S,5S)-tert-butyl 2-(hydroxymethyl)-5-methylpyrrolidine-1-carboxylate
To a solution of (2S,5S)-1-(tert-butoxycarbony1)-5-methylpyrrolidine-2-
carboxylic acid (5.91
g, 25.8 mmol) in tetrahydrofuran at 0 C, was added borane in dimethylsulfide
(1.0 M, 3.4 mL, 34
mmol) dropwise. The reaction was stirred for 4 hours at 0 C then 18 hours at
room temperature. The
mixture was then cooled to 0 C and methanol (70 mL) was added dropwise. The
reaction was
warmed to room temperature and the solvents were removed in vacuo. The residue
was taken up in
dichloromethane (200 mL) and extracted with saturated sodium bicarbonate. The
organic layer was
dried with sodium sulfate and the solvent was removed in vacuo to yield
(hydroxymethyl)-5-methylpyrrolidine-l-carboxylate as a clear oil (5.15 g, 23.9
mmol, 93%) and was
used directly in the following step.
(2S,5S)-tert-butyl 2-formy1-5-methylpyrrolidine-1-carboxylate
To a solution of (2S,5S)-tert-butyl 2-(hydroxymethyl)-5-methylpyrrolidine-l-
(5.15 g, 23.9 mmol) in dichloromethane, was added TEMPO (0.075 g, 0.48 mmol),
sodium bromide
(0.246 g, 2.39 mmol) and sodium bicarbonate (0.442 g, 5.26 mmol). Sodium
hypochlorite (2.67 g,
35.9 mmol) of a 6% solution was added and the biphasic mixture was vigorously
stirred for 2 hours at
room temperature. The reaction mixture was extracted two times with
dichloromethane (2x100mL).
The organic layers were combined and washed with saturated sodium thiosulfate
solution, dried with
sodium sulfate and the solvent was removed in vacuo to yield (25,5S)-tert-
butyl 2-formy1-5-
methylpyrrolidine-1 -carboxylate (3.9 g, 18.29 mmol, 77%) as a slight colored
oil and was used
directly in the following step.
(2S,5S)-tert-butyl 2-(1H-imidazol-2-y1)-5-methylpyrrolidine-1-carboxylate
To a solution of (2S,5S)-tert-butyl 2-formy1-5-methylpyrrolidine-l-carboxylate
(3.9g, 18.30
mmol) in Me0H (15 mL) and ammonium hydroxide (15 mL, 99.9%), glyoxal (11.7 mL,
40% w/v in
water, 102.40 mmol) was added dropwise. The biphasic mixture turned orange and
turbid. The
reaction was stirred vigorously overnight at room temperature. The solvent was
removed in vacuo.
The crude mixture was redissolved in ethyl acetate and washed with water. The
aqueous layer was
washed an additional time with ethyl acetate. The organic layers were combined
and washed with
brine, dried with sodium sulfate and the solvent was removed in vacua. The
purified by column chromatography 85% to 100% ethyl acetate in hexanes to
yield (2S,5S)-tert-butyl
2-(1H-imidazol-2-y1)-5-methylpyrrolidine-l-carboxylate as an off white solid
(3.47 g, 13.8 mmol,
75%). LCMS-ESr: calc'd for CI3H211\1302: 251.16 (M); Found: 252.20 (MH-FF).
(2S,5S)-tert-butyl 2-(4,5-diiodo-1H-imidazol-2-y1)-5-methylpyrrolidine-l-
earboxylate
A 500 mL round bottom flask was charged with (2S,5S)-tert-butyl 2-(1H-imidazol-
methylpyrrolidine-l-carboxylate (3.47 g, 13.8 mmol), iodine (7.7 g, 30.4 mmol)
and sodium
carbonate (4.54 g, 42.8 mmol). Dioxane (70 mL) and water (45 mL) was added to
mixture and the
reaction was stirred vigorously overnight in the dark. The reaction was then
partitioned between ethyl
acetate and a 10% aqueous solution of sodium thiosulfate and extracted. The
extracted an additional time with ethyl acetate. The organic layers were
combined, dried with sodium
sulfate and the solvent was removed in vacua. The crude material was filtered
through a plug of silica
with 25% ethyl acetate in hexanes to yield (2S,5S)-tert-butyl 2-(4,5-diiodo-1H-
methylpyrrolidine-1 -carboxylate as a white solid (4.28 g, 8.50 mmol, 62%).
LCMS-ES1+: calc'd for
Ci3H i912N302: 502.96 (M +); Found: 503.94 (M+H+).
(2S,5S)-tert-butyl 2-(5-iodo-1H-imidazol-2-y1)-5-methylpyrrolidine-1-
To a solution of (2S,5S)-tert-butyl 2-(4,5-diiodo-1H-imidazol-2-y1)-5-
methylpyrrolidine-l-
carboxylate (4.28 g, 8.50 mmol) in ethanol (75 mL) and water (75 mL), sodium
thiosulfate (10.72 g,
85.1 mmol) was added and the reaction mixture was stirred vigorously for 1
hour at 100 C, 16 hours
at 90 C, and 5 hours at 100 C. The reaction mixture was partitioned between
ethyl acetate and
water. The aqueous layer was washed additionally with ethyl acetate and the
combined. The organic layer was dried with sodium sulfate, concentrated and
purified by column chromatography to yield (2S,5S)-tert-butyl 2-(5-iodo-1H-
methylpyrrolidine-l-carboxylate as a white solid (2.34 g, 6.20 mmol, 73%).
IHNMR (400 MHz,
cdc13) 5 7.04 (s, 1H), 4.89 (dd, 1H), 3.92 (m, 1H), 2.91 (s, 1H), 2.18 -2.06
(m, 2H), 1.78 (m, 1H),
1.52 (m, 1H), 1.48 (s, 9H), 1.13 (d, 3H).
(2S)-1-1(2S,5S)-2-(5-iodo-1H-imidazol-2-y1)-5-methylpyrrolidin-1-y11-2-[(1-
methoxyethenyl)aminol-3-methylbutan-1-one
A round bottom flask was charged with (2S,5S)-tert-butyl 2-(5-iodo-1H-imidazol-
methylpyrrolidine-l-carboxylate (1.5 g, 3.98 mmol) and treated with an excess
of hydrochloric acid
(100 mL of 4.0M in dioxane). The mixture was stirred vigorously for 3 hours in
which time a
precipitate formed and the solvent was removed in vacua. To a mixture of the
crude intermediate, (S)-
2-(methoxycarbonylamino)-3-methylbutanoic acid (0.836 g, 4.77 mmol), HATU
(1.81 g, 4.77 mmol)
in dichloromethane (25 mL), diisopropylethylamine (3.46 mL, 19.9 mmol) was
then added dropwise
and was stirred over night under nitrogen. The reaction mixture was
partitioned ethyl acetate and
saturated sodium bicarbonate. The organic layer was dried with sodium sulfate,
the solvent removed
in vacuo. The crude product was purified by column chromatography to yield
(2S)-1-[(2S,5S)-2-(5-
iodo-1H-imidazol-2-y1)-5-methylpyrrolidin-1 -y11-2-[(1-methoxyethenyl)amino]-3-
methylbutan-1-one
as a white solid (1.63 g, 3.75 mmol, 94%). LCMS-ESr: calc'd for CI5H231N403:
434.08 (NI +);
Found: 435.51 (M+H+).
Example NP
\NN
W-1114 N Boc
Pd(PPh3)4, PdC12(dPIDf),
(2S,4S)-tert-butyl 4-(methoxymethy0-2-(9-(4,4,5,5-
tetramethy1-1,3,2-dioxaborolan-2-y1)-5H-naphtho
(c,g)chromeno[8,9-d]imidazol-211)pyrrolidine-
)\¨N. 0
¨0 1/4-1 \ 4450 H1. HC!, Et0H, 60 C
H,0 N07
tert-butyl (2S,4S)-2-[9-(2-{(2S,5S)-1[N-(methoxycarbony1)-L-valy1]-5- 0
methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-3,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1]-4- COMU, DIPEA,
¨0 N AL
Nji¨N N
Methyl {(28)-1-[(25,53)-2-(5-{2-[(2S,45)-1-{(2R)-2-
[(methoxycarbonyl)amino]-2-phenylacety1}-4-
(methoxymethyl)pyrrolidin-2-y1]-1,11 dihydroisochromeno
[4',3':6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-5-
methylpyrrolidin-1-y1]-3-methy1-1-oxobutan-2-ylIcarbamate
Methyl f(2S)-11(2S,5S)-2-(5-12-1(2S,4S)-1-{(2R)-2-Rmethoxycarbonypamino1-2-
phenylacetyl)-4-
(methoxymethyl)pyrrolidin-2-y1]-1,11 dihydroisochromeno 14',3':6,71naphtho[1,2-
y1}-1H-imidazol-2-y1)-5-methylpyrrolidin-l-y11-3-methyl-1-oxobutan-2-
yl}carbamate
The synthesis of this compound was prepared according to the procedure of
with the following modification. During the Suzuki coupling, (2S)-1-[(2S,5S)-2-
(5-iodo-1H-imidazol-
2-y1)-5-methylpyrrolidin-l-y1]-2-[(1-methoxyethenyl)amino]-3-methylbutan-1-one
was used in lieu of
(2S)-1-[(2S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-l-y1]-2-[(1-
methoxyethenypamino]-3-
methylbutan-1-one. The crude material was purified by preparative HPLC to
provide methyl {(2S)-1-
[(2S,5S)-2-(5-{2-[(2S,4S)-1 -{(2R)-2-[(methoxycarbonypamino]-2-phenylacetyl -4-
pyrrolidin-2-y1]-1,11 dihydroisochromeno [41,31:6,7]naphtho[1,2-d]imidazol-9-
5-methylpyrrolidin-1-y1]-3-methy1-1-oxobutan-2-ylIcarbamate as a white solid
(17 mg, 0.019 mmol,
17%). 'H NMR (400 MHz, cd3od) 6 8.63 (s, 1H), 8.19 (d, 1H), 8.04 (m, 1H), 7.87
(m, 2H), 7.66 (m,
2H), 7.52 ¨ 7.39 (m, 6H), 5.50 (m, 2H), 5.32 (s, 2H), 5.16 (m, 1H), 4.12 (m,
1H), 3.80 (m, 4H), 3.66
(s, 6H), 3.43 (m, 4H), 3.23 (s, 3H), 2.72-1.99 (m, 9H), 1.56 (d, 3H), 1.29 (m,
(d, 3H).
Example NQ
¨0 N
7-'01 Ili Boc ___________________________
2-y1)-1,11-dihydroisochromeno[43.:6,71naphtho[1,2-
0 H 1. HCI, Et0H, 60 C
7N,7N AI N
xo-U H ,0
tert-butyl (2S)-2-[9-(2-{(2S,5S)-14N-(methoxycarbony1)-L-valy1]- 0 H
5-methylpyrrolidin-2-y11-1H-imidazol-5-y1)-3,11-
¨0n
\ = j\ N
N N N
1-1'N
methyl {(2S)-1-[(2S,5S)-2-(5-{2-[(2S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-
phenylacetyl}pyrrolidin-2-y1]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
c1imidazol-9-y1}-1H-imidazol-2-y1)-5-methylpyrrol
idin-1-y1]-3-methy1-1-oxobutan-2-yl}carbamate
Methyl 1(2S)-1-[(2S,5S)-2-(5-{2-[(25)-1-{(2R)-2-1(methoxyearbonyl)amino1-2-
phenylacetyl}pyrrolidin-2-y1]-1,11-dihydroisochromeno14',3%6,71naphtholl,2-
1H-imidazol-2-y1)-5-methylpyrrolidin-1-y11-3-methyl-1-oxobutan-2-ylicarbamate
example LQ with
the following modification. During the Suzuki coupling, (2S)-1-[(2S,5S)-2-(5-
iodo-1H-imidazol-2-
y1)-5-methylpyrrolidin-l-y1]-2-[(1-methoxyethenyl)amino]-3-methylbutan- I -one
(2S)-1-[(2S)-2-(5-bromo-1 H-imidazol-2-yppyrrolidin-1 -y1]-24( 1 -
methylbutan-1 -one. The crude material was purified by preparative HPLC to
[(2S,5S)-2-(5-12-[(25)-1 -{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl
pyrrolidin-2-y1]-1,11 -
y1]-3-methyl-1 -oxobutan-2-ylIcarbamate as a white solid (110 mg, 0.131 mmol,
57 A). 'H NMR
(400 MHz, cd3od) ö 8.65 (s, 1H), 8.21 (d, 1H), 8.04 (m, 2H), 7.91 (s, 1H),
7.81 (m, 1H), 7.67 (m, 2H),
7.46 (m, 6H), 5.59 (s, 1H), 5.50 (dd, 1H), 5.33 (s, 2H), 5.22 ¨ 5.09 (m, 1H),
1H), 3.65 (m, 6H), 3.52 ¨ 3.37 (m, 2H), 2.60¨ 1.89 (m, 11H), 1.56 (d, 3H),
1.29 (d, 1H), 0.99 (d, 3H),
0.88 (d, 3H).
Example NR
\ = ly? 1. HCI, Et0H, 60 C
N N N b0C 2. 0
tert-butyl (25)-249-(2-{(2S,55)-1-[N-(methoxycarbony1)-L-
H,0 N)Lok
valy1]-5-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-3,11-
yllpyrrolidine-1-carboxylate COMU, DIPEA, DMF, RT
---\s'¨fo \ N
-N N HCI, Dioxane
H' Boc
methyl {(2S)-1-[(25,5S)-2-(5-{2-[(2S)-1-{(2R)-2-[(tert-butoxycarbonyl)amino]-
2-phenylacetyllpyrrolidin-2-y11-3,11-
dihydroisochromeno[4',3.:6,7]naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-2-y1)-
5-methylpyrrolidin-1-y11-3-methy1-1-oxobutan-2-yl)carbamate
Nl)\¨ 0
methyl [(25)-1-{(2S,55)-245-(2-{(25)-1-[(2R)-2-amino-2-phenylacetyl]pyrrolidin-
2-y1}-
1,11-dihydroisochromeno[4',3':6,71naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-
methylpyrrolidin-1-y1}-3-methyl-1-oxobutan-2-ylicarbamate
Methyl 1(2S)-1-{(2S,5S)-2-15-(2-1(2S)-1-1(2R)-2-amino-2-
phenylacetyl]pyrrolidin-2-y1}-1,11-
dihydroisochromeno[4',3':6,71naphtho11,2-diimidazol-9-y1)-1H-imidazol-2-y11-5-
methylpyrrolidin-1-y11-3-methy1-1-oxobutan-2-ylicarbamate
The synthesis of this compound was prepared according to Example NQ with the
modifications. During the amide coupling, (R)-2-(tert-butoxycarbonylamino)-2-
was used in lieu of (R)-2-(methoxycarbonylamino)-2-phenylacetic acid. This was
then treated with
an excess of hydrochloric acid (15 mL, 4.0 M in Dioxane) for 2 hours. The
crude product was
purified by HPLC to provide methyl [(2S)-1-{(2S,5S)-245-(2-{(2S)-1-[(2R)-2-
amino-2-
phenylacetyl]pyrrolidin-2-y11-1,11-dihydroisochromeno[41,31:6,7]naphtho [1,2-
d]imidazol-9-y1)-1H-
imidazol-2-y1]-5-methylpyrrolidin-1-y11-3-methy1-1-oxobutan-2-yl]carbamate as
a white solid (153
mg, 0.196 mmol, 74%). '14 NMR (400 MHz, cd3od) 5 8.63 (s, 1H), 8.20 (d, 1H),
7.99 (m, 1H), 7.93
(m, 2H), 7.80 (m, 2H), 7.72 ¨7.64 (m, 2H), 7.63 ¨7.52 (m, 5H), 5.52 (dd, 1H),
2H), 5.21 ¨5.10 (m, 1H), 4.80 (m, 2H), 4.14 (m, 1H), 4.02 (m, 1H), 3.75 (s,
1H), 3.67 (s, 3H), 3.12
(dd, 1H), 2.72 ¨ 2.13 (m, 7H), 2.00 (m, 3H), 1.56 (d, 3H), 1.30 (d, 1H), 0.98
(d, 3H), 0.88 (d, 3H).
Example OE
TFA 0
H0)(1HCO2Me
HATU, DIPEA
EtOf _______________________________________________ DMF
(2S,5S)-ethyl 5- (S)-2-
methylpyrrolidine-2- (methoxycarbonylamino)
carboxylate-TFA -3-methylbutanoic acid
NHCO2Me NHCO2Me
0r\t: LiOH 0
Et0/ \¨/ H20/Me0H HO
(2S,5S)-ethyl 1-((S)-2- (2S,5S)-1-((S)-2-
(methoxycarbonylamino)-3- (methoxycarbonylamino)-3-
methylbutanoyI)-5- methylbutanoyI)-5-
methylpyrrolidine-2-carboxylate methylpyrrolidine-2-carboxylic acid
(2S,5S)-Ethyl 14(S)-2-(methoxycarbonylamino)-3-methylbutanoy1)-5-
(2S,5 S)-Ethyl 5-methylpyrrolidine-2-carboxylate-TFA (10.0 g, 39.3 mmol), (S)-
(methoxycarbonylamino)-3-methylbutanoic acid (6.88 g, 39.3 mmol) and HATU
(14.9 g, 39.3 mmol)
were combined in DMF (100 mL) and DIPEA (15.0 mL, 86.5 mmol) was added. After
stirring for 1 h
at RT, the reaction mixture was diluted with Et0Ac. The organic phase was
washed successively with
10% HC1, saturated aqueous NaHCO3 and brine, then dried over MgSO4, filtered
under reduced pressure to afford (2S,5S)-ethyl 1-((S)-2-(methoxycarbonylamino)-
3-methylbutanoy1)-
5-methylpyrrolidine-2-carboxylate. The crude material was carried on without
further purification.
(2S,5S)-14(S)-2-(Methoxycarbonylamino)-3-methylbutanoy1)-5-methylpyrrolidine-2-
carboxylate (39.3 mmol, assuming complete conversion from the previous
transformation) was
suspended in Me0H (200 mL) and aqueous LiOH (1.0 M, 100 mL, 100 mmol) was
added. The
reaction mixture was stirred o/n, then concentrated under reduced pressure to
remove most of the
Me0H. The aqueous solution was washed 2x with DCM before being acidified to pH-
1-2 with 10%
HC1. The acidic aqueous phase was then extracted 5x with Et0Ac. The combined
Et0Ac extracts
were dried over MgSO4filtered and concentrated under reduced pressure to
afford (2S,5S)-1-((S)-2-
(Methoxycarbonylamino)-3-methylbutanoy1)-5-methylpyrrolidine-2-carboxylic acid
(6.89 g, 56%
over 2 steps).
Example OF
0 vinyltrifluoroborate, 0
Cl 11 =
Pd(OAc)2, SPhos, K2CO3
propanol __ = / = So
(reflux)
3-chloro-10,11-dihydro-5H- 3-viny1-10,11-dihydro-5H-
0 rs Boc
1. NBS 2 N Cs2CO3
H20/THF/DMS0 0 0 ____________________________ =
=2. Mn02, DCM Br
OMe 2-Me-THF
3-(2-bromoacetyI)-10,11-dihydro-5H- (2S,4S)-1-(tert-butoxycarbonyI)-
pyridinium tribromide,
N) 0 ao= = 0 DCM/Me0H
Boc =
(2S,4S)-1-tert-butyl 2-(2-oxo-2-(8-oxo-8,9,10,11-
tetrahydro-5H-dibenzo[c,g]chromen-3-yl)ethyl) 4-
(methoxymethyl)pyrrolidine-1,2-dicarboxylate
NHCO2Me
Me010 01)7
_______________ 0 0
Boc = Br
HO/ 2-
MeTHF;
(2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,g]chromen-3-y1)-2-oxoethyl) 1-tert-butyl 4-
(2S5S)-1-((s)-2-
methylbutanoyI)-5-methylpyrrolidine-2-
MeO 0
NH40Ac,
N3 0 p 0 0, N 2-methoxyethanol
Boc 0)\-- ______________ PhMe; __ =
(2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoy1)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-
dibenzo[c,g)chromen-3-y1)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-
Me02C1-111....<
=0
Boc NI / \N I Mn02
N DCM
tert-butyl (2S,4S)-245-(2-{(2S,5S)-14N-(methoxycarbony1)-L-
valy1]-5-methylpyrrolidin-2-y1}-1,4,5,11-
tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1)-
1H-imidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate
Me02CHNI)_.<
.?""11)---1-N
N I N 1. HCl/dioxane; DCM
Boc / I 2. HATU, DIPEA, DMF
).L../NHCO2Me (2S 3S)-2-
tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyI)-L- HO
valyI]-5-methylpyrrolidin-2-y1}-1,11- -3-methylpentanoic
1H-imidazol-2-y1]-4-(methoxymethyl)pyrrolidine-1-carboxylate
MeO2CHN
\----14N¨N Ai¨L
N V. IN
Me02CHN 0
methyl {(2S,3S)-1-[(2S,4S)-2-(5-{2-[(2S,5S)-1-{(2S)-2-
[(methoxycarbonypamino]-3-methylbutanoy1}-5-methylpyrrolidin-2-y1]-1,11-
y1)-4-(methoxymethyl)pyrrolidin-1-y1]-3-methyl-1-oxopentan-2-yl}carbamate
3-Vinyl-10,11-dihydro-5H-dibenzolc,gjchromen-8(9H)-one
A 3-neck oven-dried 500 mL round-bottom flask was cooled under Ar, then
charged with 3-
Chloro-10,11-dihydro-5H-dibenzo[c,g1chromen-8(9H)-one (12.0 g, 42.1 mmol),
vinyltrifluoroborate (8.47 g, 6.32 mmol), Pd(OAc)2 (473 mg, 2.11 mmol), SPhos
(1.74 g, 4.25 mmol),
K2CO3(17.5 g, 126 mmol) and anhydrous propanol (120 mL). The reaction mixture
was sparged with
Ar for 16 min, then heated to reflux for 5.5 h. Upon completion, the reaction
mixture was cooled to
RT and concentrated under reduced pressure. The crude residue was suspended in
DCM, then washed
with H20 and brine. The organic solution was dried over MgSO4, filtered and
reduced pressure. The resulting residue was further purified via silica plug,
eluting with DCM to
afford 3-vinyl-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (10.2 g, 87%).
3-(2-Bromoacety1)-10,11-dihydro-5H-dibenzoic,gIchromen-8(9H)-one
3-Vinyl-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (9.98 g, 36.1 mmol) was
dissolved in a stirred solution of THF (70 mL), DMSO (70 mL) and H20 (35 mL).
NB S (6.75 g, 37.9
mmol) was added in a single portion and the reaction mixture was stirred at RT
for 33 min. Upon
completion, the reaction medium was diluted with Et0Ac and washed twice with
H20 and once with
brine. The organic phase was dried over MgSO4, filtered and concentrated under
reduced pressure.
The resulting crude bromohydrin was suspended in DCM (200 mL) and treated with
activated Mn02
(62.7 g, 722 mmol). After stirring for 15 h at RT, the reaction mixture was
filtered over celite and the
filter cake was rinsed several times with DCM. The combined filtrate (-400 mL)
was treated with
Me0H (-100 mL) and the mixture was gradually concentrated under reduced
pressure, causing solid
material to precipitate from solution. When the liquid volume reached -200 mL,
the solid was filtered
off and rinsed with Me0H. The concentration/precipitation/filtration/rinsing
sequence was performed
2x more, resulting in the collection of 3 crops of powdered 3-(2-bromoacety1)-
10,11-dihydro-5H-
dibenzo[c,g]chromen-8(9H)-one (7.49 g, 56% over 2 steps).
(4S)-1-tert-Butyl 2-(2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-
dibenzolc,glchromen-3-yl)ethyl) 4-
(methoxymethyl)py rrolidine-1,2-dica rboxylate
3-(2-Bromoacety1)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (7.47 g, 20.1
mmol)
and (2S,4S)-1-(tert-butoxycarbony1)-4-(methoxymethyl)pyrrolidine-2-carboxylic
acid (5.22 g, 20.1
mmol) were suspended in 2-Me-THF (75 mL) and treated with Cs2CO3(3.27 g, 10.1
mmol). After
stirring 4 h at RT, the reaction mixture was diluted with diluted with DCM.
The organic layer was
washed with H20. The aqueous layer was then back extracted 2x with DCM. The
combined organics
purified by silica column chromatography (10% to 50% Et0Ac/DCM) to afford (4S)-
1-tert-butyl 2-
(2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)ethyl) 4-
(methoxymethyl)pyrrolidine-1,2-dicarboxylate (7.73 g, 70%).
(2S,4S)-2-(2-(9-Bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzofc,gIchromen-3-y1)-
tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate
(4 S)-1-tert-Butyl 2-(2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,g]chromen-3 -
yl)ethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (7.66 g, 13.9 mmol)
was dissolved in a
solution of DCM (100 mL) and Me0H (40 mL), then treated with pyridinium
tribromide (4.90 g, 15.3
mmol). After stirring at RT for 1.75 h, the reaction mixture was diluted with
DCM and washed
successively with 10% HC1, saturated aqueous NaHCO3 and brine. The organic
phase was dried over
MgSO4, filtered and concentrated under reduced pressure and the crude material
was carried on
without further purification.
(2R,4R)-1-tert-Butyl 2-(2-(94(2S,5S)-14(S)-2-(methoxycarbonylamino)-3-
methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzolc,gichromen-3-y1)-2-
oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate
(2 S,4 S)-2-(2-(9-Bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-
oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (8.76 g,
13.94 mmol) was
treated with a solution of (2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-
methylpyrrolidine-2-carboxylic acid (6.85 g, 23.92 mmol) in 2-Me-THF (70 mL)
and Cs2CO3 (3.63 g,
11.15 mmol). The stirred reaction mixture was heated to 50 C for 20 h, then
cooled to RT and diluted
with Et0Ac. The organic phase was washed with H20 and brine, then dried over
MgSO4, filtered and
chromatography (0% to 30% Me0H/Et0Ac) to afford (2R,4R)-1-tert-butyl 2-(2-(9-
((2S,5S)-1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoy1)-5-methylpyrrolidine-2-carbonyloxy)-8-
oxo-8,9,10,11-
tetrahydro-5H-dibenzo[c,g]chromen-3-y1)-2-oxoethyl) 4-
(methoxymethyl)pyrrolidine-1,2-
dicarboxylate (10.47 g, 90%).
tert-Butyl (2S,4S)-2-15-(2-{(2S,5S)-1-IN-(methoxycarbony1)-L-valy1]-5-
1,4,5,11-tetrahydroisochromeno14',3%6,71naphtho[1,2-djimidazol-9-y1)-1H-
5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,g]chromen-3-y1)-2-
oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (10.47 g, 12.56 mmol)
and NH40Ac (50.9
g, 660 mmol) were suspended in a solution of 10:1 PhMe/2-methoxyethanol (132
mL). The stirred
reaction mixture was heated to 110 C for 4.5 h, then cooled to RT and diluted
with Et0Ac. The
organic phase was washed 3x with saturated aqueous NaHCO3, then dried over
chromatography (0% to 30% Me0H/Et0Ac) to afford tert-butyl (2S,4S)-245-(2-
(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y11-1,4,5,11-
tetrahydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y1]-
(methoxymethyppyrrolidine-1-carboxylate (8.33 g, 84%).
tert-Butyl (2S,4S)-2-15-(2-{(2S,5S)-1-IN-(methoxycarbony1)-L-valy111-5-
1,11-dihydroisochromeno14',3%6,71naphthol1,2-diimidazol-9-y1)-1H-imidazol-2-
(methoxymethyppyrrolidine-1-carboxylate
yl -1,4,5,11-tetrahydroisochromeno[41,31:6,71naphtho[1,2-d]imidazol-9-y1)-1H-
imidazol-2-y11-4-
(methoxymethyppyrrolidine- I -carboxylate (8.33 g, 1.049 mmol) was suspended
in DCM and
activated Mn02 (55.0 g, 630 mmol) was added in a single portion. After 13 h,
Me0H (200 mL) was
added and the slurry was filtered over celite. The filter cake was washed with
Me0H (600 mL) and
the filtrate was concentrated under reduced pressure. The crude material was
(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-yll -1,11-
dihydroisochromeno[4',31:6,7]naphtho[1,2-djimidazol-9-y1)-1H-imidazol-2-y1]-4-
(methoxymethyppyrrolidine-l-carboxylate (4.85 g, 58%).
Methyl {(2S,3S)-1-1(2S,4S)-2-(5-12-1(2S,5S)-1-{(2S)-2-(methoxycarbonyl)aminol-
methylbutanoy1}-5-methylpyrrolidin-2-y11-1,11-
dihydroisochromeno[4',31:6,7]naphtholl,2-
dlimidazol-9-y1}-1H-imidazol-2-y1)-4-(methoxymethyl)pyrrolidin-1-y11-3-methyl-
1-oxopentan-2-
yllearbamate
y11-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-dlimidazol-9-y1)-1H-imidazol-
(methoxymethyppyrrolidine- 1 -carboxylate (179 mg, 0.226 mmol) was dissolved
in DCM (4 mL) and
HC1 (4.0 M in dioxane, 1 mL) was added. The reaction mixture was stirred for 1
h at RT then
concentrated under reduced pressure. The resulting residue was treated with
(methoxycarbonylamino)-3-methylpentanoic acid (51 mg, 0.27 mmol), HATU (95 mg,
0.25 mmol),
DMF (2 mL) and DIPEA (0.39 mL, 2.3 mmol). After stirring for 6 min, the
reaction was quenched
with H20, filtered and purified by reverse phase HPLC to afford methyl
{(2S,3S)-1-[(2S,4S)-2-(5-12-
R2S,5S)-1-{(2S)-2-Rmethoxycarbonypamino]-3-methylbutanoy11-5-methylpyrrolidin-
(methoxymethyl)pyrrolidin-l-y1]-3-methyl-l-oxopentan-2-ylIcarbamate (116 mg,
59%). MS (ESI)
adz 864 [M + H]. NMR (400 MHz, ed3od) 6 8.57 (d, J¨ 14.7 Hz, 1H), 8.45 (s,
1H), 8.20 (d, J-
14.4 Hz, 1H), 8.15 ¨7.98 (m, 2H), 7.91 (dd, J= 21.8, 14.1 Hz, 2H), 7.85 ¨ 7.69
(m, 2H), 7.69 ¨ 7.48
(m, 2H), 5.42 ¨ 5.12 (m, 5H), 4.34 (dd, J= 22.3, 13.7 Hz, 1H), 4.30 ¨ 4.10 (m,
2H), 3.87 ¨ 3.73 (m,
1H), 3.73 ¨3.63 (m, 7H), 3.62 ¨ 3.48 (m, 2H), 3.48 ¨ 3.38 (m, 4H), 3.35 (s,
2.70 ¨ 2.55 (m, 2H), 2.55 ¨2.20 (m, 2H), 2.20¨ 1.91 (m, 3H), 1.77 (d, J 42.0
Hz, 1H), 1.65 (d, J=
6.6 Hz, 3H), 1.43 (t, J= 24.6 Hz, 1H), 1.28 (d, J= 6.2 Hz, 1H), 1.23¨ 1.01 (m,
3H), 0.98 (d, J= 6.6
Hz, 3H), 0.90 (dd, J= 13.1, 5.9 Hz, 10H).
Example OG
0 Me000CI, 0
HO'NH2 NaOH HO
)..1\1HCO2Me
ix*
H20/
(2S,3R)-2-amino-3- (2S,3R)-2-(methoxycarbonylamino)-
methylpentanoic acid 3-methylpentanoic acid
Me02CH11...<
jy 0
0 1. HCl/dioxane; DCM
Boc * \N I 2. HATU, DIPEA, DMF
= N 0
NHCO2 Me (2S,3R)-2-
tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbony1)-L- H
valy1]-5-methylpyrrolidin-2-y11-1,11- -3-methylpentanoic
Me02CH11....<
A& Ark rh\
N - \
Me02CHN
methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-14N-(methoxycarbony1)-L-
alloisoleucyl]-4-
(methoxymethyppyrrolidin-2-y1]-1H-imidazol-5-y1}-1,11-
d]imidazol-2-y1)-5-methylpyrrolidin-1-y1]-3-methy1-1-oxobutan-2-yl}carbamate
Methyl {(2S)-1-[(2S,5 S)-2-(9-{2-[(2S,4S)-14N-(methoxyearbony1)-L-
(methoxymethyl)pyrrolidin-2-y1]-1 H-imidazol-5-y11-1,11-
d]imidazol-2-y1)-5-methylpyrrolidin-1-y1]-3-methyl-l-oxobutan-2-ylIcarbamate
was prepared from
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y1]-4-
(methoxymethyl)pyrrolidine- 1 -carboxylate by the same method employed in the
synthesis of
{(2S,3S)-1-[(2S,4S)-2-(5-{2-[(2S,5S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
dlimidazol-9-y11-1H-
imidazol-2-y1)-4-(methoxymethyl)pyrrolidin-1-y1]-3-methy1-1-oxopentan-2-
yl}carbamate, replacing
(2S,3S)-2-(methoxycarbonylamino)-3-methylpentanoic acid with (2S,3R)-2-
(methoxycarbonylamino)-3-methylpentanoic acid. MS (ESI) m/z 864 [M + F1] . 11-
1NMR (400 MHz,
cd3od) ö 8.62 ¨ 8.41 (m, 1H), 8.22 (s, 1H), 8.07 (dt, J= 20.1, 10.0 Hz, 1H),
7.89 (dt, J= 35.6, 15.6
Hz, 2H), 7.77 (dd, J= 20.3, 7.0 Hz, 2H), 7.68 ¨7.48 (m, 2H), 5.95 (d, J= 5.0
Hz, 1H), 5.42 ¨ 5.13
(m, 4H), 4.47 (t, J= 5.5 Hz, 1H), 4.40 ¨ 4.09 (m, 2H), 3.80 ¨ 3.73 (m, 1H),
3.73 ¨3.62 (m, 6H), 3.57
(dt, J= 16.1, 9.7 Hz, 2H), 3.40 (s, 3H), 3.34 (d, J= 7.5 Hz, 1H), 2.81 (dd, J=
18.4, 12.5 Hz, 1H), 2.63
(td, J= 13.3, 6.8 Hz, 2H), 2.55 ¨ 2.18 (m, 2H), 2.16 ¨ 1.77 (m, 4H), 1.65 (d,
J= 6.6 Hz, 3H), 1.50 ¨
1.31 (m, 1H), 1.26 (dd, J= 15.6, 6.7 Hz, 2H), 1.17¨ 1.03 (m, 2H), 0.98 (dd, J=
6.7, 4.5 Hz, 5H), 0.89
(dd, J= 15.5, 7.8 Hz, 3H), 0.86 ¨ 0.74 (m, 3H).
Example OH
Me02CF-1
.y.õ()"=10
Boc / 2. COMU, DIPEA, DMF
õLNHCO2Me
HO -
tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1)-1H-
imidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate (R)-2-
Me02C1-11
methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S,5S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoy11-5-methylpyrrolidin-2-y1]-1,4,5,11-
d]imidazol-9-y1}-1H-imidazol-2-y1)-4-(methoxymethyppyrrolidin-1-y1]-2-oxo-1-
Methyl 1(1R)-2-1(2S,4S)-2-(5-12-1(2S,5S)-1-{(2S)-2-1(methoxyearbonyl)aminol-3-
methylbutanoy1}-5-methylpyrrolidin-2-ylj-1,4,5,11-
tetrahydroisochroment0',3':6,71naphtho11,2-dlimidazol-9-y1}-1H-imidazol-2-y1)-
(methoxymethyl)pyrrolidin-l-y11-2-oxo-1-phenylethylicarbamate
y11-1,4,5,11-tetrahydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-
HC1 (4.0 M in dioxane, 2.0 mL, 8.0 mmol) was added. After stirring at RT for
30 min, the solution
was concentrated under reduced pressure. The residue was treated with (R)-2-
(methoxycarbonylamino)-2-phenylacetic acid (29 mg, 0.141 mmol), COMU (60 mg,
0.141 mmol),
DMF (3.0 mL) and DIPEA (0.223 mL, 1.28 mmol). After stirring at RT for 20 min,
mixture was diluted with Et0Ac. The organic solution was washed with saturated
aqueous NaHCO3
and brine, then dried over MgSO4, filtered and concentrated under reduced
material was purified by reverse-phase HPLC to afford methyl 1(1R)-2-[(2S,4S)-
2-(5-12-[(2S,5S)-1-
{ (2S)-2-Rmethoxycarbonyl)amino]-3 -methylbutanoyl} -5 -methylpyrrolidin-2-y1]-
tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1 -1H-imidazol-2-y1)-
(methoxymethyppyrrolidin- I -y1]-2-oxo- 1 -phenylethyl carbamate as the bis-
TFA salt (82.4 mg, 60%).
MS (ESI) m/z 866 [M + H]. 'H NMR (400 MHz, cd3od) 6 7.94 - 7.67 (m, 4H), 7.59
(d, J= 9.1 Hz,
I H), 7.52 (s, 1H), 7.48 -7.33 (m, 4H), 7.11 (d, J= 18.7 Hz, 1H), 5.68 (d, J=
6.3 Hz, 1H), 5.48 - 5.33
(m, 1H), 5.23 (dd, J= 24.1, 15.7 Hz, 1H), 5.17 - 5.03 (m, 3H), 4.22 (dd, J=
17.0, 9.6 Hz, 1H), 4.16 -
4.01 (m, 1H), 3.91 (d, J= 24.1 Hz, 1H), 3.83 -3.68 (m, 1H), 3.68 - 3.59 (m,
3H), 3.59 - 3.49 (m,
3H), 3.38 (ddd, J= 15.9, 9.6, 5.7 Hz, 2H), 3.28 -3.14 (m, 5H), 3.10 (dd, J=
14.0, 8.2 Hz, 1H), 3.00
(dd, J= 17.8, 9.6 Hz, 1H), 2.92 (dd, J= 14.5, 6.7 Hz, 1H), 2.73 -2.41 (m, 2H),
2.40 - 2.11 (m, 2H),
2.11 - 1.83 (m, 2H), 1.54 (t, J= 9.7 Hz, 2H), 1.24 (d, J= 6.2 Hz, 1H), 1.06
(t, J= 8.0 Hz, 1H), 0.99
(d, J= 6.8 Hz, 1H), 0.94 (d, J= 6.6 Hz, 2H), 0.85 (d, J= 6.7 Hz, 2H).
Example 'DI
Me0 0
0 it, Ati o
Boc WBr
tetrahydro-5H-dibenzo[c,g]chromen-3-y1)-2-
Me0 (methoxymethyl)pyrrolidine-1,2-dicarboxylate
=0 1-1,137$1,t,
OMe 1. HCl/dioxane; DCM
Boc NI / \N I 2. HATU, DIPEA, DMF
)1xNHCO2Me
tert-butyl (2S,4S)-2-(5-{2-[(2S,4S)-1-(tert-butoxycarbony1)-4- HO (S)-2-
(methoxymethyl)pyrrolidin-2-yI]-1,11-
dihydroisochromeno[4',3:6,7]naphtho[1,2-d]imidazol-9-y11-1H- -3-
methylbutanoic acid
imidazol-2-y1)-4-(rnethoxymethyl)pyrrolidine-1-carboxylate
MeO2CHIl
EN1 JAL
W-- 191
4-(methoxymethyl)pyrrolidin-2-y11-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1}-
1H-imidazol-2-y1)-4-(methoxymethyl)pyrrolidin-1-y1]-3-methy1-1-oxobutan-2-
tert-Butyl (2S,4S)-2-(5-12-[(2S,45)-1-(tert-butoxycarbony1)-4-
y11-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-
(methoxymethyl)pyrrolidine- 1 -earboxylate was prepared from (2S,4S)-2-(2-(9-
bromo-8-oxo-
8,9,10,11 -tetrahydro-5H-dibenzo[c,g]chromen-3-yI)-2-oxoethyl) 1-tert-butyl 4-
(methoxymethyl)pyrrolidine-1,2-dicarboxylate by the same method employed in
the synthesis of tert-
butyl (2S,4S)-245-(2-{(25,5S)-14N-(methoxycarbony1)-L-valy1]-5-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y1]-4-
(methoxymethyl)pyrrolidine-l-carboxylate, replacing (2S,5S)-1-((S)-2-
methylbutanoy1)-5-methylpyrrolidine-2-carboxylic acid with (2S,4S)-1-(tert-
(methoxymethyl)pyrrolidine-2-carboxylic acid.
Methyl {(2S)-1-1(2S,4S)-2-(5-12-1(2S,4S)-1-{(2S)-2-1(methoxycarbonyl)am11101-3-
methylbutanoy1}-4-(methoxymethyl)pyrrolidin-2-y11-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-dlimidazol-9-y11-1H-imidazol-2-y1)-4-
(methoxymethyl)pyrrolidin-l-y11-3-methyl-l-oxobutan-2-ylIcarbamate
tert-Butyl (2S,4S)-2-(5- {2-[(2S,4S)-1-(tert-butoxycarbony1)-4-
y1]-1,11-dihydroisochromeno [41,31:6,71naphtho[1,2-d]imidazol-9-y11-1H-
(methoxymethyl)pyrrolidine-l-carboxylate (137 mg, 0.179 mmol) was dissolved in
DCM (5 mL) and
HC1 (4.0 M in dioxane, 1 mL) was added. After stirring at RT for 1.5 h, the
(methoxycarbonylamino)-3-methylbutanoic acid (69 mg, 0.39 mmol), HATU (149 mg,
DMF (2.0 mL) and DIPEA (0.31 mL, 1.8 mmol). After stirring for 15 min at RT,
the reaction mixture
was quenched with water and purified by HPLC to provide methyl {(2S)-1-
[(2S,4S)-2-(5-{2-[(2S,4S)-
1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoy11-4-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-4-
(methoxymethyppyrrolidin-1-y1]-3-methyl-l-oxobutan-2-ylIcarbamate (123 mg). MS
(ESI) ni/z 880
[M + 'H NMR (400 MHz, cd3od) S 8.48 (s, 1H), 8.05 (t, J= 11.2 Hz, 1H),
7.92 (dd, J= 19.7,
10.1 Hz, 2H), 7.74 (s, 2H), 7.59 ¨ 7.44 (m, 2H), 5.49 (s, 1H), 5.40 (dt, J=
16.3, 8.1 Hz, 1H), 5.31 ¨
5.15 (m, 3H), 4.47 ¨ 4.10 (m, 4H), 3.86 ¨ 3.44 (m, 12H), 3.39 (dd, J = 13.2,
7.1 Hz, 6H), 2.94 ¨ 2.57
(m, 4H), 2.25¨ 1.94 (m, 4H), 1.02¨ 0.82 (m, 12H).
Example OJ
Me0-?...NITT1
OH Bocr\ 1. HCl/dioxane; DCM
OMe lo
Boc NI / 410 / 2. HATU, DIPEA, DMF
,NHCO2Me (2S,3S)-2-
tert-butyl (2S,4S)-2-(5-{2-[(2S,4S)-1-(tert-butoxycarbonyI)-4-
(methoxymethyl)pyrrolidin-2-yI]-1,11- NO' -3-methylpentanoic
dihydroisochromeno[4',3':6,7]naphtho[1,2-djimidazol-9-y11-1H-
imidazol-2-y1)-4-(methoxymethyl)pyrrolidine-1-carboxylate
Me02CHNt
0 FNisy
N 410 Alp OMe
methyl {(2S,3S)-1-[(2S,4S)-2-(5-{2-1(2S,4S)-1-{(2S,3S)-2-
methylpentanoy1}-4-(methoxymethyppyrrolidin-2-y1]-1,11-
(methoxymethyppyrrolidin-1-y1]-3-methy1-1-oxopentan-2-ylIcarbamate
Methyl {(2S,3S)-1-[(2S,4S)-2-(5-{2-[(2S,4S)-1-{(2S,3S)-2-
methylpentanoy11-4-(methoxymethyppyrrolidin-2-y1]-1,11-
(methoxymethyl)pyrrolidin- 1 -y1]-3-methyl-l-oxopentan-2-ylIcarbamate was
prepared from tert-Butyl
(2S,4S)-2-(5-12-[(2S,4S)-1-(tert-butoxycarbony1)-4-(methoxymethyppyrrolidin-2-
(methoxymethyppyrrolidine-1-carboxylate using the same method employed in the
methyl {(2S)-1-[(2S,4S)-2-(5-{2-[(2S,4S)-1-1(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoy11-
4-(methoxymethyppyrrolidin-2-y1]-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-
d]imidazol-9-y11-
1H-imidazol-2-y1)-4-(methoxymethyl)pyrrolidin-1-y1]-3-methyl-l-oxobutan-2-y1
carbamate,
replacing with (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid with (2S,3S)-
(methoxycarbonylamino)-3-methylpentanoic acid. MS (ESI) /viz 908 [M + H].
Example OK
o = = 0
Me02CHII
\1 2. COMU, DIPEA, DMF
Boc 411 ID. IN 0
HOJNHCO2Me
tert-butyl (2S,4S)-2-[5-(2-{(2S)-1-[N-
(methoxycarbony1)-L-valyl]pyrrolidin-2-y1}-1,4,5,11- Ph
tetrahydroisochromeno[4',31:6,7]naphtho[1,2- (R)-2-
d]imidazol-9-y1)-1H-imidazol-2-y1]-4- (methoxycarbonylamino)
(methoxymethyl)pyrrolidine-1-carboxylate -2-phenylacetic acid
Me02CHril
0 H N
P h, Nc)
/ N
methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyl}pyrrolidin-2-y1]-1,4,5,11-
tetrahydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-2-
y1)-4-(methoxymethyppyrrolidin-1-y1]-2-oxo-1-phenylethyl}carbamate
tert-Butyl (2S,4S)-245-(2-1(2S)-14N-(methoxycarbony1)-L-valyl]pyrrolidin-2-y11-
1,4,5,1 1-
tetrahydroisochromeno[41,3':6,7]naphtho[l ,2-d]imidazol-9-y1)-1 H-imidazol-2-
y1]-4-
(methoxymethyl)pyrrolidine-l-carboxylate was synthesized from (2S,4S)-2-(2-(9-
8,9,1 0,1 1 -tetrahydro-5 H-dibenzo[c,gichromen-3-y1)-2-oxoethyl) 1 -tert-
(methoxymethyl)pyrrolidine-1,2-dicarboxylate using the same methods described
for the synthesis of
1 ,4,5,1 1 -tetrahydroisochromeno[4',3 ':6,7]naphtho[l ,2-d]imidazol-9-y1)-1 H-
(methoxymethyl)pyrrolidine-l-carboxylate, substituting (S)-1-((S)-2-
methylbutanoyl)pyrrolidine-2-carboxylic acid for (2S,5S)-1-((S)-2-
methylbutanoy1)-5-methylpyrrolidine-2-carboxylic acid.
Methyl {(1R)-2-[(2S,4S)-2-(5-12-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyllpyrrolidin-2-y1]-1,4,5,11-
tetrahydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-9-
y11-1H-imidazol-2-y1)-4-(methoxymethyppyrrolidin-1-y11-2-oxo-1 -phenylethyl }
carbamate was
synthesized from tert-butyl (2S,4S)-2-[5-(2-{(2S)-14N-(methoxycarbony1)-L-
valyl]pyrrolidin-2-y11-
1,4,5,11-tetrahydroisochromeno[4',3':6,7]naphtho[1,2-dlimidazol-9-y1)-1H-
(methoxymethyppyrrolidine- 1 -carboxylate using the same method employed for
the synthesis of
methyl {(1R)-2-{(2S,4S)-2-(5-12-[(2S,5S)-1-{(2S)-2-Rmethoxycarbonyl)amino]-3-
5-methylpyrrolidin-2-y1]-1,4,5,11-tetrahydroisochromeno[41,31:6,7]naphtho[1,2-
imidazol-2-y1)-4-(methoxymethyl)pyrrolidin-l-y1]-2-oxo-l-phenylethyllcarbamate
substituting tert-
1 0 butyl (2S,4S)-245-(2-1(2S)-14N-(methoxycarbony1)-L-valyl]pyrrolidin-2-
y11-1,4,5,1 I-
tetrahydroisochromeno[41,31:6,7]naphtho [1,2-d]imidazol-9-y1)-1H-imidazol-2-
(methoxymethyppyrrolidine-l-carboxylate for tert-Butyl (2S,4S)-2-[5-(2-
tetrahydroisochromeno[4',31:6,7]naphtho [1,2-d]imidazol-9-y1)-1H-imidazol-2-
(methoxymethyl)pyrrolidine-l-carboxylate. MS (ESI) m/z 871 [M + H]t 'H NMR
(400 MHz, cd3od)
6 7.87 (ddd, J¨ 20.5, 15.3, 6.8 Hz, 4H), 7.65 (s, 1H), 7.50 ¨7.38 (m, 5H),
7.17 (s, 1H), 5.41 (d, J=
24.5 Hz, 1H), 5.28 (t, J¨ 8.3 Hz, 1H), 5.20 (d, J= 7.3 Hz, 3H), 4.24 (d, J=
7.2 Hz, 1H), 4.12 (d, J-
10.3 Hz, 1H), 4.03 ¨3.94 (m, 1H), 3.89 (dd, J¨ 15.4, 8.6 Hz, 1H), 3.77 (t, J=
9.6 Hz, 1H), 3.72 ¨
3.64 (m, 4H), 3.63 ¨3.52 (m, 4H), 3.43 (qd, J= 9.5, 5.6 Hz, 3H), 3.30 (s, 3H),
2.97 (dd, J= 11.6, 5.4 Hz, 2H), 2.59 (dt, J= 21.1, 7.8 Hz, 3H), 2.29 (s, 1H),
¨1.85 (m, 2H), 0.92 (dd, J= 15.8, 6.7 Hz, 6H).
Example OL
Me02CHI..<
)<)1 MnO
Boc N1 / 4104 DCM
tert-butyl (2S,4S)-245-(2-{(2S)-1-[N-(methoxycarbony1)-L-valyl]pyrrolidin-
2-y11-1,4,5,11-tetrahydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-
y1)-1 H-imidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate
Me02C1-111
1-N1
Boc N1 / ilk. IN
tert-butyl (2S,4S)-2-[5-(2-{(2S)-11N-(methoxycarbony1)-L-valylipyrrolidin-
2-y11-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-
imidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate
Me02CHI
Ph,
I /
H2N 0
methyl {(2S)-14(2S)-2-(9-(24(2S,4S)-11(2R)-2-amino-2-
phenylacetyl]-4-(methoxynnethyl)pyrrolidin-2-y1]-1H-imidazol-5-y1}-
1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-dlimidazol-2-
y1)pyrrolidin-1-y1]-3-methy1-1-oxobutan-2-yl}carbamate
tert-Butyl (2S,4S)-245-(2-{(2S)-14N-(methoxycarbony1)-L-valyl]pyrrolidin-2-yll-
1,11 -
dihydroisochromeno[41,3':6,71naphtho[ I ,2-d] imidazol-9-y1)- 1 H-imidazol-2-
(methoxymethyl)pyrrolidine-l-carboxylate was prepared according to the method
described for the
synthesis of tert-butyl (2S,4S)-245-(2-{(2S,5S)-14N-(methoxycarbony1)-L-valy1]-
methylpyrrolidin-2-y1 -1,1 1 -dihydroisochromeno[4',3':6,7]naphtho[l ,2-
d]imidazol-9-y1)-1 H-
imidazol-2-y1]-4-(methoxymethyppyrrolidine- 1 -carboxylate, substituting tert-
butyl (2S,4S)-2-[5-(2-
{ (2S)-1 [N-(methoxycarbonye-L-valyl]pyrrolidin-2-y1 -1 ,1 1 -
1 0 dihydroisochromeno[41,3':6,71naphtho[1,2-d]imidazol-9-y1)-1 H-imidazol-
1(2S,5S)-1-[N-
(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y11-1,4,5,1 1 -
tetrahydroisochromeno[41,3':6,7]naphtho [ 1,2-d]imidazol-9-y1)-1 H-imidazol-2-
(methoxymethyl)pyrrolidine-l-carboxylate.
Methyl {(2S)-1 -[(2S)-2-(9-{2-[(2 S,4S)- 1 -[(2R)-2-amino-2-phenylacety1]-4-
(methoxymethyppyrrolidin-2-y11- 1 H-imidazol-5-y11- 1,11 -
dihydroisochromeno[41,31:6,7]naphtho [1 ,2-
d]imidazol-2-yl)pyrrolidin- 1 -y1]-3 -methyl-1 -oxobutan-2-yll carbamate was
prepared according to the
method described for the synthesis of methyl (S)-1 -((2S,4S)-2-(2'-((2S,4S)-1 -
((R)-2-amino-2-
phenylacety1)-4-(methoxymethyppyrrolidin-2-y1)- 1H,1 1H-7,7'-binaphtho [1 ,2-
methylpyrrolidin-1 -y1)-3 -methyl-1 -oxobutan-2-ylcarbamate, substituting
methyl (S)- 1 -((2 S,4S)-2-(2'-
1 0 ((2 S,4 S)- 1 -((R)-2-tert-butoxycarbonylamino-2-phenylacety1)-4-
(methoxymethyppyrrolidin-2-y1)-
1 H, 1 'H-7,7'-binaphtho[1 ,2-d]imidazol-2-y1)-4-methylpyrrolidin-1 -y1)-3-
methyl- 1 -oxobutan-2-
ylcarbamate with
tert-butyl (2 S,4 S)-2- [5-(2- { (2S)- 1 -[N-(methoxycarbony1)-L-
valyl]pyrrolidin-2-y11- 1,11 -
dihydroisochromeno [41,31:6,7]naphtho[1 ,2-d]imidazol-9-y1)- 1 H-imidazol-2-
1 5 (methoxymethyl)pyrrolidine- 1 -carboxylate. MS (ESI) m/z 811 [M + H]*.
Example OM
0 gio -a- 0
3-(2-bromoacetyI)-10,11-dihydro-
5H-dibenzo[c,g]chromen-8(9H)-one
OMe Mn02
tert-butyl (2S,4S)-249-(2-{(2S,5S)-1-[N-(methoxycarbony1)-L-valy1]-5-
methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-1,4,5,11-
tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y11-4-
0 i.4 _ 8.41-N = AIL N OMe 1.
HCl/dioxane; DCM
o2. HATU, DIPEA, DMF IIIP-
H0).L,...,NHCO2Me
tert-butyl (2S,4S)-2-[9-(2-{(2S,5S)-1-[N-(methoxycarbonyI)- (2S,3R)-
L-valy1]-5-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-1,11- µ"µ'0 methoxy-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y11- I
(nnethoxycarbonyla
4-(methoxymethyl)pyrrolidine-1-carboxylate mino)butanoic acid
Me02CHN 0_
0 jOi .Nvom
N e
Me02CHN 0 N N
[(methoxycarbonyl)amino]butanoy1}-4-(methoxymethyl)pyrrolidin-211]-
1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1}-1H-
innidazol-2-y1)-5-methylpyrrolidin-1-y1]-3-methyl-1-oxobutan-2-yl}carbamate
tert-Butyl (2 S,4S)-219-(2-1(2 S,5 S)-1 -[N-(methoxycarbony1)-L-valy1]-5-
yl - I H-imidazol-5-y1)- 1,4,5,11 -tetrahydroisochromeno[41,31:6,7]naphtho[l
,2-d] imidazol-2-y1]-4-
(methoxymethyl)pyrrolidine- 1 -carboxylate was synthesized from 3-(2-
bromoacety1)- 1 0,1 1 -dihydro-
5H-dibenzo [c,g]chromen-8(9H)-one, by the same methods employed in the
synthesis of tert-butyl
(2S,4S)-245-(2-{(2S,5S)-14N-(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-
y11-1,4,5,1 1 -
tetrahydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-9-y1)-1 H-imidazol-2-
(methoxymethyl)pyrrolidine- 1 -carboxylate, substituting (2 S,5 S)- 1 -((S)-2-
1 0 methylbutanoy1)-5-methylpyrrolidine-2-carboxylic acid for (2S,4S)- 1 -
(tert-butoxycarbony1)-4-
(methoxymethyl)pyrrolidine-2-carboxylic acid and (2 S,4 S)- 1 -(tert-
(methoxymethyl)pyrrolidine-2-carboxylic acid for (2 S,5 S)-1 -((S)-2-
y11-1H-imidazol-5-y1)-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-
(methoxymethyppyrrolidine-1-carboxylate was prepared according to the method
synthesis of tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-14N-(methoxycarbony1)-L-
methylpyrrolidin-2-y11-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-
imidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate, substituting tert-
{(2S,5S)-14N-(methoxycarbony1)-L-valy11-5-methylpyrrolidin-2-y11-1H-imidazol-5-
y1)-1,4,5,11-
tetrahydroisochromeno[41,31:6,7]naphtho[1,2-djimidazol-2-y1]-4-
(methoxymethyppyrrolidine-l-
carboxylate for tert-butyl (2S,4S)-245-(2-{(2S,5S)-14N-(methoxycarbony1)-L-
1 0 methylpyrrolidin-2-y11-1,4,5,11-
tetrahydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-
imidazol-2-y1]-4-(methoxymethyppyn-olidine-1-carboxylate.
[(methoxycarbonyl)amino]butanoy11-4-(methoxymethyppyrrolidin-2-y11-1,11-
dihydroisochromeno[41,3':6,71naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-5-
y1]-3-methy1-1-oxobutan-2-yllcarbamate was prepared from tert-butyl (2S,4S)-2-
[9-(2-{(2S,5S)-14N-
(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y11-1H-imidazol-5-y1)-1,11-
carboxylate according to the same method described for the synthesis of methyl
(S)-1-((2S,4S)-2-(2'-
((2S,4S)-1-((2S,3R)-2-methoxycarbonylamino-3 -methoxybutanoy1)-4-
y1)-1H,l'H-7,7'-binaphtho[1,2-dlimidazol-2-y1)-4-methylpyrrolidin-1 -y1)-3 -
ylcarbamate, substituting (2S,4S)-tert-Butyl 2-(2'-((2S,4S)-1-((S)-2-
methylbutanoy1)-4-methylpyrrolidin-2-y1)-1H,l'H-7,71-binaphtho[1,2-dlimidazol-
(methoxymethyppyrrolidine- 1 -carboxylate with tert-butyl (2S,4S)-249-(2-
(methoxycarbony1)-L-valy11-5-methylpyrrolidin-2-y11-1H-imidazol-5-y1)-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-dlimidazol-2-y1]-4-
carboxylate. MS (ESI) m/z 866 [M + Hr. 'H NMR (400 MHz, cd3od) 8 8.44 (d, J=
19.8 Hz, 1H),
8.02 (t, J= 8.6 Hz, 2H), 7.98 ¨ 7.81 (m, 3H), 7.74 (dd, J= 22.2, 13.6 Hz, 2H),
5.79 (d, J= 6.0 Hz, 1H), 5.42 (dt, J= 43.3, 21.5 Hz, 2H), 5.31 ¨5.10 (m, 5H),
4.85 ¨4.70 (m, 1H),
4.52 (d, J= 3.8 Hz, 1H), 4.31 (t, J= 8.2 Hz, 1H), 4.17 (dd, J= 20.8, 8.8 Hz,
1H), 3.80 (dt, J= 19.0,
7.3 Hz, 2H), 3.73 ¨3.63 (m, 7H), 3.63 ¨3.49 (m, 3H), 3.39 (d, J= 9.7 Hz, 4H),
3.35 (s, 5H), 3.28 (d,
J= 4.4 Hz, 3H), 2.84 (d, J= 8.8 Hz, 1H), 2.72 (dd, J= 12.5, 6.6 Hz, 1H), 2.59
¨ 2.45 (m, 1H), 2.45 ¨
2.11 (m, 4H), 2.11¨ 1.82 (m, 2H), 1.56 (d, J= 6.6 Hz, 3H), 1.35 ¨ 1.21 (m,
1.10 ¨ 1.01 (m, 2H), 0.99 (d, J= 6.6 Hz, 3H), 0.91 (d, J= 6.7 Hz, 3H).
Example ON
AIL MIL FN-I M
N / w w ,
methyl {(2S)-1-R2S,4S)-2-(5-{2-R2S,5S)-1-{(2S,3S)-2-[(methoxycarbonyl)amino]-3-
methylpentanoy1}-4-(methoxymethyl)-2-y1]-1 ,1 1-
dihydroisochromeno[41,3':6,7]naphtho[1 ,2-d]imidazol-9-y1}-1 H-imidazol-2-y1)-
rnethylpyrrolidin-1-y1]-3-methyl-1-oxobutan-2-yl}carbamate
Methyl {(2S)-1-[(2S,4S)-2-(5-12-[(2S,5S)-1-{(2S,3S)-21(methoxycarbonypamino]-3-
methylpentanoy11-4-(methoxymethyl)-2-y1]-1 ,11 -dihydroisochromeno
[4',3':6,7]naphtho[1,2-
d]imidazol-9-y1}-1H-imidazol-2-y1)-5-methylpyrrolidin-1 -y1]-3-methyl- 1 -
was prepared according to the method described for the synthesis of methyl
{(2S,3S)-1-[(2S,4S)-2-(5-
{2-[(2S,4S)-1-{(2S,3S)-2-[(methoxycarbonyl)amino]-3-methylpentanoy11-4-
(methoxymethyppyrrolidin-2-y1]-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-
d] imidazol-9-y1 -
1H-imidazol-2-y1)-4-(methoxymethyl)pyrrolidin-l-y1]-3 -methyl-l-oxopentan-2-y1
I 0 substituting tert-butyl (2S,4S)-249-(2-{(2S)-14N-(methoxycarbony1)-L-
valyl]pyrrolidin-2-y11-1H-
imidazol-5-y1)-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y11-
(methoxymethyppyrrolidine-1-carboxylate for tert-Butyl (2S,4S)-215-(2-{(2S,5S)-
14N-
(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y11-1,11-
(methoxymethyl)pyrrolidine-1-carboxylate. MS (ESI) m/z 863 [M + . `1-1NMR
ö 8.43 (d, J= 24.6 Hz, 1H), 8.01 (dt, J= 16.1, 8.0 Hz, 1H), 7.95 ¨ 7.78 (m,
7.59 ¨ 7.41 (m, 2H), 5.79 (d, J= 5.8 Hz, 1H), 5.39 (dt, J= 46.2, 23.1 Hz, 1H),
4.85 ¨ 4.72 (m, 1H), 4.42 (t, J= 8.6 Hz, 1H), 4.31 (d, J= 7.9 Hz, 1H), 4.17
(dd, J= 19.7, 8.7 Hz, 1H),
3.81 (dd, J= 23.6, 13.3 Hz, 1H), 3.69 (d, J= 10.0 Hz, 5H), 3.60 (dd, J= 14.7,
7.8 Hz, 2H), 3.42 (s,
3H), 3.17 (d, J= 6.1 Hz, 1H), 3.07 (s, 1H), 2.99 ¨ 2.91 (m, 1H), 2.85 (s, 1H),
2.73 (dd, J=12.5, 6.4
Hz, 1H), 2.62 ¨ 2.48 (m, 1H), 2.45 ¨ 2.14 (m, 3H), 2.10 ¨ 1.91 (m, 2H), 1.83
(s, 1H), 1.57 (d, J= 6.6
Hz, 3H), 1.44 (d, J= 7.4 Hz, 1H), 1.34¨ 1.23 (m, 1H), 1.20¨ 0.96 (m, 5H), 0.90
(dt, J= 14.8, 6.7 Hz,
9H).
Boc,
0 1. HCl/dioxane. DCM
= W Atik I-Nlome 2. COMU, DIPEA, DMF /
\I
Me02CHN 0 A,,,,NHBoc
HO - (R)-2-(tert-
.75pxnayr. raocneyt ca mi Id ) - 2 -
tert-butyl (2S,4S)-2-[9-(2-{(2S)-14N-(methoxycarbony1)-L-
Ph b u t og
valyl]pyrrolidin-2-y1}-1H-imidazol-5-y1)-1,11-
dihydroisochromeno[4',3':6,7]naphthor ,2-dlimidazol-2-y1]-4-
BocHN
-iiiPh
AL\ A¨L
methyl {(2S)-1-[(2S)-2-(5-{2-[(2S,4S)-1-{(2R)-2-[(tert-
butoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyppyrrolidin-211]-
1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-cl]imidazol-9-y1}-1H-
imidazol-2-y1)pyrrolidin-1-y1]-3-methyl-1-oxobutan-2-yl}carbamate
H2N
(N(11-r-Ni FN-I/ 411 FN-1
methyl {(2S)-1-[(2S)-2-(5-{2-[(2S,4S)-1-[(2R)-2-amino-2-phenylacety1]-4-
(methoxymethyppyrrolidin-2-y1]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-9-y1}-1H-imidazol-2-y1)pyrrolidin-1-y1]-3-methyl-1-oxobutan-2-
Methyl { (2 S)-1 -[(2S)-2-(5 - { 2-[(2 S,4S)-1 -R2R)-2-amino-2-phenylacety11-4-
(methoxymethyppyrrolidin-2-y1]-1,1 1 -dihydro isochromeno[4',31:6,7]naphtho[
1,2-d] imidazol-9-y11-
1H-imidazol-2-yl)pyrrolidin-l-y1]-3-methyl-l-oxobutan-2-ylIcarbamate was
prepared according to
the method described for the synthesis of methyl (S)-1-((2S,4S)-2-(2'-((2S,4S)-
1-((R)-2-amino-2-
phenylacety1)-4-(methoxymethyl)pyrrolidin-2-y1)-1 H, 1 'H-7,7'-binaphtho [1 ,2-
methylpyrrolidin-l-y1)-3-methyl-l-oxobutan-2-ylcarbamate, substituting tert-
butyl (2S,4S)-249-(2-
{(2S)-1 [N-(methoxycarbony1)-L-valyl]pyrrolidin-2-y11-1 H-imidazol-5 -y1)-
dihydroisochromeno[41,3':6,71naphtho[1,2-d]imidazol-2-y1]-4-
carboxylate for (2S,4S)-tert-butyl 2-(2'-((2S,4S)-1-((S)-2-
methylbutanoy1)-4-methylpyrrolidin-2-y1)- 1 H,1 'H-7,7'-binaphtho[l ,2-
(methoxymethyppyrrolidine- 1 -carboxylate. MS (ESI) m/z 811 [M + H].
Example OP
Boc 1. HCl/dioxane; DCM
2. COMU, DIPEA, DMF)IIP
I z 4110
I OMe
)NHCO2Me
NHCO2Me HO
tert-butyl (2S,4S)-249-(2-{(2S,5S)-14N-(methoxycarbony1)-
L-valy1]-5-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-1,4,5,11- (R)-2-
tetrahydroisochromeno[41,3
(methoxycarbonylamino)1:6,7]naphtho[1,2-d]imidazol-2- -2-phenylacetic acid
y1]-4-(methoxymethyppyrrolidine-1-carboxylate
01"Ph
rA0 N N
methyl {(1R)-2-[(2S,4S)-2-(9-{2-[(2S,5S)-1-{(2S)-2-[(methoxycarbonyl)amino]-
3-methylbutanoy1}-5-methylpyrrolidin-2-y1]-1H-imidazol-5-y11-1,4,5,11-
(methoxymethyppyrrolidin-1-y1]-2-oxo-1-phenylethyl}carbamate
Methyl 1(1R)-2- [(2 S,4 S)-2-(9-12- [(2 S,5 S)-1- { (2S)-2-
methylbutanoy11-5-methylpyrrolidin-2-y1]-1H-imidazol-5-y1 -1,4,5,11 -
tetrahydroisochromeno[4',31:6,71naphtho[1,2-d]imidazol-2-y1)-4-
(methoxymethyppyrrolidin-l-y11-2-
oxo-1-phenylethyllcarbamate was synthesized according to the protocol
described for the preparation
of methyl {(1R)-2-[(2S,4S)-2-(5-12-[(2S)-1-1(2S)-2-[(methoxycarbonypamino]-3-
methylbutanoylf pyrrolidin-2-y11-1,4,5,11-
tetrahydroisochromeno[41,31:6,7]naphtho[1,2-djimidazol-9-
y1 -1 H-imidazol-2-y1)-4-(methoxymethyppyrrolidin-l-y1]-2-oxo-1-phenylethyll
substituting tert-butyl (2S,4S)-249-(2-1(2S,5S)-14N-(methoxycarbony1)-L-valy1]-
2-y11-1H-imidazol-5-y1)-1,4,5,11-tetrahydroisochromeno[41,31:6,7]naphtho[1,2-
(methoxymethyppyrrolidine- 1 -carboxylate for tert-butyl (2S,4S)-2-[5-(2-1(2S)-
(methoxyearbony1)-L-valyllpyrrolidin-2-y11-1,4,5,11
tetrahydroisochromeno[4',3%6,7]naphtho[1,2-
d]imidazol-9-y1)-1H-imidazol-2-y1]-4-(methoxymethyppyrrolidine- I -
carboxylate. MS (ESI) m/z 886
[M + H]. IFINMR (400 MHz, cd3od) 8 8.02 ¨ 7.85 (m, 2H), 7.85 ¨7.68 (m, 2H),
7.58 (d, J= 21.5
Hz, 1H), 7.55 ¨ 7.35 (m, 4H), 7.31 (d, J= 13.6 Hz, 1H), 5.43 (d, J= 19.1 Hz,
1H), 5.28 (t, J= 8.3 Hz,
1H), 5.25 ¨ 5.10 (m, 3H), 4.13 (t, J= 9.5 Hz, 1H), 3.93 ¨ 3.54 (m, 7H), 3.42
(qd, J= 9.5, 5.5 Hz, 2H),
3.34 (d, J= 7.9 Hz, 1H), 3.28 (s, 3H), 3.19 (t, J= 7.8 Hz, 2H), 3.00 (t, J=
(m, 3H), 2.44 ¨ 2.15 (m, 2H), 2.12 ¨ 1.86 (m, 2H), 1.56 (d, J= 6.7 Hz, 2H),
1.29 (d, J= 6.3 Hz, 1H),
Example OQ
0Et
H----")
HO2C7-'N
0 (2S,4S)-1-(tert-butoxycarbonyI)-4-
CI *
Ili o
= Br ethoxypyrrolidine-2-carboxylic acid ,
DIPEA, MeCn
9-bromo-3-chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one
õs0Et NH40Ac 0
AL 0 0 Flµ H 1,,-)-1 D
ci 40 , N
_______________________________________________________________ ' CI 11 S I
Wit 0 IN1-- tol.
Boc Me0Et0H
(2S,4S)-1-tert-butyl 2-(3-chloro-8-oxo- tert-butyl (2S,4S)-2-(9-chloro-
tetrahydroisochromeno[4',3':6,71naphtho[1,2-
9-y1) 4-ethoxypyrrolidine-1,2-dicarboxylate d]imidazol-2-y1)-4-
ethoxypyrrolidine-1-carboxylate
-,1)D
Mn02 N 1) HCI
N ,
________________ . CI 411 41110 N
/ Boc 2) HATU
Moc-Val
tert-butyl (2S,4S)-2-(9-chloro-1,11-
cl]imidazol-2-y1)-4-ethoxypyrrolidine-1-carboxylate
0Et pEt
Cl *
H 1-1)
* N I Lo-Pd(dppf)Cl2 Nõ....- 0 ,13 N d
11, N om'' (PinB)2 -7-----0 I
W. Th
HN HN.10-..
methyl {(2S)-1-[(2S,4S)-2-(9-chloro-1,11- methyl [(2S)-1-{(2S,4S)-4-ethoxy-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1)-4- tetramethy1-
1,3,2-dioxaborolan-2-y1)-1,11-
ethoxypyrrolidin-1-y1]-3-methy1-1-oxobutan-2-yl}carbamate
yllpyrrolidin-1-y1}-3-methyl-1-oxobutan-2-yl]carbamate
o H H
Pd(PPh3)4N
....P
PdC12(dP0 . ) Bo_c<L,
lik iiii.N N o
DME c_. H H HN.....\c,---
tert-butyl (2S)-245-(2-{(2S,4S)-4-ethoxy-14N-(methoxycarbgny1)-L-
valyl]pyrrolidin-2-y1}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-9-y1)-1H-imidazol-2-yilpyrrolidine-1-carboxylate
)\-NH ,, 0
1) HCI -0
_________________ . ,==---- I N \
2) HATU ---- N -..< -Nit N\ 11 11011, N do__
Moc- Val
H H HN-1
methyl {(2S)-1-[(2S)-2-(542-[(2S,4S)-4-ethoxy-1-{(2S)-2-
methylbutanoyl}pyrrolidin-2-y1]-1,11-dihydroisochromeno[4',3':6,71naphtho[1,2-
d]imidazol-9-y1}-1H-imidazol-211)pyrrolidin-1-y1]-3-methy1-1-oxobutan-2-
dibenzolc,g]chromen-9-y1) 4-
ethoxypyrrolidine-1,2-dicarboxylate
To a slurry of 9-bromo-3-chloro-10,11-dihydro-5H-dibenzo[c,g1chromen-8(9H)-one
(2.50 g,
6.8 mmol) in MeCN (20 mL) was added (2S,4S)-1-(tert-butoxycarbony1)-4-
ethoxypyrrolidine-2-
carboxylic acid (2.68 g, 10.3 mmol) and DIPEA (1.3 mL, 7.5 mmol). The reaction
was heated with
stirring to 50 C for 18 h. The reaction was then cooled to room temperature
and diluted with Et0Ac.
The solution was washed with HCI (1N) and brine. The aqueous layers were
backextracted with
Et0Ac and the resulting organic layers were combined, dried (Na2SO4) and
chromatography (15% to 50 %
Et0Ac/Hexanes) to afford (2S,4S)-1-tert-butyl 2-(3-chloro-8-oxo-8,9,10,11-
dibenzo[c,g]chromen-9-y1) 4-ethoxypyrrolidine-1,2-dicarboxylate (2.08 g, 56%).
Tert-butyl (2S,4S)-2-(9-chloro-1,4,5,11-
tetrahydroisochromeno[4',3%6,71naphtho[1,2-
d]imidazol-2-y1)-4-ethoxypyrrolidine-1-carboxylate
To a solution of (2S,4S)-1-tert-butyl 2-(3-chloro-8-oxo-8,9,10,11-tetrahydro-
dibenzo[c,g]chromen-9-y1) 4-ethoxypyrrolidine-1,2-dicarboxylate (2.08 g, 3.8
mmol) in a mixture of
toluene (30 mL) and methoxyethanol (4 mL) was added ammonium acetate (2.90 g,
37.7 mmol). The
solution was heated with stirring to 80 C for 18 h. The reaction was then
cooled to room temperature
and diluted with Et0Ac. The solution was washed with brine, and the resulting
backextracted with Et0Ac. The resulting organic layers were combined, dried
(Na2SO4), and
chromatography (10% to 75 % Et0Ac(w/5% Me0H)/Hexanes) to afford tert-butyl
(2S,4S)-2-(9-
chloro-1,4,5,11-tetrahydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1)-4-
carboxylate (0.99 g, 50%).
Tert-butyl (2S,4S)-2-(9-chloro-1,11-dihydroisochromeno 14%3 ':6,71naphtho[1,2-
dlimidazol-2-y1)-
4-ethoxypyrrolidine-l-carboxylate
To a solution of (2S,4S)-2-(9-chloro-1,4,5,11-
d]imidazol-2-y1)-4-ethoxypyrrolidine-1 -carboxylate (0.99 g, 1.9 mmol) in
CH2C12 (18 mL) was added
Mn02 (4.52 g, 52.0 mmol). The resulting slurry was stirred at room temperature
for 18 h. The
reaction was filtered through celite, washed with CH2Cl2, and concentrated
under reduced pressure.
The crude residue was purified by silica column chromatography (10% to 75 %
Et0Ac(w/5%
Me0H)/Hexanes) to afford tert-butyl (2S,4S)-2-(9-chloro-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1)-4-ethoxypyrrolidine-
1-carboxylate (0.71
g, 72%)
Methyl {(2S)-1-[(2S,4S)-2-(9-chloro-1,11-
dihydroisochromeno14',3%6,7]naphtho11,2-dlim idazol-
2-y1)-4-ethoxypyrrolidin-l-y11-3-methyl-1-oxobutan-2-ylIcarbamate
To a solution of (2S,4S)-2-(9-chloro-1,11-
d]imidazol-2-y1)-4-ethoxypyrrolidine-l-carboxylate (0.46 g, 0.9 mmol) in a
mixture of CH2C12 (9.0
mL) and Me0H (1.5 mL) was added HC1 (in dioxanes, 4M, 6.5 mL, 26.0 mmol). The
resulting
solution was stirred at room temperature for 2 h. The solution was
concentrated to dryness under
reduced pressure. To the crude intermediate in CH2C12 (10.0 mL) was added (S)-
(methoxycarbonylamino)-3-methylbutanoic acid (0.17 g, 0.9 mmol), HATU (0.41 g,
1.1 mmol), and
DIPEA (0.5 mL, 2.9 mmol). The resulting solution was stirred at room
temperature for 48 h and
diluted with CH2C12. The solution was washed with aqueous HC1 (1N) and brine.
The aqueous layers
were backextracted with CH2C12 (2x). The resulting organic layers were
combined, dried (Na2SO4),
and concentrated under reduced pressure. The crude residue was purified by
silica column
chromatography (20% to 100 % Et0Ac(w/5% Me0H)/Hexanes to 80% Me0H/Et0Ac) to
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-
y1)-4-ethoxypyrrolidin-l-y1]-3-methyl-1-oxobutan-2-ylIcarbamate (0.46 g, 90%).
Methyl 1(2S)-1-{(2S,4S)-4-ethoxy-2-19-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-
2-y1)-141-
dihydroisochromeno14',3%6,71naphthoil,2-dlimidazol-2-yl]pyrrolidin-1-yl}-3-
oxobutan-2-yllearbamate
To a solution of methyl {(2S)-1-[(2S,4S)-2-(9-chloro-1,11-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d] imidazol-2-y1)-4-ethoxypyrrolidin-
l-y1]-3-methyl- 1-
oxobutan-2-yll carbamate (0.46 g, 0.84 mmol) in dioxane (8.5 mL) was added
4,4,4',4',5,5,51,5'-
octamethy1-2,2'-bi(1,3,2-dioxaborolane) (0.32 g, 1.3 mmol), potassium acetate
(0.25 g, 2.5 mmol),
bis(dibenzylideneacetone)palladium (0.032 g, 0.035 mmol), and 2-
dicyclohexylphosphino-2',4',6'-
triisopropylbiphenyl (Xphos, 0.032 g, 0.067 mmol). The resulting solution was
degassed with argon
for 5 min and heated, with stirring, to 90 C for 6 h. The reaction was cooled
to room temperature,
diluted with Et0Ac, and filtered through celite. The crude residue was
methyl [(2S)-1-1(2S,4S)-4-ethoxy-2-[9-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-
2-y1)-1,1 1-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-l-yll-3-
methyl-1-oxobutan-2-
yl]carbamate (0.41 g, 73%).
Tert-butyl (2S)-2-15-(2-{(2S,4S)-4-ethoxy-1 -[N-(methoxycarbony1)-L-
valyllpyrrolidin-2-y1}-1,11-
dihydroisochromenol4',3%6,71naphthol1,2-d]imidazol-9-y1)-1H-imidazol-2-
To a solution of methyl [(2S)-1-{(2S,4S)-4-ethoxy-2-[9-(4,4,5,5-tetramethy1-
dioxaborolan-2-y1)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-
yl]pyrrolidin-1-y1 -
3-methyl-l-oxobutan-2-yl]carbamate (0.41 g, 0.61 mmol) in a mixture of DME
(6.1 mL) and DMF
(1.0 mL) was added (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-l-
carboxylate (0.39 g,
1.2 mmol), tetrakis(triphenylphosphine)palladium (0.021 g, 0.018 mmol), [1,1'-
bis(diphenylphosphino)ferrocene]dichloropalladium (0.030 g, 0.041 mmol), and
aqueous potassium
carbonate (2M, 1.0 mL, 2.0 mmol). The solution was degasses with argon for 5
min and heated, with
stirring, to 85 C for 6 h. The solution was cooled to room temperature and
diluted with Et0Ac. The
organic layer was washed with water and brine. The aqueous layers were
backextracted with Et0Ac
(3x). The combined organic layers were dried over Na2SO4 and concentrated
The crude residue was purified by silica column chromatography (20% to 100 %
Me0H)/Hexanes to 80% Me0H/Et0Ac) to afford tert-butyl (2S)-245-(2-1(2S,4S)-4-
ethoxy-14N-
(methoxycarbony1)-L-valyllpyrrolidin-2-y11-1,11-
dihydroisochromeno[4',3%6,7]naphtho[1,2-
d]imidazol-9-y1)-1H-imidazol-2-yl]pyrrolidine-1-carboxylate (0.16 g, 33%).
Methyl {(2S)-1-1(2S)-2-(5-{2-1(2S,4S)-4-ethoxy-1-{(2S)-2-
(methoxycarbonyl)amino]-3-
methylbutanoyl}pyrrolidin-2-y1]-1,11-dihydroisochromeno[4',31:6,71naphtholl,2-
y11-1H-imidazol-2-y1)pyrrolidin-1-y11-3-methyl-1-oxobutan-2-y1}carbamate
To a solution of tert-butyl (2S)-2-[5-(2-{(2S,4S)-4-ethoxy-14N-
(methoxycarbony1)-L-
valyl]pyrrolidin-2-y11-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-9-y1)-1H-imidazol-
2-yl]pyrrolidine-1-carboxylate (0.048 g, 0.062 mmol) in a mixture of CH2Cl2
(1.0 mL) and Me0H
(0.25 mL) was added HC1 (in dioxanes, 4M, 0.47 mL, 1.9 mmol). The solution was
stirred at room
temperature for 3 h, and then concentrated to dryness under reduced pressure.
To the crude
intermediate suspended in CH2C12 (1.5 mL) was added (S)-2-
methylbutanoic acid (0.012 g, 0.069 mmol), HATU (0.029 g, 0.076 mmol), and
DIPEA (0.050 mL,
0.28 mmol). The resulting solution was stirred at room temperature for 1.5 h.
diluted with DMF and aqueous LiOH (2.5 M, 4 drops) was added. The solution was
concentrated to
remove the CH2C12 and the crude residue was purified by preparative reverse
phase HPLC (10% to 52
% MeCN/water with 0.1% TFA). The desired fractions were combined and
reduced pressure to remove volatile organics. The addition of aqueous sodium
bicarbonate with
stirring resulted in precipitation of a white solid. The precipitate was
filtered through a membrane
filter and washed with water. Drying under reduced pressure afforded methyl
{(2S)-1-[(2S)-2-(5-{2-
[(2S,4S)-4-ethoxy-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyll
pyrrolidin-2-y1]-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-9-yll-IH-imidazol-2-
methyl-l-oxobutan-2-yl}carbamate (0.008 g, 17%). 1H-NMR: 400 MHz, (Me0D) 6:
(Mixture of
rotomers) 8.37 (s, 1H), 7.97 (s, 2H), 7.37-7.76 (m, 5H), 5.38-5.54 (m, 1H),
5.18 (s, 2H), 5.14-5.16 (m,
1H), 4.21-4.31 (m, 4H), 3.87-4.09 (m, I H), 3.79-3.85 (m, 2H), 3.66 (s, 3H),
3.64 (s, 3H), 3.46-3.55
(m, 2H), 2.30-2.35 (m, 3H), 2.04-2.06 (m, 3H), 1.11 (m, 2H), 0.95 (d, 3H),
0.88 (d, 3H). MS (ESI)
in/z 836.02 [M + Fl]+.
Example OR
N\ /AL N N \ 1) HCI
ploc I N W-410. N 2) COMU
HN.....\_( Moc- Phg
tert-butyl (2S)-2-[5-(2-{(2S,4S)-4-ethoxy-14N-(methoxycarbony1)-L-
valylipyrrolidin-2-y1}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-9-y1)-1H-imidazol-2-yl]pyrrolidine-1-carboxylate
0 p-\
0 H 1-)1
----0)\--NH N\ N N
= N N
methyl {(1R)-2-[(2S)-2-(5-{2-R2S,4S)-4-ethoxy-1-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]irnidazol-9-y1}-1H-
imidazol-2-yppyrrolidin-1-y1]-2-oxo-1-phenylethyl}carbamate
Methyl {(1R)-2-1(2S)-2-(5-12-1(2S,4S)-4-ethoxy-1-1(2S)-2-
[(methoxyearbonyl)aminol-3-
methylbutanoyl}pyrrolidin-2-y1]-1,11-dihydroisochromeno14',3%6,71naphtho[1,2-
y1}-1H-imidazol-2-yl)pyrrolidin-l-y11-2-oxo-l-phenylethyllearbamate
valyl]pyrrolidin-2-y1 -1,11-dihydroisochromeno[41,31: 6,7]naphtho [1,2-
2-yl]pyrrolidine-1-carboxylate (0.11 g, 0.14 mmol) in a mixture of CH2C12 (2.0
mL) and Me0H (0.5
mL) was added HC1 (in dioxanes, 4M, 1.0 mL, 4.0 mmol). The solution was
intermediate suspended in CH2Cl2 (1.5 mL) was added (R)-2-
acid (0.044 g, 0.21 mmol) and DIPEA (0.075 mL, 0.43 mmol). The resulting
solution was cooled to -
40 C and COMU (0.096 g, 0.22 mmol) was added. The reaction was allowed to
slowly warm to 0 C
over 1 h. The reaction was diluted with DMF. The solution was concentrated to
remove the CH2C12
and the crude residue was purified by preparative reverse phase HPLC (10% to
55% MeCN/water
with 0.1% TFA). The desired fractions were combined and concentrated under
reduced pressure to
remove volatile organics. The addition of aqueous sodium bicarbonate with
stirring resulted in
precipitation of a white solid. The precipitate was filtered through a
membrane filter and washed with
water. Drying under reduced pressure afforded methyl {(1R)-2-[(2S)-2-(5-{2-
[(2S,4S)-4-ethoxy-1-
{ (2S)-2 -[(methoxycarbonyl)amino]-3-methylbutanoyl pyrrolidin-2-y1]-1,11-
dihydro isochromeno [41,31:6,71naphtho [1,2-d]imidazol-9-y1 -1H-imidazol-2-
yppyrrolidin-l-y1]-2-oxo-
1-phenylethyll carbamate (0.022 g, 18%). 1H-NMR: 400 MHz, (Me0D) 6: (Mixture
of rotomers)
8.28 (d, 1H), 7.88 (d, 1H), 7.52-7.70 (m, 3H), 7.28-7.38 (m, 5H), 6.90-6.96
(m, 2H), 5.44-5.47 (m,
1H), 5.31 (s, 1H), 5.12 (s, 2H), 4.16-4.48 (m, 3H), 3.81-3.19 (m, 1H), 3.62-
3.76 (m, 2H), 3.58 (s, 3H),
2.56 (s, 3H), 2.42-2.57 (m, 1H), 2.31 (m, 1H), 1.81-2.41 (m, 5H), 1.04 (t,
3H), 0.87 (d, 3H), 0.81 (d,
3H). MS (ESI) m/z 869.55 [M +
Example OS
o_c_< jjõ.. N Br 1 ) H C I -.
_______________________________________________ õ7¨V )--Br
H H 2) HATU
Moc-MeThr
/b H H
(S)-tert-butyl 2-(5-bromo-1H-imidazol-2-
yl)pyrrolidine-1-carboxylate methyl (2S,3R)-1-((S)-2-(5-bromo-
imidazol-2-yl)pyrrolidin-1-y1)-3-methoxy-
1-oxobutan-2-ylcarbamate
Methyl (2S,3R)-14(S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-l-y1)-3-methoxy-l-
ylcarbamate
To a solution of (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-
carboxylate (1.00
g, 3.2 mmol) in a mixture of CH2C12 (30 mL) and Me0H (5 mL) was added HCI (in
dioxane, 4 M,
11.5 mL, 46.0 mmol). The solution was stirred at 40 C for lh, cooled to room
temperature, and
concentrated to dryness under reduced pressure. To the crude intermediate
suspended in CH2C12 (30
mL) was added (2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid (0.67 g,
3.5 mmol),
HATU (1.47 g, 3.8 mmol), and DIPEA (1.00 mL, 6.0 mmol), The resulting solution
was stirred at
room temperature for 24 h. DMF (2 mL) and aqueous LiOH (2.5 M, 1 mL) were
reaction was concentrated to dryness under reduced pressure. The crude
material was diluted with
Et0Ac and washed with H20 and brine. The aqueous layers were backextracted
combined organic layers were dried over Na2SO4 and concentrated under reduced
residue was purified by silica column chromatography (20% to 100 % Et0Ac(w/5%
Me0H)/CH2C12)
to afford methyl (2S,3R)-1-((S)-2-(5-bromo-1H-imidazol-2-yppyrrolidin-l-y1)-3-
methoxy-1-
oxobutan-2-ylcarbamate (1.2g, 100%).
Example OT
¨o N H H
H [)10 methyl (2S,3R)-1-((S)-2-(5-
_.-013 N N imidazol-211)pyrrolidin-1-y1)-
3-methoxy-
110 Boc 1-oxobutan-2-ylcarbamate
tert-butyl 4-(methoxymethyl)-249-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
NH H 1) HCI
J. I Noc 2) MCOMU
N N N oc- Phg
/U H
tert-butyl (2S,4S)-2-[9-(2-{(2S)-1-[N-(methoxycarbony1)-0-methyl-L-
threonyl]pyrrolidin-
2-y11-1H-imidazol-5-y1)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-2-y1]-
,¨o
()NN\ 41110N IN N
/ H H o
methyl {(1R)-2-[(2S,4S)-2-(9-{2-[(2S)-1-{(2S,3R)-3-methoxy-2-
[(methoxycarbonyl)amino]butanoyllpyrrolidin-2-y1]-1H-imidazol-5-y1)-
1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1)-4-(metho
xymethyppyrrolidin-1-y11-2-oxo-1-phenylethyl}carbamate
Tert-butyl (2S,4S)-249-(2-{(2S)-1-IN-(methoxycarbony1)-0-methyl-L-threonyll
pyrrolid
H-imidazol-5-y1)-1,11-dihydroisochromeno 14',3': 6,7] na phtho [1,2-d]imidazo
1-2-y1I-4-
(methoxymethyl)pyrrolidine- 1 -carboxylate
To a solution of tert-butyl 4-(methoxymethyl)-2-[9-(4,4,5,5-tetramethy1-1,3,2-
y1)-1,11-dihydroisochromeno[4',3':6,7]-naphtho[1,2-d]imidazol-2-yl]pyrrolidine-
1 -carboxylate (1.0 g,
3.2 mmol) in a mixture of DMSO (2.0 mL) and dioxanes (2.0 mL) was added methyl
(2S,3R)-1-((S)-
2-(5-bromo-1H-imidazol-2-yl)pyrro11din-l-y1)-3-methoxy-1-oxobutan-2-
ylearbamate (0.24 g, 0.62
mmol), tetrakis(triphenylphosphine)palladium (0.050 g, 0.043 mmol), [1,1'-
carbonate (2M, 0.65 mL, 1.3 mmol). The solution was degasses with argon for 5
min and heated,
with stirring, to 85 C for 6 h. The solution was cooled to room temperature
The organic layer was washed with water and brine. The aqueous layers were
Et0Ac (3x). The combined organic layers were dried over Na2SO4 and
concentrated under reduced
pressure. The crude residue was purified by silica column chromatography (20%
to 100 %
Et0Ac(w/5% Me0H)/Hexanes to 60% Me0H/Et0Ac) to afford tert-butyl (2S,4S)-2-[9-
(2-{(2S)-1-
[N-(methoxycarbony1)-0-methyl-L-threonyl]pyrrolidin-2-yll-1H-imidazol-5-y1)-
Methyl {(1R)-2-1(2S,4S)-2-(9-12-1(2S)-1-{(2S,3R)-3-methoxy-2-
Rmethoxyearbonyl)aminolbutanoyl}pyrrolidin-2-ylp1H-imidazol-5-y1}-1,11-
dihydroisochromenol4',3':6,7]flaphtho[1,2-dlimidazol-2-y1)-4-
2-oxo-l-phenylethyl}earbamate
To a solution of tert-butyl (2S,4S)-249-(2-{(2S)-14N-(methoxycarbony1)-0-
threonyl]pynolidin-2-yll -1 H-imidazol-5-y1)-1,11-dihydroisochromeno
d]imidazol-2-y1]-4-(methoxymethyppyrrolidine-1 -carboxylate (0.20 g, 0.26
CH2Cl2 (3.0 mL) and Me0H (0.5 mL) was added HC1 (in dioxanes, 4M, 2.0 mL, 8.0
solution was stirred at 40 C for 1 h, and then cooled to room temperature and
concentrated to dryness
under reduced pressure. To the crude intermediate suspended in CH2Cl2 (3.0 mL)
was added (R)-2-
(methoxycarbonylamino)-2-phenylacetic acid (0.081 g, 0.39 mmol) and DIPEA
(0.150 mL, 0.86
mmol). The resulting solution was cooled to -40 C and COMU (0.180 g, 0.42
mmol) was added.
The reaction was allowed to slowly warm to room temperature over 30 min and
maintained for 1.5 h.
The solution was diluted with CH2Cl2 and washed with aqueous bicarbonate. The
backextracted with CH2C12. The combined organic layers were dried over Na2SO4
under reduced pressure. The crude residue was purified by preparative reverse
phase HPLC (10% to
50% MeCN/water with 0.1% TFA). The desired fractions were combined and
{(1R)-2-[(2S,4S)-2-(9-
{2-[(2S)-1-1(2S,3R)-3-methoxy-2-[(methoxycarbonypamino]butanoyll pyrrolidin-2-
y1]-1H-imidazol-
5-y11-1,11-dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-y1)-4-
(methoxymethyl)pyrrolidin-
1-y1]-2-oxo-l-phenylethylIcarbamate (0.10 g, 46%). 1H-NMR: 400 MHz, (Me0D) 3:
rotomers) 8.34 (s, 1H), 7.92-7.97 (m, 2H), 7.33-7.69 (m, 10H), 5.53 (s, 1H),
5.36-5.39 (m, 1H), 5.15-
5.21 (m, 3H), 4.44 (d, 1H), 3.86-3.93 (m, 2H), 3.68-3.75 (m, 2H), 3.66 (s,
3H), 3.65 (s, 3H), 3.46-3.57
(m, 2H), 3.28 (s, 3H), 3.19 (s, 3H), 2.47-2.60 (m, 3H), 2.22-2.36 (m, 4H),
1.99-2.08 (m, 3H), 1.15 (d,
Example OU
H 17:1)D 1H CI
4iN IBloc 2) HATU
tert-butyl 4-(methoxymethyl)-2-[9-(4,4,5,5-tetramethy1-1,3,2-
d]imidazol-2-ylipyrrolidine-1-carboxylate
N _____________________________________________________________
Bo_y_
,-0 N N
0 H H H
yv N
Z WI" N
HN.¨\\/0_ --
methyl (1-{4-(methoxymethyl)-2-[9-(4,4,5,5-tetramethy1-1,3,2-
d]imidazol-2-yl]pyrrolidin-1-y1}-3-methoxy-1-oxobutan-2-
yl)carbamate
0 H 1-)1 o/ 1) HCI
Bo i11. N
2) COMU
N N N Moc- Phg
HN-1
tert-butyl (2S)-2-(5-{2-[(2S,4S)-1-[N-(methoxycarbony1)-0-methyl-L-threony1]-4-
d]imidazol-9-y1}-1H-imidazol-2-y1)pyrrolidine-1-carboxylate
\ N N
N 0, IN
methyl {(1R)-2-[(2S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methoxybutanoy1}-4-
(methoxymethyl)pyrrolidin-2-y11-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
imidazol-211)pyrrolidin-1-y1]-2-oxo-1-phenylethyl}carbamate
Methyl (1-14-(methoxymethyl)-2-19-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
dihydroisochromeno[4',3':6,7]naphthoil,2-cljimidazol-2-yljpyrrolidin-1-y1}-3-
oxobutan-2-yl)carbamate
To a solution of tert-butyl 4-(methoxymethyl)-249-(4,4,5,5-tetramethy1-1,3,2-
y1)- l ,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-
yl]pyrrolidine-1-carboxylate (0.25 g,
0.41 mmol) in a mixture of CH2C12 (4.0 mL) and Me0H (1.0 mL) was added HC1 (in
dioxanes, 4M,
3.0 mL, 12.0 mmol). The resulting solution was stirred at 40 C for 45 min.
The solution was cooled
to room temperature and concentrated to dryness under reduced pressure. To the
crude intermediate
in CH2C12 (4.0 mL) was added (2S,3R)-3-methoxy-2-
(methoxycarbonylamino)butanoic acid (0.08 g,
0.42 mmol), HATU (0.17 g, 0.45 mmol), and D1PEA (0.4 mL, 2.3 mmol). The
resulting solution was
stirred at room temperature for 48 h and diluted with CH2C12. The solution was
washed with brine.
The aqueous layer was backextracted with CH2C12 (2x). The resulting organic
layers were combined,
dried (Na2SO4), and concentrated under reduced pressure. The crude residue was
column chromatography (30% to 100 % Et0Ac(w/5% Me0H)/Hexanes to 80%
Me0H/Et0Ac) to
afford methyl (1-{4-(methoxymethyl)-249-(4,4,5,5-tetramethy1-1,3,2-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-l-y11-3-
methoxy-1-oxobutan-2-
y1)carbamate (0.24 g, 92%).
Tert-butyl (2S)-2-(5-{2-1(2S,4S)-1-IN-(methoxycarbony1)-0-methyl-L-threonyll-4-
(methoxymethyl)pyrrolidin-2-y11-1,11-dihydroisochromeno14',3%6,71naphtholl,2-
diimidazol-9-
yI}-1H-imidazol-2-yl)pyrrolidine-l-earboxylate
To a solution of methyl (1-14-(methoxymethyl)-249-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-
2-y1)-1,11-dihydroisochromeno[41,31:6,7Thaphtho[1,2-d]imidazol-2-yl]pyrrolidin-
l-yll-3-methoxy-1-
oxobutan-2-y1)carbamate (0.15 g, 0.22 mmol) in a mixture of DMSO (2.0 mL) and
dioxane (2.0 mL)
was added (S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yppyrrolidine-l-carboxylate
tetrakis(triphenylphosphine)palladium (0.028 g, 0.024 mmol), [1,1'-
carbonate (2M, 0.35 mL, 0.70 mmol). The solution was degasses with argon for 5
pressure. The crude residue was purified by preparative reverse phase HPLC
(10% to 55%
MeCN/water with 0.1% TFA). The desired fractions were combined and
pressure to remove volatile organics. The remaining solution was basified with
aqueous bicarbonate
and extracted with CH2C12 (3x). The combined organic layers were dried over
Na2SO4 and
concentrated under reduced pressure to provide tert-butyl (2S)-2-(5-{2-
[(2S,4S)-14N-
(methoxycarbony1)-0-methyl-L-threonyl]-4-(methoxymethyl)pyrrolidin-2-y1]-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-djimidazol-9-y11-1H-imidazol-2-
y1)pyrrolidine-1-
carboxylate (0.013 g, 7%).
Methyl 1(1 R)-2-K2S)-2-(5-12-1(2S,4S)-1-{(2S)-2-1(m ethoxyea rbonyl)aminol-3-m
ethoxybutanoyI}-
4-(methoxymethyl)pyrrolidin-2-y11-1,11-dihydroisochromenol4',3%6,71naphthol
1,2-dl imidazol-
9-y11-1 H-imidazol-2-yl)pyrrolidin-1-y11-2-oxo-1-phenylethyl}ca rbamate
To a solution of tert-butyl (2S)-2-(5-{2-[(2S,4S)-14N-(methoxycarbony1)-L-
(methoxymethyppyrrolidin-2-y11-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-
1H-imidazol-2-yl)pyrrolidine-1-carboxylate (0.013 g, 0.016 mmol) in a mixture
of CH2Cl2 (0.5 mL)
and Me0H (0.02 mL) was added HC1 (in dioxanes, 4M, 0.20 mL, 0.80 mmol). The
stirred at room temperature for 1 h, and then concentrated to dryness under
reduced pressure. To the
crude intermediate suspended in CH2Cl2 (0.5 mL) was added (R)-2-
phenylacetic acid (0.006 g, 0.029 mmol) and DIPEA (0.05 mL, 0.28 mmol). The
resulting solution
was cooled to 0 C and COMU (0.012 g, 0.028 mmol) was added. The reaction was
stirred at 0 C
for 30 min. The solution was diluted with DMF and aqueous LiOH (2.5 M, 2
drops) and concentrated
under reduced pressure to remove the CH2C12. The crude residue was purified by
preparative reverse
phase HPLC (10% to 55% MeCN/water with 0.1% TFA). The desired fractions were
combined and
concentrated under reduced pressure to remove volatile organics. The addition
of aqueous sodium
bicarbonate with stirring resulted in precipitation of a white solid. The
precipitate was filtered
through a membrane filter and washed with water. Drying under reduced pressure
afforded methyl
{(1R)-2-[(2S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methoxybutanoyl -4-
(methoxymethyppyrrolidin-2-y1]-1,11-dihydroisochromeno[4',31:6,7Thaphtho[1,2-
1H-imidazol-2-yl)pyrrolidin-1-y1]-2-oxo-1-phenylethylIcarbamate (0.008 g,
61%). 'H-NMR: 400
MHz, (Me0D) 6: (Mixture of rotomers) 8.37 (m, 1H), 7.96-7.98 (m, 2H), 7.60-
7.79 (m, 3H), 7.35-
7.52 (m, 6H), 6.98-7.03 (m, 1H), 5.52 (s, 1H), 5.26-5.39 (m, 2H), 5.20 (s,
2H), 4.44 (m, 1H), 4.27 (m,
1H), 3.64 (s, 6H), 3.50-3.57 (m, 3H), 3.37 (s, 3H), 3.29-3.44 (m, 3H), 3.20
(s, 3H), 2.68-2.72 (m, 2H),
2.57-2.62 (m, 2H), 1.89-2.15 (m, 6H), 1.18 (d, 3H). MS (ES!) m/z 885.73 [M +
H]t
Example OV
Bo_c<11.. /
0(2S,4S)-tert-butyl 2-(5-iodo-1H-imidazol-2-y1)-4-
W-11,
HN.,.,.\(0, Pd(PPh3)4
PdC12(dPIDO
DME, DMF
methyl R2S)-1-{(2S,4S)-349-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-y1)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1]-
2-azabicyclo[3.1.0]hex-2-y11-3-methy1-1-oxobutan-2-yl]carbamate
0 HH
\ 11µ N$N \.õ
W114 N1) HCI
H H HN.--.\c Moc- Phg
tert-butyl (2S,4S)-2-[5-(2-{(1S,3S,5S)-2-[N-(methoxycarbony1)-L-valy1]-2-
azabicyclo[3.1.0]hex-3-y1}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-
9-y1)-1H-imidazol-2-y1]-4-(methoxymethyl)pyrrolidine-1-carboxylate
=----0)\---0 \ /AL\ N
W. ch
H NH HN
methyl {(1R)-2-[(25,4S)-2-(5-{2-[(15,3S,5S)-2-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoy11-2-azabicyclo[3.1.0]hex-3-y11-1,11-
dihydroisochromeno[4,3':6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol
-2-y1)-4-(methoxymethyl)pyrrolidin-1-y11-2-oxo-1-phenylethyl}carbamate
Methyl 1(2S)-1-{(2S,4S)-3-19-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y1)-
dihydroisochromenol4',3':6,71naphtholl,2-diimidazol-2-y11-2-
azabicyclo13.1.01hex-2-yll-3-
methyl-l-oxobutan-2-ylicarbamate
Methyl [(2S)-1-1(2S,4S)-319-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1]-2-
azabicyclo[3.1.0Thex-2-y11-3-methyl- 1 -
oxobutan-2-yl]carbamate was prepared following the procedure for methyl [(2S)-
1-{(2S,4S)-4-
ethoxy-249-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-l-yll-3-
yl]carbamate by substitution of (1S,3S,5S)-2-(tert-butoxycarbony1)-2-
azabicyclo[3.1.0]hexane-3-
carboxylic acid for (2S,4S)-I -(tert-butoxycarbony1)-4-ethoxypyrrolidine-2-
carboxylic acid.
Tert-butyl (2S,4S)-2-15-(2-{(1S,3S,5S)-2-IN-(methoxycarbony1)-L-valy1]-2-
azabicyclo[3.1.01hex-
3-y1}-1,11-dihydroisochromeno[4',3':6,71naphtholl,2-djimidazol-9-y1)-1H-
To a solution of methyl [(2S)-1-{(2S,4S)-349-(4,4,5,5-tetramethy1-1,3,2-
1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1]-2-
azabicyclo[3.1.01hex-2-y11-3-
methy1-1-oxobutan-2-ylicarbamate (0.19 g, 0.30 mmol) in a mixture of DMSO (2.0
mL) and dioxane
(2.0 mL) was added (2S,4S)-tert-butyl 2-(5-iodo-1H-imidazol-2-y1)-4-
(methoxymethyl)pyrrolidine-l-
carboxylate (0.20 g, 0.55 mmol), tetrakis(triphenylphosphine)palladium (0.035
g, 0.030 mmol), [1,1'-
stirring, to 90 C for 6 h. The solution was cooled to room temperature,
filtered through celite. The filtrate was concentrated under reduced pressure
and purified by silica
column chromatography (2% to 25 % CH2C12/Me0H) and preparative reverse phase
HPLC (10% to
reduced pressure to remove volatile organics. The aqueous layer was basified
with aqueous sodium
bicarbonate and extracted with CH2C12 (3x). The organic layers were combine,
dried over Na2SO4,
and concentrated under reduced pressure to afford tert-butyl (2S,4S)-245-(2-
1(1S,3S,5S)-24N-
(methoxycarbony1)-L-valy1]-2-azabicycloP.1.0Thex-3-y11-1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-dlimidazol-9-y1)-1H-imidazol-2-y1]-4-
(methoxymethyl)pyrrolidine-1 -carboxylate (0.025 g, 11%).
Methyl {(1R)-2-1(2S,4S)-2-(5-{2-1(1S,3S,5S)-2-{(2S)-2-Kmethoxycarbonyl)aminol-
methylbutanoyll-2-azabicyclo[3.1.01hex-3-y11-1,11-
dihydroisochromeno[4',3':6,71naphthol1,2-
dlimidazol-9-y11-1H-imidazol-2-y1)-4-(methoxymethyl)pyrrolidin-1-y11-2-oxo-1-
To a solution of tert-butyl (2S,4S)-245-(2-1(1S,3S,5S)-24N-(methoxycarbony1)-L-
va1y11-2-
azabicyclo[3.1.0]hex-3-y11-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
dlimidazol-9-y1)-1H-
imidazol-2-y1]-4-(methoxymethyppyrrolidine- 1 -carboxylate (0.025 g, 0.032
CH2C12 (1.0 mL) and Me0H (0.25 mL) was added HC1 (in dioxanes, 4M, 0.50 mL,
2.0 mmol). The
solution was stirred at room temperature for 12 h, and then concentrated to
dryness under reduced
pressure. To the crude intermediate suspended in CH2C12 (0.5 mL) was added (R)-
(methoxycarbonylamino)-2-phenylacetic acid (0.012 g, 0.057 mmol) and DIPEA
mmol). The resulting solution was cooled to 0 C and COMU (0.023 g, 0.054
mmol) was added. The
reaction was stirred at 0 C for 30 min. The solution was diluted with DMF and
aqueous LiOH (2.5
M, 2 drops) and concentrated under reduced pressure to remove the CH2C12. The
purified by preparative reverse phase HPLC (10% to 55% MeCN/water with 0.1%
TFA). The desired
fractions were combined and concentrated under reduced pressure to remove
volatile organics. The
addition of aqueous sodium bicarbonate with stirring resulted in precipitation
of a white solid. The
precipitate was filtered through a membrane filter and washed with water.
Drying under reduced
pressure afforded methyl {(1R)-2-[(2S,4S)-2-(5-12-[(1S,3S,5S)-2-{(2S)-2-
[(methoxycarbonypamino]-3-methylbutanoyll-2-azabicycloP.1.0Thex-3-y1]-1,11-
dihydroisochromeno[41,3':6,71naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-2-y1)-4-
(methoxymethyppyrrolidin-1-y1]-2-oxo-l-phenylethylIcarbamate (0.015 g, 55%).
1H-NMR: 400
MHz, (Me0D) .3: (Mixture of rotomers) 8.35 (m, 1H), 7.94-7.96 (m, 2H), 7.54-
7.00 (m, 1H), 5.72 (m, 1H), 5.46 (s, I H), 5.19 (s, 2H), 5.14-5.16 (m, 1H),
3.63 (s, 3H), 3.42-3.49 (m, 2H), 3.24 (s, 3H), 2.67-2.78 (m, 2H), 2.41-2.62
2H), 1.86-1.99 (m, 3H), 0.99-1.03 (m, 2H), 0.90 (d, 3H). MS (ESI) m/z 882.23
[M + 1-1]+.
Example OW
methyl (2S,3S)-14(2S,5S)-2-(5-iodo-1H-
imidazol-2-y1)-5-methylpyrrolidin-1-y1)-3-
0H methyl-1-oxopentan-2-
= Boc Pd(Plph3)4
PdC12(dPPO
methyl (1-{4-(methoxymethyl)-249-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-y1)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-
ylipyrrolidin-1-y1}-3-methyl-1-oxobutan-2-y1)carbamate
e, 0 H 1-)1 1) HCI
=-0 uc 2) COMU
1 Bo Moc- Phg
N\ 4111 N
tert-butyl (2S,4S)-249-(2-{(2S,5S)-1-[N-(methoxycarbony1)-L-isoleucy1]-5-
dihydroisochromeno[43':6,7]naphtho[1,2-
d]imidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate
)\--- 0
H D
N 1111 N
H H 0
methyl {(1R)-2-[(2S,4S)-2-(9-{2-R2S,5S)-1-{(2S,3S)-2-[(methoxycarbonyl)amino]-
methylpentanoy11-5-methylpyrrolidin-2-y1]-1H-imidazol-5-y1}-1,11-
y1)-4-(methoxymethyppyrrolidin-1-y11-2-oxo-1-phenylethylIcarbamate
Tert-butyl (2S,4S)-249-(2-{(2S,5S)-l-IN-(methoxycarbony1)-L-isoleucy11-5-
y1}-1H-imidazol-5-y1)1,11-dihydroisochromenol4',3':6,71naphtholl,2-dlimidazol-
To a solution of methyl (1-{4-(methoxymethyl)-249-(4,4,5,5-tetramethyl-1,3,2-
2-y1)-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-
l-y11-3-methy1-1-
was added methyl (2S,3S)-1-((2S,5S)-2-(5-iodo-1H-imidazol-2-y1)-5-
methylpyrrolidin-l-y1)-3-
methyl-1 -oxopentan-2-ylcarbamate (0.26 g, 0.72 mmol),
tetrakis(triphenylphosphine)palladium
(0.090 g, 0.078 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium
(0.061g, 0.083
mmol), and aqueous potassium carbonate (2M, 1.2 mL, 2.4 mmol). The solution
was degasses with
argon for 5 min and heated, with stirring, to 90 C for 6 h. The solution was
temperature, diluted with Et0Ac, and filtered through celite. The filtrate was
reduced pressure and diluted with Et0Ac. The organic solution was washed water
and brine and the
aqueous layers were backextracted with Et0Ac. The combined organic layers were
Na2SO4 and concentrated under reduced pressure. The crude residue was purified
by silica column
chromatography (10% to 100% Et0Ac (5% Me0H)/CH2C12) to afford tert-butyl
(2S,4S)-2-[9-(2-
{(2S,5S)-14N-(methoxycarbony1)-L-isoleucyl]-5-methylpyrrolidin-2-y11-1H-
imidazol-5-y1)-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-y1]-4-
Methyl {(1R)-2-1(2S,4S)-2-(912-1(2S,5S)-1-{(2S,3S)-2-1(methoxyearbonyl)amino1-
methylpentanoy1}-5-methylpyrrolidin-2-y11-1H-imidazol-5-y11-1,11-
dihydroisochromeno[4',3%6,71naphtholl,2-d]imidazol-2-y1)-4-
2-oxo-1-phenylethyl}carbamate
To a solution of tert-butyl (2S,4S)-249-(2-{(2S,5S)-1-[N-(methoxycarbony1)-L-
isoleucyl]-5-
dlimidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate (0.175 g, 0.21
CH2C12 (2.0 mL) and Me0H (0.5 mL) was added HC1 (in dioxanes, 4M, 1.6 mL, 6.4
solution was stirred at 40 C for I h, cooled to room temperature, and then
under reduced pressure. To the crude intermediate suspended in CH2C12 (3.0 mL)
mmol). The resulting solution was cooled to -40 C and COMU (0.15 g, 0.35
reaction was warmed to room temperature over 30 min and diluted with CH2C12.
The solution was
washed with saturated aqueous sodium bicarbonate. The aqueous layer was
CH2C12, and the combined organic layers were dried over Na2SO4 and
pressure to remove volatile organics. The addition of aqueous sodium
bicarbonate with stirring
resulted in precipitation of a white solid. The precipitate was filtered
through a membrane filter and
washed with water. Drying under reduced pressure afforded methyl {(1R)-2-
[(2S,4S)-2-(9-12-
[(2S,5S)-1-1 (2S,3S)-2-Rmethoxycarbonyl)amino]-3-methylpentanoyll-5-
methylpyrrolidin-2-y1]-1 H-
imidazol-5-y11-1,11-dihydroisochromeno[4',31:6,7Jnaphtho[1,2-d]imidazol-2-y1)-
(methoxymethyl)pyrrolidin-1-y1]-2-oxo-l-phenylethylIcarbamate (0.079 g, 41%).
'H-NMR: 400
7.48 (m, 7H), 5.53 (s, I H), 5.36-5.39 (m, 1H), 5.17 (d, 2H), 5.08 (m, 1H),
4.14-4.35 (m, 1H), 3.74 (m,
4H), 3.64 (s, 3H), 3.62 (s, 3H), 3.46 (m, 1H), 3.19 (s, 3H), 2.76 (m, 1H),
2.46-2.60 (m, 3H), 2.24-2.35
(m, 1H), 2.08-2.18 (m, 2H), 1.91 (m, 1H), 1.61-1.87 (m, 2H), 1.48 (d, 3H),
0.97 (m, 3H). MS (ESI) m/z 898.24 [M + H].
Example OX
0 1-1,51 1) HCI
Boc 2) HATU
NI N 111 41041 N Moc-Val
tert-butyl (2S,4S)-249-(2-{(2S,5S)-14N-(methoxycarbony1)-L-isoleucyl]-5-
N\ N
H H HN,Ic0,
methyl {(2S)-1-R2S,4S)-2-(9-{2-[(2S,5S)-1-{(2S,3S)-2-Rmethoxycarbonyl)amino1-3-
methylpentanoy11-5-
methylpyrrolidin-2-y1]-1H-imidazol-5-y1}-1,11-
y1)-4-(methoxymethyppyrrolidin-1-y11-3-methyl-1-oxobutan-2-y1}carbamate
Methyl {(2S)-1-[(2S,4S)-2-(9-{2-1(2S,5S)-1-{(2S,3S)-2-1(methoxyearbonyl)aminol-
methylpentanoy1}-5-methylpyrrolidin-2-y11-1H-imidazol-5-yl}-1,11-
dihydroisochromenoj4',3':6,71naphthol1,2-diimidazol-2-y1)-
44methoxymethyl)pyrrolidin-1-y11-
3-methyll-oxobutan-2-yl}earbamate
To a solution of tert-butyl (2S,4S)-249-(2-{(2S,5S)-14N-(methoxycarbony1)-L-
methylpyrrolidin-2-y1 -1H-imidazol-5-y1)-1,11-dihydroisochromeno
[4',31:6,7]naphtho [1,2-
d]imidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate (0.075 g, 0.09
CH2Cl2 (1.0 mL) and Me0H (0.25 mL) was added HC1 (in dioxanes, 4M, 0.7 mL, 2.8
solution was stirred at 40 C for 1 h, cooled to room temperature, and then
was added (S)-2-
(methoxycarbonylamino)-3-methylbutanoic acid (0.020 g, 0.14 mmol), HATU (0.043
g, 0.11 mmol)
and DIPEA (0.10 mL, 0.57 mmol). The reaction was stirred at room temperature
for 2 h. The
reaction was diluted with DMF and aqueous LiOH (2.5 M, 3 drops) and the CH2C12
was removed
{(2S)-1-[(2S,4S)-2-(9-
{2-[(2S,5S)-1-1(2S,3S)-2-[(methoxycarbonyl)amino]-3-methylpentanoy11-5-
methylpyrrolidin-2-y1]-
1H-imidazol-5-y11-1,11-dihydroisochromeno[4',3':6,71naphtho[1,2-djimidazol-2-
(methoxymethyppyrrolidin- 1 -yI]-3-methyl- 1 -oxobutan-2-y1 carbamate (0.031
g, 38%). 'H-NMR:
400 MHz, (Me0D) 6: (Mixture of rotomers) 8.34 (m, 1H), 7.91-9.97 (m, 2H), 7.50-
7.81 (m, 3H),
7.35-7.38 (m, 2H), 5.17-5.26 (m, 3H), 5.08 (m, 1H), 4.14-4.33 (m, 4H), 3.64
(s, 3H), 3.63 (s, 3H),
3.51- 3.59 (m, 3H), 3.37 (s, 3H), 2.71 (m, 1H), 2.55-2.59 (m, 1H), 2.23-2.33
2H), 1.77-1.89 (m, 1H), 1.60 (m, 1H), 1.48 (d, 1H), 1.11-1.22 (m, 2H), 0.81-
0.98 (m, 12H). MS (ES!)
m/z 864.27 [M + H].
Example PF
_L....-
'B =
0N,
----1
____ B B __ II i i N
244-(methoxymethyppyrrolidin-2-y11-9-(4,4,5,5-
tert-butyl (2S,4S)-4-(methoxymethyl)-249-(4,4,55-
dihydroisochromeno[43':6,7]naphtho[1,2-d]imidazole
/ 0 H
N----)
\C) 41 N U k
Moc-Val-OH, HATU, 'B .
DIPEA, DMF 7-0, iii. N oh,'
______________________________________________________________________ ,
_____________ An- N =.... Pd(PPh3)4,
PdC12(dppf),
H' \ K2CO3, DME/ DMF, 85 C
methyl R2S)-1-{(2S,4S)-4-ethoxy-249-(4,4,5,5-tetramethy1-1,3,2-
dioxaborolan-2-y1)-1,11-dihydroisochromeno[4',3':6,71naphtho[1,2-
d]imidazol-2-yl]pyrrolidin-1-y1}-3-methy1-1-oxobutan-2-yl]carbamate
1.\-11 n. HCI
it 11 '-r--- N Ethanol
N,/----N ii= N ,-.õ.\.,\--, ---
..-
U i-I 0
,N,e)
tert-butyl 245-(2-{14N-(methoxycarbonyl)valy1]-4-(methoxymethyppyrrolidin-2-
y1}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1)-1H-
imidazol-2-y1]-4-rnethylpyrrolidine-1-carboxylate
N Moc-D-PhGly-OH,
H 4/ 41. iii \/,,,, COMU,
N N ________________________________________________ or
.:
methyl {144-(methoxymethyl)-2-{942-(4-methylpyrrolidin-2-y1)-1H-
imidazol-5-y1]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-2-yllpyrrolidin-1-y1]-3-methy1-1-oxobutan-2-ylIcarbamate
0 s=
N\N ai
µ1-1 0 0
methyl {1-[2-{9-[2-(1-{[(methoxycarbonyl)amino](phenyl)acetyll-4-
2-y1)-1H-imidazol-5-ylp,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-
2-y11-4-(methoxymethyl)pyrrolidin-1-y
l]-3-methyl-1-oxobutan-2-yl}carbamate
tert-butyl (2S,4S)-4-(methoxymethyl)-2-19-(4,4,5,5-tetramethyl-1,3,2-
dihydroisochromenol4',3':6,71naphtholl,2-diimidazol-2-yllpyrrolidine-1-
The title compound was obtained as in example LQ but using (2S,4S)-1-(tert-
butoxycarbony1)-4-(methoxymethyppyrrolidine-2-carboxylic acid in place of (S)-
1-(tert-
butoxycarbonyl)pyrrolidine-2-carboxylic acid.
2-14-(methoxymethyl)pyrrolidin-2-y11-9-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-
dihydroisoehromeno14',3':6,71naphtho[1,2-dlimidazole
Tert-butyl (2S,4S)-4-(methoxymethyl)-249-(4,4,5,5-tetramethy1-1,3,2-
1 0 1,11 -dihydroisochromeno [4',31:6,7]naphtho [1,2-dlimidazol-2-ylipyrro
li dine- 1 -carboxylate ( 3 1 Omg,
0.507mmol) was treated with 2mL 1.25N HC1 in ethanol and stirred at room
temperature for 2h then
at 50 C for 2h. The reaction mixture was concentrated under reduced pressure
to give a dark yellow
solid that was directly in the next step.
methyl R2S)-1-{(2S,4S)-4-ethoxy-2-19-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
dihydroisochromeno14',3%6,7inaphthoi1,2-dlimidazol-2-yllpyrrolidin-1-y11-3-
A mixture of (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (107mg,
0.608mmol),
HATU (231mg, 0.608mmol) and 6mL 10% DIPEA in DMF was pre-activated for 5
minutes, then it
was added to the amine salt from the step above and allowed to stir overnight.
was partitioned between ethyl acetate and saturated sodium bicarbonate. The
organic phase was
concentrated and purified by silica gel chromatography. (103mg)
tert-butyl 2-15-(2-11-1N-(methoxycarbonyl)yaly11-4-(methoxymethyl)pyrrolidin-2-
y11-1,11-
dihydroisochromeno14',3':6,71naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y11-4-
The title compound was obtained as in example LQ but using methyl R2S)-1-
ethoxy-249-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-y1)- 1,11 -
dihydroisochrorrieno[41,31:6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-1 -y11-3
-methyl-1 -oxobutan-2-
yl]carbamate (103mg, 0.154mmol) in place of tert-butyl 2-[9-(4,4,5,5-
2-y1)-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-
yl]pyrrolidine-l-carboxylate and
methyl (S)-1-((S)-2-(5-iodo-1H-imidazol-2-yl)pyrrolidin-l-y1)-3-methyl-l-
(58mg, 0.154mmol)in place of methyl (S)-1-((S)-2-(5-bromo-1H-imidazol-2-
methyl-1-oxobutan-2-ylcarbamate. (50.0mg)
methyl 11-14-(methoxymethyl)-2-19-12-(4-methylpyrrolidin-2-y1)-1H-imidazol-5-
yli-1,11-
dihydroisochromenop',3':6,71naphtholl,2-diimidazol-2-ylIpyrrolidin-1-y11-3-
oxobutan-2-y1}earbamate
tert-butyl 2-[5-(2-{14N-(methoxycarbonyl)valy1]-4-(methoxymethyppyrrolidin-2-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y11-4-
1-carboxylate (50mg, 0.063mmol) was treated with 2mL 1.25N HC1 in ethanol and
heated at 60 C for
2h, then it was concentrated under reduced pressure and pumped dry under high
vacuum and used
directly in the next step.
methyl 11-12-{9-12-(1-11(methoxycarbonyl)aminol(phenypacetyl}-4-
methylpyrrolidin-2-y1)-1H-
imidazol-5-y1J-1,11-dihydroisochromenopl',3%6,71naphtho11,2-dlimidazol-2-y1}-4-
1 5 (methoxymethyl)pyrrolidin-1-y11-3-methyl-l-oxobutan-2-y1}carbamate
A mixture of (R)-2-(methoxycarbonylamino)-2-phenylacetic acid (13mg,
COMU (30mg, 0.069mmol) in 0.500mL DMF and DIPEA (0.033mL, 0.189mmol) was
allowed to
preactivate for 15 minutes before it was added to the solid crude amine salt
from the previous step and
stirred overnight. The product was purified by reverse phase HPLC. The product
was converted to
the free base by dissolution in 2mL 1:1 acetonitrile:methanol and passage
through a prepacked
cartridge of polymer supported carbonate. Concentration and drying gave an off
white powder.
(23.3mg).
MS (ESI) m/z 883.8 [M + Hr
'H NMR (CD3CN) 8.176 (s, 1H), 7.778 (m, 1H), 7.596-7.521 (m, 4H), 7.455-7.347
(m, 6H),
7.218 (s, 1H), 5.482 (s, 1H), 5.310 (m, 1H), 5.192 (m, 1H), 4.999 (q, 2H, J=
14 Hz), 4.372 (d, 1H, J-
6 .4 Hz), 4.279 (m, 1H), 3.800-3.697 (m, 2H), 3.632 (s, 3H) 3.597-3.445 (m,
7H), 3.355 (s, 3H), 2.876
(m, 2H), 2.761 (m, 1H), 2.583 (m, 2H), 2.220 (m, 2H), 1.764 (m, 1H), 1.070 (d,
3H, J= 6.4 Hz),
1.020 (d, 3H, J = 6.4 Hz), 0.898 (d, 3H, J = 6.4 Hz).
Example PG
41, N
N ch.0
0,,
methyl [(25)-3-methy1-1-{(25,45)-4-methyl-2-[9-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-y1)-1,11-dihydroisochromeno[43':6,7]naphtho[1,2-
d]imidazol-2-yl]pyrrolidin-1-y1}-1-oxobutan-2-ylicarbamate
=0 0
N ..,=K HCI
tert-butyl (2S,4S)-2-[5-(2-{(2S,4S)-1-[N-(methoxycarbony1)-L-valy1]-4-
methylpyrrolidin-2-y1}-1,11-dihydroisochromenoW,3':6,7Thaphthop,2-
cilimidazol-9-y1)-1H-imidazol-2-y11-4-methylpyrrolidine-1-carboxylate
Moc-D-PhGly-OH,
N\ =41=YN
N COMU, DIPEA, DMF
methyl {(25)-3-methy1-1-[(25,45)-4-methyl-2-(9-{2-[(25,45)-4-methylpyrrolidin-
2-y11-1H-imidazol-5-y1}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-2-yhpyrrolidin-1-y1]-1-oxobutan-2-yl}carbamate
N \ 41
1-1µ
methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(2S,4S)-1-{(2S)-2-[(methoxycarbonypamino]-
3-methylbutanoy1}-4-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3:6,7]naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-2-y1)-
4-methylpyrrolidin-1-yI]-2-oxo-1-phenylethyllcarbamate
tert-butyl (2S,4S)-2-15-(2-{(2S,4S)-1-IN-(methoxycarbony1)-L-valy11-4-
1,11-dihydroisochromeno[4',3':6,71naphtholl,2-dlimidazol-9-y1)-1H-imidazol-2-
1(2S,4S)-4-methyl-249-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y1)-1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-dlimidazol-2-yl]pyrrolidin-1-y11-1-
yl]carbamate (307mg, 0.481mmol) in place of tert-butyl 249-(4,4,5,5-
2-y1)-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-
yllpyrro1idine-1-carboxylate and
(181mg, 0.481mmol)in place of methyl (S)-1-((S)-2-(5-bromo-1H-imidazol-2-
yl)pyrrolidin-l-y1)-3-
methyl-1 -oxobutan-2-ylcarbamate. (200.8mg)
methyl {(2S)-3-methyl-l-R2S,4S)-4-methyl-2-(9-{2-[(2S,4S)-4-methylpyrroliclin-
imidazol-5-y11-1,11-dihydroisochromeno14',3':6,71naphthoil,2-dpmidazol-2-
y1)pyrrolidin-1-y1]-
1-oxobutan-2-ylicarbamate
y11-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-djimidazo1-9-y1)-1H-imidazol-
methylpyrrolidine- 1 -carboxylate (200mg, 0.262mmol) was treated with 2mL
1.25N HC1 in ethanol
and heated at 60 C for 2h, then it was concentrated under reduced pressure and
pumped dry under
high vacuum and used directly in the next step.
methyl {(1R)-2-1(2S,4S)-2-(5-12-1(2S,4S)-1-{(2S)-2-1(methoxycarbonyl)aminol-3-
dihydroisochromeno14',3':6,7inaphthoH,2-
dlimidazol-9-y1}-1H-imidazol-2-y1)-4-methylpyrrolidin-1-y11-2-oxo-1-
COMU (30mg, 0.069mmol) in 1.5mL DMF was allowed to preactivate for 5 minutes
before it was
added to a solution of the amine from the previous salt in 1.5mL DMF and DIPEA
(0.137mL,
0.786mmo1) and stirred overnight. The product was purified by reverse phase
HPLC. The product
was converted to the free base by dissolution in 2mL 1:1 acetonitrile:methanol
and passage through a
prepacked cartridge of polymer supported carbonate. Concentration and drying
gave an off white
powder. (25.8mg).
MS (ESI)m/z 853.8 [M + H].
'H NMR (CD3CN) 8.164 (s, 1H), 7.781 (m, 1H), 7.609 (m, 2H), 7.535 (m, 2H),
(m, 6H), 7.229 (s, 1H), 5.482 (s, 1H), 5.290 (in, 1H), 5.191 (m, 1H), 4.997
(m, 2H), 4.372 (d, 1H, J=
6.4 Hz), 4.267 (in, 1H), 3.735-3.445 (m, 10H), 2.573 (in, 4H), 2.197 (m, 2H),
2.017 (in, 1H), 1.760
(m, 1H), 1.204 (d, 3H, J= 6.4 Hz), 1.068 (d, 3H, J = 6.4 Hz), 1.010 (d, 3H, J
= 6.8 Hz), 0.887 (d, 3H,
J = 6.8 Hz).
Example PH
10% Pd/C, H2 N
Bog ,N oo
N Bog
110 N Et0H
tert-butyl (2S,4S)-2-[5-(2-{(2S)-1- tert-butyl (2S,4S)-4-
(methoxymethyl)-2-(5-{2-[(2S)-
[(benzyloxy)carbonyl]pyrrolidin-2-y1}-1
pyrrolidin-2-y11-1 11-
,11-
dihydroisochromeno[4',3':6,7Inaphtho[1,2-
dihydroisochromeno[4',3':6,71naphtho[1,2-d)imidazol-9-y1)- d]imidazol-9-y1}-
1H-imidazol-2-yppyrrolidine-1-
1H-imidazol-2-y1]-4-(methoxymethyl)pyrrolidine-1- carboxylate
1) Moc-D-PhGly-OH, COMU,
2) HCI, Et0H
Jo-
-0 - 0 0
)LN 0
H \ p OH -0 - 0 N N\
'N= N N
k 0 HATU, DIPEA, DMF /0
H 1-1.NL
0- 0 0--
methyl {(1R)-2-[(2S)-2-(9-{2-[(2S,4S)-4-(methoxymethyppyrrolidin-2-
y11-1H-imidazol-5-y1}-1,11-dihydroisochromeno[4',3.:6,7]naphtho[1,2- methyl
((1R)-2-[(2S)-2-(9-{2-[(2S.4S)-1-[N-(methoxycarbonyl)-0-
d]imidazol-2-y1)pyrrolidin-1-ylj-2-oxo-1-phenylethyl)carbamate
methyl-L-threony1]-4-(methoxymethyl)pyrrolidin-2-y1]-1H-imidazol-
5-y1}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-
y1)pyrr
011din-l-y1]-2-oxo-l-phenylethyl}carbamate
Moc-Val-OH, HATU,
N\ /\
¨ =N
14N-e)
methyl {(2S)-1-[(2S,4S)-2-(5-{2-[(2S)-1-{(2R)-2-
Rmethoxycarbonyl)amino1-2-phenylacetyllpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-
2-y1)-4-(methoxymeth
Apyrrolidin-1-y1]-3-methyl-l-oxobutan-2-yl}carbamate
tert-butyl (2S,4S)-2-15-(2-1(2S)-1-1(benzyloxy)carbonyllpyrrolidin-2-y1}-1,11-
dihydroisochromeno14',3':6,71naphtholl,2-dlimidazol-9-y1)-1H-imidazol-2-y11-4-
The title compound was obtained as in example OF (compound tert-butyl (2S,4S)-
2-[5-(2-
1 0 {(2S,5 S)- 1 [N-(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y1 -1
,4,5,1 1 -
tetrahydroisochromeno[4',31:6,71naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y1]-
(methoxymethyppyrrolidine-l-carboxylate) but using (S)-1 -
(benzyloxycarbonyl)pyrrolidine-2-
carboxylic acid in place of (2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-
methylpyrrolidine-2-carboxylic acid in step 6.
tert-butyl (2S,4S)-4-(methoxymethyl)-2-(5-{2-1(2S)-pyrrolidin-2-y1]-1,11-
dihydroisochromeno14',3':6,71naphtho[1,2-dlimidazol-9-y1}-1H-imidazol-2-
A mixture of tert-butyl (2S,4S)-245-(2-{(2S)-1-[(benzyloxy)carbonyl]pyrrolidin-
dihydroi sochromeno [4',3':6,7]naphtho [1,2-d]imidazol-9-y1)-1H-imidazo 1-2-
(methoxymethyl)pyrrolidine-1 -carboxylate (724mg, 0.96mmol) and 70mg 10%Pd/C
in 20mL ethanol
was hydrogenated at latm overnight. Additional 10%Pd/C (300mg) and a portion
of solid NaHCO3
was added and hydrogenation continued for 4 hours. Filtration through celite
and concentration of the
filtrate under reduced pressure gave the product as a dark brown solid, 454mg.
Purification by reverse
phase HPLC gave 65mg purified product.
methyl {(1R)-2-1(2S)-2-(9-12-1(2S,4S)-4-(methoxymethyl)pyrrolidin-2-y11-1H-
imidazol-5-y11-
1,11-dihydroisochromenop',3':6,71naphtholl,2-dllimidazol-2-y1)pyrrolidin-1-y11-
2-oxo-1-
COMU (45mg, 0.069mmol), and tert-butyl (2S,4S)-4-(methoxymethyl)-2-(5-{2-[(2S)-
pyrrolidin-2-
y1]-1,11 -dihydroisochromeno [4',3':6,7]naphtho[1,2-cliimidazol-9-y11-1H-
carboxylate (65mg, 0.105mmol) in 1.5mL 10% DIPEA in DMF was stirred for 1.5h.
mixture was partitioned between ethyl acetate and saturated sodium
bicarbonate. The organic phase
was dried over sodium sulphate, filtered and concentrated under reduced
intermediate was treated with 8mL 1.25N HC1 in ethanol at 50 C for 4h. Added
saturated sodium
bicarbonate and extracted the free base into dichloromethane. (106mg).
methyl {(2S)-1-1(2S,4S)-2-(5-{2-1(2S)-1-1(2R)-2-1(methoxyearbonyl)amino]-2-
phenylacetyl}pyrrolidin-2-y1]-1,11-dihydroisochromeno[4',31:6,71naphtholl,2-
dlimidazol-9-y11-
1H-imidazol-2-y1)-4-(methoxymethyppyrrolidin-1-y11-3-methyl-1-oxobutan-2-
A mixture of methyl {(1R)-2-[(2S)-2-(9-{2-[(2S,4S)-4-(methoxymethyppyrrolidin-
imidazol-5-y11-1,11-dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-
yppyrrolidin-l-y1]-2-
oxo-l-phenylethylIcarbamate (55mg, 0.077mmol), (S)-2-(methoxycarbonylamino)-3-
acid (14mg, 0.077mmol), HATU (32mg, 0.085mmol) and 0.4mL 10% DIPEA in DMF was
stirred at
room temperature for 1 hour. The product was purified by reverse phase HPLC.
The product was
converted to the free base by dissolution in 2mL 1:1 acetonitrile:methanol and
passage through a
prepacked cartridge of polymer supported carbonate. The eluent was
concentrated, the taken up in
I %TFA in 1:1 aeetonitrile:water, frozen, and lyophilized to give the product
as a trifluoroacetate salt.
(30.7mg)
MS (ESI) m/z 869.9 [M + H].
methyl 1(1R)-2-1(2S)-2-(9-12-R2S,4S)-1-1N-(methoxycarbony1)-0-methyl-L-
threony11-4-
(methoxymethyl)pyrrolidin-2-y11-1H-imidazol-5-y1}-1,11-
dihydroisochromeno14',3%6,71naphthol1,2-dlimidazol-2-yppyrrolidin-1-y11-2-oxo-
A mixture of methyl {(1R)-2-[(2S)-2-(9-{2-[(2S,4S)-4-(methoxymethyl)pyrrolidin-
imidazol-5-y1}-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-2-
yl)pyrrolidin-l-y11-2-
oxo-l-phenylethyllcarbamate (51mg, 0.072mmol), (2S,3R)-3-methoxy-2-
(methoxycarbonylamino)butanoic acid (14mg, 0.072mmol), HATU (30mg, 0.079mmol)
and 0.4mL
10% DIPEA in DMF was stirred at room temperature for 1 hour. The product was
purified by reverse
phase HPLC. The product was converted to the free base by dissolution in 2mL
acetonitrile:methanol and passage through a prepacked cartridge of polymer
supported carbonate.
The eluent was concentrated, the taken up in 1%TFA in 1:1 acetonitrile:water,
frozen, and lyophilized
to give the product as a trifluoroacetate salt. (24mg)
MS (ES!) m/z, 885.8 [M + H]';
7.164 (m,
1H), 6.983 (m, 1H), 6.747 (m, 2H), 6.127 (m, 1H), 5.584 (d, 1H, J= 6.4 Hz),
5.431 (m, 1H), 5.145
(m, 1H), 4.729 (s, 2H), 4.442 (m, 1H), 4.029 (m, 2H), 3.838 (m, 1H), 3.662-
3.534 (m, 2H), 3.572 (s,
3H) 3.552 (s, 3H), 3.444-3.310 (m, 3H), 3.240 (s, 3H), 3.225 (s, 3H), 2.618
(m, 1H), 2.464 (m, 1H),
2.304 (m, 1H), 2.129 (m, 1H), 2.041 (m, 1H), 1.899 (m, 2H), 1.107 (d, 3H, J=
6.4 Hz).
Example PI
0 H 0 H
Boq \ = 40 10% Pd/C, H2 Boc \
N N w N H
0 Et0H
"=\
tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-
[(benzyloxy)carbony1]-5-methylpyrrolidin-2-y11-1,11- tert-butyl (2S,4S)-4-
(methoxymethyl)-2-(5-(2-[(2S,5S)-5-
dihydroisochromeno[43',6,71naphtho[1,2- methylpyrrolidin-2-y1]-1,11-
d]imidazol-9-y1)-1H-imidazol-2-y1]-4-
(methoxymethyl)pyrrolidine-1-carboxylate y11-1H-imidazol-2-y1)pyrrolidine-1-
)\--N
-O -0 (2S,3R)-3-
p OH (methoxycarbonyla
mino)butanoic acid 0 H
1) HATU, DIPEA, DMF
H N N-Fr'N
2) HCI in Ethanol N ,L-N = N
r;j 0
methyl {(2S,3R)-3-methoxy-1-[(2S,5S)-2-(9-(2-[(2S,4S)-4-
(methoxymethyl)pyrrolidin-2-y1]-1H-imidazol-5-y1)-1,11-
dihydroisochromeno[4',3.:6,7]naphtho[1,2-cllimidazol-2-y1)-
5-methylpyrrolidin-1-y11-1-oxobutan-2-yl}carbamate
Moc-Val-OH, HATU, -0 N rcõN
DIPEA, DMF -)N WO N
--fcL
methyl {(2S)-1-[(2S,4S)-2-(5-(2-[(2S,5S)-1-{(2S,3R)-3-methoxy-2-
Rmethoxycarbonyl)aminojbutanoy1}-5-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3',6,7]naphtho[1,2-d]imidazol-9-y1}-1H-
y1)-4-(methoxymethyppyrrolidin-1-y1]-3-methyl-1-oxobutan-2-
tert-butyl (2S,4S)-215-(2-{(2S,5S)-1-1(benzyloxy)carbonyll-5-methylpyrrolidin-
2-y1}-1,11-
dihydroisochromenol4',3':6,71naphtho11,2-dlimidazol-9-y1)-111-imidazol-2-y11-4-
245-(2-
{(2S,5S)-14N-(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y11-1,4,5,11-
tetrahydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1)-1 H-imidazol-2-
I 0 (methoxymethyl)pyrrolidine-l-carboxylate) but using (2S,5S)-1-
(benzyloxycarbony1)-5-
methylpyrrolidine-2-carboxylic acid in place of (2S,5S)-1-((S)-2-
tert-butyl (2S,4S)-4-(methoxymethyl)-2-(5-{2-1(2S,5S)-5-methylpyrrolidin-2-y11-
dihydroisochromeno14',3':6,71naphtholl,2-dlimidazol-9-y1}-1H-imidazol-2-
A mixture of tert-butyl (2S,4S)-245-(2-1(2S,5S)-1-[(benzyloxy)carbonyl]-5-
methylpyrrolidin-2-y11-1,11-dihydroisochromeno[41,3':6,7]naphtho[1,2-
imidazol-2-y1]-4-(methoxymethyppyrrolidine- 1 -carboxylate (830mg, 1.08mmol)
and 100mg
10%Pd/C in 20mL ethanol was hydrogenated at latm overnight. Additional 10%Pd/C
(300mg) and a
portion of solid NaHCO3 was added and hydrogenation continued for 4 hours.
Filtration through
celite and concentration of the filtrate under reduced pressure gave the
product as a dark brown solid,
722mg. Purification by reverse phase HPLC gave 100mg purified product.
tert-butyl (2S,4S)-2-15-(2-{(2S,5S)-1-1N-(methoxycarbonyI)-0-methyl-L-
threonyll-5-
methylpyrrolidin-2-y1}-1,11-dihydroisochromeno14',3':6,71naphtholl,2-d I
imidazol-9-y1)-1H-
imidazol-2-yll-4-(methoxymethyl)pyrrolidine-l-carboxylate
A mixture of tert-butyl (2S,4S)-4-(methoxymethyl)-2-(5-{2-[(2S,5S)-5-
y1]-1,11-dihydroisochromeno [41,31:6,7]naphtho[1,2-d] imidazol-9-y1 -1H-
imidazol-2-yppyrrolidine-l-
carboxylate (101mg, 0.159mmol), (2S,3R)-3-methoxy-2-
(methoxycarbonylamino)butanoic acid
(30mg, 0.159mmol), HATU (61mg, 0.159mmol) and 2mL 10% DIPEA in DMF was stirred
at room
temperature for 1.5 hours. Saturated sodium bicarbonate was added and the
product was extracted
into dichloromethane, dried over sodium sulphate, filtered and concentrated
This crude product was treated with 5mL 1.25N HC1 in ethanol at 50 C for 4h
and then it was
concentrated under reduced pressure. Saturated sodium bicarbonate was added
and the product was
extracted into dichloromethane, dried over sodium sulphate, filtered and
pressure. (74.6mg)
methyl {(2S)-1-R2S,4S)-2-(5-12-1(2S,5S)-1-{(2S,3R)-3-m ethoxy-2-
Kmethoxycarbonyl)aminolbutanoy11-5-methylpyrrolidin-2-y11-1,11-
dihydroisochromeno[4',3%6,7]naphthoil,2-dlimidazol-9-y1}-1H-imidazol-2-y1)-4-
(methoxymethyl)pyrrolidin-l-y11-3-methy1-1-oxobutan-2-y1}carbamate
A mixture of methyl {(2S,3R)-3-methoxy-1-[(2S,5S)-2-(9-12-[(2S,4S)-4-
(methoxymethyppyrrolidin-2-y1]-1H-imidazol-5-y1 1-1 ,11-
d]imidazol-2-y1)-5-methylpyrrolidin- 1-y1]-1 -oxobutan-2-y1 carbamate (74.6mg,
0.1 05mmol), (S)-2-
(methoxycarbonylamino)-3-methylbutanoic acid (18.5mg, 0.105mmol), HATU (44mg,
0.116mmol)
and 0.6mL 10% DIPEA in DMF was stirred at room temperature for 1 hour. The
product was
purified by reverse phase HPLC. (48.1mg)
MS (ES!) m/z 866.1 [M +
Example PJ
o 1. 4N HCI in dioxane
H 2. HATU, DIPEA, DMF
--0 O N JAL wirm\\ 0
Nj"-N N Boc HO NHCH202Me
(S)-3-methy1-2-
(methylperoxymethylami
no)butanoic acid
F-t\
tert-butyl (2S,4S)-2-(9-{2-[(2S,4S)-1-[N-
(methoxycarbony1)-L-valy1]-4-
(trifluoromethyl)pyrrolidin-2-y1]-1H-imidazol-5-y1}-1,11-
2-yI)-4-(methoxymethy
1)pyrrolidine-1-carboxylate a/
¨o N it AL
\NN N
methyl {(1R)-2-[(2S,4S)-2-(9-{2-[(2S,4S)-1-{(2S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoy1}-4-
(trifluoromethyl)pyrrolidin-2-y1]-1H-imidazol-5-y11-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imid
azol-2-y1)-4-(methoxymethyppyrrolidin-1-y1]-2-oxo-1-
tert-butyl (2S,4S)-2-(9-12-1(2S,4S)-1-INI-(methoxycarbony1)-L-valy11-4-
(trifluoromethyl)pyrrolidin-2-y11-1H-imidazol-5-y11-1,11-
dihydroisochromenol4',3%6,71naphtho11,2-diimidazol-2-y1)-4-
The title compound was prepared as in example OF for compound tert-butyl
(2S,4S)-245-(2-
1(2S,5S)-14N-(methoxyearbony1)-L-valy1]-5-methylpyrrolidin-2-y11-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1 ,2-d]imidazol-9-y1)-1H-imidazol-2-y1]-4-
1 0 (methoxymethyl)pyrrolidine-l-carboxylate, by using (2S,4S)-1-((S)-2-
methylbutanoy1)-4-(trifluoromethyl)pyrrolidine-2-carboxylic acid in place of
butoxycarbony1)-4-(methoxymethyppyrrolidine-2-carboxylic acid and (2S,4S)-1-
(tert-
butoxycarbony1)-4-(methoxymethyppyrrolidine-2-carboxylic acid in place of
(2S,5S)-1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoy1)-5-methylpyrrolidine-2-carboxylic
methyl 1(1R)-2-1(2S,4S)-2-(9-12-1(2S,4S)-1-{(2S)-2-[(methoxyearbonyl)amino]-3-
methylbutanoy11-4-(trifluoromethyl)pyrrolidin-2-y11-1H-imidazol-5-y1}-1,11-
dihydroisochromeno14',3':6,71naphthol1,2-ctlimidazol-2-y1)-4-
2-oxo-1-phenylethyllearbamate
tert-butyl (2S,4S)-2-(9-12-[(2S,4S)-1 4N-(methoxycarbony1)-L-valy1]-4-
(trifluoromethyppyrrolidin-2-y1]-1H-imidazol-5-y11-1,11 -
dihydroisochromeno[4',31:6,7]naphthop ,2-
d]imidazol-2-y1)-4-(methoxymethyppyrrolidine-1-carboxylate (<0.412mmol, crude
from previous
step) was treated with 6mL 4N HC1 in dioxane at room temperature overnight and
then at 50 C for 1
hour. Diethyl ether (20mL) was added and the precipitate of hydrochloride salt
was collected by
vacuum filtration. (126mg, 0.16mmol). This material was combined with (R)-2-
(methoxycarbonylamino)-2-phenylacetic acid (34mg, 0.16mmol), COMU (70mg,
0.16mmol), and
1.6mL of 10% D1PEA in DMF. After 1 hour at room temperature, the mixture was
added dropwise
into 25mL saturated sodium bicarbonate, with stirring and the resulting
precipitate was collected by
vacuum filtration and washed with 2mL water. The product was purified, then re-
phase HPLC. (3.5mg).
MS (ESI) m/z 938.1 [M + Hr.
Example PK
H HCI
----\\/
0 1. HATU, DIPEA, DMF 0
2. LiAIH4, THF, -78- 0 C
glyoxal, NH4OH, Me0H
N---)LOH ___________________________________
(2S,4S)-1-(tert-butoxycarbonyI)-4-methylpyrrolidine-2- (2S,4S)-tert-butyl 2-
formy1-4-
carboxylic acid methylpyrrolidine-1-carboxylate
---\\/ 0 1. 12, Na2CO3, dioxane, H20 ---\\/ 0
2. Na2S03, Et0H, H20
_____________________________________________ vs- NJ-N1
. ,
4S)-tert-butyl
(2S,4S)-tert-butyl 2-(1H-imidazol-2-y1)-4-
(2S,yI)-4-meth
rrolidine-1-carbox2-(5-iodo-1H-imidazol-2-
methylpyrrolidine-1-carboxylate ylpy ylate
(2S,4S)-tert-butyl 2-formy1-4-methylpyrrolidine-l-earboxylate:
A mixture of (2S,4S)-1-(tert-butoxycarbony1)-4-methylpyrrolidine-2-carboxylic
acid (5.2g,
22.7 mmol), 0,N-dimethylhydroxylamine hydrochloride (2.4g, 24.9mmol), HATU
(10.4g, 27.2mmol)
and DIPEA (9.5mL, 54.5mmol) in 114mL DMF was stirred at room temperature
overnight. The
mixture was extracted into ethyl acetate and washed with saturated bicarbonate
and water, dried over
sodium sulphate, filtered, and concentrated. It was then dissolved in diethyl
ether (100mL) and
washed with water to remove residual DMF, dried, filtered, and concentrated to
a pale yellow oil
(5.30g, 19.5mmol) of (2S,4S)-tert-butyl 2-(methoxy(methyl)carbamoyI)-4-
carboxylate.
(2S,4S)-tert-butyl 2-(methoxy(methyl)carbamoy1)-4-methylpyrrolidine-l-
carboxylate (5.30g,
19.5mmol) was dissolved in 120mL THF, cooled to -78 C and treated with lithium
aluminum hydride
(1M in THF, 19.5mL, 19.5mmol) dropwise via addition funnel. After 1 hour, the
brought to 0 C and kept at that temperature for 2 hours. It was quenched by
dropwise addition of a
50mL solution of 3.0g KHSO4 in water, removed from the ice bath, and stirred
15 minutes at room
temperature. The product was extracted with three 75mL portions of ethyl
acetate and washed with
brine. The organic phase was dried over sodium sulphate, filtered, and
concentrated to give crude
(2S,4S)-tert-butyl 2-formy1-4-methylpyrrolidine-1-carboxylate. (4.89g)
(2S,4S)-tert-butyl 2-(1H-imidazol-2-y1)-4-methylpyrrolidine-1-carboxylate:
(4.89g,
22.9mmol), ammonium hydroxide (17mL) and water (17mL) was added, dropwise,
glyoxal (40% in
water, 14.6mL, 128mmol) and the resulting mixture was stirred at room
temperature overnight.
Saturated sodium bicarbonate (100mL) was added and the mixture was extracted
with four 75mL
portions of dichloromethane. The organic phase was washed with water, dried
over sodium sulphate,
filtered and concentrated, and then purified by silica gel chromatography to
give a total of 3.76g
carboxylate:
A mixture of (2S,4S)-tert-butyl 2-(1H-imidazol-2-y1)-4-methylpyrrolidine-1 -
(1.0g, 3.97mmol), iodine (2.22g, 8.75mmol) and sodium carbonate (1.3g,
12.31mmol) in 20mL
dioxane and 13.25mL water was covered in foil and stirred at room temperature
mixture was diluted with ethyl acetate and treated with 10% sodium thiosulfate
(5mL) and stirred for
10 minutes. The organic phase was washed with brine, and then the aqueous
phase was back
extracted with ethyl acetate. The combined organic phases were dried over
sodium sulphate, filtered
and concentrated to provide crude (2S,45)-tert-butyl 2-(4,5-diiodo-1H-imidazol-
methylpyrrolidine-1-carboxylate (2.25g) as a pale yellow solid.
A solution of (2S,4S)-tert-butyl 2-(4,5-diiodo-1H-imidazol-2-y1)-4-
carboxylate (2.25g, 4.4mmol) in 18mL ethanol and 18mL water was treated with
(5.59g, 44.4 mmol) and heated at 90 C overnight. The mixture was partitioned
between ethyl acetate
and water. The aqueous phase was extracted with more ethyl acetate and the
combined organic phase
was washed with brine, dried over sodium sulphate, filtered, concentrated, and
purified by silica gel
chromatography to give 766mg (2S,4S)-tert-butyl 2-(5-iodo-1H-imidazol-2-y1)-4-
1-carboxylate.
Example PL
Boc20
Bn0 H HCI DIPEA, DMAP Bn0
0 DCM 0
(2S,3aS,6aS)-benzyl (2S,3aS,6aS)-2-benzyl 1-tert-butyl
octahydrocyclopenta[b]pyrrole- hexahydrocyclopenta[b]pyrrole-
2-carboxylate hydrochloride 1,2(2H)-dicarboxylate
Pd/C, H2(excess)
V,01
Et0Ac HO Boc
(2S,3aS,6aS)-1-(tert-
butoxycarbonyl)octahydrocyclop
enta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-2-benzyl 1-tert-butyl hexahydrocyclopentalblpyrrole-1,2(2H)-
To a solution of commercially available (2S,3aS,6aS)-2-benzyl 1-tert-butyl
hexahydrocyclopenta[b]pyrrole-1,2(2H)-dicarboxylate (4.70 g, 16.68 mmol) in
(42 mL) was added Di-tert-butyl dicarbonate (7.28 g, 33.36 mmol) N,N-
diisopropylethylamine (5.82
mL, 33.36 mmol) and 4-(Dimethylamino)pyridine (0.20 g, 1.67 mmol). The
solution was stirred
under air for 16 hours. Upon completion, the reaction was concentrated in
vacuo, diluted in ethyl
acetate, and washed with IN HC1. The aqueous layers were backextracted twice
with ethyl acetate
and the combined organic layers were dried over sodium sulfate, filtered and
concentrated. The
resulting residue was purified by silica gel chromatography (5-40% ethyl
acetate in hexanes) to afford
(2S,3aS,6aS)-2-benzyl 1-tert-butyl hexahydrocyclopenta[b]pyrrole-1,2(2H)-
dicarboxylate which was
used without further purification. MS (ESI) m/z 368.47 [M + Na].
(2S,3aS,6aS)-1-(tert-butoxycarbonyl)octahydrocyclopentarblpyrrole-2-carboxylic
To a 250mL round bottom flask charged with a stir bar and (2S,3aS,6aS)-2-
benzyl 1-tert-
butyl hexahydrocyclopenta[b]pyrrole-1,2(2H)-dicarboxylate (5.76 g, 16.68 mmol)
was added 10%
Palladium on carbon (I .77g). Ethanol was poured over the mixture and the
evacuated and flushed with hydrogen gas three times. The suspension was
temperature under and atmosphere of hydrogen for 24 hours. Upon completion,
was filtered through celite and concentrated to give (2S,3aS,6aS)-1-(tert-
butoxycarbonypoctahydrocyclopenta[b]pyrrole-2-carboxylic acid (4.45g, >99%).
MS (ESI) m/z
256.21 [M + H].
Example PM
HO B00
0 (2S,3aS,6aS)-1-(tert- 0
0 butoxycarbonyl)octahydrocy 0
CI = clopenta[b]pyrrole-2- CI
Br carboxylic acid = O'>
9-bromo-3-chloro-10,11- (2S,3aS,6aS)-1-tert-butyl 2-(3-
dihydro-6H-naphtho[2,3- chloro-8-oxo-8,9,10,11-
c]chromen-8(9H)-one tetrahydro-6H-naphtho[2,3-
c]chromen-9-y1)
hexahydrocyclopenta[b]pyrrole-
01,2(2H)-dicarboxylate
N.KCSD
CI N
NH40Ac 110 N Boc Mn02
tert-butyl (3aS,6aS)-2-(9-chloro-1,4,5,12-
tetrahydrochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-2-yOhexahydrocyclopenta[b]pyrrole-
1(2H)-carboxylate
0 *H,71--)1 Ccõ)
Ny-CSN D 1) HC1 N
a. CI 41 46,
N II. 1
N Boc 2) HATU =
MocVal
tert-butyl (3aS,6aS)-2-(9-chloro-1,12- methyl {(2S)-1-[(2S,3aS,6aS)-2-(9-
chloro-
dihydrochromeno[4',3':6,7]naphtho[1,2-d]imidazol- 1 ,1 1-
2-yl)hexahydrocyclopenta[b]pyrrole-1 (2H)-
carboxylate d]imidazol-2-
yl)hexahydrocyclopenta[b]pyrrol-1 (2H)-y1]-3-
methyl-1 -oxobutan-2-yl}carbamate
0 H,1-7.-1)Cc3 Boc
Pd2dba3 An¨k r\J
-7L0 N
HN-e- tert-butyl 2-(5-
Bis-PinB imidazol-2-
XPhos methyl {(2S)-3-methyl-1-oxo-1- 0 carboxylate
[(2S,3aS,6aS)-2-[9-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yI)-1,1 1-
dihydroisochromeno[4',3':6,7]naphtho[l ,2- Pd(PPh3)4
dlimidazol-2- PdC1(dppf)
yl]hexahydrocyclopenta[b]pyrrol-1 (2H)-
yl]butan-2-ylIcarbamate
0 H...7H)C0
3c)t= N
N N NN
HN-e-
tert-butyl 2-[5-(2-{(2S,3aS,6aS)-1-[N-
valyl]octahydrocyclopenta[b]pyrrol-2-y1}-1 ,1 1 -
dihydroisochromeno[4',3':6,7]naphtho[1 ,2-
d]imidazol-9-y1)-1H-imidazol-2-yllpyrrolidine-1-
tert-butyl 2-15-(2-1(2S,3aS,6aS)-1-IN-(methoxyearbony1)-L-
yalylloctahydrocyclopentalblpyrrol-
2-y11-1,11-dihydroisochromeno14',3':6,7inaphtholl,2-dlimidazol-9-y1)-1H-
yllpyrrolidine-l-earboxylate
This compound was made in an analogous manner to tert-butyl (2R)-245-(2-{(2S)-
(methoxycarbony1)-L-valylipyrrolidin-2-y11-3,11-
dlimidazol-9-y1)-1F1-imidazol-2-yllpyrrolidine-1-carboxylate substituting
butoxycarbonypoctahydrocyclopenta[b]pyrrole-2-carboxylic acid for the initial
alkylation of 9-
bromo-3-chloro-10,11-dihydro-6H-naphtho[2,3-c]chromen-8(9H)-one. Reactions in
tert-butyl 245-(2-1(2S,3aS,6aS)-14N-(methoxycarbony1)-L-
valyl]octahydrocyclopenta[b]pyrrol-2-
y11-1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-dlimidazol-9-y1)-1H-imidazol-
2-yl]pyrrolidine- 1 -
carboxylate gave similar product yields as in the synthesis of tert-butyl (2R)-
245-(2-1(2S)-14N-
(methoxycarbony1)-L-valyl]pyrrolidin-2-y11-3,11-
dihydroisochromeno[4',3':6,71naphtho[1,2-
d]imidazol-9-y1)-1H-imidazol-2-yllpyrrolidine-l-carboxylate. MS (ES1) m/z
774.1 [M +
Example PN
N N 1) HCI
NBoc N *40,
0 HN-10_,...
2) COMU,
R-MocPhg
tert-butyl 2-[5-(2-{(2S,3aS,6aS)-14N-
valylloctahydrocyclopenta[b]pyrrol-2-y1}-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-cliimidazol-9-
y1)-1H-imidazol-2-ylipyrrolidine-1-carboxylate
HNO 0 HH)nõdi
o's
methyl {(1R)-2-[2-(5-{2-R2S,3aS,6aS)-1-{(2S)-2-[(methoxycarbonyl)amino]-
3-methylbutanoylloctahydrocyclopenta[b]pyrrol-2-y1]-1,11-
2-yppyrrolidin-1-y1]-2-oxo-1-phenylethylIcarbamate
methyl {(1R)-2-12-(5-12-1(2S,3aS,6aS)-1-{(2S)-2-1(methoxyearbonyl)aminol-3-
methylbutanoyl}oetahydrocyclopentarblpyrrol-2-y11-1,11-
dihydroisochromenol4',3':6,71naphtholl,2-dlimidazol-9-y1}-1H-imidazol-2-
y1)pyrrolidin-1-y11-2-
oxo-1-phenylethyllearbamate
To a solution of tert-butyl 2-[5-(2-{(2S,3aS,6aS)-14N-(methoxycarbony1)-L-
valyfloctahydrocyclopenta[b]pyrrol-2-yll-1,11-
dihydroisochromeno[41,31:6,7]naphtho[ 1 ,2-d]imidazol-
9-y1)-1H-imidazol-2-ylipyrrolidine-1-carboxylate (0.128 g, 0.165 mmol) in a
mL) and Me0H (0.33 mL) was added HC1 (4M in 1,4-dioxane, 1.24 mL, 4.9 mmol).
was stirred at room temperature for 1.5 h and concentrated to dryness.
The intermediate was dissolved in CH2C12 (1.6 mL). (R)-2-
phenylacetic acid (0.052 g, 0.25 mmol) and DIPEA (0.087 mL, 0.496 mmol) were
then added to the
solution. The reaction mixture was cooled to -40 C (external temperature,
MeCN/CO2(s) bath).
cOmU (0.113 g, 0.265 mmol) was then added and solution was allowed to warm to
0 C over 1.5 h.
Upon completion by LCMS, the solution was diluted with DMF and concentrated.
The crude product
was purified by preparative HPLC (Gemini column, 10-47% MeCN/H20 with 0.1%
TFA) and the
desired fractions were combined. The solution was concentrated until the
aqueous layer remained and
aqueous bicarbonate (sat.) was slowly added until the solution was basic. The
stirred at room temperature for 2h and filtered. The resulting solid was dried
in vacuo to provide
methyl {(1R)-242-(5-12-[(2S,3aS,6aS)-1-1(2S)-2-[(methoxycarbonypamino]-3-
methylbutanoylloctahydrocyclopenta[b]pyrrol-2-y1]-1,11-
d]imidazol-9-y11-1H-imidazol-2-yppyrrolidin-1-y1]-2-oxo-l-
phenylethylIcarbamate (0.068 g, 48%).
MS (ES!) m/z 865.7 [M +1-1]+. 'H NMR (400 MHz, cd3od) 6 8.44 - 8.30 (m, 1H),
(m, 2H), 7.81 -7.58 (m, 4H), 7.50 - 7.11 (m, 6H), 7.09 - 6.83 (m, 2H), 5.72 -
1H), 5.34 - 5.28 (m, 1H), 5.22 (s, 3H), 4.69 -4.64 (m, 1H), 4.26 - 4.19 (m,
1H), 4.03 - 3.98 (m, 1H),
3.96 - 3.91 (m, 1H), 3.66 (d, 4H), 2.98 - 2.91 (m, 1H), 2.88 - 2.83 (m, 1H),
2.58 - 2.48 (m, IH), 2.27
-2.12 (m, 4H), 2.11 -2.00 (m, 3H), 2.00 - 1.89 (m, 2H), 1.77 - 1.72 (m, 1H),
Example PO
tiL. .1) HCI
BOC)L0HN-1,0, 2) HATU,
S-MocVal
valylloctahydrocyclopenta[b]pyrrol-2-y11-1,11-
y1)-1H-imidazol-2-yl]pyrrolidine-1-carboxylate
H...7H)CP
reN w N
HN-10--
methyl {(2S)-1-[2-(5-{2-[(2S,3aS,6aS)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyl}octahydrocyclopenta[b]pyrrol-2-y1]-1,11-
dihydroisochromeno[4',3':6,71naphtho[1,2-d]imidazol-9-y11-1H-imidazol-
2-yppyrrolidin-1-y1]-3-methy1-1-oxobutan-2-ylIcarbamate
methyl {(2S)-1-12-(5-{2-1(2S,3aS,6aS)-1-{(2S)-2-1(methoxycarbonyl)amino1-3-
methylbutanoyl}oetahydrocyclopentalb]pyrrol-2-y11-1,11-
dihydroisochromeno[4',3%6,71naphtholl,2-d]imidazol-9-y1}-1H-imidazol-2-
y1)pyrrolidin-l-y11-3-
methyl-1-oxobutan-2-ylIcarbamate
To a solution of tert-butyl 245-(2-{(2S,3aS,6aS)-14N-(methoxycarbony1)-L-
dihydroisochromeno[41,31:6,7]naphtho[1,2-dlimidazol-
9-y1)-1H-imidazol-2-yl]pyrrolidine-1 -carboxylate (0.030 g, 0.039 mmol) in a
mixture of CH,CI, (0.39
mL) and Me0H (0.078 mL) was added HC1 (4M in 1,4-dioxane, 0.29 mL, 1.16 mmol).
The intermediate was dissolved in CH2C12 (0.39 mL). (S)-2-
methylbutanoic acid (0.007 g, 0.043 mmol) and DIPEA (0.020 mL, 0.116 mmol)
were then added to
the solution. HATU (0.018 g, 0.047 mmol) was added and solution was allowed to
stir at room temp.
Upon completion, the solution was diluted with DMF and concentrated. The crude
purified by preparative HPLC (Gemini column, 10-47% MeCN/H20 with 0.1% TFA)
and the desired
fractions were combined and lyophilized to provide methyl {(2S)-1 42-(5-{2-
[(2S,3aS,6aS)-1-{(2S)-2-
Rmethoxycarbonypamino]-3 -methylbutanoyl octahydrocyclopenta[b]pyrrol-2-y1]-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y11-1 H-imidazol-2-
methy1-1-oxobutan-2-yllcarbamate (0.010g, 31%). MS (ESI) m/z 832.2 [M +14]+.
Example PP
Ni .46N, Nim,s, r, erF\ii N 0 =
methyl [(1S)-2-[2-(5-{21(2S,3aS,6aS)-1-{(2S)-2-
methylbutanoylloctahydrocyclopenta[b]pyrrol-2-yl]-1 ,11-
dihydroisochromeno[4',3':6,71naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-
2-Apyrrolidin-1-y1]-2-0x0-1-(tetrahydro-2H-pyran-4-ypethyl]carbamate
methyl 1(1S)-2-12-(5-{2-1(2S,3aS,6aS)-1-{(2S)-2-1(methoxycarbonypaminol-3-
methylbutanoyl}oetahydrocyclopentalblpyrrol-2-yll-1,11-
dihydroisochromeno14',3%6,71naphtholl,2-dlimidazol-9-y1}-1H-imidazol-2-
yl)pyrrolidin-1-y11-2-
oxo-1-(tetrahydro-211-pyran-4-yl)ethyllearbamate
This compound was made in an analogous manner to methyl {(2S)-142-(5-12-
[(2S,3aS,6aS)-
1-{(2S)-2-[(methoxycarbonypamino]-3-
methyl-1-oxobutan-2-ylIcarbamate, substituting (S)-2-(methoxycarbonylamino)-2-
(tetrahydro-2H-
pyran-4-yl)acetic acid for (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid
to give methyl [(1S)-
242-(5-{2-[(2S,3aS,6aS)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
dihydroisochromeno[4',31:6,7]naphtho[l ,2-
d]imidazol-9-y1 -1H-imidazol-2-yl)pyrrolidin-l-y1]-2-oxo-1-(tetrahydro-2H-
pyran-4-
ypethydcarbamate (0.039, 56%). MS (ESI) m/z 874.34 [M + Hr. 'FINMR (400 MHz,
cd3od) 6 8.58
(s, 2H), 8.26¨ 8.08 (m, 2H), 7.96 ¨7.75 (m, 4H), 7.65 ¨7.54 (m, 5H), 5.36 ¨
4.04 (m, 4H), 3.97 ¨ 3.79 (m, 4H), 3.65 (s, 4H), 3.53 ¨ 3.44 (m, 2H), 2.68
¨2.47 (m, 4H), 2.32 ¨2.02
(m, 7H), 1.95 ¨ 1.82 (m, 3H), 1.77¨ 1.54 (m, 4H), 1.49¨ 1.24 (m, 5H), 1.10¨
0.85 (m, 4H).
Example PQ
.---0
0HH F 1) HCI
3o3)1I_ *N
N N N 'ss 2) COMU,
HN¨If0-- MocPhg
tert-butyl 215-(2-{(2S,4S)-4-[(difluoromethoxy)methy1]-
1-[N-(methoxycarbony1)-L-valyl]pyrrolidin-2-y11-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-dlimidazol-9-
0/ ---0
HNO0 1 i
0 1,17> F
N N 0 ='s
H\ II I
methyl {(1R)-2-[2-(5-{2-R2S,4S)-4-[(difluoromethoxy)methy1]-1-{(2S)-
24(methoxycarbonyl)amino]-3-methylbutanoyllpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3',6,7]naphtho[1,2-d]imidazol-9-y1}-1H-imid
azol-2-yl)pyrrolidin-1-y1]-2-oxo-1-phenylethyl}carbamate
tert-butyl 2-15-(2-{(2S,4S)-4-1(difluoromethoxy)methy1]-1-1N-(methoxyearbony1)-
valyllpyrrolidin-2-y1}-1,11-dihydroisochromeno14',3%6,71naphthol1,2-dpmidazol-
9-y1)-1 H-
imidazol-2-yllpyrrolidine-l-earboxylate
This compound was made in an analogous manner to tert-butyl 2-[5-(2-
1(2S,3aS,6aS)-14N-
(methoxycarbony1)-L-valylloctahydrocyclopenta[b]pyrrol-2-y11-1,11-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-
carboxylate substituting (2S,4S)-1-(tert-butoxycarbony1)-4-
((difluoromethoxy)methyppyrrolidine-2-
carboxylic acid for the initial alkylation of 9-bromo-3-chloro-10,11-dihydro-
6H-naphtho[2,3-
c]chromen-8(9H)-one. Reactions in the synthesis of tert-butyl 245-(2-{(2S,4S)-
Rdifluoromethoxy)methy1]-14N-(methoxycarbony1)-L-valyl]pyrrolidin-2-yll -1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d] imidazol-9-y1)-1H-imidazol-2-
carboxylate gave similar product yields as in the synthesis of tert-butyl 2-[5-
(2-{(2S,3aS,6aS)-1-[N-
(methoxycarbony1)-L-valyfloctahydrocyclopenta[b]pyrrol-2-y11-1,11-
dihydroisochromeno[4',3':6,71naphtho[1,2-djimidazol-9-y1)-1H-imidazol-2-
carboxylate. MS (ESI) miz 815.04 [M + F1] . 'H NMR (400 MHz, cd3od) 6 8.58 (s,
1H), 7.96 ¨ 7.85 (m, 3H), 7.70 (s, 1H), 7.60 (d, 1H), 7.50 ¨ 7.38 (m, 4H),
7.10 (s, 1H), 6.46 (t, 1H),
5.51 (s, 1H), 5.39 ¨ 5.36 (m, 1H), 5.31 ¨5.28 (m, 2H), 4.43 ¨ 4.36 (m, 1H),
4.24 (d, 1H), 4.13 ¨4.02
(m, 3H), 3.75 ¨ 3.62 (m, 7H), 3.51 ¨3.47 (m, 1H), 3.18 ¨ 3.11 (m, 2H), 2.93
¨2.83 (m, 2H), 2.75 ¨
2.69 (m, 1H), 2.47 ¨ 2.36 (m, 2H), 2.23 ¨2.09 (m, 3H), 2.01 ¨ 1.94 (m, 2H),
0.87 (dd, 6H).
Example PR
HO N
(1R,5R)-2-(tert- 0
0 butoxycarbony1)-2-
41 * azabicyclo[3.1.0Thexane-3- .1
* *Am
= Br carboxylic acid W
\N"
(1R,5R)-2-tert-butyl 3-(3-chloro-8-oxo-
9-bromo-3-chloro-10,11- 8,9,10,11-tetrahydro-6H-naphtho[2,3-
dihydro-6H-naphtho[2,3- c]chromen-9-y1) 2-
c]chromen-8(9H)-one azabicyclo[3.1.0]hexane-2,3-
.edicavrboxioylatNe N
0 H yrpr
0Mn02 CI
NH40Ac 1.,7H)C-7
CI * 14 NI Boc
tert-butyl (1R,5R)-3-(9-chloro-1,12-
tert-butyl (1R,3S,5R)-3-(9-chloro- dihydrochromeno[4',3':6,7]naphtho[1,2-
1,4,5,11- 2-azabicyclo[3.1.0]hexane-2-carboxylate
tetrahydroisochromeno[4',3':6,7]naphtho[
1,2-d]imidazol-2-y1)-2-
azabicyclo[3.1.0]hexane-2-carboxylate
0 1-1H)7
1) HCI
2) HATU NI N Pd2dba3
MocVal 41 .../C
HN-1 Bis-PinB
XPhos
methyl {(2S)-1-[(1R,3S,5R)-3-(9-chloro-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-y1)-2-
azabicyclo[3.1.0]hex-2-y11-3-methy1-1-oxobutan-2-
\ z.z
0¨ 0C.7
(2S,4S)-tert-butyl 2-(5- N N N \
0 H.,7H)C7 iodo-1H-imidazol-2-y1)- Kl3c
411. *ID%k (methoxym4e-thy H Hppyrrolid HN-e¨
IHN-10¨ ine-1-carboxylate 0
tert-butyl (2S,4S)-2-[5-(2-{(1 R,3S,5R)-2-[N-
0 Pd(PPh3)4
methyl [(2S)-3-methyl-1-oxo-1-{(1R,3S,5R)-3- PdC1(dppf)
azabicyclo[3.1.0]hex-3-y11-1,11-
[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
y1)-1,11- cl]imidazol-9-y1)-1H-
dihydroisochromeno[4',3':6,7Inaphtho[1,2- (methoxymethyl)py
d]imidazol-2-y1]-2-azabicyclo[3.1.0]hex-2-
rrolidine-1-carboxylate
yllbutan-2-yl]carba
1) HCl/dioxane
HNO 0 H.,7H)C7
0 N\ 0. NI N
2) R-MocPhg, COMU N * N
DIPEA, DCM HN-e¨
\ 0
methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(1R,3S,5R)-2-{(2S)-2-
Rmethoxycarbonyl)amino]-3-methylbutanoy11-2-
azabicyclo[3.1.0]hex-3-y1]-1,11-
dihydroisochromeno[43':6,7]naphtho[1,2-d]imidazol-9-y1}-1H-
-2-y1)-4-(methoxymethyl)pyrrolidin-1-y1]-2-oxo-1-
tert-butyl (2S,4S)-2-15-(2-{(1R,3S,5R)-2-1N-(methoxycarbony1)-L-valy1]-2-
azabicyclo13.1.01hex-
3-y1}-1,11-dihydroisochromeno14',3':6,71naphthol1,2-dlimidazol-9-y1)-1 H-
(methoxymethyl)pyrrolidine-1 -ca rboxy late
This compound was made in an analogous manner to tert-butyl (2R)-245-(2-1(2S)-
d]imidazol-9-y1)-1H-imidazol-2-yl]pyrrolidine-1 -carboxylate substituting
(1R,5R)-2-(tert-
butoxycarbony1)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid for the initial
alkylation of 9-bromo-3-
chloro-10,11-dihydro-6H-naphtho[2,3-c]chromen-8(9H)-one, and substituting
(2S,4S)-tert-butyl 2-(5-
iodo-1H-imidazol-2-y1)-4-(methoxymethyppyrrolidine-1-carboxylate for the
Suzuki- Miyara coupling.
Reactions in the synthesis of tert-butyl (2S,4S)-2-[5-(2-{(1R,3S,5R)-24N-
valy1]-2-azabicyclo[3.1.0Thex-3-y11-1,11-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-y1)-
1H-imidazol-2-y1]-4-(methoxymethyppyrrolidine- 1 -carboxylategave similar
synthesis of tert-butyl (2R)-2-[5-(2-{(2S)-14N-(methoxycarbony1)-L-
carboxylate. MS (ESI) m/z 791.0 [M + Hr.
methyl {(1R)-2-1(2S,4S)-2-(5-{2-1(1R,3S,5R)-2-{(2S)-2-1(methoxyearbonyl)amino]-
methylbutanoy1}-2-azabieyelo[3.1.01hex-3-y11-1,11-
dihydroisochromeno14',3':6,71naphtho11,2-
dlimidazol-9-y1}-1H-imidazol-2-y1)-4-(methoxymethyppyrrolidin-1-y11-2-oxo-1-
phenylethyl}earbamate
To a solution of tert-butyl (2S,4S)-2-[5-(2-{(1R,3S,5R)-24N-(methoxycarbony1)-
azabicyc1o3.1.0Thex-3-y11-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
diimidazol-9-y1)-11-1-
imidazol-2-y1]-4-(methoxymethyl)pyrrolidine-1-carboxylate (0.060 g, 0.076
CH2C12 (0.76 mL) and Me0H (0.15 mL) was added HC1 (4M in 1,4-dioxane, 0.570
mL, 2.28 mmol).
The solution was stirred at room temperature for 2 h and concentrated to
dryness.
The intermediate was dissolved in CH2C12 (0.76 mL). (R)-2-
phenylacetic acid (0.024 g, 0.114 mmol) and DIPEA (0.040 mL, 0.228 mmol) were
TFA) and
lyophilized to provide methyl {(1R)-2-[(2S,4S)-2-(5-{2-[(1R,3S,5R)-2-{(2S)-2-
[(methoxycarbonypamino]-3-methylbutanoy11-2-azabicycloP.1.0Thex-3-y11-1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y1}-1H-imidazol-2-y1)-4-
(methoxymethyppyrrolidin-l-y1]-2-oxo-l-phenylethylIcarbamate (0.028 g, 42%).
881.8 [M + Fl]+. 1H NMR (400 MHz, cd3od) ö 8.45 -8.33 (m, 1H), 8.02 - 7.94 (m,
1H), 7.91 -7.75
(m, 2H), 7.72 - 7.67 (m, 1H), 7.61 (s, 1H), 7.59 - 7.34 (m, 6H), 7.09 - 6.91
(m, 2H), 5.62 - 5.38 (m,
2H), 5.29 (t, 1H), 5.24 - 5.09 (m, 3H), 4.61 (d, 1H), 4.37 - 4.26 (m, 1H),
3.83 - 3.73 (m, 1H), 3.69 -
3.56 (m, 6H), 3.50 - 3.40 (m, 1H), 3.20 - 3.11 (m, 1H), 2.99 (s, 1H), 2.83 (d,
2H), 2.47 -2.34 (m, 2H), 2.29 - 2.13 (m, 2H), 2.10 - 1.95 (m, 2H), 1.37 - 1.23
(m, 3H), 1.19 - 1.10
(m, 1H), 1.03 -0.78 (m, 7H).
Example PS
0 [1.7H)n F 1) HCl/dioxane
3c\L
N N Boc 2) MocVal, HATU
H H DIPEA, DMF
tert-butyl (2S,4S)-2-(9-{2-R2S,5S)-1-(tert-
butoxycarbony1)-5-methylpyrrolidin-2-y1]-1H-
imidazol-5-y1}-1,11-
dihydroisochromeno[4',3'.6,7Thabhtho[1,2-
cl]imidazol-2-y1)-4-Rdifluoromethoxy)methyl]byrroli
dine-1 -carboxylate
HNO 0
N=
1.1,11--)1 N
lyal N
methyl {(2S)-1-R2S,5S)-2-(5-{2-[(2S,4S)-4-
[(difluoromethoxy)methyl]-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyl}pyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y1}
-1H-imidazol-2-y1)-5-methylpyrrolidin-1-y1]-3-methy1-1-oxobutan-
2-ylIcarbamate
tert-butyl (2S,4S)-2-(9-12-[(2S,5S)-1-(tert-butoxyearbony1)-5-methylpyrrolidin-
2-y11-11-1-
imidazol-5-y11-1,11-dihydroisochromeno[4',3%6,7Inaphtho[1,2-djimidazol-2-y1)-4-
1(difluoromethoxy)nethyllpyrrolidine-1-earboxylate
This compound was made in an analogous manner to tert-butyl (2S,4S)-245-(2-
1(2S,5S)-1-
[N-(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y11-1,11-
dihydroisochromeno[4',31:6,7]naphtho[1,2-d]imidazol-9-y1)-1H-imidazol-2-y1]-4-
(methoxymethyppyrrolidine-l-carboxylate substituting (2S,5S)-1-(tert-
1 0 methylpyrrolidine-2-carboxylic acid for the initial alkylation of 3-(2-
bromoacety1)-10,11-dihydro-5H-
dibenzo[c,dchromen-8(9H)-one, and substituting (2S,4S)-1-(tert-butoxycarbony1)-
((difluoromethoxy)methyl)pyrrolidine-2-carboxylic acid for the other
alkylation in the sequence.
Reactions in the synthesis of tert-butyl (2S,4S)-2-(9-12-[(2S,5S)-1 -(tert-
methylpyrrolidin-2-y1]-1H-imidazol-5-y11-1,11-
d]imidazol-2-y1)-4-[(difluoromethoxy)methyl]pyrrolidine- 1 -carboxylategave
similar product yields as
in the synthesis of tert-butyl (2S,4S)-245-(2-1(2S,5S)-14N-(methoxycarbony1)-L-
methylpyrrolidin-2-y11-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-
imidazol-2-y1]-4-(methoxymethyppyrrolidine-l-carboxylate. MS (ES!) m/z 772.03
[M +
methyl {(2S)-1-R2S,5S)-2-(5-42-1(2S,4S)-4-1(difluoromethoxy)methy11-1-{(2S)-2-
1(methoxycarbonyl)aminol-3-methylbutanoylIpyrrolidin-2-y11-1,11-
dihydroisochromeno14',3':6,71flaphtholl,2-d1imidazol-9-y1}-111-imidazol-2-y1)-
methylpyrrolidin-1-y11-3-methyl-l-oxobutan-2-ylIcarbamate
To a solution of tert-butyl (2S,4S)-2-(9-12-[(2S,5S)-1-(tert-butoxycarbony1)-5-
d]imidazol-2-y1)-4-[(difluoromethoxy)methyl]pyrrolidine-1-carboxylate (0.081
g, 0.105 mmol) in a
mixture of CH2Cl2 (1.05 mL) and Me0H (0.210 mL) was added HC1 (4M in 1,4-
dioxane, 0.788 mL,
3.15 mmol). The solution was stirred at room temperature for 2 h and
concentrated to dryness.
fractions were combined. The solution was concentrated until the aqueous layer
remained and
methyl {(2S)-1-[(2S,5S)-2-(5-{2-[(2S,4S)-4-[(difluoromethoxy)methyl]-1-1(2S)-2-
[(methoxycarbonypamino]-3-methylbutanoyll pyrrolidin-2-y11-1,11-
dihydroisochromeno[41,3?:6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-y1)-5-
y1J-3-methyl-1-oxobutan-2-yll carbamate (0.025 g, 27%). MS (ESI) m/z 886.1 [M
+ H1+. 'H NMR
(400 MHz, cd3od) 6 8.49 - 8.25 (m, 2H), 8.08 - 7.82 (m, 2H), 7.79 - 7.27 (m,
5H), 6.45 (t, 1H), 5.36
-5.26 (m, 1H), 5.22 - 5.07 (m, 3H), 4.78 - 4.49 (m, 2H), 4.45 -4.19 (m, 3H),
4.16 -4.05 (m, 2H),
3.99 - 3.92 (m, 1H), 3.85 -3.71 (m, 2H), 3.66 (s, 3H), 2.88 - 2.70 (m, 2H),
2.69 - 2.49 (m, 2H), 2.42
-2.26 (m, 2H), 2.23 -2.10 (m, 2H), 2.07 - 1.87 (m, 3H), 1.51 (d, 2H), 1.34 -
1.20 (m, 2H), 1.17 -
0.76 (m, 12H).
Example PT
0 41 * iiiii
N 1 1) HCl/dioxane eie,N II \1 Boc
F¨& 2) MocVal, HATU
0¨ DIPEA, DMF
tert-butyl (2S,4S)-2-(5-{2-R2S,5S)-1-(tert-butoxycarbony1)-
5-methylpyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3.:6,7]naphtho[1,2-d]imidazol-9-y1}-
1H-imidazol-2-y1)-4-[(difluoromethoxy)methyl]pyrroli
dine-1-carboxylate
HN/0 0 HH1,,%
L N\ II N I \
I 11,....111111 41. N
0,NH
0J /0
methyl {(2S)-1-R2S,4S)-4-[(difluoromethoxy)methy1]-2-(5-{2-[(2S,5S)-1-
{(2S)-2-[(nnethoxycarbonyl)amino]-3-methylbutanoy1}-5-
methylpyrrolidin-2-yI]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imida
zol-9-y1}-1H-imidazol-2-y1)pyrrolidin-1-y1]-3-methyl-1-oxobutan-2-
methyl {(2S)-1-1(2S,4S)-4-1(difluoromethoxy)methyll-2-(5-{2-1-(2S,5S)-1-{(2S)-
l(methoxyearbonyl)aminol-3-methylbutanoy1}-5-methylpyrrolidin-2-y11-1,11-
dihydroisochromenol4',3':6,71naphtholl,2-dlimidazol-9-y11-1H-imidazol-2-
[N-(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-yll -1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y1)-11-1-imidazol-2-y1]-
I 0 (methoxymethyl)pyrrolidine-l-carboxylate substituting (2 S,4 S)-1-(tert-
((difluoromethoxy)methyppyrrolidine-2-carboxylic acid for the initial
alkylation of 3-(2-
bromoacety1)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one, and substituting
butoxycarbony1)-5-methylpyrrolidine-2-carboxylic acid for the other alkylation
in the sequence.
Reactions in the synthesis of tert-butyl (2S,4S)-2-(5-{2-[(2S,5S)-1-(tert-
methylpyrrolidin-2-y1]-1,11-dihydroisochromeno[4',31:6,7]naphtho[1,2-
imidazol-2-y1)-4-Rdifluoromethoxy)methyl]pyrrolidine- 1 -carboxylategave
similar product yields as in
the synthesis of tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-14N-(methoxycarbony1)-L-
methylpyrrolidin-2-yll -1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-
imidazol-2-y1]-4-(methoxymethy1)pyrro1idine- 1 -carboxylate. MS (ES!) m/z
methyl {(2S)-1-1(2S,4S)-4-1(difluoromethoxy)methyll-2-(5-12-1(2S,5S)-1-{(2S)-2-
dihydroisochromeno[4',31:6,7]naphthol1,2-dlimidazol-9-y11-1H-imidazol-2-
To tert-butyl (2S,4S)-2-(5-{2-[(2S,5S)-1-(tert-butoxyearbony1)-5-
1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y11-1H-imidazol-2-
Rdifluoromethoxy)methyljpyrrolidine-l-carboxylate (0.057 g, 0.074 mmol) in a
mixture of CH2C12
(0.739 mL) and Me0H (0.148 mL) was added HCI (4M in 1,4-dioxane, 0.555 mL,
2.218 mmol). The
solution was stirred at room temperature for 2 h and concentrated to dryness.
The intermediate was dissolved in CH2Cl2 (0.739 mL). (S)-2-
fractions were combined and lyophilized to provide methyl {(2S)-1-[(2S,4S)-4-
[(difluoromethoxy)methyl]-2-(5-{2-[(2S,5S)-1-{(2S)-24(methoxycarbonyl)amino]-3-
methylbutanoy11-5-methylpytTolidin-2-y11-1,11-
d]imidazol-9-y1}-1H-imidazol-2-yl)pyrrolidin-1-y1]-3-methyl-1-oxobutan-2-
yllcarbamate (0.011 g,
17%). MS (ESI) in/z 886.1 [M + 11-1 NMR (400 MHz, cd3od) 6 8.67 ¨ 8.51 (m,
1H), 8.26¨ 8.11
(m, 1H), 8.04 ¨ 7.75 (m, 3H), 7.69 ¨ 7.58 (m, 2H), 6.43 (t, 1H), 5.41 ¨5.15
(m, 4H), 4.48 ¨ 3.90 (m,
6H), 3.82 (s, 1H), 3.71 ¨3.57 (m, 5H), 3.53 ¨3.43 (m, 1H), 3.20 ¨ 3.01 (m,
2.60 ¨ 2.25 (m, 4H), 2.15 ¨ 1.86 (m, 4H), 1.57 (d, 3H), 1.24 (d, 2H), 1.07
(dd, 2H), 0.98 ¨ 0.77 (m,
Example PU
)---F
0 1,1,71-1)n
N N F 1) HCl/dioxane
=N Boc
H H 2) MocVal, HATU
\ DIPEA, DMF
tert-butyl (2S,4S)-2-[5-(2-{(2S,4S)-1-(tert-
[(difluoromethoxy)methyl]byrrolidin-2-y1}-1 -
dihydroisochromeno[4',3':6,7]naphtho[i ,2-
(methoxymethy
hbyrrolidine-1-carboxylate
0 .--0
1-1,h7)-1
-Thsss 11 \ It N Al
I N o'ss
methyl {(2S)-1 -[(2S,4S)-2-(5-{2-[(2S,4S)-4-[(difluoromethoxy)methyl]-
1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-y1]-
1 ,11-dihydroisochromeno[4',3':6,7]naphtho[1 ,2-d]imidazol-9-y1)
-1 H-imidazol-2-y1)-4-(methoxymethyppyrrolidin-1-y1]-3-methy1-1-
tert-butyl (2S,4S)-2-15-(2-{(2S,4S)-1-(tert-butoxyearbonyI)-4-
[(difluoromethoxy)methyl]pyrrolidin-2-y1}-1,11-
dihydroisochromenop',3%6,71naphthol1,2-
dlimidazol-9-y1)-1H-imidazol-2-y1]-4-(methoxymethyl)pyrrolidine-l-carboxylate
[N-(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y1 -1,11 -
dihydroisochromeno [4',3':6,7]naphtho[1,2-dlimidazol-9-y1)-1H-imidazol-2-y1]-4-
(methoxymethyppyrrolidine-l-carboxylate substituting (2S,4 S)-1-(tert-
(methoxymethyl)pyrrolidine-2-carboxylic acid for the initial alkylation of 3-
(2-bromoacety1)-10,11-
dihydro-5H-dibenzo[c,dchromen-8(9H)-one, and substituting (2S,4S)-1-(tert-
Reactions in the synthesis of tert-butyl (2S,4S)-245-(2-{(2S,4S)-1-(tert-
[(difluoromethoxy)methyl]pyrrolidin-2-y11-1,11-
1 5 d]imidazol-9-y1)-1H-imidazol-2-y1]-4-(methoxymethyppyrrolidine-l-
carboxylate gave similar
product yields as in the synthesis of tert-butyl (2S,4S)-245-(2-{(2S,5S)-14N-
valy1]-5-methylpyrrolidin-2-y11-1,11-dihydroisochromeno[4',3':6,7]naphthop ,2-
imidazol-2-y1]-4-(methoxymethyppyrrolidine- 1 -carboxylate. MS (ESI) m/z 801.1
methyl {(2S)-1-1(2S,4S)-2-(5-12-K2S,4S)-4-1(difluoromethoxy)methy11-1-{(2S)-2-
1(methoxycarbonyl)aminol-3-methylbutanoyl}pyrrolidin-2-y1l-1,11-
dihydroisochromeno14',3%6,71naphtho[1,2411imidazol-9-y1}-1H-imidazol-2-y1)-4-
(methoxymethyl)pyrrolidin-1-y1F-3-methyl-1-oxobutan-2-ylicarbamate
To tert-butyl (2S,4S)-2-[5-(2-{(2S,4S)-1-(tert-butoxycarbony1)-4-
[(difluoromethoxy)methyl]pyrrolidin-2-y11-1,11
d]imidazol-9-y1)-1H-imidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate
(0.092 g, 0.115
mmol) in a mixture of CH2C12 (1.15 mL) and Me0H (0.230 mL) was added HC1 (4M
in 1,4-dioxane,
0.862 mL, 3.446 mmol). The solution was stirred at room temperature for 2 h
and concentrated to
The intermediate was dissolved in CH2C12 (1.149 mL). (S)-2-
methyl { (2 S)-1-[(2S,4S)-2-(5-{ 2-[(2 S,4S)-4-[(d ifluoromethoxy)methy1]-1-
{(2 S)-2-
[(methoxycarbonyl)amino]-3-methylbutanoyllpyrrolidin-2-y1]-1,11-
(methoxymethyppyrrolidin-1-y1]-3-methyl-l-oxobutan-2-yllcarbamate (0.042 g,
m/z 916.30 [M + NMR (400 MHz, cd3od) 6 8.55 ¨ 8.25 (m, 1H), 8.15 ¨ 7.85
7.26 (m, 5H), 6.44 (t, 1H), 5.37 ¨ 5.02 (m, 4H), 4.47 ¨ 4.35 (m, 1H), 4.33
(m, 3H), 3.81 ¨3.45 (m, 11H), 3.39 (s, 3H), 2.90 ¨ 2.27 (m, 5H), 2.22¨ 1.92
(m, 4H), 1.12¨ 0.73 (m,
Example PX
0_0 9
F)(OH
F-OH 2,2-difluoro-2-
(fluorosulfonyl)acetic Hj--\
¨0FF
0 Boc 0 Boc
(2S,4S)-1-tert-butyl 2- Cul (2S,4S)-1-tert-butyl 2-
methyl 4- ACN, 40 C methyl 4-
(hydroxymethyl)pyrrolidin ((difluoromethoxy)methyl)pyr
e-1,2-dicarboxylate rolidine-1,2-dicarboxylate
HO)r- HV1\1'--\
((difluoromethoxy)methyl)pyrrol
idine-2-carboxylic acid
(2S,4S)-1-tert-butyl 2-methyl 4-((difluoromethoxy)methyl)pyrrolidine-1,2-
A 100 mL round-bottom flask was charged with (2S,4S)-1-tert-butyl 2-methyl 4-
(hydroxymethyl)pyrrolidine-1,2-dicarboxylate (3.33 g, 12.84 mmol), Cul (0.489
g, 2.56 mmol), and
anhydrous acetonitrile (57.1 mL). The reaction was heated to 45 C (ext. oil
bath). 2,2-difluoro-2-
(fluorosulfonyl)acetic acid (2.655 mL, 25.68 mmol) was added at 45 C over 30
minutes via syringe
pump. The reaction was heated for 30 minutes. Upon completion as monitored by
TLC, the reaction
mixture was cooled to room temperature and concentrated in vacuo. The crude
residue was diluted in
Et0Ac and washed with sodium bicarbonate (aq). The bicarbonate layer was back
extracted with
ethyl acetate twice. Combined organic layers were washed with brine, dried
filtered and concentrated. The resulting residue was further purified via
silica gel chromatography (10
to 40 % Et0Ac/Hexanes) to afford (2S,4S)-1-tert-butyl 2-methyl 4-
((difluoromethoxy)methyl)pyrrolidine-1,2-dicarboxylate (2.41 g, 61%). MS
(ESI)m/z 210.21 [M + H
- Boer.
(2S,4S)-1-(tert-butoxycarbony1)-4-((difluoromethoxy)methyl)pyrrolidine-2-
To a solution of (25,4S)-1-tert-butyl 2-methyl 4-
((difluoromethoxy)methyl)pyrrolidine-1,2-
dicarboxylate (2.41 g, 7.79 mmol) in a mixture of THF (39 mL) and Me0H (15.6
LiOH (2.5 M aqueous, 15.6 mL, 38.9 mmol). The resulting solution was stirred
for lb. Upon completion by TLC the reaction mixture was and acidified with
aqueous HCI (1N).
The desired product was extracted with CH2C12 (3x). The combined organic
layers were dried over
Na2SO4 and concentrated to provide (2S,4S)-1-(tert-butoxycarbony1)-4-
((difluoromethoxy)methyl)pyrrolidine-2-carboxylic acid (2.4 g, 99%). MS
(ESI)m/z 294.96 [M - Hr.
'H-NMR: 400 MHz, (acetone-d5) 5 (mixture of rotomers): 6.50 (t, 1H), 4.36-4.17
(m, 1H), 3.93 (d,
2H), 3.77-3.67 (m, 1H), 3.63-3.59 (m, 1H), 3.26-3.12 (m, 1H), 2.72-2.41 (m,
1.41 (s, 9H).
Example PY
0 H 1. HCI
BocN
11 2. COMU, DIPEA, DMF
NN7L¨N
0 -N 0 HO
H y N N
tert-butyl (2S,4S)-245-(2-{(2S,5S)-14N-(methoxycarbony1)-L-valy1]-5- (R)-2-
methylpyrrolidin-2-y11-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
dlimidazol-9-y1)-1H-imidazol-2-y1]-4-(methoxymethyppyrrolidine-1- 2-
0 N H
0 H _____________________________________
0 N 1\1=---(NN
111101 NN;-.N N
H y N
methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(25,4S)-1-{(2R)-2-
[(methoxycarbonyl)amino]-2-phenylacety1}-4-(methoxymethyppyrrolidin-
2-y11-1H-imidazol-5-y11-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
cl]imidazol-2-y1)-5-methylpyrrolidin-1-y1]-3-methyl-1-oxobutan-2-
Methyl {(2S)-1-1(2S,5S)-2-(9-{2-1(2S,4S)-1-1(2R)-2-1(methoxyearbonyl)aminol-2-
phenylacety1}-4-
(methoxymethyl)pyrrolidin-2-y1]-1H-imidazol-5-y1}-1,11-
dihydroisochromenol4',31:6,71naphtho[1,2-dlimidazol-2-y1)-5-methylpyrrolidin-1-
y11-3-methyl-
imidazol-2-y1]-4-(methoxymethyppyrrolidine- 1 -carboxylate (150 mg, 0.19 mmol)
in 1.25 N HC1 in
Et0H (3 mL) was stirred overnight then heated to 50 C for 3h. The reaction
was concentrated and
the crude material dissolved in DMF (2 mL). To this solution was added a
solution of (R)-2-
0.21 mmol).
To the resulting solution was added diisopropylethylamine (0.099 mL, 0.57
mmol). After stirring for
2h at room temperature, the reaction was quenched with IN HCI (0.200 mL) and
purified by HPLC.
After lyophilization, the TFA salt was dissolved in Et0Ac and washed with
saturated NaHCO3. The
organic phase was dried over Na2SO4 and concentrated. The free base was then
dissolved in
MeCN/H20 and lyophilized to afford methyl {(2S)-1-[(2S,5S)-2-(9-12-[(2S,4S)-1-
Rmethoxycarbonyl)amino]-2-phenylacety11-4-(methoxymethyppyrrolidin-2-y1]-1 H-
1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-djimidazol-2-y1)-5-
methylpyrrolidin-l-y1]-3-methyl-
1-oxobutan-2-ylIcarbamate (65 mg, 39%). LCMS-ESI+: calculated for C49H54N808:
882.4; observed
[M+1]+: 884.1. Diagnostic peaks in NMR 'H NMR (CD30D): 8.28 (s, 1H), 8.21 (s,
1H), 8.04 (s, 1H),
7.91-7.01 (m, 10H), 3.62 (s, 3H), 3.34 (s, 3H), 3.23 (s, 3H), 1.56 (d, 3H),
1.03 (d, 3H), 0.94 (d, 3H).
Example PY-1
0 410 0 HO
. * 0 0
* 11 0
Br = ______ Br = Br _______ Br = Br
3-(2-bromo-1- 9-bromo-3-(2-bromo-1-
hydroxyethyl)-1 0,1 1 - hydroxyethyl)-10,11- 9-bromo-3-
(2-bromoacetyI)-
dihydro-5H- dihydro-5H- 10,11-dihydro-5F-I-
d ibenzo[c,g]chromen- dibenzo[c,g]chromen- dibenzo[c,g]chromen-8(9H)-
8(9H)-one 8(9H)-one one
1 0 9-bromo-3-(2-bromoacety1)-10,11-dihydro-5H-dibenzok,glehromen-8(9H)-one
To 3-(2-bromo-1-hydroxyethyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one
(20.3g,
54.4 mmol) in DCM (365 mL) was added Me0H (22 mL) and pyridinium tribromide
(18.24 g, 57.0
mmol). After 2h, water was added (100mL) and after briefly agitating the
layers split and the bottom
organic layer was collected. The organic layer was then washed with 1M HC1
(100 mL) and the
bottom organic layer containing 9-bromo-3-(2-bromo-l-hydroxyethyl)-10,11-
dihydro-5H-
dibenzo[c,dchromen-8(9H)-one was collected. 400 MHz 'H NMR (CDC13) 7.75 (d, J
= 8.1 Hz, 1H),
7.68 (s, 1H), 7.61 (s, 1H), 7.42 (d, J = 7.5 Hz, 1H), 7.24 (s, 1H), 5.13 (s,
2H), 4.99-4.96 (m, 1H), 4.73
(dd, J = 4.1, 4.1 Hz, 1H), 3.69-3.66 (m, 1H), 3.58-3.53 (m, 1H), 3.35-3.27 (m,
2.58-2.44 (m, 2H), C-OH not observed.
To 9-bromo-3-(2-bromo-l-hydroxyethyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-
(approx. 54.4 mmol) in DCM (365mL) was added sodium bicarbonate (5.45 g),
sodium bromide (6.14
g), TEMPO (16.55 mg) and water (60 mL). The solution was cooled between 0-5 C
and 6% bleach
(91.5 mL) was added. After lh isopropyl alcohol (20 mL) was added and the
warmed to room temperature. Agitation was stopped, the layers separated and
the lower organic layer
was collected and concentrated removing approximately 345 g of solvent. The
slurry was filtered and
the cake washed with 50 mL water and then 50 mL DCM (pre-cooled to 5 C). The
solids were
collected and dried under vacuum to obtain 9-bromo-3-(2-bromoacety1)-10,11-
dibenzo[c,g]chromen-8(9H)-one (18.6 g, 76% yield). 400 MHz 'H NMR (CDC13) 6
8.03-8.01 (m,
1H), 7.85 (d, J= 8.2 Hz, 1H), 7.82 (s, 1H), 7.71 (s, 1H), 7.67 (s, 1H), 5.19
(s, 2H), 4.74 (dd, J= 4.1,
4.1 Hz, 1H), 4.45 (s, 2H), 3.37-3.29 (m, 1H), 2.99-2.92 (m,11-1), 2.59-2.46
(m, 2H); 100 MHz13C
NMR (CDC13) 6 190.4, 189.6, 154.2, 136.6, 134.1, 133.9, 132.9, 131.8, 129.3,
127.2, 125.6, 124.2,
123.3, 117.0, 68.1, 49.9, 31.8, 30.4, 25.5.
0 = 40 0 PyHBr3
ii ik 0
Br = 9:1 DCM/Me0H Br W. Br
3-(2-bromoacetyI)-10,11- 9-bromo-3-(2-
dihydro-5H- bromoacetyI)-10,11-
dibenzo[c,g]chromen- dihydro-5H-
8(9H)-one dibenzo[c,g]chromen-
9-bromo-3-(2-bromoacety1)-10,11-dihydro-5H-dibenzolc,gichromen-8(9H)-one
A mixture of 3-(2-bromoacety1)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one
6.95 mmol), pyridinium tribromide (2.56 g, 8.0 mmol), dichloromethane (22mL)
and methanol
(2.5mL) was stirred at about 20 C for 3 hours to obtain a slurry. The
precipitated product was
filtered , washed with dichloromethane (10mL) and dried in a vacuum oven at 40
C to give 9-bromo-
3-(2-bromoacety1)-10,11-dihydro-5H-dibenzo[c,gichromen-8(9H)-one (2.62 g, 84%
yield). 400 MHz
'H NMR (CDC13) 6 8.03-8.01 (m, 1H), 7.85 (d, J= 8.2 Hz, 1H), 7.82 (s, 1H),
7.71 (s, 1H), 7.67 (s,
1H), 5.19 (s, 2H), 4.74 (dd, J= 4.1, 4.1 Hz, 1H), 4.45 (s, 2H), 3.37-3.29 (m,
1H), 2.99-2.92 (m,1H),
2.59-2.46 (m, 2H).
41 0 TMS ____________________ = H
1.- TMS AK\ 0 TFA, to-120
41 ..
Cl =
PdC12(MeCN)2, X-Phos 65 C
K3PO4, MeCN, 65 C
3-chloro-10,11-dihydro- 3-((trimethylsilyl)ethyny1)-
5H- 10,11-dihydro-5H-
dibenzo[c,g]chromen- dibenzo[c,g]chromen-8(9H)-
8(9H)-one one
0 = . 0 PyHBr3 0 ii AL 0
Me III DCM, Me0H Br
35 C Will Br
3-acetyl-10,11-dihydro- 9-bromo-3-(2-bromoacetyI)-10,11-
5H- dihydro-5H-dibenzo[c,g]chromen-
dibenzo[c,g]chromen- 8(9H)-one
3-((trimethylsilypethyny1)-10,11-dihydro-5H-dibenzoic,glehromen-8(9H)-one
A 300 mL flask equipped with an overhead stirrer and a reflux condenser under
atmosphere of nitrogen was charged with 3-chloro-10,11-dihydro-5H-
dibenzo[c,g]chromen-8(9H)-
one (10.0g, 35.12 mmol), powdered anhydrous tripotassium phosphate (22.4 g,
105.4 mmol), XPhos
(1.34 g, 2.81 mmol), and PdC12(MeCN)2 (364 mg, 1.40 mmol). Acetonitrile (140
followed by TMSacetylene (18 mL, 141 mmol). The mixture was heated to 65 C.
After 6h, the
reaction was judged complete, and the mixture was cooled to 20 C. The mixture
was filtered through
a fritted funnel, and the filtercake was washed with acetonitrile. The
filtrate was concentrated to
about 150 mL under reduced pressure and extracted with heptane (50 mL, 3 x100
mL). N-Acetyl
cysteine (15 g) was added to the acetonitrile phase, and the mixture was
agitated for 5 h at 45 C. The
mixture was cooled to ambient temperature, filtered through a fritted funnel,
and the filtercake was
washed with acetonitrile. The filtrate was concentrated to about 120 mL under
Water (120 mL) was added and the mixture was agitated for 40 minutes at 45 C
and then cooled to
ambient temperature. After 30 minutes the mixture was filtered through a
fritted funnel to provide 3-
((trimethylsilypethyny1)-10,11-dihydro-5H-dibenzo[c,dchromen-8(9H)-one (4.07
g, 33.4% yield ) as
a yellow solid: 400 MHz 'El NMR (CDC13) 6 7.65 (d, J = 8.1 Hz, 1H), 7.60 (s,
(dd, J = 8.1, 1.4 Hz, 1H), 7.27 (s, 1H), 5.06 (s, 2H), 2.95 (t, J = 6.1 Hz,
2H), 2.67 ¨ 2.59 (m, 2H), 2.18
¨2.08 (m, 2H), 0.26 (s, 9H).
3-acety1-10,11-dihydro-511-dibenzoic,gichromen-8(9H)-one
A 20 mL vial with stir bar was charged with 3-((trimethylsilyl)ethyny1)-10,11-
dibenzo[c,g]chromen-8(9H)-one (850 mg, 2.44 mmol) and formic acid (9.8 mL).
heated to 65 C. After 3 h, the reaction was judged complete. The mixture was
reduced pressure; the resulting residue was taken up in CH2C12 and loaded onto
a prepacked 25g silica
gel cartridge. The product was purified by chromatography on a prepacked 80g
silica gel column
eluting with a solvent gradient from 5% to 85% Et0Ac/hexanes. The product
containing fractions
were combined and concentrated to provide 3-acety1-10,11-dihydro-5H-
one (616 mg, 86%): 400 MHz 'FINMR (CDC13) 6 8.00 ¨ 7.94 (m, 1H), 7.81 (d, J =
8.2 Hz, 1H), 7.77
(s, 1H), 7.64 (s, 2H), 5.16 (s, 2H), 2.98 (t, J = 6.1 Hz, 2H), 2.69 ¨ 2.64 (m,
2H), 2.63 (s, 3H), 2.21 ¨
A 20 mL vial with a stir bar was charged with 3-acety1-10,11 -dihydro-5H-
dibenzo[c,g]chromen-8(9H)-one (100 mg, 0.366 mmol), 9:1 CH2C12/Me0H (3.4 mL)
and pyridinium
tribromide (246 mg, 0.769 mmol). The solution was heated to 35 C. After 30
minutes, the reaction
was judged complete. The mixture was cooled to ambient temperature, diluted
with Et0Ac (50 mL)
and sequentially washed with saturated aqueous Na2S203 (20 mL), 2% aqueous
NaHCO3 (20 mL),
water (20 mL), and brine (10 mL). The organic phase was dried over MgSO4,
concentrated under reduced pressure resulting in 9-bromo-3-(2-bromoacety1)-
dibenzo[c,g]chromen-8(9H)-one (68 mg, 41%): 400 MHz ILINMR (CDCI3) 6 8.03 -
7.85 (d, J= 8.2 Hz, 1H), 7.82 (s, I H), 7.71 (s, 1H), 7.67 (s, 1H), 5.19 (s,
2H), 4.74 (dd, J= 4.1, 4.1
Hz, 1H), 4.45 (s, 2H), 3.37-3.29 (m, 1H), 2.99 -2.92 (m,1 H), 2.59 -2.46 (m,
K2CO3,
Br 0 40 jak\ o
Br õ,.L
CH2Cl2
9-bromo-3-(2- (2S,5S)-1-(tert-butoxycarbonyI)-
bromoacetyI)- 5-methylpyrrolidine-2-carboxylic
dibenzo[c,g]chrorn
en-8(9H)-one
N-7. Wr. Br
"Sc)
oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate
(2S, 5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzole,g]chromen-3-yI)-
9-bromo-3-(2-bromoacety1)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one (1.43
g, 3.17
mmol) was treated with a solution of (2S,5S)-1-(tert-butoxycarbony1)-5-
carboxylic acid (800 mg, 3.49 mmol) in dichloromethane (14 mL) and K2CO3 (658
The stirred reaction mixture was stirred at RT and diluted with CH2C12 and
extracted 3X. The organic
phase was washed with brine, then dried over MgSO4, filtered and concentrated
pressure to afford ((2S,5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-
dibenzo[c,g]chromen-3-y1)-
2-oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate (1.61 g, 84%).
This synthesis may be used to make a variety of compounds described herein,
including the
compound exemplified in PY.
Example PZ
Bo N /µ N2
2. HATU, NMM ).=
H ON,sss y 0
HO - )1,
H N 0
0 (S)-2-
tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyI)-L-valy1]-5-
methylpyrrolidin-2-y11-1,11-dihydroisochromeno[4',3.:6,7]naphtho[1,2-
d]imidazol-9-y1)-1H-innidazol-2-y11-4-(methoxymethyppyrrolidine-1-
0)LN-H
N AL N 2
0>No's
methyl {(2S)-1-R2S,5S)-2-(9-{2-[(2S,4S)-1-{(2S)-2-
Rmethoxycarbonyl)amino1-3-methylbutanoy1}-4-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidaz
ol-2-y1)-5-methylpyrrolidin-1-y1]-3-methyl-l-oxobutan-2-y1}carbamate
Methyl {(2S)-1-1(2S,5S)-2-(9-12-1(2S,45)-1-{(2S)-2-1(methoxycarbonyl)amino1-3-
methylbutanoy11-4-(methoxymethyl)pyrrolidin-2-y1]-1H-imidazol-5-y11-1,1 1-
dihydroisochromeno14',3':6,71naphtholl,2-dlimidazol-2-y1)-5-methylpyrrolidin-1-
y11-1,11-dihydroisochromeno[41,3':6,7]naphtho [1,2-d] imidazol-9-y1)-1H-
(methoxymethyppyrrolidine-1-carboxylate (100 mg, 0.13 mmol) in 1.25 N HC1 in
Et0H (3 mL) was
heated to 50 C for 3h and then concentrated under reduced pressure. The crude
residue was treated
with (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (34 mg, 0.20 mmol),
HATU (54 mg, 0.14
mmol) and DMF (1.3 mL), then N-methylmorpholine (0.043 mL, 0.39 mmol) was
added dropwise.
After 3h, the mixture was quenched with IN HC1 (0.100 mL) and then purified by
HPLC to afford
methyl {(2S)-14(2S,5S)-2-(9-{ 2-[(2S,4S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-
methylbutanoyll
4-(methoxymethyppyrrolidin-2-y1]-1H-imidazol-5-y11-1,11-
dihydroisochromeno[41,31:6,7]naphtho[1,2-dlimidazol-2-y1)-5-methylpyrrolidin-1-
y1]-3-methy1-1-
oxobutan-2-y1 carbamate ( 91 mg, 82%).
LCMS-ESL: calculated for C46H56N808: 848.4; observed [Whi]': 850.2.
Example QA
Boc N ,NN 2. HATU, NMM, DMF
N2s,
N =N
HO,- ,
HN N
d]imidazol-9-y1)-1H-imidazol-2-y1]-4-(methoxymethyl)pyrrolidine-1- butanoic
IDAN-E1 0
N 410 /AL
methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2S,3S)-3-methoxy-2-
[(methoxycarbonyl)amino]butanoy11-4-(methoxymethyl)pyrrolidin-2-
y1]-1H-imidazol-5-01-1,11-
dihydroisochromeno[4',3:6,7]naphtho[1,2-d]imidazol-2-y1)-5-
methylpyrrolidin-1-y1]-3-methyl-1-oxobutan-2-ylIcarbamate
Methyl {(2S)-1-1(2S,5S)-2-(9-{2-1(2S,4S)-1-{(2S,3S)-3-methoxy-2-
[(methoxycarbonyl)aminoibutanoy1}-4-(methoxymethyppyrrolidin-2-y1]-1H-imidazol-
1,11-dihydroisochromeno[4',3':6,71naphtholl,2-dlimidazol-2-y1)-5-
methylpyrrolidin-1-y1]-3-
methyl-1-oxobutan-2-yl}carbamate
Tert-butyl (2S,4S)-245-(2-1(2S,5S)-1 4N-(methoxycarbony1)-L-valy1]-5-
y1 1-1,11-dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-9-y1)-1H-
(methoxymethyppyrrolidine- 1 -carboxylate (119 mg, 0.15 mmol) in 1.25 N HC1 in
with (2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid (43 mg, 0.23
mmol), HATU (63
mg, 0.17 mmol) and DMF (2 mL), then N-methylmorpholine (0.050 mL, 0.45 mmol)
dropwise. After 3 hr, the mixture was quenched with 1N HC1 (0.100 mL) and then
purified by HPLC
to afford methyl { (2S)- 1-[(2S,5 S)-2-(9-{ 2-[(2S,4S)-1-{ (2S,3S)-3-methoxy-2-
[(methoxycarbonypamino]butanoy11-4-(methoxymethyppyrrolidin-2-y1]-1H-imidazol-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-y1)-5-methylpyrrolidin-l-
y1]-3-methyl-1-
oxobutan-2-ylIcarbamate ( 76 mg, 59%).
LCMS-ESI+: calculated for C46H56N809: 864.4; observed [M+1]+: 866.1.
Example QB
Boc N 2,HATU,DIPEA
HOr, Ncr
(2S,4S)-tert-butyl 2-(5-bromo-1 H- (2S,3S)-2-
imidazol-2-y1)-4-methylpyrrolidine-1- (methoxycarbonylamino)-3-
carboxylate methylpentanoic acid
)NH 0 H
+ 11 41. Ni Boc
çNNJBr H
tetramethyl-1,3,2-dioxaborolan-2-y1)- 1,11-
methyl (2S,3S)-1-((2S,4S)-2-(5-bromo-1 H-
imidazol-2-y1)-4-methylpyrrolidin-l-y1)-3-
d]imidazol-2-yhpyrrolidine-1-carboxylate
methyl-1-oxopentan-2-ylcarbamate
ON.H
Pd(PPh3)4,is,
N AL N-3(Nri
1111, N Boc
Pd(dppf)2C12,
DME=
8500 tert-butyl (2S,4S)-249-(2-{(2S,4S)-14N-
(methoxycarbony1)-
L-alloisoleucyl]-4-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-
1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-
2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate
1. HCI ONH 0 H \
2. COMU, DIPEA, DNIF \ = 40 W
e No el
HO N0-N
0 H 0
(R)-2-(methoxycarbonylamino)- methyl
{(1R)-2-[(2S,4S)-2-(9-{2-[(2S,4S)-1-{(2S,3R)-2-
2-phenylacetic acid [(methoxycarbonyl)amino]-3-methylpentanoyI}-4-
2-y11-1H-imidazol-5-y1}-1,11-
yI)-4-(methoxymethyl)pyrrolidin-1-y1]-2-oxo-1-
Methyl (2S,3S)-1-42S,4S)-2-(5-bromo-1H-imidazol-2-y1)-4-methylpyrrolidin-1-y1)-
3-methyl-1-
oxopentan-2-ylcarbamate
(2S,4S)-tert-butyl 2-(5-bromo-1H-imidazol-2-y1)-4-methylpyrrolidine-1-
mg, 0.13 mmol) in 1.25 N HC1 in Et0H (15 mL) was heated to 50 C for 3h and
then concentrated
under reduced pressure. The crude residue was treated with (2S,3S)-2-
methylpentanoic acid (625 mg, 3.30 mmol), HATU (1.05 g, 2.77 mmol) and DMF (10
DIPEA (1.33 mL, 7.62 mmol) was added dropwise. After 2h, the mixture was
poured into saturated
aqueous NaHCO3 and then extracted with Et0Ac. The organic phase was washed
with successively
with 5% aqueous LiCI and Brine. The organics were dried over Na2SO4, filtered
chromatography (30 to 90%
of 10%Me0H/EtoAc to Hexanes) afforded methyl (2S,3S)-1-((2S,4S)-2-(5-bromo-1H-
1 0 4-methylpyrrolidin-l-y1)-3 -methyl-1 -oxopentan-2-ylcarbamate ( 932 mg,
Tert-butyl (2S,4S)-2-19-(2-{(2S,4S)-1-IN-(methoxyearbony1)-L-alloisoleuey11-4-
2-y1}-1H-imidazol-5-y1)-1,11-dihydroisochromeno 14',3%6,7Inaphtho I 1,2-di
(methoxymethyl)pyrrolidine-1 -carboxylate
(2S,4S)-Tert-butyl 4-(methoxymethyl)-2-(9-(4,4,5,5-tetramethy1-1,3,2-
1,11-dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-yppyrrolidine-1-
1.4 mmol), methyl (2S,3S)-1-((2S,4S)-2-(5-bromo-1H-imidazol-2-y1)-4-
methylpyrrolidin-1-y1)-3-
methyl-1-oxopentan-2-ylcarbamate (932 mg, 2.1 mmol), Pd(PPh3)4 (162 mg, 0.14
PdC12(dppf)2 (102 mg, 0.14 mmol), and K2CO3(2M in H20, 2.31 mL, 4.62 mmol)
were combined in
DMSO (8 mL) and dioxanes (8 mL). The mixture was degassed with bubbling Argon
for 10 min the
heated to 95 C for lh. After cooling, the reaction mixture was diluted with
Et0Ac, and washed
successively with saturated aqueous NaHCO3 and brine. The organics were dried
over Na2SO4,
(methoxycarbony1)-L-alloisoleucy1]-4-methylpyrrolidin-2-y1 -1H-imidazol-5-y1)-
dihydroisochromeno[4',3':6,7]naphtho[1,2-djimidazol-2-y1]-4-
Methyl 1(1R)-2-1(2S,4S)-2-(9-12-1(2S,4S)-1-{(2S,3R)-2-1(methoxycarbonyl)amino1-
methylpentanoy1}-4-methylpyrrolidin-2-yli-1H-imidazol-5-y1)-1,11-
dihydroisochromeno14',3%6,71naphthol1,2-d]imidazol-2-y1)-4-
(methoxymethyl)pyrrolidin- 1-y1i-
2-oxo-1-phenylethylIcarbamate
A solution of tert-butyl (2S,4S)-249-(2-{(2S,4S)-14N-(methoxycarbony1)-L-
methylpyrrolidin-2-yll -1H-imidazol-5-y1)-1,11-
dihydroisochromeno[4',3':6,71naphtho [1,2-
d]imidazol-2-y1]-4-(methoxymethyppyrrolidine- 1 -carboxylate (218 mg, 0.27
mmol) in 1.25 N HC1 in
Et0H (3 mL) was heated to 50 C for 3h. The reaction was concentrated and the
dissolved in DMF (3 mL). To this solution was added a solution of (R)-2-
2-phenylacetic acid (73 mg, 0.35 mmol) and COMU (127 mg, 0.30 mmol). To the
was added diisopropylethylamine (0.141 mL, 0.81 mmol). After stirring for 2h
at room temperature,
the reaction was quenched with 1N HC1 (0.200 mL) and purified by HPLC. After
lyophilization, the
TFA salt was dissolved in Et0Ac and washed with saturated NaHCO3. The organic
phase was dried
over Na2SO4 and concentrated. The free base was then dissolved in MeCN/H20 and
lyophilized to
afford methyl {(1R)-2-[(2S,4S)-2-(9-12-[(2S,4S)-1-{(2S,3R)-2-
methylpentanoy11-4-methylpyrrolidin-2-y1]-1H-imidazol-5-y11-1,11-
dihydroisochromeno[41,3':6,71naphtho[ 1 ,2-dlimidazol-2-y1)-4-
(methoxymethyppyrrolidin- I -y1]-2-
oxo-l-phenylethyll carbamate
(121 mg, 50%). LCMS-ESI : calculated for C501-156N808: 896.4; observed [M+1]:
897.5.
Example QC
0)L 0 H \
N N\ 4/1
N 13oc 2. HATU, NMM
\Z 0
tert-butyl (2S,4S)-2-[9-(2-{(2S,4S)-1-[N-(methoxycarbonyI)-L-
alloisoleucy1]-4-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-1,11-
dihydroisochromeno[4',3.:6,7]naphtho[1,2-d]imidazol-2-y1]-4-(S)-2-
(methoxymethyl)pyrrolidine-1-carboxylate (methoxycarbonylamino
methylbutanoic acid)-3-
0-LN,H
0 H _______ \
N \ \ 1\--CN
methyl {(2S)-1-[(2S,4S)-2-(9-{2-[(2S,4S)-1-{(2S,3R)-2-
[(methoxycarbonyl)amino]-3-methylpentanoy11-4-methylpyrrolidin-2-y1J-
1H-imidazol-5-y1}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-
d]imidazol-2-y1)-4-(methoxyniethyppyrrolidin-1-y1]-3-methy1-1-
Methyl {(2S)-1-1(2S,4S)-2-(9-12-1(2S,4S)-1-{(2S,3R)-2-kmethoxycarbonyl)aminol-
dihydroisochromeno[4',3':6,71naphtho[1,2-dlimidazol-2-y1)-4-
3-methyl-1-oxobutan-2-ylIcarbamate
tert-butyl (2S,4S)-2-[9-(2-{(2S,4S)-11N-(methoxycarbony1)-L-alloisoleucyl]-4-
dihydroisochromeno[4',31:6,71naphtho[1,2-
d]imidazol-2-y1]-4-(methoxymethyl)pyrrolidine-1-carboxylate (105 mg, 0.13
mmol) in 1.25 N HCI in
Et0H (3 mL) was heated to 50 C for 3h and then concentrated under reduced
(32 mg, 0.18 mmol),
HATU (59 mg, 0.16 mmol) and DMF (1.3 mL), then N-methylmorpholine (0.043 mL,
0.39 mmol)
was added dropwise. After 3h, the mixture was quenched with IN HC1 (0.100 mL)
and then purified
by HPLC to afford methyl {(2S)-1-[(2S,4S)-2-(9-{2-[(2S,4S)-1-{(2S,3R)-2-
[(methoxycarbonyl)amino]-3-methylpentanoy11-4-methylpyrrolidin-2-y1]-1H-
imidazol-5-y11-1,11-
(methoxymethyppyrrolidin-l-y1]-3-
methy1-1-oxobutan-2-yllcarbamate ( 80 mg, 71%).
Example QD
0 H \
N -3(N N 1. HCI
__________________________________________________________________ =
44/. N Boo 2. HATU, NMM, DMF
tert-butyl (2S,4S)-2-19-(2-{(2S,4S)-14N-(methoxycarbony1)-L- HO,- ,
= /
alloisoleucyl1-4-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-1,11-
0 H .F
N 11 1\1=--rNI/
methyl {(2S,3R)-1-[(2S,4S)-2-(5-{2-[(2S,4S)-1-[N-
(methoxycarbonyI)-0-methyl-L-allothreony1]-4-
(methoxymethyl)pyrrolidin-2-y1]-1,11-
dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-9-y11-1H-
imidazol-2-y1)-4-methylpyrrolidin-1-y1]-3-methyl-1-oxopentan-2-
Methyl {(2S,3R)-1-1(2S,4S)-2-(5-{2-1(2S,4S)-1-IN-(methoxycarbony1)-0-methyl-L-
allothreonylj-
4-(methoxymethyDpyrrolidin-2-y11-1,11-dihydroisochromeno141,3':6,71naphthol1,2-
dlimidazol-
9-yll-IH-imidazol-2-y1)-4-methylpyrrolidin-1-yll-3-methyl-1-oxopentan-2-
tert-butyl (2S,4S)-2-[9-(2- {(2S,4S)-14N-(methoxycarbony1)-L-alloisoleucyl]-4-
dlimidazol-2-y1]-4-(methoxymethyppyrrolidine-1-carboxylate (105 mg, 0.13 mmol)
residue was treated with (2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic
acid (35 mg, 0.18
mmol), HATU (59 mg, 0.16 mmol) and DMF (1.3 mL), then N-methylmorpholine
mmol) was added dropwise. After 3 hr, the mixture was quenched with 1N HC1
(0.100 mL) and then
purified by HPLC to afford methyl {(2S,3R)-1-[(2S,4S)-2-(5-12-[(2S,4S)-14N-
(methoxycarbony1)-0-
methyl-L-allothreony1]-4-(methoxymethyl)pyrrolidin-2-y1]-1, I 1-
dihydroisochromeno [4',31:6,7]naphtho[1,2-d] imidazol-9-y11-1H-imidazol-2-y1)-
y1]-3-methy1-1-oxopentan-2-ylIcarbamate ( 92 mg, 81%).
Example QE
0)1.N.H
N slµ1 = "-(Ni N2 2. HATU, NMM
NNZN 13oc
Hoy,
tert-butyl (2S,4S)-2-[9-(2-{(2S,4S)-14N-(methoxycarbonyI)-L- (2S,3S)-2-
alloisoleucy1]-4-methylpyrrolidin-2-y1}-1H-imidazol-5-y1)-1,11- 3-
methylpentanoic acid
la Am=
methyl {(3R)-1-[(2S,45)-2-(9-{24(2S,4S)-1-{(2S,3R)-2-
[(methoxycarbonyl)amino]-3-methylpentanoy1}-4-methylpyrrolidin-2-y1]-1H-
imidazol-5-01-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-cliimidazol-
2-y1)-4-(methoxymethyppyrrolidin-1-y1]-3-methyl-1-oxopentan-2-
Methyl {(3R)-1-K2S,4S)-2-(9-{2-1(2S,4S)-1-{(2S,3R)-2-1(methoxyearbonyl)aminol-
methylpentanoy11-4-methylpyrrolidin-2-y11-1H-imidazol-5-y11-1,11-
dihydroisochromeno[4',3':6,71naphtholl,2-dlimidazol-2-y1)-4-
3-methyl-1-oxopentan-2-ylIcarbamate
residue was treated with (2S,3S)-2-(methoxyearbonylamino)-3-methylpentanoic
mmol) was added dropwise. After 3h, the mixture was quenched with IN HC1
purified by HPLC to afford methyl {(3R)-1-[(2S,4S)-2-(9-{2-[(2S,4S)-1-{(2S,3R)-
[(methoxycarbonyeamino]-3-methylpentanoy11-4-methylpyrrolidin-2-y1]-1H-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-y1)-4-
methyl-I -oxopentan-2-ylIcarbamate ( 98 mg, 86%).
LCMS-ESI': calculated for C48H60N808: 876.5; observed [M+1] : 878.2.
Example QF
HO Cl 41 41
ci * AL o
---'s DIPEA =
Ili Br + 0 N cõ, MeCN
Bod 0
9-bromo-3-chloro- (2S,5S)-1-(tert- Bod
10,11-dihydro-5H- butoxycarbonyI)-5-
dibenzo[c,g]chromen methylpyrrolidine-2-
-8(9H)-one carboxylic acid
(2S,5S)-1-tert-butyl 2-(3-chloro-8-oxo-
Mn02 0 H :
NH40Ac = Cl ill it ao \NN
. N eoc CH2c12 = N
xylenes
dihydro-5H-naphtho[c,g1chromeno[8,9- c,g]chromeno[8,9-c]imidazol-2-y1)-5-
d]imidazol-2-y1)-5-(methyl) methylpyrrolidine-1-carboxylate
0 H 3. \
1. HCI AL i\IN)'"" bis(pinacolato)diboron
2. HATU, Cl lit 1
WI r. N X-
Phos, Pd2dba3, Kank
NMM Dioxane
V 0 100 C
HOINJ.(0, 1-1"N10N
(S)-2- 0
(methoxycarbonylamino)-3- methyl {(2S)-1-[(2S,5S)-2-(9-chloro-
methylbutanoic acid 1,11-
dihydroisochromeno[4',3':6,7]naphtho[1
,2-d]imidazol-2-y1)-5-methylpyrrolidin-1-
yI]-3-methyl-1-oxobutan-2-yl}carbamate
0 H. 0NH 0
Pd(dP1302C12, K2CO3
---ci m_re No j),,s, = 0
)''' 85 C
zNN)II--Br
1-1-N .,¨()
n - \ __ i'
0 .-
methyl R2S)-3-methyl-1-{(2S,5S)-2-methy1-5-[9-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y1)- methyl (S)-1-((2S,4S)-2-(5-
1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2- imidazol-2-y1)-4-
methylpyrrolidin-1-y1)-
d]imidazol-2-yl]pyrrolidin-1-y1}-1-oxobutan-2- 3-methyl-1-oxobutan-2-
yl]carbamate
0 H 1H CI
yocN N
N 2. COMU, DIPEA,
DrV1F
N -0AN;r0H
tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N- (R)-2-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-9-y1)- -2-phenylacetic
1H-imidazol-2-y1]-4-methylpyrrolidine-1-carboxylate
N" 0
N 111 N
r\lzU-N 4/11 N
methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R?-2-
[(methoxycarbonyl)amino]-2-phenylacety11-4-
dihydroisochromeno[41,31:6,7]naphtho[1,2-d]imidazol-2-y1)-
5-methylpyrrolidin-1-yI]-3-methyl-1-oxobutan-2-
dibenzolc,gichromen-9-y1) 5-
5 To a solution of 9-bromo-3-chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-
8(9H)-one (1.41
carboxylic acid (980 mg, 4.27 mmol) and DIPEA (1.49 mL, 8.54 mmol). After
stirring for 18 h at 50
C, the solution was diluted with Et0Ac and washed successively with IN HC1,
saturated aqueous
NaHCO3 and brine. The organics were dried over Na2SO4, filtered and
10 pressure. The crude residue was purified by silica column chromatography
dibenzo[c,g]chromen-9-y1) 5-methylpyrrolidine-1,2-dicarboxylate (1.63 g, 81%).
(2S,5S)-tert-butyl 2-(9-ch1oro-4,5-dihydro-5H-naphtholc,dchromeno[8,9-
(methyl)pyrrolidine-1-carboxylate
15 (2S,5 S)- 1- ter t-butyl 2-(3-chloro-8-oxo-8,9,10,11-tetrahydro-5H-
5-methylpyrrolidine-1,2-dicarboxylate (1.63 g, 3.18 mmol) was added toluene
(30 mL), 2-
methoxyethanol (3 mL), and ammonium acetate (3.68 g, 77.1 mmol) and the
solution was heated to
reflux overnight. The following morning, the solution was cooled to rt and was
diluted with Et0Ac
and washed successively with water, saturated aqueous NaHCO3 and brine. The
20 over Na2SO4, filtered and concentrated under reduced pressure. The crude
silica column chromatography (40% to 80 % Et0Ac/hexanes) to afford (2S,5S)-
chloro-4,5-dihydro-5H-naphtho[c,dchromeno[8,9-d]imidazol-2-y1)-5-
((2S,5S)-tert-butyl 2-(9-chloro-5H-naphthoic,gichromeno18,9-dlimidazol-2-y1)-5-
d]imidazol-2-y1)-5-(methyppyrrolidine-1 -carboxylate (1.13 g, 2.3 mmol) in
added Mn02 (9.98 g, 115 mmol). The reaction mixture was stirred overnight then
reduced pressure to afford the crude product (2S,5S)-tert-butyl 2-(9-chloro-5H-
naphtho[c,g]chromeno[8,9-d]imidazol-2-y1)-5-methylpyrrolidine-1-carboxylate
Methyl {(2S)-1-1(2S,5S)-2-(9-chloro-1,11-
dihydroisochromeno14',3':6,71naphtho[1,2-dlimidazol-
2-y1)-5-methylpyrrolidin-l-y11-3-methyl-l-oxobutan-2-yl}carbamate
methylpyrrolidine-1 -carboxylate (931 mg, 1.9 mmol) in 1.25 N HC1 in Et0H (8
mL) was heated to
50 C for 3h and then concentrated under reduced pressure. The crude residue
was treated with (S)-2-
(methoxycarbonylamino)-3-methylbutanoic acid (499 mg, 2.9 mmol), HATU (795 mg,
2.1 mmol) and
DMF (10 mL), then N-methylmorpholine (0.627 mL, 5.7 mmol) was added dropwise.
After stirring
for 1 h, the reaction was diluted with Et0Ac and washed successively with
NaHCO3, 5% LiC1, and brine. The organics were dried over Na2SO4, filtered and
Et0Ac/hexanes) to afford methyl {(2S)-1-[(2S,5S)-2-(9-chloro-1,11-
dihydroisochromeno [41,31:6,7]naphtho[1,2-d]imidazol-2-y1)-5-methy lpyrro
lidin-l-y1]-3-methy1-1-
oxobutan-2-yllcarbamate (950 mg, 91%).
Methyl 1(2S)-3-methyl-1-{(2S,5S)-2-methyl-5-19-(4,4,5,5-tetramethyl-1,3,2-
1,11-dihydroisochromeno14',3':6,71naphtho[1,2-d]imidazol-2-ylipyrrolidin-1-y1}-
yllicarbamate
To methyl {(2S)-1-[(2S,5S)-2-(9-chloro-1,11-
dJimidazol-2-y1)-5-methylpyrrolidin-l-y1]-3-methy1-1-oxobutan-2-yl}carbamate
in dioxane (17 mL) was added bis(pinacolato)diboron (662 mg, 2.61 mmol), KOAc
mmol), X-Phos (25 mg, 0.05 mmol), and Pd2dba3 (80 mg, 0.08 mmol). The solution
was degassed
with N2 for 10 min, then heated to 90 C for 16 h. The solution was cooled to
rt, diluted with Et0Ac,
washed with saturated aqueous NaHCO3, brine, dried with Na2SO4, and
concentrated. Purification by
silica gel chromatography (30% to 75 % gradient using 5%Me0H/Et0Ac to Hexanes)
to afford
methyl R2S)-3-methy1-1-{(2S,5S)-2-methyl-549-(4,4,5,5-tetramethyl-1,3,2-
dihydroisochromeno[41,3':6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-1 -y11-1 -
ylicarbamate (800 mg, 72%).
tert-butyl (2S,4S)-2-I5-(2-{(2S,5S)-14N-(methoxyearbonyl)-L-valyll-5-
1,11-dihydroisochromeno14',3%6,71naphtho[1,2-dlimidazol-9-y1)-1H-imidazol-2-
To a solution of R2S)-3-methy1-1-{(2S,5S)-2-methyl-549-(4,4,5,5-tetramethyl-
1-oxobutan-2-yl]carbamate (269 mg, 0.42 mmol), methyl (S)-1-((2S,4S)-2-(5-
bromo-1H-imidazol-2-
y1)-4-methylpyrrolidin-l-y1)-3-methyl-1-oxobutan-2-ylcarbamate (206 mg, 0.54
tetrakis(triphenylphosphine) palladium(0) (49 mg, 0.042 mmol) and
dichloro[1,1'-
bis(diphenylphosphino)ferrocene]palladium(II) (31 mg, 0.042 mmol) in DMSO (3
mL) and dioxanes
(3 mL) was added a solution of potassium carbonate (2M in water, 0.69 mL, 1.39
resulting mixture was degassed and then heated to 95 C for 2h. After cooling
the reaction was diluted with ethyl acetate. The organics were washed with
bicarbonate and brine, dried over Na2SO4 and concentrated. The crude residue
chromatography (Ito 20% Me0H/Et0Ac) to yield tert-butyl (2S,4S)-2-[5-(2-
{(2S,5S)-1-[N-
1-carboxylate (202 mg, 63%).
Methyl 1(2S)-1-1(2S,5S)-2-(9-12-1(2S,4S)-1-{(2R)-2-Kmethoxycarbonyl)aminol-2-
dihydroisochromenol4',3':6,71naphtholl,2-
dl imidazol-2-y1)-5-methylpyrrolidin-l-yll-3-methyl-1-oxobutan-2-ylIcarbamate
A solution of tert-butyl 1,11(2S,4S)-245-(2-1(2S,5S)-14N-(methoxycarbony1)-L-
methylpyrrolidin-2-y11- -
dihydroisochromeno[4',3':6,7]naphtho[1,2-dlimidazol-9-y1)-1H-
imidazol-2-y1]-4-methylpyrrolidine- 1 -carboxylate (80 mg, 0.11 mmol) in 1.25
N HC1 in Et0H (2
mL) was heated to 50 C for 3h. The reaction was concentrated and the crude
material dissolved in
DMF (1.5 mL). To this solution was added a solution of (R)-2-
phenylacetic acid (29 mg, 0.14 mmol) and COMU (52 mg, 0.12 mmol). To the
added diisopropylethylamine (0.057 mL, 0.33 mmol). After stirring for 2h at
reaction was quenched with IN HC1 (0.200 mL) and purified by HPLC. After
lyophilization, the TFA
salt was dissolved in Et0Ac and washed with saturated NaHCO3. The organic
Na2SO4 and concentrated. The free base was then dissolved in MeCN/H20 and
lyophilized to afford
methyl {(2S)-1-[(2 S,5 S)-2-(9-{24(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-
phenylacety11-4-
dlimidazol-2-y1)-5-methylpyrrolidin-1-y1]-3-methyl-l-oxobutan-2-yll carbamate:
(42 mg, 45%).
LCMS-ESL: calculated for C48H52N807: 852.4; observed [M+1]+: 854.2.
Example QG
WID=
/µ rx\v_Ir-NN
No 2. HATU,
NMM
H-N 0
N HoN_L(o,
tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N- (S)-2-
(methoxycarbony1)-L-valy1]-5-methylpyrrolidin-2-y11-1,11- methylbutanoic
=Nõ.711--N
,N 0
dihydroisochromeno[43.:6,7]naphtho[1,2-d]imidazol-2-
y1)-5-methylpyrrolidin-1-y1]-3-methy1-1-oxobutan-2-
Methyl {(25)-1-1(2S,5S)-2-(9-12-1(2S,4S)-1-{(2S)-2-1(methoxyearbonyl)aminol-3-
methylbutanoy1}-4-methylpyrrolidin-2-y111-1H-imidazol-5-y1}-1,11-
dihydroisochromeno14',3':6,71naphtho[1,2-dlimidazol-2-y1)-5-methylpyrrolidin-1-
methylpyrrolidine- 1 -carboxylate (60 mg, 0.079 mmol) in 1.25 N HC1 in Et0H (2
0.095 mmol)
and DMF (1.5 mL), then N-methylmorpholine (0.027 mL, 0.24 mmol) was added
dropwise. After 3h,
the mixture was quenched with 1N HC1 (0.100 mL) and then purified by HPLC to
afford methyl
{(2S)-1 -R2S,5S)-2-(9-12-R2S,4S)-1 -{(2S)-2-[(methoxycarbonyl)amino]-3 -
dihydroisochromeno[4',3':6,7Thaphtho[1,2-
d]imidazol-2-y1)-5-methylpyrrolidin-l-y1]-3-methyl-l-oxobutan-2-yllcarbamate (
33 mg, 51%).
LCMS-ES1+: calculated for C45H54N807: 818.4; observed [M+1]+: 820.2.
Example QH
Ei3cic N 2. HATU, NMM, DMF
NNAN
tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-14N-(methoxycarbony1)-L-
valy1]-5-methylpyrrolidin-2-y1}-1,11- A name could not be
dihydroisochromeno[4',3.:6,7]naphtho[1,2-d]imidazol-9-y1)-1H- generated for
imidazol-2-y1]-4-methylpyrrolidine-1-carboxylate structure.
NN/ft-- N N
methyl {(2S)-1-R2S,5S)-2-(9-{2-[(2S,4S)-1-{(2S,3S)-3-methoxy-
2-[(methoxycarbonyl)amino]butanoyll-4-methylpyrrolidin-2-y1]-
1H-imidazol-5-y11-1,11-
methylpyrrolidin-1-yI]-3-methyl-1-oxobutan-2-yl}carbamate
Methyl {(2S)-1-1(2S,5S)-2-(9-12-1(2S,45)-1-{(2S)-2-1(methoxyearbonyl)aminol-3-
methylbutanoy11-4-methylpyrrolidin-2-y11-1H-imidazol-5-y1}-1,11-
dihydroisochromeno14',3%6,71naphthol1,2-dlimidazol-2-y1)-5-methylpyrrolidin-1-
yll -1,11 -dihydroisochromeno[41,3':6,7]naphtho[ 1,2-d]imidazol-9-y1)- 1 H-
(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid (8 mg, 0.04 mmol),
mmol) and DMF (0.5 mL), then N-methylmorpholine (0.009 mL, 0.078 mmol) was
After 3h, the mixture was quenched with 1N 1-1C1 (0.100 mL) and then purified
by HPLC to afford
methyl {(2S)-1 -[(2S,5S)-2-(9-12-[(2S,4S)-1 -{(2S)-2-[(methoxycarbonyl)amino]-
3-methylbutanoyl -
4-methylpyrrolidin-2-y1]-1 H-imidazo1-5-yll - 1 ,1 1-
d]imidazol-2-y1)-5-methylpyrrolidin-1 -y1]-3-methyl-1 -oxobutan-2-yll
carbamate ( 7.5 mg, 35%).
LCMS-ESr: calculated for C45H54N808: 834.4; observed [M+1]+: 835.7.
Compounds 478-647
Using procedures similar to those described herein, the following compounds of
disclosure were prepared.
# Compound LCMS
(observed
(M+H)+)
/ (chiral)
_,-:-
4 ¨0 879.4
0 H i.---
o L ...e, Ni \ it .
---1 N -_,--1-- N \ N
il_f0
---0 N -
493 0 hi, ,---=¨f 838.2
O (Chiral)
494 H,N .:,---- 837.3
0 N,,--
\ N .,`\ L.
c .,.. N 0
H - N y 0,
:,...-
495 ).-- NH 0 835.73
0 ,µ\__0 N
,.......4 .
¨CN 441 1 \
. N .---"s
7....)1, N - H
0 Et n
498 0 N 835.34
,Nj'N\ = 0 \ N .D''')==`\1--,
Fi-Ny
-'------It'N-H
4990 0 823.35
...----- N
1110 r.. N ji-- N\ = aii
, ,,,
H-Ny ----
¨ o oL \ iiN -n .
503 -_C 837.35
--"\ Nj . _ N =
0 (Chiral)
¨ o )\--; ,H ojt \ = a oil E i.
-IC
507 N 0
NN¨ 865.32
UH H 'NJ¨
z.--
0 H 'n
0 0 N --ir- N, ,,\,..___
510 NI \ 0 0/ \ N ,1---"S a, 880.0
11. rsl--,....VLN -
H > HN.--f-
.....;_a
f- it
¨o o_)sL \ = 4iii
N...roN
516 ----A N hl, N 0 836.04
c___Zi H H, ---.
/\LN'H 0 Fl fir
..." 0
-\\ = W.L
(Chiral)
Ft 'n \
526 ¨oH N,..cr-N 806.11 o 1 \ = 14
,N,.._e
U H H 0 ¨
,).\--N'H
..."0 0 N Ni \ . . y"--"N ,.........
536 . N....7LN
* o 838.29 o¨
U I-1
H Wo
588 ,---N:H 0 FI\ r> 842.10 ill __
..{N
--0 -;-/() N -
¨--f J . 1N C
4 % 0 HN.?
--o H 0 H H -----\>
602 o H NI \ . I
11/I N o),\\
H,N..._f0
.---N'
603 o \....._//0
N\ = ii 1\117N 27
A I w_.
\\\S'c----- 1-1
H,y
---0 H 0 H H ---)
617 ---11' 0 0
0ij,
---\ \ N o
H ,N-....r
-----0)LNH 0
-1-- 0
N *
626 E Nj N 0 885.80
-(5 U H * N
0./H
"0 /0
¨0/
¨0 H 0 H H -----
--.-N...: 0 \N -._7--N , 878.15
643 0 Nili \111\1
: N
H,k1-..
¨o/
¨o H 0 H H
0 N 0/
N 10,
s.0\\µ -
BIOLOGICAL ASSAYS
Effect of serum proteins on replicon potency: Replicon assays are conducted in
cell culture medium (DMEM + 10%FBS) supplemented with physiologic
concentrations of human
5 serum albumin (40 mg/mL) or a-acid glycoprotein (1 mg/mL). EC50s in the
presence of human
serum proteins are compared to the EC50 in normal medium to determine the fold
shift in potency.
MT-4 Cell Cytotoxicity: MT4 cells are treated with serial dilutions of
compounds for a five
day period. Cell viability is measured at the end of the treatment period
using the Promega CellTiter-
Glo assay and non-linear regression is performed to calculate CC50.
Compound Concentration Associated with Cells at EC50: Huh-luc cultures are
incubated
with compound at concentrations equal to EC50. At multiple time points (0 ¨ 72
hours), cells are
washed 2X with cold medium and extracted with 85% acetonitrile; a sample of
the media at each
time-point will also be extracted. Cell and media extracts are analyzed by
LC/MS/MS to determine
the Molar concentration of compounds in each fraction. Representative
have shown activity.
Solubility and Stability: Solubility is determined by taking an aliquot of 10
mM DMSO
stock solution and preparing the compound at a final concentration of 100 1AM
in the test media
solutions (PBS, pH 7.4 and 0.1 N HC1, pH 1.5) with a total DMSO concentration
of 1%. The test
media solutions are incubated at room temperature with shaking for 1 hr. The
solutions will then be
centrifuged and the recovered supernatants are assayed on the HPLC/UV.
Solubility will be
calculated by comparing the amount of compound detected in the defined test
solution compared to
the amount detected in DMSO at the same concentration. Stability of compounds
after an 1 hour
incubation with PBS at 37 C will also be determined.
Stability in Cryopreserved Human, Dog, and Rat Hepatocytes: Each compound is
incubated for up to 1 hour in hepatocyte suspensions (100 [tl, 80,000 Cells
per well) at 37 C.
Cryopreserved hepatocytes are reconstituted in the serum-free incubation
medium. The suspension is
transferred into 96-well plates (50 viL/well). The compounds are diluted to 2
!..iM in incubation
medium and then are added to hepatocyte suspensions to start the incubation.
Samples are taken at 0,
10, 30 and 60 minutes after the start of incubation and reaction will be
quenched with a mixture
consisting of 0.3% formic acid in 90% acetonitrile/10% water. The
concentration of the compound in
each sample is analyzed using LC/MS/MS. The disappearance half-life of the
compound in
hepatocyte suspension is determined by fitting the concentration-time data
with a monophasic
exponential equation. The data will also be scaled up to represent intrinsic
hepatic clearance and/or
total hepatic clearance.
Stability in Hepatic S9 Fraction from Human, Dog, and Rat: Each compound is
incubated for up to 1 hour in S9 suspension (500 IA, 3 mg protein/mL) at 37 C
(n = 3). The
compounds are added to the S9 suspension to start the incubation. Samples are
taken at 0, 10, 30, and
60 minutes after the start of incubation. The concentration of the compound in
each sample is
analyzed using LC/MS/MS. The disappearance half-life of the compound in S9
suspension is
determined by fitting the concentration-time data with a monophasic
exponential equation.
Caco-2 Permeability: Compounds are assayed via a contract service (Absorption
Systems,
Exton, PA). Compounds are provided to the contractor in a blinded manner. Both
forward (A-to-B)
and reverse (B-to-A) permeability will be measured. Caco-2 monolayers are
grown to confluence on
collagen-coated, microporous, polycarbonate membranes in 12-well Costar TRANS
WELL plates.
The compounds are dosed on the apical side for forward permeability (A-to-B),
and are dosed on the
basolateral side for reverse permeability (B-to-A). The cells are incubated at
37 C with 5% CO2 in a
humidified incubator. At the beginning of incubation and at 1 hr and 2 hr
after incubation, a 200- L
aliquot is taken from the receiver chamber and replaced with fresh assay
buffer. The concentration of
the compound in each sample is determined with LC/MS/MS. The apparent
permeability, Papp, is
calculated.
Plasma Protein Binding: Plasma protein binding is measured by equilibrium
dialysis. Each
compound is spiked into blank plasma at a final concentration of 21.IM. The
spiked plasma and
phosphate buffer is placed into opposite sides of the assembled dialysis
cells, which will then be
rotated slowly in a 37 C water bath. At the end of the incubation, the
concentration of the compound
in plasma and phosphate buffer is determined. The percent unbound is
calculated using the following
equation:
( CI \
% Unbound = 100
C + C>
Where Cf and Cb are free and bound concentrations determined as the post-
dialysis buffer and
plasma concentrations, respectively.
CYP450 Profiling: Each compound is incubated with each of 5 recombinant human
CYP450 enzymes, including CYP1A2, CYP2C9, CYP3A4, CYP2D6 and CYP2C19 in the
and absence of NADPH. Serial samples will be taken from the incubation mixture
the incubation and at 5, 15, 30, 45 and 60 minutes after the start of the
incubation. The concentration
of the compound in the incubation mixture is determined by LC/MS/MS. The
percentage of the
compound remaining after incubation at each time point is calculated by
comparing with the sampling
at the start of incubation.
Stability in Rat, Dog, Monkey and Human Plasma: Compounds will be incubated
for up
to 2 hours in plasma (rat, dog, monkey, or human) at 37 C. Compounds are added
to the plasma at
final concentrations of 1 and 10 [tg/mL. Aliquots are taken at 0, 5, 15, 30,
60, and 120 minutes after
adding the compound. Concentration of compounds and major metabolites at each
time point are
measured by LC/MS/MS.
Evaluation of cell-based anti-HCV activity: Antiviral potency (EC50) was
using a Renilla luciferase (RLuc)-based HCV replicon reporter assay. To
perform the assay for
genotype 1 and 2a JFH-1, stable HCV la RLuc replicon cells (harboring a
dicistronic genotype la
H77 replicon that encodes a RLuc reporter), stable HCV lb RLuc replicon cells
(harboring a
dicistronic genotype lb Conl replicon that encodes a RLuc reporter), or stable
HCV 2a JFH-1 Rluc
replicon cells (harboring a dicistronic genotype 2a JFH-1 replicon that
encodes a RLuc reporter; with
L31 present in NS5A) were dispensed into 384-well plates for EC50 assays. To
genotype 2a (with M31 present in NS5A) or 2b, NS5A chimeric genotype 2a JFH-1
replicons that
encodes a RLuc-Neo reporter and either genotype 2a J6 strain NS5A gene or
genotype 2b MD2b-1
strain NS5A gene (both with M31 present) respectively, were either transiently
transfected (t) into
Huh-Lunet cells or were established as stably replicating replicon cells (s)
is provided. Either cells
were dispensed into 384-well plates for EC50 assays. To perform the assay for
genotype 3 and 4,
NS5A chimeric genotype lb Conl replicons that encodes a Pi-RLuc reporter and
either genotype 3a
S52 strain NS5A gene or genotype 4a ED43 strain NS5A gene respectively, were
transiently
transfected (t) into Huh-Lunet cells, which were subsequently dispensed into
384-well plates.
Compounds were dissolved in DMSO at a concentration of 10 mM and diluted in
DMSO either
manually or using an automated pipeting instrument. Serially 3-fold diluted
compounds were either
manually mixed with cell culture media and added to the seeded cells or
directly added to the cells
using an automated instrument. DMSO was used as a negative (solvent; no
inhibition) control, and the
protease inhibitor ITMN-191 was included at a concentration > 100 x EC50as a
positive control. 72
hours later, cells were lysed and Renilla luciferase activity quantified as
manufacturer (Promega-Madison, WI). Non-linear regression was performed to
calculate EC50
values.
To determine the antiviral potency (EC50) against resistance mutants,
resistance mutations,
including M28T, Q30R, Q30H, L31M, and Y93C in genotype 1 a NS5A and Y93H in
genotype lb
NS5A, were introduced individually into either 1 a Pi-Rluc or lb Pi-Rluc
replicons by site directed
mutagenesis. Replicon RNA of each resistant mutant was transiently transfected
into Huh-7-derived
cured-51 cells and antiviral potency was determined on these transfected cells
as described above.
The EC50 ranges for genotype 1 a, la Q30R, and 2a JFH are as follows: A 44 nM,
B = 1 nM
to 43.99 nM, C < 1 nM. The EC50 ranges for genotype 2a J6, 2b, 3a, and 4a are
as follows: A? 5 nM,
B = 1 nM to 4.99 nM, C < 1 nM. The EC50 ranges for genotype 2a J6, 2b, and 4a
correspond to the
assay of transiently transfected cells (t). If this data is unavailable, the
EC50 range for the stably
replicating cells (s) is provided.
IV and PO Single Dose Pharmacokinetic Studies in SD Rats: The pharmacokinetics
selected compounds was characterized in male Sprague-Dawley (SD) rats (250-
300g). In this study,
two groups of naïve purebred SD rats (N=3 per group, fasted over night)
received the selected
compound either as an intravenous (IV) infusion (1 mg/kg over 30 minutes) via
the jugular vein or by
oral gavage (2 mg/kg). The intravenous (IV) dosing vehicle was 5% ethanol, 35%
glycol 400 (PEG 400) and 60% water pH 2Ø The oral dosing vehicle was 5%
ethanol, 55% PEG 400
and 40% citrate buffer pH 2.2.
Serial blood samples (approximately 0.3 mL each) were collected from jugular
vein or other
suitable vein at specified time points. For the IV infusion group, the blood
samples were collected
predose and at 0.25, 0.48, 0.58, 0.75, 1.5, 3, 6, 8, 12 and 24 hours after the
start of infusion. For the
oral group, the blood samples were collected predose and at 0.25, 0.50, 1, 2,
4, 6, 8, 12 and 24 hours
after dosing. The blood samples were collected into Vacutainer'" tubes
containing EDTA-K3 as the
anti-coagulant and were centrifuged at approximately 4 C to obtain plasma. The
plasma samples
were stored at -20 C until analysis by LC/MS/MS.
A bioanalytical method utilizing high performance liquid chromatography
coupled to tandem
mass spectrometry (LC/MS/MS) was developed for analysis of the selected
compound in rat plasma.
Detection was performed using selected reaction monitoring (SRM); Ions
representing the precursor
(M+H) species was selected in quadrupole 1 (Q1) and collided with argon gas
in the collision cell
(Q2) to generate specific product ion, which was subsequently monitored by
quadrupole 3 (Q3).
Standard curve and quality control samples were prepared in male rat plasma
and processed in the
same way as the test samples to generate quantitative data.
Pharmacokinetic parameters were generated using non-compartmental
pharmacokinetic
analysis (Phoenix WinNonlin, version 6.3). Values below the lower limit of
quantification (LLOQ)
were assigned a value of zero if predose and treated as missing thereafter.
Area under the curve
(AUC) was calculated using the linear trapezoidal rule. The oral
bioavailability (%F) was determined
by comparison of the area under the curve (AUC) of the compound and/or a
metabolite generated
in plasma following oral administration to that generated following
intravenous administration.
# Example lb la la 2a 2a 2b 3a 4a
la la 2a 2a J6 2a J6 2b (t) 2b (s) 3a 4a (t) 4a (s) Rat
%F
No. (nM) Q3OR JFH J6 (nM) Q3OR JFH (t)
(s) (nM) (nM) (nM) (nM) (nM)
(nM) (nM) (nM) (nM)
422 MC 0.017 C C C B C CC 0.016 0.990 0.004 1.155 3.523 0.162 0.375
423 LQ 0.020 C C C CC CC 0.022 0.135 0.004 0.134 0.543 0.012 0.035
0.005 0.008 0.02
426 MD 0.033 C C C CC CC 0.035 0.192 0.006 0.073 0.439 0.016 0.038
427 ME 0.049 C
B _ C B C CC 0.033 2.514 0.012 3.428 16.075 0.198 0.701
434 MG 0.055 C C C CC CC 0.054 0.663 0.012 0.337 2.288
0.070 0.010 0.024 0.08
435 MF 0.058 C C C C C CC 0.059 0.768 0.012 0.476 2.136
478 478 0.048 C C BCCC 0.045 0.011 3.654
493 493 0.030 C C ACCC 0.036 0.008 5.036
494 494 0.021 C C C C C CC 0.037 0.118 0.005 0.098
495 495 0.026 C C C CC CC 0.021 0.201 0.008 0.280 1.016 0.135 0.541
0.024 0.014 0.014 4=,
498 498 0.016 C C C C C CC 0.030 0.040 0.004 0.012 0.039 0.010 0.013
499 499 0.032 C C CCCC 0.057 0.008
0.206 _ 0.040 0.010 0.021 0.005 co
503 503 0.041 C C CCCC 0.062 0.012 0.155
507 507 1.503 B C AB CC 3.698 0.297 20.096
510 510 0.050 C C CCCC 0.021
0.009 0.007 0.018 0.017 0.020 0.008 0.016 0.072
518 518 0.010 C _C BCCC 0.005 0.006
2.493 0.643 0.005 0.004 0.011 0
536 536 0.013 C C C CCCC 0.008 0.048 0.004 0.040 0.154 0.011 0.037
538 LR-1 0.016 C C C CC CC 0.011 0.015 0.005 0.018 0.048 0.010 0.024
539 LT 0.016 C
C _ C _ C C _ C C 0.009 0.010 0.004 , 0.010 0.047 0.009 0.039 0.012
543 MY 0.015 C C C CC CC 0.016 0.024 0.005 0.047 0.165 0.016 0.047
544 MM 0.026 C C C CC C C 0.022 0.044 0.007 0.018 0.064 0.015 0.042
551 OQ 0.018 C C C CC CC 0.015 0.102 0.007 0.378 1.492 0.265 0.982
552 OR 0.033 C C C CC CC 0.030 0.059 0.011 0.068 0.160 0.037 0.109
555 MN 0.021 C C C CC CC 0.014 0.018 0.008 0.017 0.071 0.013 0.040
0.034 0.024 0.007 1.5
556 MS 0.008 C C A A C 0.008 0.005 , 15.564
558 PQ 0.014 C C C C C
C 0.014 0.106 0.005 0.025 0.155 0.032 0.057 0.015 0.017
561 MP 0.010 C C C CC CC 0.006 0.031 0.004 0.039 0.336 0.032 0.184
0.015 0.015 0.013 24.2
562 MO 0.019 C C C CC CC 0.013 0.052 0.007 0.089 0.471 0.137 0.427
563 MT 0.007 C C A ABC 0.003_
0.021 44.444 44.444 1.092 0.015 0.025
565 NB 0.017 C C C C C C C 0.010 0.034 0.004 0.020 0.138 0.007
566 NC 0.009 C C C C C C C 0.007 0.060 0.005 0.089 0.762 0.068
569 ND 0.024 C C C C C C C 0.020 0.057 0.014 0.314 2.338 0.270
571 00 0.114 C C C C C C C 0.072 0.139 0.015 0.028 0.259 0.020
572 PF 0.044 C C C C C C C 0.032 0.034 0.014 0.025 0.127 0.023
0.117 0.072 0.050 0.018 4.3
573 PG 0.030 C C C C C C C 0.033 0.043 0.018 0.045 0.335 0.027
574 PN 0.016 C C C C C C C 0.015 0.030 0.009 0.027 0.277 0.014
575 PP 0.029 C C C C C C C 0.014 0.043 0.011 0.061 0.403 0.038
576 PO 0.014 C C _ B C C C 0.013 0.011 3.135 _
579 OI 0.034 C C C
C C C C 0.024 0.086 0.010 0.061 0.326 _ 0.178 0.629 0.206 0.036 0.007
580 OJ 0.017 C C CCCC 0.018 0.013 0.502
582 NF 0.010 C C C C C C C 0.011 0.017 0.006 0.031 0.218 0.018
585 NG 0.009 C C C C C C C 0.006 0.243 0.010 0.370 1.672 0.063
587 MR 0.041 C C C C C C C 0.028 0.128 0.017 0.079 0.176 0.039
0.053 0.078 0.045 o
n.)
588 588 0.017 C C C C C C C 0.012 0.087 0.004 0.038 0.140 0.012
0.017 0.027 0.019 co
589 MQ 0.011 C C C C C C C 0.008 0.023 0.004 0.017 0.095 0.009
0.023 0.016 0.011 .4
1-,
590 MU 0.014 C C C C C C C 0.008 0.023 0.004 0.013 0.046 0.009
0.025 0.017 0.011 "
592 NI 0.015 C C C
C C - C - C 0.015 0.059 0.007 0.026 0.169 _ 0.019 0.054 0.022 0.020
24.1 n.)
594 NP 0.013 C C C
C C _ C C 0.014 0.032 _ 0.007 0.010 0.096 0.011 0.043 0.020 0.028
(xi
597 NJ 0.005 C C C C C C C 0.007 0.025 0.007 0.099 0.939 0.094
599 PY 0.009 C C C
C C C C 0.012 0.013 , 0.006 0.009 0.098 0.007 0.030 0.017 0.018
27.7 '
600 PZ 0.007 C C C C C
C 0.009 0.057 0.005 0.175 1.712 0.071 0.386 0.025 1-,
601 MV 0.014 C C C C C C C 0.010 0.012 0.004 0.047
602 602 0.025 C C C C C 0.025 0.010 0.053
0.036, 0.036 0.013
603 603 0.015 C C C C C C C 0.009 0.146 0.007 0.194
604 NR 0.020 C C C C C 0.026 0.006 0.118
605 NQ 0.015 C C C C C C 0.017 0.039
0.006 0.064 0.013 0.012 0.013
606 OK 0.034 C , C C C , C _ C 0.026 0.039
607 OL 0.067 C C C C _ 0.047 _ 0.012 0.070
608 OH 0.017 C C C C , C _ C - 0.016 0.031
0.007 0.054 0.023 0.022 0.026 22.7
609 QF 0.005 C C C C _ C _ C _ 0.008 0.032
610 QA , 0.013 _ C , C C , C C _ C 0.012 0.045
0.007 0.094 0.052 0.040 0.038 7.46
612 QH 0.005 C C C C C _ C 0.007 0.051
613 QG 0.005 C C C C C _ C 0.005 0.071
614 , OP 0.013 C C C C C C 0.013 0.026
615 OM 0.019 C C C C C C 0.014 0.035 _
617 617 0.005 C C C C C C 0.009 0.024
618 OT 0.020 C C C C C C 0.011 0.041
619 OF 0.007 C C C C 0.010 0.008 0.445
620 NK 0.081 C C C C 0.049 0.018 0.056
621 NL 0.013 C C C C 0.011 0.007 0.043
622 NM 0.016 C C C C C C 0.011 0.028
0.006 0.012 0.013 0.024 6.93
623 ON 0.006 C C C C 0.005 0.004 0.068
625 PH 0.031 C C C C C C 0.024 0.051
626 626 0.030C,C C CCC 0.021 0.041 ,
627 PI 0.039 C C-C CCC 0.031 0.094
628 OG 0.009 C , C C C 0.009 0.008 0.601
631 PS 0.006 C _ C C C A 0.005 0.004 0.077
632 PT 0.008 C C C C 0.007 , 0.007 0.383
0.182 co
633 PR 0.020 C C C C C C 0.013 0.045
0.007 0.022 0.028 _ 0.018 o.
634 PU 0.015 C C C C 0.012 0.006 0.068
0.442 N.)
635 OU 0.041 C C C C 0.047 0.016 0.040
0.035 o"
636 OV 0.011 C_C,C CCC 0.010 0.031
0.007 , 0.113 0.046 0.013
637 OW 0.009 C C C C C C 0.009 0.019
0.006 0.009 0.008 0.013 13.3 o1
638 OX 0.009 C C C C 0.007 _ 0.006 0.113
639 QB 0.011 C C C C C C 0.011 0.029
0.008 0.021 0.022 0.028 9.56 1-,
1640 QE
640 QE 0.015 C C C C 0.013 0.011 0.291
641 QD 0.030 C C C C 0.025 0.013 0.103
642 QC 0.014 C C C C 0.012 0.008 0.157
643 643 0.015 C C C C 0.015 0.013 0.206
644 MW 0.026 C C C C C 0.012 0.012 0.020
645 MX 0.076 C C C C C 0.036 0.024 0.035
. - - -
648 PJ 0.088 C C C C C 0.068 0.058 0.136
2016-08-24 R30(2) - Failure to Respond
GILEAD PHARMASSET LLC
Abstract 2015-03-11 1 6
Description 2015-03-11 235 10,270
Claims 2015-03-11 14 259
Correspondence 2015-03-27 1 149